,id,ticker,title,category,content,date,provider,url,article_id
115676,337191,HSIC,FTC gets mixed ruling from administrative judge in dental supply fight,news,"WASHINGTON  Reuters    An administrative law judge at the Federal Trade Commission has ruled that Benco Dental Supply Co and  Patterson Companies Inc   O PDCO  violated antitrust law by refusing to compete for the business of buying groups but dismissed a complaint against a third company   Henry Schein  Inc  O HSIC   the agency said on Wednesday 
The FTC had accused the three companies  the three largest U S  full service distributors of supplies ranging from chairs to cement to gloves  of violating antitrust law in February 2018 
Judge Michael Chappell said in a decision dated Tuesday that  complaint Counsel  FTC  has shown that there was an agreement between Benco and Patterson to refuse to offer discounted prices or otherwise negotiate with buying groups  As held below  that agreement unreasonably restrained trade in the full service dental distribution market in the United States  
Henry Schein Chief Executive Stanley Bergman welcomed the judge s decision to sever them from the case  saying   Henry Schein has always been committed to doing business in an ethical manner wherever we operate  
Patterson said in a statement that it strongly disagreed with the judge s decision and was considering an appeal to the full commission 
  We  believe the facts demonstrate the company s independent decision making in a highly competitive industry   the statement said 
Benco did not immediately respond to a request for comment ",2019-10-16,Reuters,https://www.investing.com/news/stock-market-news/ftc-gets-mixed-ruling-from-administrative-judge-in-dental-supply-fight-1997435,1997435
115689,337204,HSIC,Henry Schein  HSIC  Expected To Beat Earnings Estimates  Should You Buy ,opinion,"Wall Street expects a year over year decline in earnings on lower revenues when Henry Schein  NASDAQ HSIC  reports results for the quarter ended September 2019  While this widely known consensus outlook is important in gauging the company s earnings picture  a powerful factor that could impact its near term stock price is how the actual results compare to these estimates 
The earnings report  which is expected to be released on November 5  2019  might help the stock move higher if these key numbers are better than expectations  On the other hand  if they miss  the stock may move lower 
While management s discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations  it s worth having a handicapping insight into the odds of a positive EPS surprise 
Zacks Consensus Estimate
This health care products maker is expected to post quarterly earnings of  0 86 per share in its upcoming report  which represents a year over year change of  16 5  
Revenues are expected to be  2 52 billion  down 23 1  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  This insight is at the core of our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction  
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for Henry Schein 
For Henry Schein  the Most Accurate Estimate is higher than the Zacks Consensus Estimate  suggesting that analysts have recently become bullish on the company s earnings prospects  This has resulted in an Earnings ESP of  0 87  
On the other hand  the stock currently carries a Zacks Rank of  3 
So  this combination indicates that Henry Schein will most likely beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
While calculating estimates for a company s future earnings  analysts often consider to what extent it has been able to match past consensus estimates  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that Henry Schein would post earnings of  0 83 per share when it actually produced earnings of  0 84  delivering a surprise of  1 20  
Over the last four quarters  the company has beaten consensus EPS estimates four times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
Henry Schein appears a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-10-28,Zacks Investment Research,https://www.investing.com/analysis/henry-schein-hsic-expected-to-beat-earnings-estimates-should-you-buy-200479683,200479683
115690,337205,HSIC,Henry Schein  HSIC  Expected To Beat Earnings Estimates  Should You Buy   Revised ,opinion,"Wall Street expects a year over year decline in earnings on lower revenues when Henry Schein  NASDAQ HSIC  reports results for the quarter ended September 2019  While this widely known consensus outlook is important in gauging the company s earnings picture  a powerful factor that could impact its near term stock price is how the actual results compare to these estimates 
The earnings report  which is expected to be released on November 5  2019  might help the stock move higher if these key numbers are better than expectations  On the other hand  if they miss  the stock may move lower 
While management s discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations  it s worth having a handicapping insight into the odds of a positive EPS surprise 
Zacks Consensus Estimate
This health care products maker is expected to post quarterly earnings from continuing operations of  0 86 per share in its upcoming report  which represents a year over year change of  16 5   The estimate for the current quarter excludes the animal health business the company spun off earlier this year 
Revenues are expected to be  2 52 billion  down 23 1  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  This insight is at the core of our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction  
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for Henry Schein 
For Henry Schein  the Most Accurate Estimate is higher than the Zacks Consensus Estimate  suggesting that analysts have recently become bullish on the company s earnings prospects  This has resulted in an Earnings ESP of  0 87  
On the other hand  the stock currently carries a Zacks Rank of  3 
So  this combination indicates that Henry Schein will most likely beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
While calculating estimates for a company s future earnings  analysts often consider to what extent it has been able to match past consensus estimates  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that Henry Schein would post earnings of  0 83 per share when it actually produced earnings of  0 84  delivering a surprise of  1 20  
Over the last four quarters  the company has beaten consensus EPS estimates four times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
Henry Schein appears a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release 
 We are reissuing this article to clarify a data  The original article  issued on October 29  2019  should no longer be relied upon  ",2019-10-30,Zacks Investment Research,https://www.investing.com/analysis/henry-schein-hsic-expected-to-beat-earnings-estimates-should-you-buy-revised-200481023,200481023
115691,337206,HSIC,Henry Schein  HSIC  Q3 Earnings Top Estimates,opinion,"Henry Schein  NASDAQ HSIC  came out with quarterly earnings of  0 90 per share  beating the Zacks Consensus Estimate of  0 86 per share  This compares to earnings of  1 03 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 4 65   A quarter ago  it was expected that this health care products maker would post earnings of  0 83 per share when it actually produced earnings of  0 84  delivering a surprise of 1 20  
Over the last four quarters  the company has surpassed consensus EPS estimates four times 
Henry Schein  which belongs to the Zacks Medical   Dental Supplies industry  posted revenues of  2 51 billion for the quarter ended September 2019  missing the Zacks Consensus Estimate by 0 51   This compares to year ago revenues of  3 28 billion  The company has topped consensus revenue estimates just once over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Henry Schein shares have lost about 16 3  since the beginning of the year versus the S P 500 s gain of 22 8  
What s Next for Henry Schein 
While Henry Schein has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Henry Schein was mixed  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  3  Hold  for the stock  So  the shares are expected to perform in line with the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  0 97 on  2 65 billion in revenues for the coming quarter and  3 46 on  9 97 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical   Dental Supplies is currently in the top 39  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-11-04,Zacks Investment Research,https://www.investing.com/analysis/henry-schein-hsic-q3-earnings-top-estimates-200482187,200482187
115692,337207,HSIC,Henry Schein To Showcase New Dental Offerings At GNYDM,opinion,"Henry Schein  Inc    NASDAQ HSIC   announced that it will be exhibiting the new lineup of products and educational offerings at the 2019 Greater New York Dental Meeting  GNYDM   which is slated to start on Nov 29  The company s suite of solutions  education  and social media activities  featuring pioneers in the dental industry  should enable oral healthcare professionals to explore new options revolutionizing digital dentistry The portfolio of digital equipment and technology solutions set to be displayed at the GNYDM includes its practice management  marketing  and patient engagement software solutions from Henry Schein One  a wide array of financial  business  and office design services and solutions from Henry Schein Financial Services  and Henry Schein ProRepair  The company will also be hosting a live event to demonstrate the optimization of Dentrix treatment plans and other workflow solutions designed to enhance productivity Products to be DemonstratedAt the meeting  Henry Schein will demonstrate the latest products and technology solutions such as 3Shape TRIOS Move  3Shape TRIOS 3 Basic  the A dec 500 chair  Convergent Dental Solea Dental Laser  and Dentsply Sirona CEREC Primescan  Henry Schein s Exclusive Product Specialists will be presenting the new Clinician s Choice Bluewave Laser  Reveal Clear Aligners  and other unique product offerings available from Clinician s Choice  Sheer White  and Sprig Oral Health Technologies Recent Developments Within Dental ArmHenry Schein s strategy of expanding digital dentistry on a global basis is encouraging  It is busy promoting digital workflows for general dentistry and dental specialties  The company is currently focusing on offering a diversified portfolio and value added services within the dental space Lately  it has been investing in acquisitions that should strengthen its international presence in the dental implant space In August  the company announced the acquisition of Cliniclands that offers dental consumables  implants  prosthetic  and orthodontic solutions and equipment to dentists in Sweden  Denmark  and Norway  In July 2019  Henry Schein announced its foray into the Italian dental practice management software market with the small but crucial acquisition of Elite Computer Italia  In June 2019  it acquired Hayes Handpiece franchise  a leading provider of dental handpiece products and services in the United States  Canada  and the United Kingdom Price Performance
In the past six months  the stock has rallied 3 4  against the  s 8 8  decline Zacks Rank and Stocks Worth a LookHenry Schein currently has a Zacks Rank  3  Hold  Some better ranked stocks from the broader medical space are Haemonetics Corporation   NYSE HAE    NuVasive  Inc    NASDAQ NUVA   and ResMed   NYSE RMD    While Haemonetics carries a Zacks Rank  1  Strong Buy   the other two carry a Zacks Rank  2  Buy   You can see Haemonetics has a projected long term earnings growth rate of 13 5  NuVasive has an expected long term earnings growth rate of 10 9  ResMed has a long term earnings growth rate of 12 9  Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through Q3 2019  while the S P 500 gained  39 6   five of our strategies returned  51 8    57 5    96 9    119 0   and even  158 9  This outperformance has not just been a recent phenomenon  From 2000   Q3 2019  while the S P averaged  5 6  per year  our top strategies averaged up to  54 1  per year ",2019-11-24,Zacks Investment Research,https://www.investing.com/analysis/henry-schein-to-showcase-new-dental-offerings-at-gnydm-200487603,200487603
115693,337208,HSIC,Why Is Henry Schein  HSIC  Up 0 8  Since Last Earnings Report ,opinion,"A month has gone by since the last earnings report for Henry Schein  NASDAQ HSIC   Shares have added about 0 8  in that time frame  underperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Henry Schein due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important catalysts  Henry Schein  Q3 Earnings Top EstimatesHenry Schein  Inc  reported adjusted earnings per share  EPS  from continuing operations of 90 cents in the third quarter of 2019  up 15 4  year over year  Adjusted EPS beat the Zacks Consensus Estimate by 4 7  on revenue growth across each of its operating segments On a reported basis  EPS from continuing operations was 91 cents  showing a 54 2  improvement on a year over year basis Revenues in DetailHenry Schein reported net sales of  2 51 billion in the third quarter  up 6 4  year over year  The metric missed the Zacks Consensus Estimate by 0 4   The year over year improvement came on the back of 3 9  internal sales growth in local currencies along with acquisition growth of 3 7   Unfavorable foreign currency exchange made a 1 1  impact on the top line Excluding  21 7 million in corporate revenues from product sales to Covetrus under the transition services agreement related to Henry Schein s Animal Health spin off  normalized internal sales growth in local currencies was 3  In the quarter under review  the company recorded sales of  1 86 billion in the North American market  up 5 7  year over year  Sales totaled  651 4 million in the international market  up 9  Segment Analysis    Henry Schein derives revenues from four operating segments  Dental  Medical and Technology and Value added Services In the third quarter  the company derived  1 55 billion of global Dental sales  up 2 1  year over year  This includes 3 6  growth in local currencies and 1 5  adverse impact from foreign currency exchange  At local currencies  internally generated sales increased 1 7  and acquisition growth was 1 9  Worldwide Medical revenues climbed 11 3  year over year to  803 7 million  Growth in local currencies was 11 4   while there was a 0 1  decline owing to adverse foreign exchange Revenues from global Technology and Value added Services grew 15 1  to  137 3 million  This included 15 8  growth in local currencies and 0 7  drop owing to adverse currency translation Margin Trend         Gross profit increased 5 4  to  761 2 million in the reported quarter  Gross margin  however  contracted 33 basis points  bps  from the year ago quarter to 30 3   Adjusted operating income improved 9 4  year over year to  186 4 million  Adjusted operating margin expanded 20 bps to 7 4  Financial PositionThe company exited third quarter 2019 with cash and cash equivalents of  75 3 million compared with  84 9 million at the end of the second quarter  Year to date net cash provided by operating activities from continuing operations was  525 2 million compared with  269 4 million in the year ago period During the quarter under review  Henry Schein repurchased 1 6 million shares of its common stock for approximately  98 million  At the end of the third quarter  the company had  75 million authorized for repurchase of common stock  GuidanceThe company tightened its EPS guidance for 2019  It expects adjusted EPS in the range of  3 41 to  3 47 compared to earlier provided range of  3 38  3 50   reflecting 8 9  growth from 2018  The Zacks Consensus Estimate for 2019 adjusted EPS of  3 46 is within the guided range The company has also initiated its 2020 adjusted EPS guidance  It expects adjusted EPS from continuing operations within  3 65 to  3 75  reflecting growth of 6  to 9   The Zacks Consensus Estimate for 2020 adjusted EPS of  3 75 is at the high end of the guided range 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in estimates review  The consensus estimate has shifted  5 92  due to these changes 
VGM Scores
At this time  Henry Schein has a nice Growth Score of B  though it is lagging a bit on the Momentum Score front with a C  Charting a somewhat similar path  the stock was allocated a grade of B on the value side  putting it in the top 40  for this investment strategy 
Overall  the stock has an aggregate VGM Score of A  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of these revisions indicates a downward shift  Notably  Henry Schein has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-12-04,Zacks Investment Research,https://www.investing.com/analysis/why-is-henry-schein-hsic-up-08-since-last-earnings-report-200490355,200490355
115698,337213,HSIC,PetIQ beats by  0 05  beats on revenue,news,PetIQ   NASDAQ PETQ   Q1 EPS of  0 09 beats by  0 05 Revenue of  115 07M   71 7  Y Y  beats by  6 49M Shares  1 6  Press ReleaseNow read ,2018-05-15,Seeking Alpha,https://www.investing.com/news/stock-market-news/petiq-beats-by-005-beats-on-revenue-1448732,1448732
115700,337215,HSIC,Notable earnings before Monday s open,news,BCC  BID  CAH  CFX  CTB  HSIC  IRWD  JEC  KOS  NWL  SEAS  SRE  STFC  TA  TSN  VST For Seeking Alpha s full earnings season calendar  click here  Now read ,2018-08-05,Seeking Alpha,https://www.investing.com/news/stock-market-news/notable-earnings-before-mondays-open-1561095,1561095
115701,337216,HSIC,Mylan prevails in Lantus patent challenge,news,Mylan N V   NASDAQ MYL  announces that the USPTO s Patent Trial and Appeal Board has ruled in its favor in its inter partes review of two formulation patents covering  Sanofi  s  NYSE SNY  long acting insulin Lantus  insulin glargine 100 U mL   clearing one hurdle for Mylan s generic versions  Patent infringement litigation is still open with no specific trial date determined Per IQVIA  the U S  market for Lantus is   2 14B and   4 39B for Lantus SoloSTAR  disposable injection pen  SNY is off a fraction premarket Now read ,2018-12-13,Seeking Alpha,https://www.investing.com/news/stock-market-news/mylan-prevails-in-lantus-patent-challenge-1720572,1720572
115703,337218,HSIC,U S  stocks mixed at close of trade  Dow Jones Industrial Average down 0 25 ,news,"Investing com   U S  stocks were mixed after the close on Friday  as gains in the Consumer Goods  Utilities and Telecoms sectors led shares higher while losses in the Oil   Gas  Consumer Services and Financials sectors led shares lower 
At the close in NYSE  the Dow Jones Industrial Average declined 0 25   while the S P 500 index gained 0 07   and the NASDAQ Composite index climbed 0 14  
The best performers of the session on the Dow Jones Industrial Average were United Technologies Corporation  NYSE UTX   which rose 1 47  or 1 77 points to trade at 122 49 at the close  Meanwhile   Pfizer  Inc  NYSE PFE  added 1 27  or 0 53 points to end at 42 23 and Cisco Systems Inc  NASDAQ CSCO  was up 1 05  or 0 49 points to 47 19 in late trade 
The worst performers of the session were UnitedHealth Group Incorporated  NYSE UNH   which fell 2 64  or 7 10 points to trade at 261 90 at the close  Walgreens Boots Alliance Inc  NASDAQ WBA  declined 1 52  or 1 08 points to end at 70 12 and Walmart Inc  NYSE WMT  was down 1 19  or 1 15 points to 95 58 
The top performers on the S P 500 were  Coty Inc   NYSE COTY  which rose 32 15  to 9 33   Mattel Inc   NASDAQ MAT  which was up 23 22  to settle at 15 23 and  Electronic Arts Inc   NASDAQ EA  which gained 16 05  to close at 97 60 
The worst performers were The  Goodyear Tire    Rubber Company  NASDAQ GT  which was down 9 05  to 18 69 in late trade   Henry Schein  Inc  NASDAQ HSIC  which lost 5 31  to settle at 59 15 and  Hanesbrands  Inc  NYSE HBI  which was down 4 65  to 17 84 at the close 
The top performers on the NASDAQ Composite were eGain Corporation  NASDAQ EGAN  which rose 47 72  to 10 990  Marathon Patent Group Inc  NASDAQ MARA  which was up 35 53  to settle at 0 515 and  Eyenovia Inc   NASDAQ EYEN  which gained 28 05  to close at 6 30 
The worst performers were  Cellect Biotechnology Ltd   NASDAQ APOP  which was down 49 78  to 1 15 in late trade  Magnegas Applied Technology Solutions Inc  NASDAQ MNGA  which lost 48 17  to settle at 0 990 and Biocept Inc  NASDAQ BIOC  which was down 47 29  to 1 070 at the close 
Falling stocks outnumbered advancing ones on the New York Stock Exchange by 1587 to 1416 and 109 ended unchanged  on the Nasdaq Stock Exchange  1343 fell and 1271 advanced  while 100 ended unchanged 
Shares in The Goodyear Tire   Rubber Company  NASDAQ GT  fell to 5 year lows  down 9 05  or 1 86 to 18 69  Shares in Henry Schein Inc  NASDAQ HSIC  fell to 5 year lows  losing 5 31  or 3 32 to 59 15  Shares in Cellect Biotechnology Ltd  NASDAQ APOP  fell to all time lows  falling 49 78  or 1 14 to 1 15  Shares in Magnegas Applied Technology Solutions Inc  NASDAQ MNGA  fell to 3 years lows  falling 48 17  or 0 920 to 0 990  
The CBOE Volatility Index  which measures the implied volatility of S P 500 options  was down 3 97  to 15 72 
Gold Futures for April delivery was up 0 27  or 3 55 to  1317 75 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in March rose 0 13  or 0 07 to hit  52 71 a barrel  while the April Brent oil contract rose 0 75  or 0 46 to trade at  62 09 a barrel 
EUR USD was down 0 14  to 1 1324  while USD JPY fell 0 04  to 109 75 
The US Dollar Index Futures was up 0 13  at 96 415 ",2019-02-08,Investing.com,https://www.investing.com/news/stock-market-news/us-stocks-mixed-at-close-of-trade-dow-jones-industrial-average-down-025-1774664,1774664
115704,337219,HSIC,Henry Schein Earnings beat  Revenue misses In Q4,news,"Investing com    Henry Schein   NASDAQ HSIC  reported fourth quarter earnings  that beat analysts  expectations on Wednesday and revenue that fell short of forecasts 
The firm reported earnings per share of  1 12 on revenue of  3 38B  Analysts polled by Investing com anticipated EPS of  0 88 on revenue of  3 46B  That compared to EPS of  0 97 on revenue of  3 32B in the same period a year earlier  The company had reported EPS of  1 03 on revenue of  3 28B in the previous quarter 

Henry Schein follows other major Healthcare sector earnings this month
 On January 22  J J reported fourth quarter EPS of  1 97 on revenue of  20 39B  compared to forecasts of EPS of  1 95 on revenue of  20 2B 
Pfizer earnings beat analyst s expectations on January 29  with fourth quarter EPS of  0 64 on revenue of  13 98B  Investing com analysts expected EPS of  0 63 on revenue of  13 9B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2019-02-20,Investing.com,https://www.investing.com/news/stock-market-news/henry-schein-earnings-beat-revenue-misses-in-q4-1784565,1784565
115707,337222,HSIC,Henry Schein Earnings Beat  Revenue Misses In Q1,news,"Investing com    Henry Schein   NASDAQ HSIC  reported first quarter earnings  that Beat analysts  expectations on Tuesday and revenue that fell short of forecasts 
The firm reported earnings per share of  0 8 on revenue of  2 36B  Analysts polled by Investing com forecast EPS of  0 75 on revenue of  2 39B  That compared to EPS of  0 95 on revenue of  3 22B in the same period a year earlier  The company had reported EPS of  1 12 on revenue of  3 38B in the previous quarter 

Henry Schein follows other major Healthcare sector earnings this month
 On April 16  J J reported first quarter EPS of  2 1 on revenue of  20 02B  compared to forecasts of EPS of  2 04 on revenue of  19 61B 
Pfizer earnings Beat analysts  expectations on April 30  with first quarter EPS of  0 85 on revenue of  13 12B  Investing com analysts expected EPS of  0 75 on revenue of  12 99B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2019-05-07,Investing.com,https://www.investing.com/news/stock-market-news/henry-schein-earnings-beat-revenue-misses-in-q1-1858662,1858662
115719,337234,HSIC,Henry Schein  HSIC  Beats Q2 Earnings Estimates,opinion,"Henry Schein  NASDAQ HSIC  came out with quarterly earnings of  0 84 per share  beating the Zacks Consensus Estimate of  0 83 per share  This compares to earnings of  1 04 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 1 20   A quarter ago  it was expected that this health care products maker would post earnings of  0 76 per share when it actually produced earnings of  0 80  delivering a surprise of 5 26  
Over the last four quarters  the company has surpassed consensus EPS estimates four times 
Henry Schein  which belongs to the Zacks Medical   Dental Supplies industry  posted revenues of  2 45 billion for the quarter ended June 2019  missing the Zacks Consensus Estimate by 1 26   This compares to year ago revenues of  3 33 billion  The company has topped consensus revenue estimates just once over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Henry Schein shares have lost about 17 8  since the beginning of the year versus the S P 500 s gain of 13 5  
What s Next for Henry Schein 
While Henry Schein has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Henry Schein was mixed  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  3  Hold  for the stock  So  the shares are expected to perform in line with the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  0 86 on  2 53 billion in revenues for the coming quarter and  3 45 on  10 01 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical   Dental Supplies is currently in the top 32  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-08-06,Zacks Investment Research,https://www.investing.com/analysis/henry-schein-hsic-beats-q2-earnings-estimates-200451318,200451318
115720,337235,HSIC,Should Value Investors Pick Henry Schein  HSIC  Stock Now ,opinion,Value investing is easily one of the most popular ways to find great stocks in any market environment  After all  who wouldn t want to find stocks that are either flying under the radar and are compelling buys  or offer up tantalizing discounts when compared to fair value One way to find these companies is by looking at several key metrics and financial ratios  many of which are crucial in the value stock selection process  Let s put Henry Schein  Inc    NASDAQ HSIC   stock into this equation and find out if it is a good choice for value oriented investors right now  or if investors subscribing to this methodology should look elsewhere for top picks PE RatioA key metric that value investors always look at is the Price to Earnings Ratio  or PE for short  This shows us how much investors are willing to pay for each dollar of earnings in a given stock  and is easily one of the most popular financial ratios in the world  The best use of the PE ratio is to compare the stock s current PE ratio with  a  where this ratio has been in the past  b  how it compares to the average for the industry sector  and c  how it compares to the market as a whole On this front  Henry Schein has a trailing twelve months PE ratio of 16 18  as you can see in the chart below  This level actually compares favorably with the market at large  as the PE for the S P 500 stands at about 17 85  If we focus on the long term PE trend  Henry Schein s current PE level puts it below its midpoint of 24 07 over the past five years  with the number having risen rapidly over the past few months  However  the current level stands below the highs for the stock  suggesting that it can be a solid entry point  However  the stock s PE also compares favorably with the Zacks Medical Market sector s trailing twelve months PE ratio  which stands at 20 59  At the very least  this indicates that the stock is relatively undervalued right now  compared to its peers  We should also point out that Henry Schein has a forward PE ratio  price relative to this year s earnings  of 17 72  so it is fair to expect an increase in the company s share price in the near future P S RatioAnother key metric to note is the Price Sales ratio  This approach compares a given stock s price to its total sales  where a lower reading is generally considered better  Some people like this metric more than other value focused ones because it looks at sales  something that is far harder to manipulate with accounting tricks than earnings Right now  Henry Schein has a P S ratio of about 0 68  This is much lower than the S P 500 average  which comes in at 3 15 right now  Also  as we can see in the chart below  this is well below the highs for this stock in particular over the past few years  Broad Value OutlookIn aggregate  Henry Schein currently has a Value Score of A  putting it into the top 20  of all stocks we cover from this look  This makes Henry Schein a solid choice for value investors For example  P CF ratio  another great indicator of value  comes in at 11 08  which is marginally better than the industry average of 11 54  Clearly  HSIC is a solid choice on the value front from multiple angles What About the Stock Overall Though Henry Schein might be a good choice for value investors  there are plenty of other factors to consider before investing in this name  In particular  it is worth noting that the company has a Growth Score of B and Momentum Score of B  This gives HSIC a Zacks VGM score   or its overarching fundamental grade   of A   You can read more about the Zacks Style Scores  Meanwhile  the company s recent earnings estimates have been mixed at the best  The current year has seen two upward and two downward revisions in the past sixty days  while the full year 2020 estimate has seen also seen two upward and two downward revisions in the same time period As a result  the current year consensus estimate rose 0 29  in the past two months  whereas the full year 2020 estimate declined 0 53   You can see the consensus estimate trend and recent price action for the stock in the chart below Henry Schein  Inc  Price and Consensus   Owing to the bearish estimate trends  the stock carries a Zacks Rank  3  Hold   which is why we are looking for in line performance from the company in the near term Bottom LineHenry Schein is an inspired choice for value investors  as it is hard to beat its incredible lineup of statistics on this front  However  with a Zacks Rank  3 it is hard to get too excited about this company overall  In fact  over the past two years  the broader industry has underperformed the market at large  as you can see below  So  value investors might want to wait for estimates and analyst sentiment to turn around in this name first  but once that happens  this stock could be a compelling pick It s Illegal in 42 States  But Investors Will Make Billions LegallyIn addition to the companies you read about above  today you get details on the newly legalized industry that s tapping into a  habit  that Americans spend an estimated  150 billion on every year That s twice as much as they spend on marijuana  legally or otherwise Zacks special report revealing how investors can profit from this new opportunity  As more states  legalize this activity  the industry could expand by as much as 15X  Zacks  has just released a Special  Report revealing 5 top stocks to watch in this space ,2019-08-21,Zacks Investment Research,https://www.investing.com/analysis/should-value-investors-pick-henry-schein-hsic-stock-now-200457625,200457625
115721,337236,HSIC,What s In Store For Patterson Companies  PDCO  In Q1 Earnings ,opinion,"Patterson Companies  Inc  s   NASDAQ PDCO   first quarter fiscal 2020 results are expected to release on Aug 29  before the market opens  While its core segments   Patterson Dental and Animal Health   are expected to impress  a highly competitive dental industry raises concern The company delivered a negative earnings surprise of 7 5  in the last reported quarter  the average trailing four quarter negative earnings surprise being 6 2  Which Way Are Estimates Headed For the quarter to be reported  the Zacks Consensus Estimate for the company s revenues is pegged at  1 37 billion  suggesting growth of 2 4  from the year ago reported number  The same for earnings is pinned at 25 cents  indicating a decline of 3 9  from the year ago reported figure Patterson Companies  Inc  Price and EPS Surprise
    Let s delve deeper Factors to ConsiderWe expect consumable and private label businesses to have witnessed robust growth in the fiscal first quarter  thereby driving Patterson Companies  core Dental Supplies segment In the last reported quarter  the segment accounted for 39 1  of revenues  For the quarter to be reported  the Zacks Consensus Estimate for the segment s revenues is pegged at  514 million  up 1 6  year over year Notably  the segment saw year over year rise in revenues in the last reported quarter  after more than two years of dismal performance  This reflects that management has been stabilizing the unit through continued investments  Notably  management expects a range of new offerings within the segment to have driven results in the quarter to be reported  Also  growth across the equipment category and consumables is expected to have boosted the segment s internal growth in the quarter The Animal Health segment  the leading distributor of veterinary supplies to clinics  public and private institutions  is also expected to have boosted the fiscal first quarter results Notably  the segment accounted for 60 2  of revenues in the last reported quarter  For the quarter to be reported  the Zacks Consensus Estimate for the segment s revenues is pinned at  850 million  up 3  year over year Management expects Companion Animal and Production Animal businesses to have driven the segment in the quarter  Also  the company is constantly adding capabilities to strengthen the Animal Health arm  It has been capitalizing on significant market opportunity in Animal Health by offering a full and comprehensive suite of solutions  For instance  Patterson Companies  NaVetor practice management software and partnership with VetSource are developments  which are expected to have driven results for the quarter to be reported However  Patterson Companies faces significant competition in the U S  dental products industry  Apart from Henry Schein Dental  a unit of Henry Schein   NASDAQ HSIC    the company faces stiff rivalry from distributors that operate on a regional level and hundreds of small local distributors  Notably  such an intensely competitive environment might weigh on Patterson Companies  margins  In fact  for fiscal 2020  management expects gross margin to decline  owing to continuous surge in operating expenses What Does Our Model Say Per our proven model  a stock needs to have a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to deliver a positive earnings surprise in the quarter  However  this is not the case here Earnings ESP  Patterson Companies has an Earnings ESP of  2 89   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  The company currently carries a Zacks Rank  5  Strong Sell  Please note that we caution against stocks with a Zacks Rank  4  Sell  or 5 going into the earnings announcement  especially when the company is seeing negative estimate revision Stocks Worth a LookHere are a few stocks  which have the right combination to come up with an earnings beat this season The Cooper Companies   NYSE COO   currently has an Earnings ESP of  1 50  and a Zacks Rank  2  You can see  Burlington Stores   NYSE BURL   has an Earnings ESP of  0 17  and a Zacks Rank  2 at present Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-08-26,Zacks Investment Research,https://www.investing.com/analysis/whats-in-store-for-patterson-companies-pdco-in-q1-earnings-200458519,200458519
115722,337237,HSIC,Why Is Henry Schein  HSIC  Down 2 2  Since Last Earnings Report ,opinion,"A month has gone by since the last earnings report for Henry Schein  NASDAQ HSIC   Shares have lost about 2 2  in that time frame  underperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is Henry Schein due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important catalysts  Henry Schein Q2 Earnings Beat EstimatesHenry Schein  Inc   reported adjusted earnings per share  EPS  from continuing operations of 84 cents in the second quarter of 2019  up 10 5  year over year  Adjusted EPS beat the Zacks Consensus Estimate by 1 2  on revenue growth across global Medical and Technology and Value added Services businesses On a reported basis  EPS from continuing operations was 78 cents  showing an 8 3  improvement on a year over year basis Revenues in DetailHenry Schein reported net sales of  2 45 billion in the second quarter  up 5 6  year over year  The metric missed the Zacks Consensus Estimate by 1 2   The year over year improvement came on the back of 3 5  internal sales growth in local currencies along with acquisition growth of 4 3   The top line was adversely impacted by 2 1  owing to unfavorable foreign currency exchange Excluding  23 9 million in corporate revenues from product sales to Covetrus under the transition services agreement related to Henry Schein s Animal Health spin off  normalized internal sales growth in local currencies was 2 4  In the quarter under review  the company recorded sales of  1 76 billion in the North American market  up 7 5  year over year  Sales totaled  683 8 million in the international market  up 1 4  year over year Segment Analysis    Henry Schein derives revenues from four operating segments  Dental  Medical and Technology and Value added Services In the second quarter  the company derived  1 60 billion of global Dental sales  down 0 7  year over year  This includes 2 1  growth in local currencies and 2 8  adverse impact from foreign currency exchange  At local currencies  internally generated sales increased 0 7  and acquisition growth was 1 4  Worldwide Medical revenues climbed 13 6  year over year to  697 6 million  Growth in local currencies was 13 8  while there was a 0 2  decline related to foreign exchange headwind Revenues from global Technology and Value added Services grew 39 9  to  125 1 million  This included 41 2  growth in local currencies and 1 3  decrease owing to adverse currency movements Margin Trend         Gross profit increased 6 8  to  767 4 million in the reported quarter  Gross margin expanded 34 basis points  bps  from the year ago quarter to 31 4  The company reported a 7 3  rise in selling  general   administrative expenses to  593 2 million in the second quarter  However  adjusted operating income improved 5 2  year over year to  174 2 million  Adjusted operating margin contracted 3 bps to 7 1  Financial PositionThe company exited second quarter 2019 with cash and cash equivalents of  84 9 million  compared with  88 1 million at the end of the first quarter  Year to date net cash provided by operating activities from continuing operations was  298 8 million compared with 111 9 million in the year  ago period During the quarter under review  Henry Schein repurchased 1 2 million shares of its common stock for approximately  77 million  At the end of the second quarter  the company had  173 million authorized for repurchase of common stock 2019 GuidanceThe company reaffirmed its EPS guidance for 2019  It expects adjusted EPS in the range of  3 38  3 50  reflecting 7 10  growth from 2018  The Zacks Consensus Estimate for 2019 adjusted EPS of  3 46 is within the guided range 
How Have Estimates Been Moving Since Then 
It turns out  estimates revision have trended upward during the past month 
VGM Scores
Currently  Henry Schein has a nice Growth Score of B  though it is lagging a bit on the Momentum Score front with a C  However  the stock was allocated a grade of A on the value side  putting it in the top quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of A  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending upward for the stock  and the magnitude of these revisions indicates a downward shift  Notably  Henry Schein has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-09-04,Zacks Investment Research,https://www.investing.com/analysis/why-is-henry-schein-hsic-down-22-since-last-earnings-report-200461843,200461843
115723,337238,HSIC,3 Best Dental Stocks To Keep An Eye On,opinion,The U S  dental supply industry has been of late seeing a rise in the usage of dental practice management software  While prominent players like Henry Schein   NASDAQ HSIC   are striving to make an entry into this space  it is time investors cash in on this industry s untapped prospects A Glance at Henry Schein s DealHenry Schein recently entered Italy s dental practice management software market with the takeover of Elite Computer Italia S r L    a full service software company providing high tech management solutions to dental practices and laboratories in the country The acquisition is in sync with Henry Schein One s strategy to deliver integrated technology platforms that enhance the productivity of dental teams and patient experience Dental Practices Management Software in DemandDental practice management software comprises tools and products which enable dentists and associated healthcare professionals monitor day to day operations like appointment scheduling  document storage and sharing  contact databases  filing and tracking insurance claims  dental history charting  patient records  and treatment plans  This software also helps dental businesses run smoothly by ensuring safe storage and easy access of critical information Meanwhile  rising use of digital automation technologies is reshaping the labor market across industries  Within the dental space  experts are massively adopting practice management tools to restructure  organize and lessen the pressure of daily processes  both in and outside offices Further  with rising awareness of oral health in the United States and Europe  and rapid innovation within the dental space  this space is currently the focal point of industry majors Market ProspectPer   the dental practice management software market is expected to see a CAGR of 10 5  in the 2019 2024 period 3 Dental Stocks to Focus OnWe have selected three companies  which we believe are well poised to provide impressive long term returns given the encouraging prospects of the global dental supply industry These stocks have a favorable estimate revision trend DENTSPLY SIRONA  Inc    NASDAQ XRAY  This Zacks Rank  2  Buy  company is a global leader in the design  development  manufacture and marketing of dental consumables  dental laboratory products  dental specialty products and consumable medical device products  Over the past 60 days  eight estimates for the company s current year earnings have been revised higher  Resultantly  the Zacks Consensus Estimate for earnings per share rose around 1 7  to  2 39  The stock has gained 31 9  against the industry s fall of 8 3  over the past year   The company is fortifying its foothold in the highly competitive MedTech space with high end products like PrimeScan and GP Ortho software  Apart from this  new products like WaveOne GOLD  X Smart iQ  VDW and CONNECT Drive are expected to expand the company s presence in Europe Henry Schein  Inc This Zacks Rank  3  Hold  company is a leading distributor of health care products and services across the globe  with the lion s share of revenues coming from its Dental business  Meanwhile  over the past 30 days  three estimates for the company s current year earnings have been revised higher  Resultantly  the Zacks Consensus Estimate for earnings per share inched up 0 3  to  3 46  The stock has risen 5 9  compared with the industry s rise of 2 3  over the past six months Henry Schein s strategy to expand digital dentistry globally is encouraging The company s recent joint venture  JV   Henry Schein One  is working on combining a host of unique and powerful dental software tools that help dentists build awareness for their practice and better communicate with existing patients  In line with this  a number of major imaging vendors have now signed up for Henry Schein s Dentrix Smart image integration solution  Apart from this  through its cloud based dental practice management system  Dentrix Ascend  Henry Schein continues to focus on enhancing practice and patient experience Henry Schein recently entered into an agreement to buy Lighthouse 360 from the Web com which will enable the company to provide easy to use dental practice management and patient communication software Patterson Companies  Inc    NASDAQ PDCO  This Zacks Rank  3 company is one of the leading distributors of dental and animal health products  Over the past 30 days  two estimates for the company s current year earnings have moved up  However  the Zacks Consensus Estimate for the same was unchanged in this period  The stock has lost 33  compared with the industry s fall of 8 3  over the past year  Despite the stock s underperformance  it is well poised to make a comeback on solid long term prospects It is encouraging to note that Patterson Companies witnessed a solid pick up in dental sales in the last reported quarter  driven by robust equipment performance on double digit growth in the CAD CAM and core equipment categories Patterson Companies has been expanding through strategic acquisitions  In the recent past  Patterson Dental Supply  Inc   a business unit of Patterson Companies  announced the takeover of Fitzpatrick Dental Design  a dental office design and dental equipment dealer  The deal has helped strengthen Patterson Companies  equipment designs and expand its dental business capabilities It s Illegal in 42 States  But Investors Will Make Billions Legally In addition to the companies you read about above  today you get details on the newly legalized industry that s tapping into a  habit  that Americans spend an estimated  150 billion on every year That s twice as much as they spend on marijuana  legally or otherwise Zacks special report revealing how investors can profit from this new opportunity  As more states legalize this activity  the industry could expand by as much as 15X  Zacks  has just released a Special Report revealing 5 top stocks to watch in this space ,2019-09-05,Zacks Investment Research,https://www.investing.com/analysis/3-best-dental-stocks-to-keep-an-eye-on-200461789,200461789
115732,337247,HSIC,U S  files complaint against three biggest dental supply firms,news,WASHINGTON  Reuters    The U S  Federal Trade Commission said on Monday it had filed a complaint against the three largest U S  dental supply companies  saying they had broken antitrust law  The FTC said that Benco Dental Supply   Henry Schein  Inc  O HSIC  and Patterson Companies  O PDCO  had conspired to refuse to serve or give discounts to dental buying groups  The three companies sell more than 85 percent of the  10 billion in gloves  cements  chairs and other products that U S  dentists purchase each year  the FTC said  Buying groups representing small dental practices had asked the big dental product suppliers to aggregate sales to them and to negotiate prices  the FTC said  Benco and Henry Schein initially entered into an agreement to refuse to compete for the buying groups  business  and Patterson joined later  Benco invited a fourth group  Burkhart Dental Supply  to join but was rebuffed  the FTC said   The complaint details communications between executives of the two companies evidencing the agreement  as well as attempts to monitor and ensure compliance with the agreement   the FTC said in a statement   A complaint was filed with an FTC internal court  with a trial set to begin on Oct  12  Attempts to reach spokespeople for the three companies were not immediately successful ,2018-02-12,Reuters,https://www.investing.com/news/stock-market-news/us-files-complaint-against-three-biggest-dental-supply-firms-1234091,1234091
115734,337249,HSIC,Med supply stocks drop as Amazon preps an entry,news,Amazon  NASDAQ AMZN  spoke with hospital executives to tailor its Amazon Business service for medical supplies  according to the WSJ                Amazon sent employees to a  large Midwestern hospital system  for a pilot program testing if officials can use Business to order health care supplies for the system s 150 outpatient facilities                 The program was customized for that system s needs to allow for price comparisons between current distributors and Amazon Business                 Hospitals typically negotiate and sign contracts to buy supplies directly from manufacturers or distributors  Group purchasing companies can also negotiate on behalf of multiple hospitals to leverage demand                 Fees  administration  marketing  and shipping costs account for up to 30  of health care supply costs  according to  Citigroup   NYSE C  Global Markets data                 Healthcare distributors and group purchasers moving on the news   Cardinal Health   NYSE CAH  down 3 7  premarket  Walgreens Boots Alliance  NASDAQ WBA  down 1 8   Owens   Minor  NYSE OMI  down 4 5    McKesson  NYSE MCK  down 4    Henry Schein   NASDAQ HSIC  down 5 5                  Amazon shares are down 0 4           Previously  Amazon  JPMorgan  NYSE JPM   and Berkshire Hathaway  NYSE BRKa  launching a healthcare company  Jan  30 Now read ,2018-02-13,Seeking Alpha,https://www.investing.com/news/stock-market-news/med-supply-stocks-drop-as-amazon-preps-an-entry-1236721,1236721
115736,337251,HSIC,Legal hurdles  not Amazon  key concern for U S  dental supply firms,news,"By Ankur Banerjee  Reuters     Henry Schein  Inc  O HSIC  and Patterson Cos Inc  O PDCO  have bigger things to worry about than Amazon com Inc  O AMZN  potentially disrupting the niche dental equipment market they dominate in the United States  Their stocks  as well as those of other U S  drug and medical equipment suppliers  have taken a beating in the past year as speculation over Amazon expanding its considerable reach gained momentum  But investors and analysts told Reuters that the larger overhang on the two dental suppliers  and privately held Benco Dental Supply  is a recent complaint filed against them by the U S  Federal Trade Commission  The complaint alleges that the three companies broke antitrust law by conspiring to refuse discounts to dentists  The administrative trial is scheduled to begin on Oct  16  The trial could last years  and even a quick settlement could force the companies to ramp up discounts to customers and in turn pressure their margins  investors and analysts said   I think for now I would avoid investing in that particular industry  and kind of keep a careful watch   said Michael Arone  chief investment strategist at State Street Global Advisors  which owns shares in Henry Schein and Patterson  All three companies have issued public statement denying the FTC s allegations  Patterson declined to comment further  Henry Schein  in a letter it sent customers on Thursday  said the FTC was  essentially asking us to stop doing something that we believe we never did in the first place   A spokeswoman for Benco Dental said the company expected  to fully resolve this issue in a way that clarifies the integrity of our people and processes    SETTLEMENT LIKELY Henry Schein shares have lost nearly a fourth of their value  while Patterson s stock is down 30 percent since May  roughly when speculation of Amazon s entry into their market started  After Henry Schein reported quarterly results on Tuesday  several analysts cut their price targets on its stock  mainly due to the risks associated with the FTC complaint   While the FTC allegation is for injunctive relief and seeks no monetary damages or fines  there is no clear timeline to a resolution of the matter   Evercore ISI analyst Ross Muken said in a research note  He lowered his rating on Henry Schein to  in line  from  outperform  and said he expected gains in the company s stock to remain muted until further clarity on the complaint  possibly in late 2018 or early 2019  The companies are likely to settle  legal experts said  In a similar complaint in 2015  a small Meridian  Idaho based provider of drug and alcohol testing services settled with the FTC months after the regulator filed a complaint alleging the company was colluding with a rival to keep prices high  Antitrust lawyers  however  said the FTC s complaint against the dental suppliers was more serious than usual and did not rely on just circumstantial evidence   It appears the FTC has evidence of an explicit agreement between at least two of these so called competitors and that is a stronger case than what you often typically see   said Nicholas Gravante  an antitrust lawyer at Boies Schiller Flexner  Gravante is not involved with the complaint  Still  Wall Street analysts mostly remain bullish about these companies  businesses  even with the looming threat of Amazon  which they said could take a while to play out  Last week  the Wall Street Journal reported that the ecommerce giant was looking to expand its business to business marketplace that already sells professional medical products and hospital consumables such as gloves  Analysts said the dental companies were shielded by their long standing relationships with dentists  while their narrow margin business model may make it tough for Amazon to undercut them   I think Amazon is certainly a threat  certainly a negative  but not to the extent to which stocks like Henry Schein sold off   said Kevin Kedra  an analyst at Gabelli   Co  
Gabelli owns less than 1 percent of Henry Schein shares and about 2 percent of Patterson ",2018-02-23,Reuters,https://www.investing.com/news/stock-market-news/legal-hurdles-not-amazon-key-concern-for-us-dental-supply-firms-1302852,1302852
115744,337259,HSIC,HSIC Vs  WST  Which Stock Should Value Investors Buy Now ,opinion,"Investors looking for stocks in the Medical   Dental Supplies sector might want to consider either Henry Schein  NASDAQ HSIC  or West Pharmaceutical Services  WST   But which of these two companies is the best option for those looking for undervalued stocks  Let s take a closer look 
The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system  The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends  while our Style Scores work to grade companies based on specific traits 
Currently  Henry Schein has a Zacks Rank of  2  Buy   while West Pharmaceutical Services has a Zacks Rank of  3  Hold   This means that HSIC s earnings estimate revision activity has been more impressive  so investors should feel comfortable with its improving analyst outlook  But this is only part of the picture for value investors 
Value investors are also interested in a number of tried and true valuation metrics that help show when a company is undervalued at its current share price levels 
The Style Score Value grade factors in a variety of key fundamental metrics  including the popular P E ratio  P S ratio  earnings yield  cash flow per share  and a number of other key stats that are commonly used by value investors 
HSIC currently has a forward P E ratio of 20 65  while WST has a forward P E of 43 19  We also note that HSIC has a PEG ratio of 2 50  This metric is used similarly to the famous P E ratio  but the PEG ratio also takes into account the stock s expected earnings growth rate  WST currently has a PEG ratio of 3 77 
Another notable valuation metric for HSIC is its P B ratio of 3 11  The P B ratio pits a stock s market value against its book value  which is defined as total assets minus total liabilities  For comparison  WST has a P B of 6 67 
These are just a few of the metrics contributing to HSIC s Value grade of B and WST s Value grade of D 
HSIC stands above WST thanks to its solid earnings outlook  and based on these valuation figures  we also feel that HSIC is the superior value option right now ",2019-07-15,Zacks Investment Research,https://www.investing.com/analysis/hsic-vs-wst-which-stock-should-value-investors-buy-now-200440294,200440294
115745,337260,HSIC,Henry Schein Closes Acquisition Of Elite Computer Italia,opinion,Henry Schein  Inc    NASDAQ HSIC   recently announced that Henry Schein One has closed a deal to acquire Elite Computer Italia S r L    a full service software company providing high tech management solutions to dental practices and laboratories in Italy Henry Schein One is a joint venture between Henry Schein and Internet Brands that delivers integrated technology to improve the quality of dental practice management The integration of Elite Computer is in sync with Henry Schein One s strategy to deliver integrated technology platforms that would enhance the productivity of dental teams and improve each stage of patient experience The Elite Computer acquisition marks Henry Schein s foray into the Italian dental practice management software market  Financial terms of the deal have not been disclosed More About the AcquisitionElite s OrisLine brand constitutes of OrisDent  OrisLab  OrisEduco  and OrisCeph Rx software products  Henry Schein expects the acquisition to have no impact on the company s 2019 earnings per diluted share but prove accretive thereafter The buyout of Elite Computer will facilitate an effective digital workflow that would help dental teams streamline office procedures  Customers will be offered a comprehensive suite of practice management systems and web based services which include a portfolio of dental merchandise and equipment Following the acquisition  Elite Computer s OrisLine brand will be retained while Henry Schein One will continue to offer the former s current products Market ProspectsPer   the dental practice management software market is expected to see a CAGR of 10 5  over the 2019 2024 period Recent Takeovers by Henry ScheinLately  Henry Schein has been investing in a few crucial acquisitions through its Henry Schein One joint venture to strengthen its position in the dental practice management software market In February 2019  Henry Schein One announced the acquisition of Kopfwerk  a leading dental practice management solutions company in Vienna  Austria  Its integration with Henry Schein One s software portfolio will enhance the latter s ability to deliver successful patient outcome using the latest technology solutions In March 2019  Henry Schein One had taken over Lighthouse 360  a provider of easy to use dental practice management and patient communication software  Since its addition to Henry Schein One s portfolio  Lighthouse 360 has been in sync with the former s strategy of integrating the highest quality of solutions into one technology system Price PerformanceIn the past three months  the stock has risen 13 7  compared with the broader  s rally of 12 4  Zacks Rank and Other Key PicksHenry Schein currently carries a Zacks Rank  2  Buy  A few other top ranked stocks in the broader medical space are Teleflex Inc    NYSE TFX    Penumbra   NYSE PEN   and NuVasive Corporation   NASDAQ NUVA    While Teleflex currently carries a Zacks Rank  2  the other two have a Zacks Rank  1  Strong Buy   You can see  Teleflex s long term earnings growth rate is expected at 13 7  Penumbra s long term earnings growth rate is projected at 21 5  NuVasive s long term earnings growth rate is expected to be 11 9  Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3   This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-07-16,Zacks Investment Research,https://www.investing.com/analysis/henry-schein-closes-acquisition-of-elite-computer-italia-200440901,200440901
115749,337264,HSIC,Why Henry Schein  HSIC  Could Beat Earnings Estimates Again,opinion,"Have you been searching for a stock that might be well positioned to maintain its earnings beat streak in its upcoming report  It is worth considering Henry Schein  NASDAQ HSIC   which belongs to the Zacks Medical   Dental Supplies industry 
This health care products maker has an established record of topping earnings estimates  especially when looking at the previous two reports  The company boasts an average surprise for the past two quarters of 3 08  
For the most recent quarter  Henry Schein was expected to post earnings of  0 76 per share  but it reported  0 80 per share instead  representing a surprise of 5 26   For the previous quarter  the consensus estimate was  1 11 per share  while it actually produced  1 12 per share  a surprise of 0 90  
Price and EPS Surprise

For Henry Schein  estimates have been trending higher  thanks in part to this earnings surprise history  And when you look at the stock s positive Zacks Earnings ESP  Expected Surprise Prediction   it s a great indicator of a future earnings beat  especially when combined with its solid Zacks Rank 
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank  3  Hold  or better produce a positive surprise nearly 70  of the time  In other words  if you have 10 stocks with this combination  the number of stocks that beat the consensus estimate could be as high as seven 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Henry Schein has an Earnings ESP of  2 41  at the moment  suggesting that analysts have grown bullish on its near term earnings potential  When you combine this positive Earnings ESP with the stock s Zacks Rank  2  Buy   it shows that another beat is possibly around the corner 
When the Earnings ESP comes up negative  investors should note that this will reduce the predictive power of the metric  But  a negative value is not indicative of a stock s earnings miss 
Many companies end up beating the consensus EPS estimate  but that may not be the sole basis for their stocks moving higher  On the other hand  some stocks may hold their ground even if they end up missing the consensus estimate 
Because of this  it s really important to check a company s Earnings ESP ahead of its quarterly release to increase the odds of success  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported ",2019-07-18,Zacks Investment Research,https://www.investing.com/analysis/why-henry-schein-hsic-could-beat-earnings-estimates-again-200441979,200441979
115750,337265,HSIC,Henry Schein  HSIC  Expected To Beat Earnings Estimates  Can The Stock Move Higher ,opinion,"Henry Schein  NASDAQ HSIC  is expected to deliver a year over year decline in earnings on lower revenues when it reports results for the quarter ended June 2019  This widely known consensus outlook gives a good sense of the company s earnings picture  but how the actual results compare to these estimates is a powerful factor that could impact its near term stock price 
The stock might move higher if these key numbers top expectations in the upcoming earnings report  which is expected to be released on August 6  On the other hand  if they miss  the stock may move lower 
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management s discussion of business conditions on the earnings call  it s worth handicapping the probability of a positive EPS surprise 
Zacks Consensus Estimate
This health care products maker is expected to post quarterly earnings of  0 83 per share in its upcoming report  which represents a year over year change of  20 2  
Revenues are expected to be  2 48 billion  down 25 5  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 0 21  higher over the last 30 days to the current level  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change 
Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  Our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction     has this insight at its core 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for Henry Schein 
For Henry Schein  the Most Accurate Estimate is higher than the Zacks Consensus Estimate  suggesting that analysts have recently become bullish on the company s earnings prospects  This has resulted in an Earnings ESP of  2 41  
On the other hand  the stock currently carries a Zacks Rank of  2 
So  this combination indicates that Henry Schein will most likely beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that Henry Schein would post earnings of  0 76 per share when it actually produced earnings of  0 80  delivering a surprise of  5 26  
Over the last four quarters  the company has beaten consensus EPS estimates four times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
Henry Schein appears a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-07-29,Zacks Investment Research,https://www.investing.com/analysis/henry-schein-hsic-expected-to-beat-earnings-estimates-can-the-stock-move-higher-200447165,200447165
115751,337266,HSIC,Henry Schein  HSIC  To Post Q2 Earnings  A Beat In Store ,opinion,Henry Schein  Inc    NASDAQ HSIC   is scheduled to report second quarter 2019 results on Aug 6  before the market opens  In the last reported quarter  the company s earnings exceeded the Zacks Consensus Estimate by 5 3   Overall  the metric surpassed estimates in three of the trailing four quarters  the average positive surprise being 2 5  Let s see how things are shaping up prior to this announcement Factors at PlayIn the second quarter  Henry Schein is expected to demonstrate solid growth across all its segments  namely Dental  Medical and Technology plus Value Added Services  Geographically  the company is gaining traction from all regions  We expect this trend to get reflected in the impending quarterly results Favorable Dental Business Trend  The company is currently making concerted efforts to expand in the field of digital dentistry  globally  In this regard  it is benefitting from the ongoing phase of digitalization in the international dental market  According to Henry Schein  over the last few quarters  end market is generally stable in the International Dental consumable market and the company is gradually gaining share in this space  On the dental equipment side too  the market is stable leading to market share gains   These trends should continue through the second quarter as well Henry Schein  Inc  Price and EPS Surprise   Notably  the company earlier stated that in March  it participated at the International Dental Show in Germany  The international dental equipment internal sales in local currency declined during the first quarter largely due to this event as dentists in Germany and the surrounding countries restrained themselves from equipment purchases until after attending the show  This typically leads to a possible rebound in sales in the second quarter Evidently  the Zacks Consensus Estimate for second quarter North American dental revenues is pegged at  1 01 billion  suggesting a 9 2  rise from the sequentially reported figure  The consensus estimate for second quarter international Dental revenues stands at  711 million  implying 14 1  growth from the prior year reported number Strong Technology and Value Added Services Business  Henry Schein is steadily progressing with the array of product launches within this business  The company s second quarter performance is expected to benefit from the contribution of its joint venture  JV  with Internet Brands on dental technology that resulted in the formation of Henry Schein One  In recent times  Henry Schein One rolled out several key platform updates for patient engagement  patient financing and clinical decision support solutions  The unveiling of OmniCore  an all in one network infrastructure solution  is also projected to aid the company s top line in the quarter under review Further  all major imaging vendors have now  signed agreementswith the company s Dentrix Smart image integration solution  This apart  the company s cloud based dental practice management system  Dentrix Ascend  is deepening its focus on improving the practice and patient experience with additional multiple enhancements to upscale business outcomes  This development should also favor the company s top line growth in the second quarter of 2019 Growing Medical Business  Henry Schein is consistently working to boost its Medical segment  We expect to see another quarter of a strong organic uptick from the existing customer base and new patient traffic  The recent acquisition of North American Rescue  a leading provider of mission critical medical products for the defense and Public Safety markets  is also anticipated to expand the Medical portfolio in the to be reported quarter What the Model SuggestsThe proven Zacks model clearly shows that a company with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  has higher chances of beating estimates if it also has a positive   You can uncover the best stocks to buy or sell before they re reported with our  Henry Schein has a Zacks Rank  2 and an Earnings ESP of  2 41   a perfect combination that increases the odds of a positive surprise this earnings season The Zacks Consensus Estimate for earnings of 83 cents  however  indicates a 20 2  decline from the year earlier reported tally Other Stocks Worth a LookHere are a few other medical stocks worth considering as these too have the right mix of elements to exceed expectations this reporting cycle Bio Techne Corporation   NASDAQ TECH   has an Earnings ESP of  1 27  and is a Zacks  2 Ranked player  You can see  Anavex Life Sciences Corp    NASDAQ AVXL   has an Earnings ESP of  4 00  and a Zacks Rank of 2 Allena Pharmaceuticals  Inc    NASDAQ ALNA   has an Earnings ESP of  7 55  and a Zacks Rank  3 Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-07-31,Zacks Investment Research,https://www.investing.com/analysis/henry-schein-hsic-to-post-q2-earnings-a-beat-in-store-200449333,200449333
115753,337268,HSIC,What s In Store For Cardinal Health  CAH  In Q4 Earnings ,opinion,Cardinal Health  Inc  s   NYSE CAH   fourth quarter fiscal 2019 results are scheduled for release on Aug 8  before the opening bell In the last reported quarter  the company delivered a positive earnings surprise of 11 2   Further  it has an average four quarter positive surprise of 14 9  Let s take a look at how things are shaping up prior to this announcement Which Way Are Q4 Estimates Treading For the to be reported quarter  the Zacks Consensus Estimate for earnings is pegged at 96 cents per share  indicating a decline of 4 9  from the year ago quarter  The same for revenues stands at  36 90 billion  suggesting growth of 4 4  from the year ago reported figure Cardinal Health  Inc  Price and EPS Surprise    Pharmaceutical to Drive Fiscal Q4Cardinal Health s Pharmaceutical segment is the second largest pharmaceutical distributor in the United States  The company is likely to witness revenue growth at Pharmaceutical segment in the to be reported quarter fueled by probable sales growth from pharmaceutical distribution and specialty customers  Better than expected performance at this segment is likely to drive the company s fourth quarter fiscal results Notably  for the fourth quarter  the Zacks Consensus Estimate for the unit s revenues stands at  32 97 billion  suggesting growth of 4 8  from the year ago quarter Other Factors at PlayCardinal Health expects to witness notable contributions from its Medical unit  In fact  the segment manufactures products such as single use surgical drapes  gowns and apparel  exam and surgical gloves  which will bolster sales in the to be reported quarter Moreover  the company remains committed toward improving efficiencies across its Medical segment by refining commercial  operational and data capabilities  We expect this step to reflect on the fourth quarter results During the fiscal third quarter earnings call  management announced that it will exceed its initial commitment of targeted annualized cost savings of  100 million in fiscal 2019  Management at Cardinal Health announced that the benefits from this and additional actions will continue to improve throughout the year in 2019  This is likely to reflect in the company s margins in the quarters ahead  Consequently  we can expect to witness a similar trend in the to be reported quarter Further  the Cardinal Health s acquisition driven strategy and diversified product portfolio are likely to contribute to the company s overall performance in the to be reported quarter    However  Cardinal Health might experience integration risks owing to the buyouts that the company continues to make Further  stiff competition in each of the company s business segments is likely to pose a threat to the margins of such segments  This in turn might put pressure on the company s profitability in the to be reported quarter  What Our Quantitative Model SuggestsOur proven model clearly indicates that a stock needs to have both   a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold    to deliver a positive earnings surprise  This is not the case here Earnings ESP  Cardinal Health has an Earnings ESP of  3 13   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Cardinal Health carries a Zacks Rank  3 Please note that we caution against stocks with a Zacks Rank  4  Sell  or 5  Strong Sell  going into the earnings announcement  especially when the company is seeing negative estimate revisions    Stocks Worth a LookHere are some other medical stocks worth considering as these too have the right combination of elements to post an earnings beat this quarter Henry Schein  Inc    NASDAQ HSIC   has an Earnings ESP of  2 41  and a Zacks Rank  2  You can see   Anavex Life Sciences Corp    NASDAQ AVXL   has an Earnings ESP of  4 00  and a Zacks Rank  2 Bio Techne Corporation   NASDAQ TECH   has an Earnings ESP of  1 27  and a Zacks Rank  2 Breakout Biotech Stocks with Triple Digit Profit Potential The biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119 and  164 in as little as 1 month  The stocks in this report could perform even better ,2019-08-01,Zacks Investment Research,https://www.investing.com/analysis/whats-in-store-for-cardinal-health-cah-in-q4-earnings-200449954,200449954
115755,337270,HSIC,Why Henry Schein  HSIC  Might Surprise This Earnings Season,opinion,Investors are always looking for stocks that are poised to beat at earnings season and Henry Schein  Inc    NASDAQ HSIC   may be one such company  The firm has earnings coming up pretty soon  and events are shaping up quite nicely for their report That is because Henry Scheinis seeing favorable earnings estimate revision activity as of late  which is generally a precursor to an earnings beat  After all  analysts raising estimates right before earnings   with the most up to date information possible   is a pretty good indicator of some favorable trends underneath the surface for HSIC in this report In fact  the Most Accurate Estimate for the current quarter is currently at 85 cents per share for HSIC  compared to a broader Zacks Consensus Estimate of 83 cents per share  This suggests that analysts have very recently bumped up their estimates for HSIC  giving the stock a Zacks Earnings ESP of  2 41  heading into earnings season Henry Schein  Inc  Price and EPS Surprise   Why is this Important A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises  and outperforming the market  Our recent 10 year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank  3  Hold  or better show a positive surprise nearly 70  of the time  and have returned over 28  on average in annual returns  see more   Given that HSIC has a Zacks Rank  2  Buy  and an ESP in positive territory  investors might want to consider this stock ahead of earnings  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here Clearly  recent earnings estimate revisions suggest that good things are ahead for Henry Schein  and that a beat might be in the cards for the upcoming report Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-08-04,Zacks Investment Research,https://www.investing.com/analysis/why-henry-schein-hsic-might-surprise-this-earnings-season-200450895,200450895
115761,337276,HSIC,Schein to split shares 2 1 effective September 15,news,Henry Schein   NASDAQ HSIC  plans to split its common shares 2 1 for shareholders of record September 1  Post split trading will commence on September 15 Now read ,2017-08-16,Seeking Alpha,https://www.investing.com/news/stock-market-news/schein-to-split-shares-21-effective-september-15-519200,519200
115763,337278,HSIC,Premarket Losers as of 9 05 am,news,S  12  on calling off merger talks with T Mobile  NASDAQ TMUS  COLL  8  on announcing that the FDA will not meet PDUFA Goal Date for sNDA for Xtampza ER HSIC  8  on Q3 earnings MTBC  7  on Q3 earnings CRNT  6  on Q3 earnings TEUM  5  on being selected to deliver subscriber messaging and marketing content TMUS  5  on calling off merger talks with Sprint  NYSE S   Now read ,2017-11-06,Seeking Alpha,https://www.investing.com/news/stock-market-news/premarket-losers-as-of-905-am-764476,764476
115764,337279,HSIC,Premarket analyst action   healthcare,news,AbbVie  NYSE ABBV  resumed with Buy rating and  103  8  upside  price target by BofAML  Acorda Therapeutics   NASDAQ ACOR  resumed with Neutral rating and  22  10  upside  price target by Piper Jaffray Bristol Myers Squibb  NYSE BMY  resumed with Neutral rating and  63  2  upside  price target by BofAML  Henry Schein   NASDAQ HSIC  initiated with Equal Weight rating and  76  9  upside  price target by Stephens  Jazz Pharmaceuticals   NASDAQ JAZZ  resumed with Buy rating and  164  19  upside  price target by BofAML Eli Lilly  NYSE LLY  resumed with Neutral rating and  84  flat  price target by BofAML Loxo Oncology  NASDAQ LOXO  initiated with Outperform rating by William Blair  Mallinckrodt   NYSE MNK  resumed with Underperform rating and  20  8  downside risk  price target by BofAML Merck  NYSE MRK  resumed with Buy rating and  64  17  upside  price target by BofAML Mylan N V   NASDAQ MYL  resumed with Neutral rating and  39  7  upside  price target by BofAML  Pfizer   NYSE PFE  resumed with Buy rating and  40  13  upside  price target by BofAML Synlogic  NASDAQ SYBX  initiated with Outperform rating and  20  97  upside  price target by Wedbush Teva Pharmaceutical Industries  NYSE TEVA  resumed with Underperform rating and  11  25  downside risk  price target by BofAML Voyager Therapeutics  NASDAQ VYGR  resumed with Overweight rating and  28  110  upside  price target by Piper Jaffray DENTSPLY SIRONA  NASDAQ XRAY  initiated with Overweight rating and  75  10  upside  price target by Stephens Source  BloombergNow read ,2017-11-28,Seeking Alpha,https://www.investing.com/news/stock-market-news/premarket-analyst-action--healthcare-920938,920938
115765,337280,HSIC,Morgan Stanley bearish on Patterson and Schein by Amazon threat,news,Dental products distributors Patterson Companies  NASDAQ PDCO  and  Henry Schein   NASDAQ HSIC  are down 4  and 3   respectively  premarket on the heels of downgrades to Underweight by  Morgan Stanley   NYSE MS   Analyst Steve Beuchaw cites market softness and the looming entry of Amazon  NASDAQ AMZN  Source  BloombergNow read ,2017-12-06,Seeking Alpha,https://www.investing.com/news/stock-market-news/morgan-stanley-bearish-on-patterson-and-schein-by-amazon-threat-959392,959392
115767,337282,HSIC,Henry Schein buys vet practice management software provider,news,Henry Schein   HSIC  1   acquires eVetPractice  a provider of cloud based practice management software for veterinary clinics  The Athens  GA based business  founded in 2011  will be folded into Schein s Veterinary Solutions group The transaction should be neutral to Schein s 2018 earnings and accretive thereafter  Specific financial details terms are not disclosed Now read ,2017-12-18,Seeking Alpha,https://www.investing.com/news/stock-market-news/henry-schein-buys-vet-practice-management-software-provider-1004015,1004015
115777,337292,HSIC,Why Is Henry Schein  HSIC  Up 2 1  Since Last Earnings Report ,opinion,"It has been about a month since the last earnings report for Henry Schein  NASDAQ HSIC   Shares have added about 2 1  in that time frame  underperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Henry Schein due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important drivers  Henry Schein Rides on Strength in Medical Arm in Q4Henry Scheinreported adjusted earnings per share  EPS  of  1 12 in the fourth quarter of 2018  up 15 5  year over year  Adjusted EPS beat the Zacks Consensus Estimate of  1 11 by 0 9  on revenue growth across global Medical and Technology and Value added Services businesses On a reported basis  EPS came in at 87 cents against net loss of 6 cents in the year ago quarter Adjusted EPS in 2018 was  4 13  up 14 7  year over year  The figure surpassed the Zacks Consensus Estimate of  4 12 by 0 2  Revenues in DetailHenry Schein reported net sales of  3 38 billion in the fourth quarter  up 1 8  year over year  However  the metric missed the Zacks Consensus Estimate by 2 9   The year over year improvement came on the back of 2 1  internal sales growth in local currencies along with acquisition growth of 1 2   The top line was adversely impacted by 1 6  from unfavorable foreign currency exchange Revenues in 2018 came in at  13 20 billion  up 5 9  year over year  However  the figure missed the Zacks Consensus Estimate of  13 30 billion In the quarter under review  the company recorded sales of  2 26 billion in the North American market  up 3 2  year over year  Sales totaled  1 11 billion in the international market  down 1 1  year over year Segment Analysis    Henry Schein derives revenues from four operating segments  Dental  Medical  Animal Health and Technology and Value added Services In the fourth quarter  the company derived  1 67 billion of global Dental sales  down 0 2  year over year  This includes 1 8  growth in local currencies and 2  adverse impact from foreign currency exchange  At local currencies  internally generated sales increased 1 5  and acquisition growth was 0 3   Internal growth at local currencies included 0 6  improvement in North America and 2 8  growth internationally The company s global Animal Health segment witnessed a 1 4  decline in revenues to  877 6 million  This includes 0 7  growth in local currencies and 2 1  adverse impact from foreign currency exchange  At local currencies  internally generated sales declined 0 6  and acquisition growth was 1 3   The internal growth in local currencies included 1 9  decline in North America and 0 8  improvement internationally Worldwide Medical revenues climbed 7 5  year over year to  684 8 million  Growth in local currencies was 7 6  Revenues from global Technology and Value added Services grew 21 4  to  139 1 million  This included 22 1  growth in local currencies and 0 7  decrease owing to adverse currency movements Margin Trend         Gross profit increased 1  to  909 9 million in the reported quarter  However  gross margin contracted 20 basis points  bps  from the year ago quarter to 26 9  on a 2 1  escalation in cost of sales   Owing to a 2 3  rise in selling  general   administrative expenses to  674 7 million  adjusted operating income declined 2 5  year over year to  235 2 million  Also  adjusted operating margin shrunk 30 bps year over year to 7  in the reported quarter Financial PositionThe company exited 2018 with cash and cash equivalents of  80 2 million  compared with  1 75 billion in 2017  Net cash provided by operating activities was  684 7 million compared with  545 5 million a year ago During the quarter under review  Henry Schein repurchased 997 000 shares of its common stock for approximately  86 million  At the end of the fourth quarter  the company had  400 million authorized for repurchase of common stock 2019 Guidance The company has provided its 2019 EPS guidance  It expects EPS in the range of  3 38  3 46  reflecting 7 9  growth from the 2018 figure of  3 17  The Zacks Consensus Estimate for 2019 adjusted EPS of  4 32 is above the guided range 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates  The consensus estimate has shifted  25 49  due to these changes 
VGM Scores
Currently  Henry Schein has a strong Growth Score of A  though it is lagging a lot on the Momentum Score front with an F  However  the stock was allocated a grade of B on the value side  putting it in the second quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of A  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of these revisions indicates a downward shift  It s no surprise Henry Schein has a Zacks Rank  4  Sell   We expect a below average return from the stock in the next few months ",2019-03-21,Zacks Investment Research,https://www.investing.com/analysis/why-is-henry-schein-hsic-up-21-since-last-earnings-report-200400148,200400148
115778,337293,HSIC,Analysts Estimate Henry Schein  HSIC  To Report A Decline In Earnings  What To Look Out For,opinion,"Henry Schein  NASDAQ HSIC  is expected to deliver a year over year decline in earnings on lower revenues when it reports results for the quarter ended March 2019  This widely known consensus outlook gives a good sense of the company s earnings picture  but how the actual results compare to these estimates is a powerful factor that could impact its near term stock price 
The earnings report  which is expected to be released on May 7  2019  might help the stock move higher if these key numbers are better than expectations  On the other hand  if they miss  the stock may move lower 
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management s discussion of business conditions on the earnings call  it s worth handicapping the probability of a positive EPS surprise 
Zacks Consensus Estimate
This health care products maker is expected to post quarterly earnings of  0 76 per share in its upcoming report  which represents a year over year change of  20  
Revenues are expected to be  2 34 billion  down 27 2  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  This insight is at the core of our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction  
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for Henry Schein 
For Henry Schein  the Most Accurate Estimate is the same as the Zacks Consensus Estimate  suggesting that there are no recent analyst views which differ from what have been considered to derive the consensus estimate  This has resulted in an Earnings ESP of 0  
On the other hand  the stock currently carries a Zacks Rank of  4 
So  this combination makes it difficult to conclusively predict that Henry Schein will beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
While calculating estimates for a company s future earnings  analysts often consider to what extent it has been able to match past consensus estimates  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that Henry Schein would post earnings of  1 11 per share when it actually produced earnings of  1 12  delivering a surprise of  0 90  
Over the last four quarters  the company has beaten consensus EPS estimates four times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
Henry Schein doesn t appear a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-04-29,Zacks Investment Research,https://www.investing.com/analysis/analysts-estimate-henry-schein-hsic-to-report-a-decline-in-earnings-what-to-look-out-for-200412989,200412989
115779,337294,HSIC,Henry Schein  HSIC  Q1 Earnings And Revenues Beat Estimates,opinion,"Henry Schein  NASDAQ HSIC  came out with quarterly earnings of  0 80 per share  beating the Zacks Consensus Estimate of  0 76 per share  This compares to earnings of  0 95 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 5 26   A quarter ago  it was expected that this health care products maker would post earnings of  1 11 per share when it actually produced earnings of  1 12  delivering a surprise of 0 90  
Over the last four quarters  the company has surpassed consensus EPS estimates four times 
Henry Schein  which belongs to the Zacks Medical   Dental Supplies industry  posted revenues of  2 36 billion for the quarter ended March 2019  surpassing the Zacks Consensus Estimate by 0 34   This compares to year ago revenues of  3 22 billion  The company has topped consensus revenue estimates two times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Henry Schein shares have lost about 19 4  since the beginning of the year versus the S P 500 s gain of 17  
What s Next for Henry Schein 
While Henry Schein has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Henry Schein was unfavorable  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  4  Sell  for the stock  So  the shares are expected to underperform the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  0 84 on  2 45 billion in revenues for the coming quarter and  3 43 on  9 90 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical   Dental Supplies is currently in the top 37  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-05-07,Zacks Investment Research,https://www.investing.com/analysis/henry-schein-hsic-q1-earnings-and-revenues-beat-estimates-200417946,200417946
115780,337295,HSIC,Danaher to buy Nobel Biocare for  2 2 billion,news,By Caroline Copley  ZURICH  Reuters    U S  healthcare group Danaher Corp  N DHR  is to buy Nobel Biocare Holding AG  S NOBN  for an agreed  2 2 billion to become the world s biggest player in a dental implants market benefiting from growing demand for cosmetic dentistry   Danaher said on Monday it would pay 17 10 Swiss francs per Nobel Biocare share in cash  about 23 percent above Nobel Biocare s closing price on July 28  the day before the Swiss firm said it was in talks with potential buyers   However  Nobel Biocare shares fell as much as 6 percent after analysts had predicted the company could fetch over 20 francs per share    From my side  it doesn t fill me with that much enthusiasm  But I don t expect there will be a second bid   Sebastien Buch  a portfolio manager at Union Investment which owns roughly 3 percent of Nobel Biocare s shares  told Reuters   Danaher is a leading provider of dental equipment  but only a small player in the fragmented dental implants market after its acquisition of low cost manufacturer Implant Direct   The purchase of Nobel Biocare  the world s No 2 dental implants maker  will bring Danaher a premium range of implants and boost its dental business to sales of around  3 billion   Vontobel analysts forecast the global dental implants market is set to double to  6 billion by 2025  helped by recovering Western economies and rising incomes in developing countries   Danaher President and Chief Executive Thomas P  Joyce told a conference call that Nobel Biocare s recent investment in high growth markets such as China  eastern Europe and Latin America   which now make up about 20 percent of sales   had made it an attractive opportunity   Fellow dental implant players such as Henry Schein  O HSIC  and Dentsply  O XRAY  had been cited as possible bidders for Nobel Biocare  while the company had reportedly also attracted interest from buyout group EQT Partners   Analysts at Berenberg said it was  by no means a certainty  that Nobel Biocare s shareholders would agree to tender their shares at Danaher s price  adding it was possible that other potential suitors could enter the fray with a higher offer   The deal  recommended by Nobel Biocare s board  requires the acceptance of 67 percent of Nobel Biocare s shareholders   But other analysts said the price was fair and counter bids looked unlikely  Swiss rival Straumann  ruled out interest in Nobel Biocare last month  while Zimmer  N ZMH  is busy with its purchase of Biomet Inc for more than  13 billion    Nobel has run an extensive sales process and we believe that Nobel is less attractive for private equity in light of its weak cash flow and no synergy opportunities   said Bank of America Merrill Lynch analyst Ed Ridley Day   Joyce said Danaher expected the deal to help it deliver a 10 percent return on invested capital  ROIC  by 2019  It expects the deal to add five cents to earnings per share by 2015 and ten cents by 2016   MEDTECH M A  The Nobel Biocare deal follows on from a wave of mergers among medical supplies makers this year  including Medtronic Inc s  N MDT   42 9 billion deal to buy Dublin based Covidien Plc  N COV  in June   Like other makers of premium implants  Nobel Biocare has struggled since the financial crisis as cash strapped consumers  particularly in southern Europe  cut back on pricey dental work which is not generally reimbursed by insurers   Nobel Biocare s stock is down 80 percent since its all time high in 2007  The company grappled with years of sliding sales and dwindling market share as it faced competition from a growing number of so called  value  players   But signs have grown that a long awaited turnaround is taking root and the company has notched up five consecutive quarters of revenue growth at constant exchange rates   Although the premium market is growing at a slower pace than the value segment  Danaher said it still expects dentists to prefer premium implants for complex cases  It expects the premium segment to keep growing in the 3 5 percent range   Nobel Biocare had sales of 567 million euros   735 million  and net profit of 42 6 million euros in 2013  It has  556 million of bonds and loans   Danaher said Nobel Biocare would continue to operate as a standalone company and maintain its own brand and identity   The deal is expected to be completed in late 2014 or early 2015  Nobel Biocare was advised by Goldman Sachs  while Credit Suisse acted as financial adviser and offer manager to Danaher   At 1315 GMT  9 15 a m  EDT   Nobel Biocare shares were down 5 5 percent at 17 1 Swiss francs      Additional reporting by Supriya Kurane in Bangalore  Editing by Louise Heavens and Mark Potter ,2014-09-15,Reuters,https://www.investing.com/news/stock-market-news/danaher-to-buy-nobel-biocare-holding-for-$2.2-billion-including-debt-309402,309402
115781,337296,HSIC,Pets are comforting  but shares of pet focused companies may not be,news,"By Tanya Agrawal  Reuters    Come economic rain or shine  Americans spend  60 billion a year on their pets  a fact that has led investors to seek shelter in pet company shares when the stock market goes to the dogs  The sector s reputation as an all weather investment may be vastly overstated  however  Shares of companies that feed  groom  treat or pamper pets generally outperform the overall stock market during recessions and market routs  but that doesn t mean they all do well  Over the last year  for example  natural pet food companies  Freshpet Inc   O FRPT  and  Blue Buffalo Pet Products Inc   O BUFF  have nosedived as thin margins and competition have eaten into their profits despite the popularity of precious puppy food  Freshpet is down 75 4 percent from its April 2014 peak  while Blue Buffalo  which went public in July 2015  has seen its shares fall 43 percent since then  In the last recession  some stocks did well and some did not  While the S P 500 was losing 57 percent between October 2007 and March 2009  shares of online pet pharmacy  PetMed Express  Inc  O PETS   animal health testing company Idexx Laboratories Inc  O IDXX  and vaccine distributor  Henry Schein  Inc  O HSIC  fell 7 1 percent  49 8 percent and 45 5 percent respectively  So far this year  with the S P down 10 percent  PetMed  Idexx and Henry Schein have fallen 5 5 percent  7 6 percent and 0 2 percent respectively   The thing with the retail side is that it s a much more competitive business  so you can get your dog food at a 100 different stores and they re all trying to protect razor thin margins   said Jarl Ginsberg  portfolio manager of the Columbia Small and Mid Cap Value Fund  in New York  Ginsberg s fund owns about 912 000 shares in VCA Inc  O WOOF   a company that runs animal hospitals  The animal healthcare industry  with companies such as Henry Schein and  Heska Corp   O HSKA   a maker of animal lab testing products  has done better  Henry Schein is up 11 percent in the last 12 months  while Heska is up 55 percent  These companies aren t affected by the U S  policy debate on human healthcare spending  do not depend on payments from insurers and are also likely to do well because of recent strides in diagnostics  said William Bell  a portfolio manager at Atlanta Capital Management   The lifetime revenue per dog  if you re doing every test that s recommended  will be  17 000   said Bell   Right now  the revenue per dog is  3 000 so there s tremendous room for growth   Bell s company owns about 645 000 shares in VCA and about 2 1 million in Idexx  VCA is down 10 2 percent year to date  PUPPY LOVE AND PROFITS Pet owners do spend on their animals   a fact made evident by the fuss surrounding this week s Westminster Kennel Club Dog Show in New York  Spending on pets in the United States has grown every year since 1994  according to the American Pet Products Association  with 2015 U S  spending   at  60 59 billion   up 4 4 percent from the previous year  Events like the Westminster show only add to the attraction  analysts say  But investors have to be selective  taking into account the fundamentals of individual companies as well as the industry  said Scott Clemons  chief investment strategist at Brown Brothers Harriman in New York  which owns about 1 5 million shares in Henry Schein  Several pet industry stocks are pricey  Idexx currently trades at 31 times forward 12 month earnings and Henry Schein at 23 6 times  compared with the 14 5 average of companies in the S P 500  according to Thomson Reuters data  Bell is still a believer  though  even as some economic indicators point to weakness in the U S  economy  
 I think you re going to see continued growth  Particularly in times of uncertainty these are the kind of stocks that people want to buy because you know what you re going to get   he said ",2016-02-15,Reuters,"https://www.investing.com/news/stock-market-news/pets-are-comforting,-but-shares-of-pet-focused-companies-may-not-be-384740",384740
115782,337297,HSIC,Why Is Henry Schein  HSIC  Down 1 6  Since Last Earnings Report ,opinion,"A month has gone by since the last earnings report for Henry Schein  NASDAQ HSIC   Shares have lost about 1 6  in that time frame  outperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is Henry Schein due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important catalysts  Henry Schein Rides on Strength in Medical Arm in Q1Henry Schein reported adjusted earnings per share  EPS  from continuing operations of 80 cents in the first quarter of 2019  up 8 1  year over year  Adjusted EPS beat the Zacks Consensus Estimate by 5 3  on revenue growth across global Medical and Technology and Value added Services businesses On a reported basis  EPS from continuing operations came in at 78 cents  an 8 3  improvement on a year over year basis Revenues in DetailHenry Schein reported net sales of  2 36 billion in the first quarter  up 3 8  year over year  The metric exceeded the Zacks Consensus Estimate by 0 9   The year over year improvement came on the back of 4 3  internal sales growth in local currencies along with acquisition growth of 2 3   The top line was adversely impacted by 2 8  from unfavorable foreign currency exchange Excluding  15 million in corporate revenues from product sales to Covetrus under the transition services agreement related to Henry Schein s Animal Health spin off  normalized internal sales growth in local currencies was 3 7  In the quarter under review  the company recorded sales of  1 68 billion in the North American market  up 5 9  year over year  Sales totaled  674 2 million in the international market  down 1  year over year Segment Analysis Henry Schein derives revenues from four operating segments  Dental  Medical  Animal Health and Technology and Value added Services In the first quarter  the company derived  1 55 billion of global Dental sales  down 0 1  year over year  This includes 3 8  growth in local currencies and 3 9  adverse impact from foreign currency exchange  At local currencies  internally generated sales increased 3 2  and acquisition growth was 0 6  Worldwide Medical revenues climbed 7 5  year over year to  683 7 million  Growth in local currencies was 7  while there was a 0 2  decline related to foreign exchange headwind Revenues from global Technology and Value added Services grew 35 1  to  115 5 million  This included 36 8  growth in local currencies and 1 7  decrease owing to adverse currency movements Margin Trend       Gross profit increased 4 5  to  751 7 million in the reported quarter  Gross margin expanded 22 basis points  bps  from the year ago quarter to 31 8    The company reported a 3 7  rise in selling  general   administrative expenses to  574 6 million in the first quarter  However  adjusted operating income improved 7 4  year over year to  177 1 million  Adjusted operating margin expanded 25 bps year over year to 7 5  in the reported quarter Financial PositionThe company exited first quarter 2019 with cash and cash equivalents of  88 1 million  compared with  56 9 million at the end of 2018  Net cash provided by operating activities from continuing operations at the end of the first quarter was  133 3 million compared with net cash used in operating activitiesfrom continuing operationsof  64 6 million a year ago During the quarter under review  Henry Schein repurchased 2 5 million shares of its common stock for approximately  150 million  At the end of the first quarter  the company had  250 million authorized for repurchase of common stock 2019 GuidanceThe company has increased the upper end of its earlier provided EPS guidance for 2019  It expects adjusted EPS in the range of  3 38  3 50  reflecting 7 10  growth from the 2018  earlier EPS expectation band was  3 38  3 46   The Zacks Consensus Estimate for 2019 adjusted EPS of  4 43 is within the guided range  
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates 
VGM Scores
Currently  Henry Schein has a subpar Growth Score of D  however its Momentum Score is doing a bit better with a C  Charting a somewhat similar path  the stock was allocated a grade of B on the value side  putting it in the second quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of C  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of these revisions indicates a downward shift  Notably  Henry Schein has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-06-05,Zacks Investment Research,https://www.investing.com/analysis/why-is-henry-schein-hsic-down-16-since-last-earnings-report-200429134,200429134
115783,337298,HSIC,HSIC Vs  MMSI  Which Stock Is The Better Value Option ,opinion,"Investors interested in Medical   Dental Supplies stocks are likely familiar with Henry Schein  NASDAQ HSIC  and Merit Medical  MMSI   But which of these two companies is the best option for those looking for undervalued stocks  Let s take a closer look 
Everyone has their own methods for finding great value opportunities  but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank  The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends  while our Style Scores work to grade companies based on specific traits 
Currently  both Henry Schein and Merit Medical are holding a Zacks Rank of   2  Buy   This means that both companies have witnessed positive earnings estimate revisions  so investors should feel comfortable knowing that both of these stocks have an improving earnings outlook  But this is only part of the picture for value investors 
Value investors are also interested in a number of tried and true valuation metrics that help show when a company is undervalued at its current share price levels 
Our Value category grades stocks based on a number of key metrics  including the tried and true P E ratio  the P S ratio  earnings yield  and cash flow per share  as well as a variety of other fundamentals that value investors frequently use 
HSIC currently has a forward P E ratio of 20 68  while MMSI has a forward P E of 29 37  We also note that HSIC has a PEG ratio of 2 50  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  MMSI currently has a PEG ratio of 2 53 
Another notable valuation metric for HSIC is its P B ratio of 3 12  The P B ratio pits a stock s market value against its book value  which is defined as total assets minus total liabilities  For comparison  MMSI has a P B of 3 46 
These metrics  and several others  help HSIC earn a Value grade of B  while MMSI has been given a Value grade of C 
Both HSIC and MMSI are impressive stocks with solid earnings outlooks  but based on these valuation figures  we feel that HSIC is the superior value option right now ",2019-06-17,Zacks Investment Research,https://www.investing.com/analysis/hsic-vs-mmsi-which-stock-is-the-better-value-option-200432551,200432551
115785,337300,HSIC,What s In Store For Patterson Companies  PDCO  In Q4 Earnings ,opinion,"Patterson Companies  Inc  s   NASDAQ PDCO   fourth quarter fiscal 2019 results are expected to release on Jun 27  before the market opens  While its core segments   Patterson Dental and Animal Health   are expected to impress  a narrowed guidance for fiscal 2019 raises concern The company has a negative average earnings surprise of 4 4  in the trailing four quarters Which Way are Estimates Headed For the quarter to be reported  the Zacks Consensus Estimate for revenues is pegged at  1 43 billion  suggesting growth of 2  from the year ago reported number  The same for earnings is pinned at 40 cents  indicating a decline of 33 3  from the year ago reported figure Patterson Companies  Inc  Price and EPS Surprise
    Factors to ConsiderWe expect consumable and private label businesses to see robust growth in the fiscal fourth quarter  thereby driving Patterson Companies  core Animal Health segment Notably  management is constantly adding new capabilities to strengthen the Animal Health arm  The company has been capitalizing on significant market opportunity in Animal Health by offering a full and comprehensive suite of solutions that allow veterinarians to offer all methods of serving their customers  including home delivery with tools that drive greater levels of compliance  This is expected to drive fiscal fourth quarter results Coming to Patterson Dental  the segment saw year over year rise in revenues in the last reported quarter  after more than two years of dismal performance  This reflects that management has been stabilizing the unit through continued investments  Additionally  the dental portfolio is also witnessing a robust demand currently However  a narrowed guidance for fiscal 2019 earnings per share is worrisome Notably  the company now expects the metric to be  1 40  1 45 compared with the previously communicated  1 40  1 50 We believe that stiff competition from Henry Schein Dental  a unit of Henry Schein   NASDAQ HSIC    and pricing pressures pose as headwinds for the company What Does Our Model Say Per our proven model  a stock needs to have a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to deliver a positive earnings surprise in the quarter  However  this is not the case here Earnings ESP  Patterson Companies has an Earnings ESP of 0 00   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Patterson Companies currently carries a Zacks Rank  3 Please note that we caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into the earnings announcement  especially when the company is seeing negative estimate revision Peer ReleasesHere are two stocks that reported solid results in this earnings season Stryker Corporation   NYSE SYK   delivered first quarter 2019 adjusted earnings per share of  1 88  beating the Zacks Consensus Estimate by 2 2   Revenues of  3 52 billion were in line with the Zacks Consensus Estimate  The stock presently carries a Zacks Rank of 3  You can see  DENTSPLY SIRONA Inc    NASDAQ XRAY   reported adjusted earnings per share of 49 cents in the first quarter of 2019  beating the Zacks Consensus Estimate of 38 cents  Revenues totaled  946 2 million and surpassed the Zacks Consensus Estimate of  917 1 million  The stock currently carries a Zacks Rank  2 Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-06-21,Zacks Investment Research,https://www.investing.com/analysis/whats-in-store-for-patterson-companies-pdco-in-q4-earnings-200433576,200433576
115807,337322,HSIC,Near Term Outlook For Dental Supplies Industry Looks Bright,opinion,"The Zacks  industry comprises designers  developers  manufacturers and marketers of dental consumables  dental laboratory products and dental specialty items  It also includes companies offering practice management and clinical software  patient education systems  and office forms and stationery 
These companies primarily have dentists  dental laboratories  institutions and healthcare professionals as customers 
Here are the three major industry themes Digital Dentistry  Latest technologies help dentists carry out procedures with precision and efficiency  saving patients unnecessary trauma  The industry participants actively promote digital workflows for general dentistry as well as dental specialties  The most recent digital systems help provide faster dental treatments and better predictability of results  In keeping with the trend  Dentsply Sirona  XRAY  recently launched a single tooth replacement solution  Azento  in the United States to revolutionize digital implant workflow in dental care  Also dental 3D printing   the process of creating three dimensional solid dental models such as implants  surgical guides  braces  dentures  crowns and bridges   has been a rage  Increased Focus on Group Practices  Dentists are increasingly choosing to operate in groups  sharing a common office space  High debts related to dental school along with escalating operating costs have been driving this practice  The group system also makes way for easier approval of insurance coverage and fixing of insurance payment rates  This in turn is driving demand for dental equipment and consumables  Alternative Financing Options  According to a December 2016 research article published by Health Affairs  a large part of the population in the United States grapples with financial issues when it comes to dental care  As a solution to this pertinent problem  dental practitioners are coming up with financing options like customized payment plans and separate yearly rates  Practitioners are trying to make the most of the opportunities that sprung from the amended six year extension of the CHIP funding program covering dental care for children until 2024  Companies in the dental industry are coming up with different packages for practitioners to allow them to cater to individual needs  For instance  Align Technology  ALGN  introduced a variety of Invisalign Clear Aligner Packages addressing a wide array of patient needs   from relapse and aesthetic treatment to clinically advanced  comprehensive treatment such as severe crowding and vertical and anterior posterior discrepancies Zacks Industry Rank Indicates Bright Prospects
The Zacks Medical Dental Supplies industry falls within the broader Zacks  sector  It carries a Zacks Industry Rank  61  which places it at the top 24  of more than 250 Zacks industries 
The group s Zacks Industry Rank  which is basically the average of the Zacks Rank of all the member stocks  indicates bright near term prospects  Our research shows that the top 50  of the Zacks ranked industries outperforms the bottom 50  by a factor of more than 2 to 1 
We will present a few stocks that have the potential to outperform the market based on a strong earnings outlook  But it s worth taking a look at the industry s shareholder returns and current valuation first 
Industry Underperforms S P 500 and Sector
The industry has underperformed the Zacks S P 500 composite and its own sector in the past year 
Stocks in this industry have collectively declined 15 5  against the Zacks Medical sector s gain of 2 7   The industry has also underperformed the S P 500 s loss of 6 6  
                                   One Year Price Performance 

Industry s Current Valuation
On the basis of the forward 12 month price to earnings  P E  ratio  which is commonly used for valuing medical stocks  the industry is currently trading at 14 88X compared with the S P 500 s 15 82X and the sector s 16 15X 
Over the last five years  the industry has traded as high as 18 29X  as low as 14 34X  and at the median of 16 30X  as the charts below show 
                                Price to Earnings Forward 12 Months  F12M  

                              Price to Earnings Forward 12 Months  F12M  

Bottom Line
According to a Global Market Insights report  extreme tobacco  sugar and alcohol intake raises the risk of chronic dental diseases  And these make the prospects better for the dental supplies industry  Further  increasing incidence of conditions like periodontitis  gingivitis  infections and oral thrush are expected to keep the industry going 
An aging population has also been a significant contributor  Higher incidence of calcium deficiency in older people leads to teeth loss  According to the National Institute of Dental and Craniofacial research  more than 24  of adults aged above 74 years have lost all teeth  People on medication for chronic and metabolic disorders also reach an edentulous state 
Here we present three stocks from the Medical   Dental Supplies industry with a Zacks Rank  3  Hold  and have solid long term growth potential  You can see  
Align Technology  This company manufactures and markets a system of clear aligner therapy  intra oral scanners and CAD CAM  computer aided design and computer aided manufacturing  digital services used in dentistry  orthodontics  and dental records storage 
The stock has a Zacks Rank  3 and has declined 28 3  in a year s time  The medical dental supplies player has an estimated long term earnings growth rate of 23 6   The company has surpassed estimates in the last four quarters  the positive earnings surprise being 16 7  
                                 Price and Consensus  ALGN 

Henry Schein  NASDAQ HSIC   HSIC   Henry Schein entered the burgeoning market of orthodontic aligners with its proprietary SLX Clear Aligner System in May 2018  Management seems to be encouraged by the positive feedback for the product from the Key Opinion Leaders and other market participants  Henry Schein plans to increase the availability of the same through a global launch this year 
This Zacks Rank  3 stock has gained 7 2  in the past year  The company has an estimated long term earnings growth rate of 7 3   The company has surpassed estimates in three of the trailing four quarters  the positive earnings surprise being 1 8  
                                 Price and Consensus  HSIC 

Patterson Companies  NASDAQ PDCO   PDCO   Headquartered in St  Paul  MN  Patterson Companies is one of the leading distributors of dental products  Its Dental segment distributes consumable products  x ray film  restorative materials  sterilization products and hand instruments   basic and advanced technology dental equipment  practice management and clinical software  patient education systems  and office forms and stationery in the United States and Canada 
Shares of the company have declined 38 9  in the past year  Patterson Companies has an estimated long term earnings growth rate of 5 6  
                               Price and Consensus  PDCO 

Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-01-18,Zacks Investment Research,https://www.investing.com/analysis/nearterm-outlook-for-dental-supplies-industry-looks-bright-200377291,200377291
115809,337324,HSIC,Henry Schein  HSIC  Earnings Expected To Grow  What To Know Ahead Of Next Week s Release,opinion,"Henry Schein  NASDAQ HSIC  is expected to deliver a year over year increase in earnings on higher revenues when it reports results for the quarter ended December 2018  This widely known consensus outlook gives a good sense of the company s earnings picture  but how the actual results compare to these estimates is a powerful factor that could impact its near term stock price 
The stock might move higher if these key numbers top expectations in the upcoming earnings report  which is expected to be released on February 20  On the other hand  if they miss  the stock may move lower 
While management s discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations  it s worth having a handicapping insight into the odds of a positive EPS surprise 
Zacks Consensus Estimate
This health care products maker is expected to post quarterly earnings of  1 11 per share in its upcoming report  which represents a year over year change of  14 4  
Revenues are expected to be  3 47 billion  up 4 6  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 0 88  higher over the last 30 days to the current level  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  This insight is at the core of our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction  
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for Henry Schein 
For Henry Schein  the Most Accurate Estimate is the same as the Zacks Consensus Estimate  suggesting that there are no recent analyst views which differ from what have been considered to derive the consensus estimate  This has resulted in an Earnings ESP of 0  
On the other hand  the stock currently carries a Zacks Rank of  3 
So  this combination makes it difficult to conclusively predict that Henry Schein will beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that Henry Schein would post earnings of  1 01 per share when it actually produced earnings of  1 03  delivering a surprise of  1 98  
Over the last four quarters  the company has beaten consensus EPS estimates three times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
Henry Schein doesn t appear a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-02-12,Zacks Investment Research,https://www.investing.com/analysis/henry-schein-hsic-earnings-expected-to-grow-what-to-know-ahead-of-next-weeks-release-200387510,200387510
115810,337325,HSIC,Can Dental Growth Drive Henry Schein s  HSIC  Q4 Earnings ,opinion,"Henry Schein  Inc    NASDAQ HSIC   is expected to report fourth quarter 2018 results on Feb 20  In the last reported quarter  the company s earnings exceeded the Zacks Consensus Estimate by 1 98   Overall  the metric surpassed estimates in three of the last four quarters  the average positive surprise being 1 8  Let s see how things are shaping up prior to this announcement Factors at PlayOver the last few quarters  Henry Schein demonstrated solid growth across all the segments  namely  Dental  Medical and Technology plus Value Added Services  Geographically  the company gained traction across all regions  We expect this trend to reflect in the impending quarterly results Favorable Dental Business Trend  The company s strategy to expand digital dentistry globally is encouraging  In this regard  management believes that the company is well positioned to benefit from the ongoing trend of digitalization in the international dental market Expanding the portfolio  last October  Henry Schein announced a new exclusive distribution agreement with Sprig Oral Health Technologies Inc  to distribute Sprig s products for crown placement 
Henry Schein  Inc  Price and EPS Surprise
    Management seems to be encouraged by the positive feedback for the SLX Clear Aligner System from the Key Opinion Leaders and other market participants We expect encouraging top line contributions from these developments in the yet to be reported quarter Furthermore  we are upbeat about management s expectations about the sustained dental equipment and consumables business growth in North America and other regions  The bullish trend is expected to reflect in the to be reported quarter results  Accordingly  the Zacks Consensus Estimate for North American dental revenues in the fourth quarter is pegged at  1 06 billion  reflecting a 2 9  year over year rise  Our consensus estimate for fourth quarter global Dental revenues is pegged at  671 million  indicating a 3 9  rise from the year ago quarter Strong Technology and Value Added Services Business  The company is steadily progressing with launches within this business  We are particularly looking forward to Henry Schein s joint venture  JV  with Internet Brands on dental technology to form Henry Schein One  The JV combines Henry Schein Practice Solutions  products and services with the dental businesses of Internet Brands  Last September  Henry Schein One announced the launch of Dentrix G7  the upgraded version of the dental practice management system  It also launched OmniCore  an all in one network infrastructure solution providing hardware and services required to meet dental practices  IT needs  in the same month Furthermore  the to be reported quarter s results are expected to benefit from Henry Schein One s additional launches like Dentrix Smart Image  enhanced Dentrix service bundles including Optimum Pro for payment management services and Ultimate Service Bundle  online booking for Dentrix and Dentrix Ascend and the Dentrix Ascend Quick Exam module  The company has also launched the Dentrix Ascend in the United Kingdom  We also look forward to updates on the company s plans to launch patient relationship management platform in the fourth quarter of 2018 Growing Medical Business  Henry Schein is consistently working on boosting its Medical segment  Notably  worldwide Medical revenues rose 4 5  year over year in the third quarter  We expect to see another quarter of strong organic growth from the existing customer base and patient traffic  We are also upbeat about the company making the Henry Schein EasyOne Air spirometer available at the end of the second quarter of 2018  We also look forward to the company s agreement with Welch Allyn to distribute the Spot Vision Screener in last September Meanwhile  Henry Schein has completed the spinoff of its global Animal Health business in February 2019  However  the company will include the performance of the segment in  the fourth quarter results What Our Model SuggestsAccording to the Zacks model  a company with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  has a good chance of beating estimates if it also has a positive   You can uncover the best stocks to buy or sell before they re reported with our  Henry Schein has a Zacks Rank  3 and an Earnings ESP of 0 00   a combination that does not conclusively show an earnings beat The Zacks Consensus Estimate for earnings of  1 11 reflects a 14 4  rise on a year over year basis Stocks Worth a LookHere are a few stocks worth considering as they have the right combination of elements to post an earnings beat in their upcoming quarterly results Masimo Corporation   NASDAQ MASI   has an Earnings ESP of  1 04  and a Zacks Rank  3  You can see  CVS Health Corporation   NYSE CVS   has an Earnings ESP of  3 29  and a Zacks Rank  3 Wright Medical Group N V    NASDAQ WMGI   has an Earnings ESP of  58 24  and a Zacks Rank  2 Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  wouldn t you like to know about our 10 finest buy and holds for the year From more than 4 000 companies covered by the Zacks Rank  these 10 were picked by a process that consistently beats the market  Even during 2018 while the market dropped  5 2   our Top 10s were up well into double digits  And during bullish 2012   2017  they soared far above the market s  126 3   reaching  181 9  This year  the portfolio features a player that thrives on volatility  an AI comer  and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs ",2019-02-14,Zacks Investment Research,https://www.investing.com/analysis/can-dental-growth-drive-henry-scheins-hsic-q4-earnings-200388720,200388720
115811,337326,HSIC,Moving Average Crossover Alert  Henry Schein,opinion,"Henry Schein  Inc    NASDAQ HSIC   could be a stock to avoid from a technical perspective  as the firm is seeing unfavorable trends on the moving average crossover front  Recently  the 50 Day Moving Average for HSIC broke out below the 200 Day Simple Moving Average  suggesting short term bearishness 
This has already started to take place  as the stock has moved lower by 21 8  in the past four weeks  And with the recent moving average crossover  investors have to think that more unfavorable trading is ahead for HSIC stock 
If that wasn t enough  HSIC isn t looking too great from an earnings estimate revision perspective either  It appears as though many analysts have been reducing their earnings expectations for the stock lately  which is usually not a good sign of things to come 
Consider that in the last 30 days  8 estimates have been reduced  while none has moved higher  Add this in to a similar move lower in the consensus estimate  and there is plenty of reason to be bearish here 
That is why we currently have a Zacks Rank  5  Strong Sell  on this stock and are looking for it to underperform in the weeks ahead  So  either avoid this stock or consider jumping ship until the estimates and technical factors turn around for HSIC  You can see  
Breakout Biotech Stocks with Triple Digit Profit Potential
The biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases 
Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2019-03-04,Zacks Investment Research,https://www.investing.com/analysis/moving-average-crossover-alert-henry-schein-200394753,200394753
115839,337354,HSIC,NuVasive  NUVA  Q3 Earnings Lag Estimates  Revenues Top Mark,opinion,NuVasive  Inc    NASDAQ NUVA   reported third quarter 2018 adjusted earnings per share  EPS  of 56 cents  reflecting a 9 8  rise from the year ago quarter  The bottom line  however  fell short of the Zacks Consensus Estimate of 63 cents per share On a reported basis  third quarter 2018 EPS was 30 cents  a huge decline from the year ago period s 64 cents Revenues in the reported quarter came in at  271 3 million  up 9 8   up 10 2  at constant exchange rate or CER  year over year  The top line also surpassed the Zacks Consensus Estimate by 2  In the quarter under view  revenues at the U S  Spinal Hardware business increased around 7  to  146 1 million  driven by product launches in the United States  namely modular 3D printed titanium implants for TLIF and XLIF  Porous PEEK offerings  expanded PLF implant offerings and RELINE Small Stature NuVasive  Inc  Price  Consensus and EPS Surprise   Revenues in the U S  Surgical Support business were  72 6 million for the quarter under review  up 17 1  year over year  driven by strong services business and a better than expected performance in Biologics  Excluding the  5 million contribution from the SafePassage acquisition  the organic U S  Surgical Support revenues grew 10  The international business recorded revenues of  52 7 million  10 4  growth at CER or 8 5  on a reported basis on solid contributions from key geographies In the reported quarter  adjusted gross margin was 72 8   down 70 basis points year over year Adjusted operating profit dipped 2 4  to  42 3 million  Accordingly  adjusted operating margin contracted 190 basis points to 15 6  The company exited the third quarter with cash and cash equivalents of  75 1 million  up from  70 1 million at the end of the second quarter OutlookNuVasive provided an update on its guidance for 2018  The projection has been adjusted for third quarter results and contemplates the updated outlook of the U S  spine market at present as compared to the figure three months back On an adjusted basis  the company continues to expect 2018 revenues in the range of  1 105  1 110 billion  reflecting 7 4 7 9  growth at CER  earlier  the guided range was  1 095  1 105  implying growth of 6 3 7 3  at CER  However  NuVasive lowered its full year adjusted EPS forecast to a new range of  2 15  2 23 from the past prediction of  2 37  2 40  The Zacks Consensus Estimate of  2 39 remains below this guided range  Additionally  adjusted operating margin for the year is anticipated within the band of 15 15 5  down from the earlier figure of 16 7   Our TakeNuVasive generated revenues ahead of the Zacks Consensus Estimate while its earnings missed the consensus mark  The company registered balanced growth in both its business wings  Also  a solid show by its international business buoys optimism among investors on the stock  The company expects to see strong demand for new products as well as positive surgeon conversion efforts as its new Lateral Single Position Surgery procedure gains traction in the market  Moreover  we are upbeat about the recently integrated SafePassage business On the flip side  the trimmed earnings as well as operating margin view was disappointing Zacks Rank   Key PicksNuVasive carries a Zacks Rank  3  Hold   A few better ranked stocks in the broader medical space are Henry Schein  Inc    NASDAQ HSIC    Humana Inc    NYSE HUM   and Inogen  Inc    NASDAQ INGN   Henry Schein is expected to release third quarter 2018 results on Nov 6  The Zacks Consensus Estimate for adjusted EPS is  1 01 and for revenues   3 35 billion  The stock carries a Zacks Rank  2  Buy   You can see  Humana is likely to release third quarter 2018 results on Nov 7  The Zacks Consensus Estimate for the quarterly EPS is pegged at  4 29 and for revenues  stands at  13 97 billion  The stock holds a Zacks Rank of 2 Inogen is slated to release third quarter 2018 results on Nov 6  The Zacks Consensus Estimate for EPS is projected at 52 cents and for revenues  at  91 08 million  The stock sports a Zacks Rank  1  Strong Buy  3 Medical Stocks to Buy NowThe greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ,2018-10-30,Zacks Investment Research,https://www.investing.com/analysis/nuvasive-nuva-q3-earnings-lag-estimates-revenues-top-mark-200352491,200352491
115840,337355,HSIC,Integra  IART  Q3 Earnings Meet Estimates  Revenue View Dips,opinion,Integra LifeSciences Holdings Corporation   NASDAQ IART   delivered adjusted earnings per share  EPS  of 59 cents in the third quarter of 2018  up 31 1  from the year ago figure  However  the same remained in line with the Zacks Consensus Estimate Revenue DiscussionTotal revenues in the reported quarter surged 31 2  year over year to  365 9 million but lagged the Zacks Consensus Estimate of  371 million  Excluding revenues from Codman acquisitions  divestitures and the effect of currency exchange rates  organic revenues rose 6 2  year over year Progress with the company s Codman integration and consistent growth with the channel expansion strategy  particularly in Regenerative Technologies  strongly contributed to the company s third quarter performance Coming to product categories  revenues from the company s Codman Specialty Surgical segment soared 45 1  to  239 million  Improvement came primarily on the back of the Codman consolidation and a solid performance in the Dural Access and Repair  Advanced Energy and Neuro Monitoring businesses Integra LifeSciences Holdings Corporation Price  Consensus and EPS Surprise   Orthopedics and Tissue Technologies revenues came in at  127 million in the third quarter  up 11 2  year over year  This upside is fueled by a continued drive in Regenerative Technologies and Private Label businesses Margin TrendGross margin contracted 266 basis points  bps  to 60 8  in the reported quarter despite a 25 7  rise in gross profit to  222 6 million  Selling  general and administrative expenses increased 18 8  to  173 4 million in the quarter under review while research and development expenses rose 35 1  to  20 3 million  However  adjusted operating margin saw a 214 bps expansion to 7 9  in the third quarter Financial PositionIntegra LifeSciences exited third quarter 2018 with cash and cash equivalents of  205 9 million  up from  183 8 million at the end of the second quarter  Year to date  net cash flow from operating activities was  156 9 million  up from  102 9 million in the year ago period 2018 OutlookThe company has lowered its full year revenue guidance to  1 467  1 472 billion  earlier  the range was  1 475  1 49 billion   The Zacks Consensus Estimate for 2018 revenues of  1 49 billion remains above the guided range  Per Integra LifeSciences  the view has been trimmed on expectation of approximately 4  organic growth for 2018 as compared to the previous projection of nearly 5  However  the company reiterates its full year forecast for adjusted earnings per share within  2 36  2 42  The Zacks Consensus Estimate for the metric is pegged at  2 40  falling under the company s envisioned range Our TakeIntegra LifeSciences exited the third quarter of 2018 on a dull note with earnings in line and revenues missing the Zacks Consensus Estimate  However  a strong year over year rise in the top line on the back of the company s recent acquired business buoys optimism We are also encouraged by the company s balanced segmental year over year revenue growth in the third quarter  Integra LifeSciences  advancement with its channel expansion strategy as well as Codman integration raises investor hope  Notably  a year ago  the company announced plans within its Orthopedics and Tissue Technologies segment to expand its sales channel  improve focus and competitiveness plus better align the product portfolio with clinical customers We believe  the company is trying to execute its growth plan through an efficient management team  Moreover  higher year over year investments in research and development are encouraging  The company s promising view also instills confidence in the stock However  significant gross margin contractions caused by escalating costs are concerns  The updated 2018 outlook does not look much promising either Zacks Rank   Key PicksIntegra LifeSciences carries a Zacks Rank  4  Sell  A few better ranked stocks in the broader medical space are Henry Schein  Inc    NASDAQ HSIC    Humana Inc    NYSE HUM   and Inogen  Inc    NASDAQ INGN   Henry Schein is expected to release third quarter 2018 results on Nov 6  The Zacks Consensus Estimate for adjusted EPS is  1 01 and for revenues   3 35 billion  The stock carries a Zacks Rank  2  Buy   You can see  Humana is likely to release third quarter 2018 results on Nov 7  The Zacks Consensus Estimate for the quarterly EPS is pegged at  4 29 and for revenues  stands at  13 97 billion  The stock holds a Zacks Rank of 2 Inogen is slated to release third quarter 2018 results on Nov 6  The Zacks Consensus Estimate for EPS is projected at 52 cents and for revenues  at  91 08 million  The stock sports a Zacks Rank  1  Strong Buy  Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-11-01,Zacks Investment Research,https://www.investing.com/analysis/integra-iart-q3-earnings-meet-estimates-revenue-view-dips-200353260,200353260
115841,337356,HSIC,HSIC Vs  WST  Which Stock Is The Better Value Option ,opinion,"Investors interested in stocks from the Medical   Dental Supplies sector have probably already heard of Henry Schein  NASDAQ HSIC  and West Pharmaceutical Services  WST   But which of these two stocks is more attractive to value investors  We ll need to take a closer look to find out 
The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system  The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions  while our Style Scores work to identify stocks with specific traits 
Henry Schein has a Zacks Rank of  2  Buy   while West Pharmaceutical Services has a Zacks Rank of  3  Hold  right now  This system places an emphasis on companies that have seen positive earnings estimate revisions  so investors should feel comfortable knowing that HSIC is likely seeing its earnings outlook improve to a greater extent  But this is only part of the picture for value investors 
Value investors are also interested in a number of tried and true valuation metrics that help show when a company is undervalued at its current share price levels 
Our Value category grades stocks based on a number of key metrics  including the tried and true P E ratio  the P S ratio  earnings yield  and cash flow per share  as well as a variety of other fundamentals that value investors frequently use 
HSIC currently has a forward P E ratio of 20 28  while WST has a forward P E of 37 88  We also note that HSIC has a PEG ratio of 2 55  This popular figure is similar to the widely used P E ratio  but the PEG ratio also considers a company s expected EPS growth rate  WST currently has a PEG ratio of 4 01 
Another notable valuation metric for HSIC is its P B ratio of 4 37  The P B ratio pits a stock s market value against its book value  which is defined as total assets minus total liabilities  For comparison  WST has a P B of 5 82 
These are just a few of the metrics contributing to HSIC s Value grade of A and WST s Value grade of C 
HSIC is currently sporting an improving earnings outlook  which makes it stick out in our Zacks Rank model  And  based on the above valuation metrics  we feel that HSIC is likely the superior value option right now ",2018-11-04,Zacks Investment Research,https://www.investing.com/analysis/hsic-vs-wst-which-stock-is-the-better-value-option-200354821,200354821
115842,337357,HSIC,Henry Schein  HSIC  Up 3  Since Last Earnings Report  Can It Continue ,opinion,"A month has gone by since the last earnings report for Henry Schein  NASDAQ HSIC   Shares have added about 3  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Henry Schein due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important drivers  Henry Schein Rides on Overall Segmental Growth in Q3Henry Schein reported adjusted earnings per share  EPS  of  1 03 in the third quarter of 2018  up 18 4  year over year  Adjusted EPS beat the Zacks Consensus Estimate of  1 01 by 2   driven by revenue growth across all business segments On a reported basis  EPS came in at 79 cents in the third quarter  down 9 2  year over year Revenues in DetailHenry Schein reported net sales of  3 28 billion in the third quarter  up 3 8  year over year  However  the metric missed the Zacks Consensus Estimate by 2 1    The year over year improvement came on the back of 3 2  internal sales growth in local currencies along with acquisition growth of 1 9  in the quarter  The top line edged down 1 3  owing to unfavorable foreign currency exchange In the quarter under review  the company recorded sales of  2 24 billion in the North American market  up 5 7  year over year  Sales totaled  1 04 billion in the international market  down 0 3  year over year Segment Analysis    Henry Schein derives revenues from four operating segments  Dental  Medical  Animal Health and Technology and Value added services In the third quarter  the company derived  1 51 billion in revenues from global Dental sales  up 2 4  year over year  This includes 4 4  growth in local currencies and 2  adverse impact from foreign currency exchange  At local currencies  internally generated sales increased 3 5  and acquisition growth was 0 9   Internal growth at local currencies included 4 7  improvement in North America and 1 6  growth internationally The company s global Animal Health segment witnessed a 1 9  rise in revenues to  899 3 million  This includes 3 4  growth in local currencies and 1 5  adverse impact from foreign currency exchange  At local currencies  internally generated sales inched up 1 1  and acquisition growth was 2 3   The internal growth in local currencies included 0 4  rise in North America and 1 8  improvement internationally Worldwide Medical revenues climbed 4 5  year over year to  721 9 million  Growth in local currencies was 4 5  Revenues from global Technology and Value added Services grew 32  to  143 9 million  This included 32 6  growth in local currencies and 0 6  decrease from adverse currency movements  Acquisitions contributed 24 8  in the quarter under review Margin Trend         Gross profit increased 6 3  to  888 6 million in the reported quarter  However  gross margin expanded 60 basis points  bps  from the year ago quarter to 27 1  despite a 2 6  escalation in cost of sales   Despite a 7 3  rise in selling  general   administrative expenses of  668 million  adjusted operating income improved 3 3  year over year to  220 6 million  Nonetheless  adjusted operating margin shrunk 10 bps year over year to 6 7  in the Sep end quarter Financial PositionHenry Schein exited the third quarter of 2018 with cash and cash equivalents of  119 7 million compared with  111 3 million at the end of second quarter 2018  For the first nine months of 2018  net operating cash flow was  390 8 million compared with  307 5 million in the year ago period During the quarter under review  Henry Schein repurchased 777 000 shares of its common stock for approximately  61 million  At the close of the third quarter  the company had  86 million authorized for repurchase of common stock 2018 Guidance ReiteratedThe company has reiterated its 2018 EPS guidance  It continues to expect EPS in the range of  4 06  4 14  reflecting 13 15  growth from the 2017 adjusted EPS figure of  3 60  The Zacks Consensus Estimate for 2018 adjusted EPS of  4 12 is within the guided range 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates 
VGM Scores
Currently  Henry Schein has a strong Growth Score of A  though it is lagging a lot on the Momentum Score front with a C  Charting a somewhat similar path  the stock was allocated a grade of B on the value side  putting it in the second quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of B  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of these revisions indicates a downward shift  Notably  Henry Schein has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2018-12-05,Zacks Investment Research,https://www.investing.com/analysis/henry-schein-hsic-up-3-since-last-earnings-report-can-it-continue-200365688,200365688
115843,337358,HSIC,Top Research Reports For Walmart  Comcast   ConocoPhillips ,opinion,"Tuesday  January 15  2018
The Zacks Research Daily presents the best research output of our analyst team  Today s Research Daily features new research reports on 16 major stocks  including Walmart  NYSE WMT   Comcast  NASDAQ CMCSA  and ConocoPhillips  NYSE COP   These research reports have been hand picked from the roughly 70 reports published by our analyst team today 
You can see 
Walmart s shares have performed nearly in line with the Zacks Supermarkets industry over the past six months   8 4  vs   8 1    due to its focus on strengthening e commerce and store operations  These factors helped the company retain its sturdy comps trend in third quarter fiscal 2019  wherein top and bottom lines improved year over year and the latter marked its third consecutive beat  
Notably  U S  comps rose for the 17th straight time  Further  e commerce sales surged  courtesy of strong Walmart com and online grocery performances  These factors encouraged management to raise view  The Zacks analyst likes Walmart s efforts to improve its International unit by shifting focus to profitable countries  
However  the company s investment in Flipkart is expected to dent the bottom line  Such investment costs and a compelling pricing strategy have been hurting Walmart s gross margin for a while  Nevertheless  the Flipkart deal bodes well for the long term and should help the company stand firm against Amazon  NASDAQ AMZN  
 You can   
Shares of Comcast have outperformed the Zacks Cable Television industry over the past year  losing  14 5  vs   18 3   The Zacks analyst thinks Comcast is benefiting from solid growth in residential high speed Internet customers  
Advertising revenues are also expected to grow due to higher spending on political advertising  Comcast s strategy to market broadband only packages to customers is likely to drive top line growth  Further  expanding Wi Fi coverage along with innovative xFi control features is improving customer experience  
Moreover  the company s Xfinity Mobile is now used by more than one million customers  Further  the Sky acquisition expands Comcast s international reach  Sky s content portfolio strength is a major growth driver  
Additionally  NBCUniversal s upcoming streaming service is a key catalyst  However  the company continues to lose voice and video subscribers due to cord cutting and stiff competition  Additionally  high debt level is a headwind 
 You can   
ConocoPhillips  shares are up  11 5  over the past year  outperforming the Zacks U S  Integrated Oil industry  which has lost  9 2  over the same period  In terms of production and proved reserves  ConocoPhillips is the largest oil and gas exploration and production  E P  player in the world  
Notably  there are significant opportunities for the upstream energy player in the Eagle Ford where it owns about 3 400 undrilled locations  The Zacks analyst thinks strong focus on two other prospective resources like Delaware basin and Bakken shale is likely to help ConocoPhillips achieve its target of more than 25  CAGR of production through 2017 to 2019 
However  rising production and operating costs are hurting the company s bottom line  Since a majority of ConocoPhillips  production comprises oil  the weak crude pricing scenario could hurt the company s operations 
 You can   
Other noteworthy reports we are featuring today include PayPal  PYPL   CME Group  NASDAQ CME  and CSX Corporation  NASDAQ CSX  
Looking for Stocks with Skyrocketing Upside 
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana      
Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look   

Mark VickerySenior Editor
Note  Sheraz Mian heads the Zacks Equity Research department and is a well regarded expert of aggregate earnings  He is frequently quoted in the print and electronic media and publishes the weekly and reports  If you want an email notification each time Sheraz publishes a new article  please 
Today s Must Read
Ecommerce Sales to Fuel Walmart  WMT   Soft Margins a Worry


High Speed Internet Subscriber Gains Benefit Comcast  CMCSA 


ConocoPhillips  COP  Banks on Bakken  Production Costs High


Featured Reports
Rising Transaction Fees Aid CME Group  CME   High Costs Ail
Per the Zacks analyst  CME Group is poised for growth banking on higher clearing and transaction fees plus access and communication fees and higher average daily volume  Higher costs are worrying 

Cost Cuts Buoy CSX Corporation  CSX   High Debt a Woe
The Zacks analyst likes the company s efforts to check costs  Improvement in operating ratio is a positive  However  high debt levels raise concerns 

Loan Growth Supports M T Bank s  NYSE MTB  Revenue  High Costs a Woe
Per the Zacks analyst  organic growth remains a key strength at M T Bank  as reflected by rising loans and deposits aiding revenue growth  However  high technology costs are a headwind 

D R  Horton  DHI  Banks on Solid Backlog  Gross Margin Soft
Per the Zacks analyst  D R  Horton is well positioned for 2019 given its solid backlog  well stocked supply of land  lots and homes 

Digital Dentistry Aids Henry Schein  NASDAQ HSIC  Amid Rising Costs
The Zacks analyst likes Henry Schein banking on digital dentistry and promoting digital workflows for general dentistry and dental specialties 

Supply Chain Strategy  Demand Aids Spirit AeroSystems  SPR 
Per the Zacks analyst  focus on executing supply chain strategy continues to be a vital growth driver for Spirit AeroSystems 

Asset Inflows  Acquisitions Aid Invesco  IVZ   Costs a Woe
Per the Zacks analyst  assets under management inflows and inorganic growth strategy will support Invesco s revenues 

New Upgrades
Southern  NYSE SO  Buoyed by AGL Acquisition  Steady Earnings
The Zacks analyst believes that the AGL Resources  NYSE GAS  buy has helped Southern to broaden its customer base and diversify business  Further  the long term power contracts should support steady earnings 

High Demand for On   Off Highway Products Aid Allison  ALSN 
Per the Zacks analyst  augmented demand for on and off highway products from global customers and price increases of certain products drive Allison s revenues 

U S  Cellular  USM  Rides on Strong Network  Customer Growth
Per the Zacks analyst  U S  Cellular s strategy to optimize customer additions while providing top quality network and national coverage for the best wireless experience bodes well for future growth 

New Downgrades
High Debt  Weather Dependence Ail Clearway Energy  CWEN 
Per the Zacks analyst Clearway Energy s high debt level is a concern  Renewable electricity generation is subject to weather conditions  which keeps on changing  adversely impacting production 

Lower than Expected Holiday Sales a Worry for Macy s  NYSE M 
Macy s posted weaker than expected sales for the holiday season  Per the Zacks analyst  this compelled management to curtail its sales and earnings outlook for fiscal 2018 

PayPal  PYPL  Hurt by Credit Portfolio Sale   Competition
Per the Zacks analyst  the sale of PayPal s U S  consumer credit receivables portfolio to Synchrony is negatively impacting top line growth  Also  rising competition from Square  NYSE SQ  poses a risk ",2019-01-14,Zacks Investment Research,https://www.investing.com/analysis/top-research-reports-for-walmart-comcast--conocophillips-200375767,200375767
115869,337384,HSIC,What s In The Offing For Thermo Fisher  TMO  In Q1 Earnings ,opinion,Thermo Fisher Scientific Inc    NYSE TMO   is slated to report first quarter 2018 results before the market opens on Apr 25  Last quarter  the company delivered a positive earnings surprise of 4 89   Moreover  Thermo Fisher has surpassed estimates in all the trailing four quarters with an average beat of 3 08  Let s see  how things are shaping up for this announcement Key CatalystsThermo Fisher has been going strong across its analytical instrument businesses with increasing global demand  Particularly  the company s acquisition of FEI has been largely contributing to its analytical instruments portfolio over the past year  The buyout has enabled Thermo Fisher to access FEI s industry leading high performance electron microscopy platform used for protein study as well as facilitating life science research  This is also a vital highlight of the quarter to be reported Thermo Fisher anticipates realizing total synergies of approximately  80 million by the end of three years following the deal s closure with about  55 million of cost synergies and roughly   25 million of adjusted operating income benefits from revenue related synergies Thermo Fisher Scientific Inc  Price and EPS Surprise    Following the completion of the deal  the company has launched a host of products and expanded its Thermo Scientific Helios G4 DualBeam platform within the scope of material science applications  This should also get reflected in first quarter 2018 performance Apart from FEI related development  another notable unveiling in the company s Analytical Instruments business is its new line of Thermo Scientific air quality monitors called the iQ Series  This platform includes mobile applications for remote monitoring and control as well as wireless connectivity and enhanced services  This in turn is likely to contribute to the company s top line in the yet to be reported quarter Overall  the Waltham MA based company is gearing up for yet another quarter of strong analytical instruments segmental growth  In the period to be reported  Thermo Fisher expects to see a positive impact from the electron microscopy business as well as a robust volume expansion plus productivity The Zacks Consensus Estimate for Analytical Instruments revenues is pegged at  1 138 billion  higher than the year ago figure of  1 05 billion Here are other factors that might influence Thermo Fisher s first quarter results The company s focus to boost growth through implementation of strategies and consolidating its product offerings is encouraging  These initiatives are likely to help it post impressive results in the first quarter The company had spent  900 million on research and development in 2017 and the same trend is continuing through 2018  We expect all innovations and product introductions to substantially drive the company s top line in the first quarter itself The company s aim to expand capabilities in the fast growing Asia Pacific zone as well as the emerging markets should also leads to solid results  Recent standout contributors are China  India and South Korea  With strategic investments to support key customer applications  Thermo Fisher forecasts to maintain a bullish momentum for 2018 Moreover  growth is estimated in applied markets such as environmental and food safeties apart from life science  In addition  the company is betting on some key areas under focus with enormous opportunities at its disposal including advancing precision medicines from mass spectrometry to the targeted gene sequencing and structural biology  However  we are apprehensive about Thermo Fisher facing a foreign exchange headwind on 2018 revenues and adjusted EPS  Also  a hostile macroeconomic condition continues to weigh heavily on the stock  Plus  stiff competition consistently poses challenges to the stock s value Here s What the Quantitative Model Predicts Per the proven Zacks model  a company with a favorable Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  has good chances of beating estimates if it also has a positive  Thermo Fisher has a Zacks Rank  3  which increases the predictive power of ESP and an Earnings ESP of  1 29   which leaves surprise prediction inconclusive  This is because a company needs positive ESP to be confident about an earnings surprise  Thus this combination does not suggest that the stock is likely to beat on earnings this quarter We caution against the Sell rated stocks   4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions You can uncover the best stocks to buy or sell before they re reported with our  Stocks to ConsiderHere are a few medical stocks worth considering with the right combination of elements to outpace expectations this time around Myriad Genetics  Inc    NASDAQ MYGN   has an Earnings ESP of  0 61  and a Zacks Rank  2  You can see  Henry Schein  Inc    NASDAQ HSIC   has an Earnings ESP of  3 34  and a Zacks Rank of 3 Quest Diagnostics Incorporated   NYSE DGX   has an Earnings ESP of  3 19  and is a Zacks  3 Ranked player Investor Alert  Breakthroughs PendingA medical advance is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating substantial revenue  and even more wondrous products are in the pipeline Cures for a variety of deadly diseases are in sight  and so are big potential profits for early investors  Zacks names 5 stocks to buy now ,2018-04-15,Zacks Investment Research,https://www.investing.com/analysis/whats-in-the-offing-for-thermo-fisher-tmo-in-q1-earnings-200305856,200305856
115870,337385,HSIC,Can S E T  Aid Zimmer  ZBH  Q1 Earnings Despite Supply Woes ,opinion,Zimmer Biomet Holdings  Inc    NYSE ZBH   is set to report first quarter 2018 results on Apr 26  before the markets open Last quarter  the company posted earnings in line with the Zacks Consensus Estimate  However  Zimmer Biomet missed the consensus mark in two of the preceding four quarters  the average being 0 29    Let s take a look at how things are shaping up prior to this announcement Key CatalystsThe company is expected to report strong topline numbers within its S E T   Surgical  Sports Medicine  Foot and Ankle  Extremities and Trauma  arm in the to be reported period  Last quarter  revenues at S E T  were driven by solid quarterly sales of the company s surgical portfolio  Also  within upper extremities business  the company saw solid demand for a comprehensive shoulder line In this regard  we note that since last November  the company has received several FDA clearances within S E T  and is particularly  excited about the approval of the Sidus Stem Free Shoulder system  We expect all these developments to significantly contribute to the company s top line in the first quarter itself Zimmer Biomet Holdings  Inc  Price and EPS Surprise    On the flip side  the company s business within S E T has been in the recent past  massively ailed by supply issues and a continued pricing pressure The Zacks Consensus Estimate of  435 million for S E T  revenues reflects a decline of 4 2  from the last quarter We are also upbeat about the Spine  Craniomaxillofacial and Thoracic  Spine   CMF  segment  which is expected to deliver another quarter of promising performance  Under the spine category  Zimmer Biomet should continue to gain from a strong uptake of Mobi C Cervical Disc  Also  we are looking forward to top line contributions from the company s recent launch of products like the Avenue T TLIF Cage and Vitality   and Vital Spinal Fixation Systems in the United States However  we are apprehensive about the ongoing revenue dissynergies related to the company s U S  spine sales force integration  Although Zimmer Biomet is working to resolve the impact of these dissynergies  chances of any near term resolution are bleak The Zacks Consensus Estimate of  186 million for Spine revenues indicates a 4 1  decrease from the year ago quarter Overall  first quarter revenues are projected at  2 03 billion  up 0 9  sequentially Other factors likely to influence Zimmer Biomet s first quarter results are Looking at the focused execution of Zimmer Biomet s sales teams  we expect the global adoption rate of the flagship personalized knee system   Persona   to be impressive  We are also enthusiastic about the launch of the Persona Partial Knee System last September  The knee system marked the latest addition to the company s portfolio of personalized and anatomically designed knee implant systems The Zacks Consensus Estimate of  700 million for Knee revenues registers a 4 2  reduction from the last quarter Within Hip business  we expect the company to once again demonstrate a sturdy performance in the Asia Pacific region  Notably  in the previous quarter  the company registered double digit sales growth within Hip in the aforementioned geography  The company is anticipated to produce improved quarterly sales from Taperloc G7 and Arcos systems  However  like all other segments  supply constraints should continue to limit Zimmer Biomet s ability to meet demand of these high growth brands The Zacks Consensus Estimate of  478 million for Knee revenues represents a 4 2  dip from the last quarter Emerging markets have always been a significant revenue generating source for Zimmer Biomet  Despite the recent economic downturn in Latin America  the company managed to drive growth through its operations in the other emerging markets  especially the Asia Pacific and EMEA  Europe  the Middle East and Africa  zones  The Zacks Consensus Estimate for first quarter revenues from EMEA of  477 million denotes an improvement of 0 8  from the last quarter However  the Zacks Consensus Estimate for revenues of  300 million from APAC in the quarter to be reported translates into a 6 5  fall from the last quarter  We believe  macroeconomic uncertainties and unfavorable currency fluctuations have been denting the company s sales for over the past few quarters  The company has also been burdened with pricing woes As a result  Zimmer Biomet struggled with a negative pricing pressure of approximately 2 5  in 2017  In absence of any favorable changes on these lines  these headwinds might be mirrored in the company s first quarter results Here s what our quantitative model predicts Per the proven Zacks model  a company with a favorable Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  has good chances of beating estimates if it also has a positive  Zimmer Biomet has a Zacks Rank  4  which lowers the predictive power of ESP and an Earnings ESP of  0 57   We caution against the Sell rated stocks  4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions  Therefore  the combination does not suggest that the company is likely to beat on earnings this quarter You can uncover the best stocks to buy or sell before they re reported with our  Stocks to ConsiderHere are a few medical stocks worth considering with the right combination of elements to beat estimates this time around Myriad Genetics  Inc    NASDAQ MYGN   has an Earnings ESP of  0 61  and a Zacks Rank  2  You can see  Henry Schein  Inc    NASDAQ HSIC   has an Earnings ESP of  3 34  and a Zacks Rank  3 Quest Diagnostics Incorporated   NYSE DGX   has an Earnings ESP of  3 19  and is a Zacks  3 Ranked player Investor Alert  Breakthroughs PendingA medical advance is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating substantial revenue  and even more wondrous products are in the pipeline Cures for a variety of deadly diseases are in sight  and so are big potential profits for early investors  Zacks names 5 stocks to buy now ,2018-04-15,Zacks Investment Research,https://www.investing.com/analysis/can-set-aid-zimmer-zbh-q1-earnings-despite-supply-woes-200305855,200305855
115871,337386,HSIC,Company News For Apr 24  2018,opinion,Alaska Air Group  Inc  s   NYSE ALK    shares rose 5 7  after reporting first quarter 2018 earnings of  0 14 per share  surpassing the Zacks Consensus Estimate of  0 11 per shareShares of Associated Banc Corp   NYSE ASB   increased 0 2  after reporting first quarter 2018 adjusted earnings of  0 50 per share  surpassing the Zacks Consensus Estimate of  0 41 per shareHenry Schein  Inc  s   NASDAQ HSIC   shares rose 6 8  on news that the company will spin off its animal health business in order to merge it with Vets First ChoiceShares of Humana Inc   NYSE HUM   increased 0 1  after the health insurer announced that it will enter into a partnership with a privately equity consortium in order to buy Curo Health Services  a privately held hospice facility provider  for  1 4 billion ,2018-04-23,Zacks Investment Research,https://www.investing.com/analysis/company-news-for-apr-24-2018-200308373,200308373
115872,337387,HSIC,Should First Trust NASDAQ 100 Equal Weighted Index Fund  QQEW  Be On Your Investing Radar ,opinion,"The First Trust NASDAQ 100 Equal Weighted Index Fund  QQEW  was launched on 04 19 2006  and is a passively managed exchange traded fund designed to offer broad exposure to the Large Cap Growth segment of the US equity market 
The fund is sponsored by First Trust Advisors  It has amassed assets over  547 47 M  making it one of the average sized ETFs attempting to match the Large Cap Growth segment of the US equity market 
Why Large Cap Growth
Companies that find themselves in the large cap category typically have a market capitalization above  10 billion  Considered a more stable option  large cap companies boast more predictable cash flows and are less volatile than their mid and small cap counterparts 
Qualities of growth stocks include faster growth rates compared to the broader market  as well as higher valuations and higher than average sales and earnings growth rates  Something to keep in mind is the higher level of volatility that is affiliated with growth stocks  They are likely to outperform value stocks in strong bull markets but over the longer term  value stocks have delivered better returns than growth stocks in almost all markets 
Costs
When considering an ETF s total return  expense ratios are an important factor  and cheaper funds can significantly outperform their more expensive counterparts in the long term if all other factors remain equal 
Annual operating expenses for this ETF are 0 60   putting it on par with most peer products in the space 
It has a 12 month trailing dividend yield of 0 45  
Sector Exposure and Top Holdings
While ETFs offer diversified exposure  which minimizes single stock risk  a deep look into a fund s holdings is a valuable exercise  And  most ETFs are very transparent products that disclose their holdings on a daily basis 
This ETF has heaviest allocation to the Information Technology sector  about 42  of the portfolio  Consumer Discretionary and Healthcare round out the top three 
Looking at individual holdings  Shire Plc  LON SHP   adr   SHPG  accounts for about 1 24  of total assets  followed by Ulta Beauty  Inc   ULTA  and Henry Schein  Inc   NASDAQ HSIC  
The top 10 holdings account for about 11 49  of total assets under management 
Performance and Risk
QQEW seeks to match the performance of the NASDAQ 100 Equal Weighted Index before fees and expenses  The NASDAQ 100 Equal Weighted Index is the equal weighted version of the NASDAQ 100 Index which includes 100 of the largest non financial securities listed on NASDAQ based on market capitalization 
The ETF has added roughly 3 91  so far this year and was up about 15 99  in the last one year  as of 05 18 2018   In the past 52 week period  it has traded between  52 79 and  63 23 
The ETF has a beta of 1 14 and standard deviation of 15 67  for the trailing three year period  making it a medium risk choice in the space  With about 103 holdings  it effectively diversifies company specific risk 
Alternatives
First Trust NASDAQ 100 Equal Weighted Index Fund carries a Zacks ETF Rank of 3  Hold   which is based on expected asset class return  expense ratio  and momentum  among other factors  Thus  QQEW is a good option for those seeking exposure to the Large Cap ETFs area of the market  Investors might also want to consider some other ETF options in the space 
The iShares Russell 1000 Growth ETF  IWF  and the PowerShares QQQ  QQQ  track a similar index  While iShares Russell 1000 Growth ETF has  41 55 B in assets  PowerShares QQQ has  62 48 B  IWF has an expense ratio of 0 20  and QQQ charges 0 20  
Bottom Line
Retail and institutional investors increasingly turn to passively managed ETFs because they offer low costs  transparency  flexibility  and tax efficiency  these kind of funds are also excellent vehicles for long term investors 
To learn more about this product and other ETFs  screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe  please visit  ",2018-05-17,Zacks Investment Research,https://www.investing.com/analysis/should-first-trust-nasdaq100-equal-weighted-index-fund-qqew-be-on-your-investing-radar-200317531,200317531
115901,337416,HSIC,Henry Schien To Distribute Grifols Product In United States,opinion,Henry Schein  Inc  s   NASDAQ HSIC   latest deal with Grifols   NASDAQ GRFS   adds stimulus to its distribution business  Both companies have signed a distribution agreement  enabling the former to market and distribute the latter s 500mL Normal Saline solution  0 9  Sodium Chloride Injection  USP  in U S  market Notably  Grifols is a leading producer of plasma derived medicines and a forerunner in the research and development of therapeutic alternatives  The company manufactures this 500mL Normal Saline solution at its industrial complex in Murcia  Spain  and received the FDA approval to market the product in the United States Only last year With growing demand for saline products in the U S  market  we believe this partnership will be strategically beneficial for Henry Schein  Per the company  this solution by Grifols has capacity to quickly meet its customers  needs during the shortage of IV solutions Both companies can gain an impetus from the global supply infrastructure as well as Henry Schein s widespread network In this regard  we note that Henry Schein s distribution business boasts a broad global footprint with 61 distribution centers located all over  Apart from North America and Europe  the company has presence across Australia and New Zealand as well as in the emerging markets like China  Brazil  Israel  Czech Republic and Poland being the latest target hub Grifols apart  the company s significant distribution partners are Terason and DENTSPLY SIRONA  While Henry Schein exclusively distributes Terason s uSmart 3200T NexGen  its Canadian dental subsidiary distributes the entire DENTSPLY SIRONA product line Share Price Movement Over the past three months  shares of Henry Schein have underperformed the  it belongs to  The stock has lost 2 3  in contrast to the industry s 3 3  gain  We expect this latest development to help boost investors  confidence in the stock Zacks Rank   Key PicksHenry Schein carries a Zacks Rank  3  Hold   Two better ranked stocks in the broader medical sector are Bio Rad Laboratories   NYSE BIO    and PerkinElmer   NYSE PKI   Bio Rad Laboratories sports a Zacks Rank  1  Strong Buy   You can see  The company has a long term expected earnings growth rate of 20  PerkinElmer has a long term expected earnings growth rate of 12 3   The stock carries a Zacks Rank  2  Buy  Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-03-05,Zacks Investment Research,https://www.investing.com/analysis/henry-schien-to-distribute-grifols-product-in-united-states-200296072,200296072
115902,337417,HSIC,Henry Schein  HSIC  Down 3 3  Since Earnings Report  Can It Rebound ,opinion,"It has been about a month since the last earnings report for Henry Schein  Inc    NASDAQ HSIC    Shares have lost about 3 3  in that time frame 
Will the recent negative trend continue leading up to its next earnings release  or is HSIC due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important drivers 
Recent EarningsHenry Schein reported adjusted earnings per share  EPS  of 97 cents in the fourth quarter of 2017  up 3 2  year over year  Adjusted EPS remained in line with the Zacks Consensus Estimate  The year over year upside in earnings was driven by strong revenue growth across all the business segments Adjusted EPS for the year 2017 was  3 60  an 8 8  improvement from the year ago period  This also remains in line with the Zacks Consensus Estimate Revenues in DetailHenry Schein reported net sales of  3 32 billion in the fourth quarter  up 6 4  year over year and marginally above the Zacks Consensus Estimate of  3 30 billion  The year over year improvement came on the back of 5 1  internal sales growth in local currencies and 2 4  increase owing to foreign currency exchange  Acquisition growth was 4  in the quarter Net sales for the full year were  12 46 billion  a 7 7  improvement from the year ago number  The top line also exceeded the Zacks Consensus Estimate of  12 44 billion In the fourth quarter  the company recorded sales of  2 19 billion in the North American market  up 3 1  year over year  Sales totaled  1 13 billion in the international market  up 13 1  year over year Segment Analysis    Henry Schein derives revenues from four operating segments  Dental  Medical  Animal Health  and Technology and Value added services In the fourth quarter  the company derived  6 05 billion in revenues from global Dental sales  up 8 9  year over year  This includes 7 9  growth in local currencies and 1  contribution from foreign currency exchange  At local currencies  internally generated sales increased 3  and acquisition growth was 6 3  The quarterly result also had a negative impact of 5 1  from an additional week in the year ago period   Internal growth at local currencies included 6 7  growth in North America and 0 1  rise internationally The company s global Animal Health segment witnessed 6 2  rise in revenues to  889 8 million  This includes 3  growth in local currencies and 3 2  increase from foreign currency exchange  At local currencies  internally generated sales increased 4 5  and acquisition growth was 3 7   One extra week in 2016 had a 5 2  negative impact on the quarterly sales performance  The internal growth in local currencies included 6  rise in North America and 2 9  improvement internationally Worldwide Medical revenues rose 2 6  year over year to  636 9 million  Growth in local currencies was 2 3   with a 0 3  increase owing to favorable foreign exchange Revenues from global Technology and Value added Services grew 2 1  to  114 6 million  This included 1  growth in local currencies and a 1 1  rise related to foreign currency exchange  Acquisitions contributed 0 6  in the quarter under review Margin Trend         Gross profit increased 4 8  to  900 9 million in the reported quarter  However  gross margin contracted 39 basis points  bps  from the year ago quarter to 27 2  due to a 6 9  rise in cost of sales  higher than the revenue growth rate   Despite a 4 8  rise in selling  general   administrative expenses of  659 8 million  adjusted operating income improved 4 8  year over year to  241 2 million  However  adjusted operating margin declined 10 bps year over year to 7 3  in the reported quarter Financial PositionHenry Schein exited the year 2017 with cash and cash equivalents of  174 7 million  compared with  62 4 million at the end of 2016  Full year net cash provided by operating activities was  238 million  compared with  264 5 million in the year ago period During the quarter under review  the company bought back approximately 3 2 million shares for almost  225 million  At the close of the fourth quarter  the company had  200 million authorized for repurchase of common stock 2018 GuidanceHenry Schein raised its 2018 EPS guidance to reflect the impact of U S  tax reform legislation  including the estimated 2 cents impact associated with certain one time cash bonus  The company currently expects EPS in the range of  4 03  4 14  reflecting 57 61  growth from the 2017 reported EPS figure of  2 57  The previous 2018 EPS guidance range was  3 85  3 96  The Zacks Consensus Estimate for 2018 adjusted EPS is  3 95  below the guided range 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates  There have been three revisions higher for the current quarter compared to six lower 
Henry Schein  Inc  Price and Consensus
    VGM Scores
At this time  HSIC has a nice Growth Score of B  however its Momentum is doing a bit better with an A  Following the exact same course  the stock was also allocated a grade of A on the value side  putting it in the top 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of A  If you aren t focused on one strategy  this score is the one you should be interested in 
Based on our scores  the stock is equally suitable for value and momentum investors while growth investors may want to look elsewhere 
Outlook
Estimates have been broadly trending downward for the stock and the magnitude of these revisions indicates a downward shift  Interestingly  HSIC has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2018-03-21,Zacks Investment Research,https://www.investing.com/analysis/henry-schein-hsic-down-33-since-earnings-report-can-it-rebound-200299970,200299970
115903,337418,HSIC,Will Walgreens   WBA  Q2 Earnings Gain From Overall Growth ,opinion,"Walgreens Boots Alliance  Inc    NASDAQ WBA   is slated to release second quarter fiscal 2018 results before the market opens on Mar 28 Last quarter  the company had delivered a positive earnings surprise of 0 79   It is noteworthy that Walgreens Boots has outperformed the Zacks Consensus Estimate in three of the preceding four quarters with an average positive earnings surprise of 2 43   Let s take a look at how things are shaping up prior to this announcement Key CatalystsOver the recent past  we have observed Walgreens Boots  Retail Pharmacy USA division to witness comparable prescription growth and benefit from strength in retail prescription market  Several planned developments  early benefits of new pharmacy contracts as well as an increase in volume owing to previously announced pharmacy partnerships have been driving growth in this space over the past few quarters  Moreover  rising expenditure on prescription drugs and growing demand for specialty drugs have been strengthening the retail pharmacy market Meanwhile  during first quarter fiscal 2018  the company exceeded 1 billion scripts on a 30 day adjusted and rolling annual basis for the first time  touching a new milestone Furthermore  the company s efforts to boost its digital capabilities have started paying off  In this regard  more than 20  of the company s retail refill scripts were initiated through digital channels with the Walgreens  mobile app  having been downloaded in excess of 50 million times since the launch We are also encouraged by the increase in sales at the Retail Pharmacy International segment  Furthermore  the company has been gaining on account of the company s strategic tie ups  which brought more patients to its U S  pharmacies 
Walgreens Boots Alliance  Inc  Price and EPS Surprise
     Meanwhile  strong market growth in certain emerging markets drove the company s Pharmaceutical Wholesale division s solid performance in the first quarter fiscal 2018  We expect these trends to get reflected in fiscal second quarter 2018 results  as well The Zacks Consensus Estimate for total revenues of  31 99 billion reflects an 8 6  rise on a year over year basis Also  we are upbeat about the company expanding its global footprint with its decision to acquire 40  stake in Sinopharm Holding Guoda Drugstores Co   Ltd   GuoDa   a subsidiary of China National Accord Medicines Corporation Ltd  On completion  this investment should provide a strong impetus to Walgreens Boots  worldwide retail pharmacy business  Notably  Shanghai based GuoDa is a large national pharmacy chain in China  It is the retail pharmacy platform of China National Pharmaceutical Group Corporation   CNPGC   Moreover  the company s acceptance of the proposal to sell part of its investment in its Chinese wholesale partner Guangzhou Pharmaceuticals Corporation for huge cash returns buoys optimism We are also upbeat about Walgreens Boots  plans to expand its existing group purchasing efforts with Express Scripts Holding Company  NASDAQ ESRX   to ensure availability of specialty brand drugs  Since biosimilars have the potential to lower production costs  the move is considered to be a prudent and timely one On the flip side  Walgreens Boots  gross margin figures continued to contract in the last reported quarter as well  Lower pharmacy margins in the U K   reflecting the reduction in funding  led to the downside  However  the company is working tirelessly to increase efficiency and provide high quality and cost effective pharmacy services  in order to reduce overall pharmacy cost Here is what our quantitative model predicts Walgreens Boots has the right combination of two main ingredients   a positive  and a Zacks Rank  3  Hold  or higher   needed for increasing the odds of an earnings beat Zacks ESP  The Earnings ESP for Walgreens Boots is  2 46   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Walgreens Boots carries a Zacks Rank  2  Buy  The Zacks Consensus Estimate for earnings of  1 55 reflects a 13 9  rise on a year over year basis Other Stocks Worth a LookHere are a few other medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter Edwards Lifesciences Corporation   NYSE EW   has an Earnings ESP of  0 07  and a Zacks Rank  2  You can see  Align Technology  Inc    NASDAQ ALGN   has an Earnings ESP of  1 99  and a Zacks Rank  3 Henry Schein   NASDAQ HSIC   has an Earnings ESP of  2 35  and a Zacks Rank  3 5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ",2018-03-25,Zacks Investment Research,https://www.investing.com/analysis/will-walgreens-wba-q2-earnings-gain-from-overall-growth-200300708,200300708
115904,337419,HSIC,Dental Implant   Prosthetic Boom Puts Spotlight On 3 Stocks,opinion,In recent years  growing healthcare cognizance has led to continuous technological innovation in the dental equipment space  With time  it has emerged as the most favored sector for medical device investors looking for consistent and attractive returns  Let s delve deeper Over the last 10 years  the has been faring better than the S P 500 index  The market has gained 119 8  eclipsing the broader market s 101 4  Per a Allied Market Research report  the global dental implants and prosthetics market is expected to catapult to a value of  12 743 million by 2023  at a CAGR of 8 8  from 2017 to 2023  And if we go by the estimates of the American Dental Association  published in Grand View Research   every year 5 million implants are carried out in the United States indicating huge market potential  In today s fast paced times  implants are preferred over conventional removable dentures owing to comfort and convenience Factors Driving Demand for Dental TreatmentHigh Demand Among Children and Teenagers  Per a Markets and Markets report  children and teenagers are expected to dominate the global orthodontic market in the coming years  A high number of patients with malocclusions and jaw disorders are likely to drive the demand  Also  rising need for fixed braces among children and teenagers will act as a major demand propeller  Notably  orthodontic treatments are more effective and successful in childhood or teenage One of the noteworthy developments in this niche space is the launch of Align Technology s clear Aligner solution for teen Class II correction   the Invisalign Technology Teen with mandibular advancement   in certain markets of Canada  EMEA and APAC in 2017 Cosmetic Needs  Growing awareness esthetic needs has also been a major growth catalyst for the dental prosthetic market  Per Markets and Markets  global cosmetic dentistry is expected to make  22 362 4 million by 2020  at a CAGR of 6 8  during 2015 2020  Moreover  an increase in disposable income gives rise to higher demand for cosmetic dental surgeries Rise in Geriatric Population  An aging population has also been a significant contributor  Higher incidence of calcium deficiency in older people leads to teeth loss  According to the National Institute of Dental and Craniofacial research  more than 24  of adults aged above 74 years have lost all teeth  People on medication for chronic and metabolic disorders also reach an edentulous state Other Factors  Poor lifestyle choices and unhygienic dental care lead to higher demand for dental procedures  Increased dental diseases are another factor  Also  dental injuries caused by road accidents lead to higher demand for dental implants and prosthetics Technological Advancement Shapes Dental Implant MarketThe global dental implant and prosthetic market is gradually shifting from conventional to a technologically advanced one  Laser dentistry is much in demand among dental patients because of its painless procedurefor extraction of teeth  orthodontics and periodontal decay  Per Markets and Markets  the dental lasers market is expected to scale to a value of  224 7 million by 2020  at a CAGR of 5 2  during 2015 to 2020 Dental 3D printing is a process of creating three dimensional solid dental models such as implants  surgical guides  braces  dentures  crowns and bridges  etc  Notably  3D printing is gaining popularity as it allows dentists to carry out procedures with more precision and efficiency  saving patients from excess trauma   Going by a report by Transparency Market Research  the global dental 3D printing market is expected to see a 16 5  CAGR from 2017 to 2025  reaching a worth of  3 427 1 million 3 Stocks in FocusWe have selected three companies  which we believe are well poised to provide impressive long term returns given the encouraging growth prospects of the global dental implants and prosthetics market Align Technology  Inc    NASDAQ ALGN   has a long term earnings growth rate of 29 2    The current quarter estimate revision trend for the stock has been encouraging with seven estimates moving upward  compared with one downward movement in the past two months  Resultantly  the Zacks Consensus Estimate for earnings per share rose around 2  to  4 52  The company s five year historical growth rate is favorable at 25 5  compared with the industry s 6 2  and the S P 500 s 2 8   The company s share price movement over the past year has been encouraging  The company yielded almost 129 6   better than the  s 5 1   Align Technology recently signed an agreement with Glidewell Dental to distribute the iTero Element intraoral scanning system with the latest glidewell io In Office Solution in North America Henry Schein  Inc    NASDAQ HSIC   has a long term earnings growth rate of 9 9   The company s historical five year earnings growth rate of 10  compares favorably with the S P 500 s 2 8  and industry s 6 2   Over the past month  shares of Henry Schein have outperformed the  it belongs to  The stock has lost 0 9  compared with the industry s fall of 5 1   Estimate revisions for the current year have been solid with nine estimates north  compared to three moving south over the past two months  Resultantly  the consensus estimate for earnings climbed around 3 3  to  4 08 Riding on the strength in the full range of the DENTSPLY SIRONA Inc    NASDAQ XRAY   line  the company has been gaining from solid uptake of products by key dental equipment manufacturers like A dec  Midmark and 3Shape  Furthermore  management believes that the company is well positioned to gain from the wave of digitalization Danaher Corporation   NYSE DHR   has a long term earnings growth rate of 10 9   Estimate revisions for the current year have been solid with nine estimates moving up  compared to no movement in the opposite direction over the past two months  Resultantly  the consensus estimate for earnings rose around 1 2  to  4 38  The company s five year historical growth rate of 5 1  is higher than 2 8  of both the industry and the S P 500 Shares of the company have rallied 14 3  in the past year  outperforming the  s decline of 13 9  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-03-26,Zacks Investment Research,https://www.investing.com/analysis/dental-implant--prosthetic-boom-puts-spotlight-on-3-stocks-200301122,200301122
115905,337420,HSIC,Will Buyouts Help Quest Diagnostics  DGX  Beat Q1 Earnings ,opinion,Quest Diagnostics Inc    NYSE DGX   is scheduled to report first quarter 2018 earnings performance before the opening bell on Apr 19 Last quarter  the company s earnings surpassed the Zacks Consensus Estimate by a penny  delivering a positive surprise of 0 73   Also  the metric outperformed the consensus mark in all the trailing four quarters with an average beat of 6 83  Let s take a look at how things are shaping up prior to this announcement Factors at PlayOn a positive note  Quest Diagnostics seems well aligned with its two point growth agenda to accelerate growth and drive operational excellence Per its new long term growth outlook  beyond 2017   revenue increase for the period 2017 2020 is expected to be 3 5  with 1 2  growth projected from acquisitions  Earnings for the period are anticipated to rise faster than revenues in the mid to high single digit range The company estimates revenue growth for the period 2017 2020 at 3 5    Per the company  its increasing number of partnerships with other health care leaders and strategic acquisitions is creating promising opportunities for the top and bottom line growth while improving the patient experience and reducing the overall cost of care In this regard  we take a note of two recent strategic M As by Quest Diagnostics  First  the acquisition of Cleveland HeartLab  which should help strengthen the company s position in the New York metropolitan marketplace  Second  the buyout of Mobile Medical Examination Service MedXM  which should fortify Quest Diagnostics  mobile provider capabilities and population health management solutions for health plans  These two transactions should garner favorable results in the yet to be reported quarter Quest Diagnostics Incorporated Price and EPS Surprise    We are also optimistic about the company s successful execution of its strategy to build esoteric testing business as well as boost profitable growth Additionally  Quest Diagnostics has recently witnessed a significant improvement via infectious disease testing  prescription drug monitoring and industry leading wellness business  Therefore we expect these growth drivers to replicate the company s success story in its upcoming quarterly results  having thus remained active throughout  Also  the performance is likely to drive the same primary metrics like the preceding quarter We strongly believe all these recent developments to have significantly contributed to the company s top line in the first quarter The company expects 2018 revenues in the range of  7 7  7 77 billion  annualized growth of 4 5    The Zacks Consensus Estimate for revenues is pegged at  7 94 billion  ahead of the company s projected range Excluding the impact of special items  amortization expense and ETB  excess tax benefit associated with stock based compensation   adjusted EPS for the full year is projected in the band of  6 50  6 70  The Zacks Consensus Estimate of  6 10 falls below this guided range On the flip side  after a phase of continual drag for several quarters in the company s revenue per requisition performance  the last three quarters saw a slight rebound  However  it still remains to be seen if this upside is here to stay or not The company s two Professional Lab Services engagements   WJ Barnabas Health and HealthONE System of HCA Holdings  Inc   HCA    also carry lower revenue per requisition due to the nature of work Further  we should take into consideration the persistent headwind of unit price  which was moderately down in less than 100 basis points  Excluding the impact of Protecting Access to Medicare Act of 2014  PAMA   the company expects unit price headwinds in 2018 to remain below 100 basis points with PAMA adding an extra headwind of approximately 50 basis points to it  This should also get reflected in the first quarter results Overall  we believe that lack of employment and slow growth of commercially insured lives will continuously affect the company s volumes  measured by the number of requisitions  till the economy turns around for better What Our Model SuggestsPer the proven Zacks model  a company with a favorable Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  has good chances of beating estimates if it also has a positive  Quest Diagnostics has a Zacks Rank  3  which increases the predictive power of ESP and an Earnings ESP of  3 19   which raises confidence about a positive surprise  Together  the combination suggests that the company is likely to beat on earnings this quarter Conversely  we caution against the Sell rated stocks   4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions You can uncover the best stocks to buy or sell before they re reported with our  Other Stocks Worth a LookHere are a few other medical stocks worth considering with the right combination of elements to surpass estimates this time around Abaxis  Inc    NASDAQ ABAX   has an Earnings ESP of  1 56  and a Zacks Rank  2  You can see  Abbott Laboratories   NYSE ABT   has an Earnings ESP of  0 89  and a Zacks Rank of 3 Henry Schein   NASDAQ HSIC   has an Earnings ESP of  3 34  and is a Zacks  3 Ranked player Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-04-09,Zacks Investment Research,https://www.investing.com/analysis/will-buyouts-help-quest-diagnostics-dgx-beat-q1-earnings-200304405,200304405
115906,337421,HSIC,Can Steady Overall Growth Drive Abbott s  ABT  Q1 Earnings ,opinion,"Abbott   NYSE ABT   is slated to report first quarter 2018 results  before the market opens on Apr 18  Last quarter  the company s earnings per share exceeded the Zacks Consensus Estimate by 1 4   Moreover  Abbott has delivered positive earnings surprises in the trailing four quarters  the average beat being 4 5   Let s see how things are shaping up for this announcement Factors at PlayOver the past few quarters  Abbott has been on a healthy growth trajectory inthe Medical Devices business  The company has been hogging the limelight for developments in the flagship  sensor based continuous glucose monitoring  CGM  system   FreeStyle Libre System  Notably  the FreeStyle Libre system is partially or fully covered in 21 countries  including France  Germany and Japan Historically  the company has been witnessing solid growth in the global Diabetes Care business  primarily on the back of contributions from FreeStyle Libre  This apart  investors are confident about Abbott s developments in other businesses which form part of the Medical Devices segment  The Zacks Consensus Estimate for Medical Devices revenues of  2 68 billion indicates a rise of 11 7  from the year ago quarter Similar to the prior quarter  Abbott is expected to gain from strong performance by the Established Pharmaceuticals Division   EPD   business  which has been recording operational sales growth in the last few quarters  Management expects high single digit sales growth in the first quarter of 2018  Furthermore  the Zacks Consensus Estimate for EPD revenues of  1 09 billion shows a rise of 14 7  from the year ago quarter 
Abbott Laboratories Price and EPS Surprise
    We are also upbeat about the Diagnostics business which has been going strong on solid contributions from all sub segments   Core Laboratories Diagnostics  Molecular Diagnostics and Point of Care  Moreover  synergies from the Alere buyout  in the form of revenues from Rapid Diagnostics  have been benefiting the company Moreover  management expects Rapid Diagnostics to contribute around  5 million in the first quarter  The Zacks Consensus Estimate for Diagnostic revenues of  1 76 billion shows a rise of 51 7  from the year ago quarter We encouragingly note that Nutrition is Abbott s fastest growing business  courtesy of an aging population  increasing rate of chronic diseases and the rise of the middle class in the emerging markets  Furthermore  Abbott s pediatric nutrition business continues to be strong in the United States  Thus  the Zacks Consensus Estimate for Nutrition revenues of  1 73 billion indicates a rise of 5 5  from the year ago quarter Favorable currency translation also had a positive impact of 2  on total revenues in the last reported quarter  We encouragingly note that management expects foreign exchange to boost results in the to be reported quarter  driving the top line by 3 5  Overall  first quarter total revenues are projected at  7 26 billion  up 14 5  from the prior year quarter What Our Model SuggestsAccording to the Zacks model  a company with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  has a good chance of beating estimates if it also has a positive   You can uncover the best stocks to buy or sell before they re reported with our  Abbott has a Zacks Rank  3 and an Earnings ESP of  0 89   a combination that suggests that the company is likely to beat estimates The Zacks Consensus Estimate for earnings of 58 cents reflects a 20 8  rise on a year over year basis Other Stocks Worth a LookHere are a few other medical stocks worth considering as they also have the right combination of elements to post an earnings beat this quarter Myriad Genetics  Inc    NASDAQ MYGN   has an Earnings ESP of  0 61  and a Zacks Rank  2  You can see  Henry Schein  Inc    NASDAQ HSIC   has an Earnings ESP of  3 34  and a Zacks Rank  3 Quest Diagnostics Incorporated   NYSE DGX   has an Earnings ESP of  3 19  and a Zacks Rank  3 5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ",2018-04-10,Zacks Investment Research,https://www.investing.com/analysis/can-steady-overall-growth-drive-abbotts-abt-q1-earnings-200304704,200304704
115907,337422,HSIC,Will Edwards   EW  Growth In All Lines Drive Q1 Earnings ,opinion,"Edwards Lifesciences Corporation   NYSE EW   is slated to report first quarter 2018 results  after the market closes on Apr 24  Last quarter  the company s earnings per share beat the Zacks Consensus Estimate by 4 4   Moreover  Edwards Lifesciences has delivered positive earnings surprises in three of the trailing four quarters  the average beat being 9 9   Let s see how things are shaping up prior to this announcement Key CatalystSimilar to the prior quarter  Edwards Lifesciences is expected to gain from strength in Transcatheter Heart Valve Therapy segment  THVT   Banking on continued therapy adoption across all geographies with notable strength in the United States  the company is expected to maintain this bullish trend in the first quarter of 2018 as well The company is expected to continue to gain from strong clinical performance from SAPIEN 3 in the United States  as well as strong therapy implementation across all regions  The Zacks Consensus Estimate for transcatheter heart valves  THV  sales in the United States of  471 million shows an increase of 1 3  from the year ago quarter Outside the United States  the underlying growth rate was solid  Double digit procedure growth in Europe was maintained last quarter  The company also continued to see strong TAVR therapy adoption in Japan driven by SAPIEN 3 Overall  first quarter total revenues are projected at  931 million  up 5 3  from the prior year quarter 
Edwards Lifesciences Corporation Price and EPS Surprise
     Here are the other factors that might influence Edwards Lifesciences  first quarter results Edwards Lifesciences is expected to continue with its strong performance based on strength in two other segments   Surgical Heart Valve Therapy and Critical Care The Surgical Heart Valve Therapy product group delivered strong performance last quarter driven by encouraging performance of new products along with strong uptake of aortic valves across all geographies  Moreover  buoyed with the continued strong adoption of INTUITY Elite valve system  management expects INTUITY Elite valve system sales to remain on track to account for 25  of global aortic sales in fiscal 2018 Per management  in January 2018  the company had rolled out INSPIRIS RESILIA aortic valves in the United States  Edwards Lifesciences also informed that the planned 2018 launch of INSPIRIS RESILIA in Japan is on track and progressing well  TheZacks Consensus Estimate for Surgical Heart Valve Therapy product sales of  210 million reflects a rise of 5  from the year ago quarter We are also upbeat about Critical Care product group sales witnessing solid growth across all product categories driven by strong growth in the company s core products  mainly in the United States and China Also  Edwards Lifesciences aims to strengthen its hold in the Critical Care technologies with the ongoing rollout of HemoSphere monitoring platform and expansion of Enhanced Surgical Recovery programs  Accordingly  the Zacks Consensus Estimate for Critical Care product group sales of  157 million shows an increase of 8 3  from the year ago quarter For the first quarter of 2018  the company projects sales between  900 million and  950 million and adjusted EPS between  1 04 and  1 14 What Our Model SuggestsAccording to the Zacks model  a company with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  has a good chance of beating estimates if it also has a positive   You can uncover the best stocks to buy or sell before they re reported with our  Edwards Lifesciences has a Zacks Rank  3 and an Earnings ESP of  0 23   a combination that suggests that the company is likely to beat estimates The Zacks Consensus Estimate for earnings of  1 10 reflects a 17  rise on a year over year basis Other Stocks Worth a LookHere are a few other medical stocks worth considering as they also have the right combination of elements to post an earnings beat this quarter 
Myriad Genetics  Inc    NASDAQ MYGN   has an Earnings ESP of  0 61  and a Zacks Rank  2  You can see  Henry Schein  Inc    NASDAQ HSIC   has an Earnings ESP of  3 34  and a Zacks Rank  3 Quest Diagnostics Incorporated   NYSE DGX   has an Earnings ESP of  3 19  and a Zacks Rank  3 5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ",2018-04-10,Zacks Investment Research,https://www.investing.com/analysis/will-edwards-ew-growth-in-all-lines-drive-q1-earnings-200304696,200304696
115908,337423,HSIC,WATCHMAN To Aid Boston Scientific  BSX  Q1 Earnings Amid Woes,opinion,Boston Scientific Corporation   NYSE BSX   is scheduled to report first quarter 2018 results before the opening bell on Apr 25 Last quarter  the company delivered earnings in line with the Zacks Consensus Estimate  However  the average trailing four quarter earnings surprise is pegged at  0 03  Let s see  how things are shaping up prior to this announcement Key CatalystsWithin structural heart  we are looking forward to Boston Scientific s WATCHMAN  ACURATE  and IRIS product lines  expected to strongly contribute to the company s top line in the yet to be reported quarter  Earlier  the company stated that in2018  it expects revenues from WATCHMAN and ACURATE TAVR franchise to gross approximately  400 million We are optimistic about the gradually improving performance in Interventional Cardiology  IC   led by an innovative portfolio and robust commercial teams  globally  More specifically  the company has of late  successfully gained within this business on strong sales of WATCHMAN Left Atrial Appendage Closure device and its portfolio of complex PCI  percutaneouscoronary intervention  products The WATCHMAN platform is anticipated to experience another excellent quarter on consistent global momentum as Boston Scientific s multiple market development efforts continue to push for growth This apart  new launches within IC business like the WOLVERINE cutting balloon and the company s next generation rotational atherectomy platform called ROTAPRO  are likely to strongly contribute to the top line in the upcoming quarter We are also upbeat about the company s ACURATE  TAVR  transcatheter aortic valve replacement  program  which has recently completed training of European sales and clinical teams Boston Scientific Corporation Price and EPS Surprise    However  ahead of the company s earnings release for the first quarter  we believe its IC business to be once again deeply impacted by the product recall issue within Europe  Notably  the company has recently announced a further delay in its earlier reported timelines for the commercial return of the LOTUS Edge Aortic Valve System in Europe as well as the United States  following the product s voluntary recall  last February Other Factors at PlayAmong the segments  MedSurg is estimated to demonstrate a steady performance  led by endoscopy  Urology and Women s Health are also projected to grow beyond market levels  driven by investment strategies in the key international geographies However  the company is expected to face some downsides within this business too in the yet to be reported quarter  These headwinds may come in the form of year over year difficult pacer comparisons and more competitions in the drug eluting stent space with some new entrants Overall  the Zacks Consensus Estimate for first quarter endoscopy revenues is pegged at  420 million  8 5  above the prior year quarter s reported count of  387 million  For Urology and Women s Health  the consensus mark of  289 million remains 9 1  ahead of the year earlier quarter s reported tally of  265 million On the flip side  severe currency headwinds that Boston Scientific have been facing of late  remain a concern  In fact  as the company records 47  of its sales from the international markets  it gets highly exposed to currency fluctuations  This apart  although immaterial for the to be reported quarter  the ongoing tensions between the United States as well as China regarding the imposition of tariffs on imports  have raised concerns for major MedTech players as any adverse move might affect the top line numbers in the future Here s What Our Quantitative Model PredictsPer the proven Zacks model  a company with a favorable Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  has good chances of beating estimates if it also has a positive  Boston Scientific has a Zacks Rank  3  which increases the predictive power of ESP and an Earnings ESP of 0 00   which makes surprise prediction difficult  Together  the combination does not suggest that the company is likely to beat on earnings this quarter We caution against the Sell rated stocks  4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions You can uncover the best stocks to buy or sell before they re reported with our  Stocks Worth a LookHere are a few medical stocks worth considering with the right combination of elements to beat estimates this time around Myriad Genetics  Inc    NASDAQ MYGN   has an Earnings ESP of  0 61  and a Zacks Rank  2  You can see  Henry Schein  Inc    NASDAQ HSIC   has an Earnings ESP of  3 34  and a Zacks Rank of 3 Quest Diagnostics Incorporated   NYSE DGX   has an Earnings ESP of  3 19  and is a Zacks  3 Ranked player Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-04-11,Zacks Investment Research,https://www.investing.com/analysis/watchman-to-aid-boston-scientific-bsx-q1-earnings-amid-woes-200305168,200305168
115909,337424,HSIC,Can Solid Overall Growth Drive Illumina s  ILMN  Q1 Earnings ,opinion,"Illumina  Inc    NASDAQ ILMN   is slated to report first quarter 2018 results  after markets close on Apr 24  Last quarter  the company delivered a positive earnings surprise of 18 03  with the average earnings beat being 13  for three of the trailing four quarters  Let s see how things are shaping up prior to this announcement Key CatalystsSimilar to the prior quarter  Illumina is expected to gain from strong Product revenues  Over the last few quarters  the company s product revenues have been gaining from rising demand for sequencing consumables and instruments as well as the microarray range Within consumables  the NovaSeq platform continues to see growth with close to 285 NovaSeq systems currently in customers  hands since the launch last January  For 2018  NovaSeq shipments are projected in the range of 330 to 350 Management is hopeful that launches like S4 flow cell  Xp workflow and Nextera DNA Flex library preparation kit will drive NovaSeq demand in the near term Given the transition in Illumina s high throughput portfolio related to the NovaSeq introduction  instrument revenues have also been rising  
Illumina  Inc  Price and EPS Surprise    Accordingly  the Zacks Consensus Estimate for Product revenues of  621 million reflects an increase of 26 5  from the year ago quarter Total Services and other revenues  which include genotyping and sequencing services  instrument maintenance contracts and revenues from oncology agreements  have also been strong  The upside is being driven by strength in genotyping services due to sequencing instrument maintenance contracts and increased consumer demand At NIPT  Illumina won Dutch National contract during the previous quarter along with some other encouraging developments  Per management  these factors will more than double sales from this business in 2018   Moreover  the company is making progress with NIPT adoption  courtesy of continued uptake of VeriSeq NIPT Solution  which includes CE IVD marked library prep and analysis software With MiniSeq and MiSeq shipments accounting for roughly 60  of the new to sequencing customer demand and growing NextSeq adoption with commercial customers using the platform in production settings  Illumina s benchtop portfolio has been encouraging The bullish trend is expected to be reflected in the to be reported quarter s results  Thus  the Zacks Consensus Estimate for Service and other revenues of  123 million shows a rise of 15  from the year ago quarter Here are the other factors that might influence Illumina s first quarter results In January 2018  Illumina announced the launch of the iSeq 100 Sequencing System  This next generation sequencing system delivers excellent data accuracy  at a low capital cost  making Illumina technology available to virtually any lab  Since the company began shipping the product in January itself  investors will be watching out for the difference it will make to the top line results in the quarter to be reported Geographically  Illumina has been witnessing growing revenues from Europe  the Middle East and Africa  EMEA  led by sequencing instruments and consumables  Solid performance in Asia Pacific propelled by 12  shipment growth in Greater China also encourages us  Recently  management has noticed an uptick in demand from customers who are attempting to set up NIPT operations in China  We believe these developments will open channels for Illumina  thereby enhancing business growth Although immaterial for the to be reported quarter  the ongoing tensions between the United States and China regarding the imposition of tariffs on imports have raised concerns for major MedTech players as any adverse move may mar sales in China in the near term Total oncology testing was up 60  in the last reported quarter  Per management  the solid results were primarily led by continued growth in the translational liquid biopsy segment  Furthermore  Illumina continues to expect robust demand for oncology testing Overall  first quarter total revenues are projected at  743 million  up 24 2  from the prior year quarter What Our Model SuggestsAccording to the Zacks model  a company with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  has a good chance of beating estimates if it also has a positive   You can uncover the best stocks to buy or sell before they re reported with our  Illumina has a Zacks Rank  3 and an Earnings ESP of  6 07   a combination that suggests that the company is likely to beat estimates The Zacks Consensus Estimate for earnings of  1 02 reflects a 59 4  rise on a year over year basis Other Stocks Worth a LookHere are a few other medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter Myriad Genetics  Inc    NASDAQ MYGN   has an Earnings ESP of  0 61  and a Zacks Rank  2  You can see  Henry Schein  Inc    NASDAQ HSIC   has an Earnings ESP of  3 34  and a Zacks Rank  3 Quest Diagnostics Incorporated   NYSE DGX   has an Earnings ESP of  3 19  and a Zacks Rank  3 Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-04-11,Zacks Investment Research,https://www.investing.com/analysis/can-solid-overall-growth-drive-illuminas-ilmn-q1-earnings-200305160,200305160
115938,337453,HSIC,What To Expect From Quest Diagnostics  DGX  In Q4 Earnings,opinion,Quest Diagnostics Inc    NYSE DGX   is scheduled to report fourth quarter and fiscal 2017 earnings results before the opening bell on Feb 1 Last quarter  the company surpassed the Zacks Consensus Estimate by four cents delivering a positive earnings surprise of 2 96   Also  it outperformed the consensus mark in all the trailing four quarters with an average beat of 7 4  Let s take a look at how things are shaping up prior to this announcement Factors at PlayAfter a phase of sustained drag for several quarters in the company s revenue per requisition performance  the last couple of quarters saw a slight rebound  However  it still remains to be seen if this upside is here to stay or not  The company s two Professional Lab Services engagements   WJ Barnabas Health and HealthONE System of HCA Holdings  Inc   HCA    carry lower revenue per requisition due to the nature of work Overall  we believe a lack of employment and slow growth of commercially insured lives to continuously affect the company s volumes  measured by the number of requisitions  till the economy turns around for better Quest Diagnostics Incorporated Price and EPS Surprise   This apart  unit price headwinds were less than 100 bps in the third quarter  While unit price challenges hovered in moderate ranges  at approximately 1   over the last few years  the company continues to expect the same for the rest of 2017 too Also  in the last couple of years  Quest Diagnostics faced several reimbursement issues hurting its revenues  The company is concerned about the CMS  Centers for Medicare   Medicaid Services  proposal related to Protecting Access to Medicare Act  We believe  reimbursement pressure will be reflected as an overhang in the company s performance this soon to be reported quarter too Notably in December  the company as a key member of the American Clinical Laboratory Association   ACLA   has come forward to support a lawsuit filed by ACLA against the Acting Secretary of the US Department of Health and Human Services  HHS   The lawsuit charged that the CMS  operating under the purview of HHS  has failed to follow a congressional directive to implement a market based laboratory payment system However  come what may  this leaves no impact on the company s yet to be reported quarter s revenue numbers On a positive note  Quest Diagnostics seems well aligned with its two point growth agenda to accelerate the same and drive operational excellence We are also optimistic about the company s successful execution of its strategy to build esoteric testing business and boost profitable growth Additionally  Quest Diagnostics has recently witnessed a significant improvement via infectious disease testing  prescription drug monitoring and industry leading wellness business  Therefore we expect these growth drivers to replicate the company s success story in its upcoming quarterly results  having thus remained active throughout  and drive the same primary metrics as well like the preceding quarter We strongly believe all these recent developments to have significantly contributed to the company s top line in the fourth quarter The company expects 2017 revenues of approximately  7 71 billion  annualized growth of approximately 3    The Zacks Consensus Estimate for full year revenues is pegged at  7 94 billion  higher than the guided range Moreover  the company s 2017 adjusted EPS range remains within  5 62  5 67  The Zacks Consensus Estimate of  5 96 for the period also remains above the company s projected range Earnings WhispersOur proven model does not conclusively show that Quest Diagnostics is likely to beat on earnings this quarter  This is because a stock needs to have both a positive  and a favorable Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  But that is not the case here as you will see below Zacks ESP  Quest Diagnostics has an Earnings ESP of  1 74   This is because the Most Accurate estimate of  1 37 is pegged lower than the Zacks Consensus Estimate of  1 39  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Quest Diagnostics has a Zacks Rank  3  which increases the predictive power of ESP  However  we need a positive ESP to be confident about an earnings surprise  Hence  this combination leaves surprise prediction inconclusive We caution against the Sell rated stocks   4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks Worth a LookHere are a few medical stocks worth considering with the right combination of elements to surpass estimates this time around Bio Rad Laboratories   NYSE BIO   has an Earnings ESP of  4 45  and a Zacks Rank  2  You can see  Myriad Genetics   NASDAQ MYGN   has an Earnings ESP of  0 42  and a Zacks Rank of 3 Henry Schein   NASDAQ HSIC   has an Earnings ESP of  0 09  and is a Zacks  3 Ranked player Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-01-22,Zacks Investment Research,https://www.investing.com/analysis/what-to-expect-from-quest-diagnostics-dgx-in-q4-earnings-200282796,200282796
115939,337454,HSIC,Can Molecular Diagnostics Drive Myriad s  MYGN  Q2 Earnings ,opinion,"Myriad Genetics  Inc    NASDAQ MYGN   is scheduled to report second quarter fiscal 2018 results on Feb 6  after the closing bell Last quarter  the company posted a positive earnings surprise of 23 8   Moreover  Myriad Genetics beat the Zacks Consensus Estimate in all of the trailing four quarters  the average being 15  Let s take a look at how things are shaping up prior to this announcement Factors Influencing Q2 ResultsSimilar to last quarter  MyriadGenetics is expected to gain from strong Molecular Diagnostics performance  led by solid contributions from the GeneSight and EndoPredict tests  Per the company  the GeneSight test represents significant opportunities  As GeneSight is placed in a highly under penetrated preventive care market  the product has huge growth potential  Also  during the last reported quarter  the company announced favorable data from a multi center  double blind and randomized controlled trial evaluating the impact of the GeneSight Psychotropic test on psychiatric treatment response in 1 200 patients with major depressive disorder  This is expected to stimulate expanded GeneSight adoption and payer coverage  Management expects consistent growth in GeneSight test revenues in the quarters ahead We also encouragingly note that  over the last few months  Myriad Genetics has been making encouraging progress with the EndoPredict test  During fiscal 2017  the company received reimbursement approval for EndoPredict in France  Quebec and an increased number of German sites  The company also received positive coverage decision for the test from Palmetto GBA  a Medicare Administrative Contractor  MAC  and Anthem   NYSE ANTM   in August  within six months of the test launch in the United States   Notably  full implementation of this decision will lend Myriad Genetics coverage for approximately 90  of breast cancer patients  Moreover  according to Myriad Genetics  EndoPredict presents a global market opportunity of more than  600 million annually  with major demand in countries like Canada and the United States 
Myriad Genetics  Inc  Price and EPS Surprise
     We are also upbeat about management s expectations of double digit volume growth in fiscal 2018 for GeneSight  Vectra DA and Prolaris revenues  all of which make up the chunk of the Molecular Diagnostics portfolio The Prolaris testing s volumes grew in double digits in the last reported quarter as well  We are also encouraged by the company s receipt of a positive final Local Coverage Determination to expand Medicare coverage of the Prolaris test from Palmetto GBA  a MAC  in the first half of 2017  Moreover  management seems upbeat about the prospects of the Prolaris test as it represents a global market opportunity of approximately  1 5 billion annually   Myriad Genetics witnessed continued year over year growth in Hereditary Cancer volumes  with pricing matching expectations in the last reported quarter  Per management  the company continued to witness a solid sample trend in this space  Last September  the company launched riskScore under its myRisk Hereditary Cancer testing portfolio  Notably  riskScore helps determine a woman s risk of developing breast cancer by combining genetic markers throughout the genome with the patient s family and clinical history Management believes that the company is well positioned in breast cancer testing market for fiscal 2018  courtesy of encouraging Hereditary cancer volumes on steady growth and predictable long term pricing  Thus  we believe the company is positioned to cash in on the huge potential in the breast cancer screening market The Zacks Consensus Estimate for fiscal second quarter revenues of  189 million reflects a decline of 4 1  from the year ago quarter reported number On the flip side unfavorable foreign currency translation continues to pose a threat  With a considerable portion of its revenues coming from outside the United States  the company faces the risk of exchange rate fluctuations  Additionally  macroeconomic uncertainty and higher expenses owing to extensive pipeline of some testsmay impact margins Earnings WhispersOur proven model does not conclusively show that Myriad Genetics is likely to beat earnings this quarter  That is because a stock needs to have both a positive   and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here as you will see below Zacks ESP  Myriad Genetics has an Earnings ESP of  3 72   This is because the Most Accurate estimate is pegged at 23 cents  while the Zacks Consensus Estimate is at 24 cents Zacks Rank  Myriad Genetics carries a Zacks Rank  3  which increases the predictive power of ESP  However  an ESP of  3 72  makes surprise prediction difficult The Zacks Consensus Estimate for second quarter 2018 adjusted earnings of 24 cents reflects a 7 7  decline from the year ago quarter Stocks Worth a LookHere are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter Bio Rad Laboratories   NYSE BIO   has an Earnings ESP of  4 45  and a Zacks Rank  1  You can see  Henry Schein   NASDAQ HSIC   has an Earnings ESP of  0 09  and a Zacks Rank  3 Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-01-24,Zacks Investment Research,https://www.investing.com/analysis/can-molecular-diagnostics-drive-myriads-mygn-q2-earnings-200283490,200283490
115940,337455,HSIC,What s In Store For GNC Holdings  GNC  This Earnings Season ,opinion,GNC Holdings  Inc    NYSE GNC   is expected to report fourth quarter 2017 results on Feb 15  before the opening bell Last quarter  the company posted a negative earnings surprise of 3   Also  GNC Holdings  trailing four quarter average earnings miss is 16 5  Let s take a look at GNC Holdings  announcement of preliminary fourth quarter results Per the announcement  GNC Holdings saw an increase in fourth quarter same store sales for domestic company owned stores  including GNC com sales  of 5 7   Also  adjusted diluted earnings per share  EPS  are expected in the range of 24 25 cents compared with 7 cents in the prior year quarter  In the year ago quarter  the EPS decline was led by a substantial fall in revenues  GNC Holdings  Inc  Price and EPS Surprise     Meanwhile  the Zacks Consensus Estimate for earnings is pegged at 24 cents  reflecting a 25  decline from last quarter  Further  the Zacks Consensus Estimate for revenues is pegged at  558 million  reflecting a 8 4  drop from the preceding quarter Other Factors at PlayDull Prospects in the U S    Canada SegmentGNC Holdings  third quarter 2017 revenues dropped 2 9  year over year  The lower sales at the U S    Canada and manufacturing wholesale segments can be cited as main reasons for the disappointing performance  In the absence of any catalyst  we expect a similar trend in the fourth quarter of 2017 The Zacks Consensus Estimate for revenues at the segment stands at  452 million  reflecting a 4 4  decline from the year ago quarter China e commerce to Drive International Segment Revenues at the international segment increased a whopping 19 3  in the last quarter  Revenues from international franchisees rose impressively  Solid performance in the China e commerce platform is likely to be the key catalyst  As a result  the Zacks Consensus Estimate for revenues at the segment is pegged at  44 2 million  reflecting growth of 11 3  from the year earlier quarter However  GNC Holdings has a number of competitors in the market that include large international pharmacy chains  supermarket firms and big U S  based companies with global operations  We expect the company to slash prices in the face of stiff competition  which in turn  might hurt margins Other DevelopmentsOn the bright side  the performance of One New GNC is improving gradually  PRO Access  the company s premium loyalty offering  has enrolled nearly 585 000 members since its launch in March 2017  Apart from this  management is working on product pricing and innovation  Meanwhile  new consumer enrolment under the myGNC Rewards Program and launch of GNC storefront on Amazon  NASDAQ AMZN  buoy optimism Earnings Whispers  Our proven model does not conclusively show an earnings beat for GNC Holdings this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here  as you will see below Zacks ESP  The Earnings ESP for GNC Holdings is 0 00   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  GNC Holdings carries a Zacks Rank  3  which increases the predictive power of ESP  However  we also need to have a positive ESP to be confident of a positive earnings surprise Stocks to ConsiderHere are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter Bio Rad Laboratories   NYSE BIO   has an Earnings ESP of  4 45  and a Zacks Rank  2  You can see  Myriad Genetics   NASDAQ MYGN   has an Earnings ESP of  0 42  and a Zacks Rank  3 Henry Schein   NASDAQ HSIC   has an Earnings ESP of  0 09  and a Zacks Rank  3 Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-02-04,Zacks Investment Research,https://www.investing.com/analysis/whats-in-store-for-gnc-holdings-gnc-this-earnings-season-200287129,200287129
115941,337456,HSIC,Henry Schein  HSIC  Q4 Earnings To Show Growth In All Lines ,opinion,"Henry Schein  Inc    NASDAQ HSIC   is expected to report fourth quarter 2017 results on Feb 20 Last quarter  the company missed earnings estimates by 3 3   However  Henry Schein s earnings surpassed the Zacks Consensus Estimate in three of the past four quarters  at an average of 1 5  Let s see how things are shaping up prior to this announcement Factors at PlayHenry Schein s third quarter 2017 results were quite impressive  recording growth across all four segments   Dental  Animal Health  Medical and Technology and Value Added Services  Geographically  the company gained traction in North America and overseas  We expect a similar trend in the fourth quarter Favorable Dental Business Trends  The company s strategy to expand digital dentistry globally is encouraging  We are also upbeat about management s expectations of at least low single digit growth in North America s dental consumable merchandise market in the second half of 2017  The Zacks Consensus Estimate for fourth quarter total revenues of  3 31 billion reflects an increase of 6 1  from the year ago quarter The company banks on digital dentistry  which is part of its strategic plan  Henry Schein is busy promoting digital workflows for general dentistry as well as dental specialties  Starting Sep 1  2017  the company started selling the full range of Dentsply Sirona dental equipment across North America  including the leading CEREC CAD CAM restoration system  This is expected to boost the top line to a considerable extent  Henry Schien will also continue to represent products from Planmeca  A dec  Midmark  3Shape and 3M as well as the dental equipment and consumer product lines of its longstanding partner Danaher  NYSE DHR  under the KaVo Kerr brands 
Henry Schein  Inc  Price and EPS Surprise
     Solid Animal Health Portfolio  We are optimistic about the well diversified Animal Health product portfolio featuring software  diagnostic equipment  and surgical instruments  The solid product offerings have been driving growth domestically as well as globally Notably  during the fourth quarter  Henry Schein acquired Merritt Veterinary Supplies and integrated it into its Animal Health business  Merritt has 4 500 veterinary clinics in Eastern United States  with a strong presence in the Southeastern part of the nation  The company offers a comprehensive line of products  including pharmaceuticals  diagnostics and equipment  However  according to Henry Schein  this acquisition will drive earnings post 2017 Growing Medical Business  Henry Schein is consistently working on boosting its Medical segment  Notably  worldwide Medical revenues rose 8  year over year in the last reported third quarter  In October  the company inked an agreement with Cerebral Assessment Systems to distribute Cognivue  This is the first computerized cognitive assessment screening device cleared by the FDA for the detection of early signs of dementia  We believe this development will bolster growth for the company in the field of mental cognitive diseases In the same month  the company announced an exclusive distribution agreement with Terason to distribute the latter s uSmart 3200T NexGen  This development remains part of Henry Schein Medical s Emergency Medical Services business Broad Distribution Network  We are also upbeat about the company s widespread distribution network  Apart from North America and Europe  the company has presence in Australia and New Zealand as well as in emerging nations like China  Brazil  Israel  Czech Republic and Poland On the flip side  Henry Schein s disappointing gross and operating margin performance over the past few quarters due to higher cost of sales and expenses is a matter of concern This apart  currency fluctuations and a tough competitive landscape add to the woes  Also  the entry of group purchasing organizations  GPOs  in the United States has intensified competition Overall  Henry Schein expects 2017 EPS in the range of  3 59  3 61  reflecting 8 9  growth from the 2016 adjusted EPS figure of  3 31 Earnings WhispersOur proven model does not conclusively show that Henry Schein is likely to beat earnings this quarter  That is because a stock needs to have both a positive   and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here as you will see below Zacks ESP  Henry Schein has an Earnings ESP of  0 94   This is because the Most Accurate estimate is pegged at 96 cents while the Zacks Consensus Estimate stands at 97 cents Zacks Rank  Henry Schein carries a Zacks Rank  3  which increases the predictive power of ESP  However  an ESP of  0 94  makes surprise prediction difficult Nonetheless  the Zacks Consensus Estimate for fourth quarter 2017 adjusted earnings of 97 cents  reflects a rise of 3 2  year over year Stocks Worth a LookHere are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter Amphastar Pharmaceuticals   NASDAQ AMPH   has an Earnings ESP of  264 7  and a Zacks Rank  1  You can see  Audro Biotech  Inc    NASDAQ ADRO   has an Earnings ESP of  2 8  and a Zacks Rank  3 The Cooper Companies  Inc    NYSE COO   has an Earnings ESP of  0 2  and a Zacks Rank  3 Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2018-02-11,Zacks Investment Research,https://www.investing.com/analysis/henry-schein-hsic-q4-earnings-to-show-growth-in-all-lines-200289490,200289490
115942,337457,HSIC,Sell These Healthcare Middlemen About to Get Amazoned,opinion,"A few weeks ago  I told my regular readers at Investors Alley about the announcement from Amazon com  Nasdaq  NASDAQ AMZN  that it was joining forces with JPMorgan  NYSE JPM  and Warren Buffett s BerkshireHathaway to disrupt the healthcare industry  More specifically  the venture is being aimed at the many middlemen in the U S  healthcare industry including insurance companies and pharmacy benefit management companies 
Speaking of middlemen  Amazon apparently is tired of dealing with the likes of FedEx Corporation  NYSE FDX  and United Parcel Service  NYSE UPS  too  It is preparing to launch a delivery service for businesses that will compete directly with the two delivery giants called  Shipping With Amazon  or SWA 
Amazon will roll out the service in Los Angeles in the coming weeks  shipping out goods for merchants that sell on the Amazon website  The company plans to expand the service to a number of other cities this year  It already delivers some of its own goods in 37 U S  cities 
While the move into delivery logistics is interesting  Amazon s ambitions in the healthcare industry should be what catches your attention  The company now looks to be moving into the healthcare supply chain business  You know the business well if you ve had a stay in the hospital and ingested one of those  100 a pill aspirins 
Amazon Steps Into the Healthcare Supply Chain
In a statement  an Amazon spokesperson said   With medical supplies specifically  we hear from both healthcare manufacturers and healthcare customers that they want to find ways to simplify purchasing and reduce costs as a means to address systemic issues that take away focus from patient need  Many large health systems have numerous satellite facilities  and as care shifts closer to the home  they need to address gaps and invent new ways to simplify supplies moving to locations beyond the hospital  
The company is already laying the groundwork for such a move into the healthcare supply chain  It has gotten approval from several states pharmaceutical boards as a wholesale distributor  This is a necessary first step toward selling medical equipment to licensed medical professionals 
Amazon has also met with executives from many of our nation s most prominent hospital systems to brainstorm ideas and point out potential problems in expanding its Amazon Business division into the healthcare supply chain business  It has already begun a pilot program with a large Midwestern hospital system to test whether all goes well in their ordering supplies for the hospital s 150 outpatient locations 
Huge Opportunity for Amazon
The focus on healthcare supplies is a smart move by Amazon since many hospital systems have been buying up medical practices as they move into the rapidly growing outpatient care market  However  most hospital distribution systems have not kept up and are still focused on just servicing the main hospital  Amazon can modernize their distribution system 
It s also a savvy move because it doesn t involve getting complex regulatory approvals  Many states don t require a license at all to sell low tech medical supplies  It s the lowest hanging  fruit  in the very big healthcare market 
And once Amazon understands how to keep the shelves stocked with band aids and gauze  it shouldn t be much of a stretch that it would move up the supply chain  while obtaining regulatory approvals  and begin to provide healthcare systems with medicines and high tech medical devices 
The healthcare supply chain is a huge opportunity for a disruptive company like Amazon  The Wall Street Journal cited a November research report by Citigroup  NYSE C  Global Markets Inc  that found fees  administration  marketing and shipping costs account for an estimated 20  to 30  of healthcare supply costs  As Rob Austin of Navigant Consulting said to the WSJ   There s a lot of people with fingers in the pie  
In other words  more middlemen that are driving up the cost of healthcare for you and me and everyone else in the country  Middlemen that are just begging to be Amazoned  As Jeff Bezos famously said   Your margin is my opportunity  
Stocks Ready to Be Amazoned
So what middlemen companies are in the sights of Amazon in the healthcare supply chain 
Some of these I ve mentioned before including drug distributors Cardinal Health  NYSE CAH  and McKesson  NYSE MCK   But it also includes companies that move basic supplies to doctors  dentists and veterinarians such as Henry Schein  NASDAQ HSIC  and Owens   Minor  NYSE OMI  
In fact  about a week ago  the CEO of Owens   Minor  Paul Cody Phipps  said on a conference call that Amazon was talking to many large hospital systems   including our customers  
These stocks have not done well despite a healthy stock market  Cardinal is down 14  over the past year while McKesson is unchanged and down 3 5  year to date  Henry Schein is down 17 3  over the past 12 months and little changed year to date  while Owens   Minor has nose dived over 53  over the past 52 weeks and is down nearly 15  year to date 
These stocks  especially OMI and HSIC  are to be avoided at all costs  Or even shorted if you have a high risk tolerance  The same goes for the two ETFs that are loaded with middlemen stocks  the iShares U S  Healthcare Providers ETF  NYSE IHF  and the SPDR S P Health Care Services ETF  NYSE XHS  
Once Amazon goes  all in  to the healthcare field  it will be a tough environment for the middlemen that have fed at the healthcare trough for many years to survive 
You are responsible for your own investment decisions  All information contained in my articles is made available solely for general information purposes and should be independently verified with the companies mentioned  You should always conduct your own research and due diligence and consider obtaining professional advice before making any investment decision ",2018-02-22,Tony Daltorio,https://www.investing.com/analysis/sell-these-healthcare-middlemen-about-to-get-amazoned-200293078,200293078
115943,337458,HSIC,Cardinal Health Strong On Medical   Pharmaceutical Segments,opinion,On Feb 20  we issued an updated research report on Cardinal Health  Inc    NYSE CAH    The stock carries a Zacks Rank  2  Buy   The company exited the second quarter on a solid note  courtesy of encouraging performance by the Medical segment  The Pharmaceutical segment also witnessed strong growth in the Specialty business and gained a large number of Pharmaceutical Distribution customers  A strong fiscal 2018 outlook buoys optimism Cardinal Health s share price movement over the last year has failed to impress  The stock has lost almost 17 4   comparing unfavorably with the  s gain of around 9 9   Cardinal Health faces the risk of losing considerable business in case of loss of a major customer  which in turn will severely impair revenues  However  the company s share price has been rising since the second quarter earnings release  The stock has gained 4 1  till yesterday s close Cardinal Health s Medical and Pharmaceutical offerings lend the company a competitive edge in the niche space  The company offers industry expertise and an expanding portfolio of safe products  Also  Cardinal Health follows an acquisition driven strategy and continues to focus on investment in key growth businesses to gain market traction and boost profits  Cardinal Health recently announced the acquisition of Medtronic s   NYSE MDT   Patient Care  Deep Vein Thrombosis and Nutritional Insufficiency business for  6 1 billion  The buyout particularly boosted the company s Medical segment Further Cardinal Health is pursuing growth via joint ventures and long term supply agreements  The company entered a long term strategic agreement with Henry Schein  NASDAQ HSIC   under which the latter purchased Cardinal Health s medical supplies for physician practices  The collaboration is expected to drive core sales and prove accretive to Cardinal Health s earnings in the long term Despite growth in business  profits at the company s Pharmaceutical segment were hurt by generic pharmaceutical pricing  Huge investments in Pharmaceutical IT platform and lackluster generics performance are likely to mar Cardinal Health s operational efficiency in the upcoming quarter  Intense competition and customer concentration are other bottlenecks Other Key PicksA couple of other top ranked stocks in the broader medical sector are PerkinElmer   NYSE PKI   and Bio Rad Laboratories   NYSE BIO   Bio Rad Laboratories has a Zacks Rank  1  Strong Buy   You can see The company has a long term expected earnings growth rate of 25  PerkinElmer has a long term expected earnings growth rate of 12 3   The stock carries a Zacks Rank  2 Zacks Top 10 Stocks for 2018In addition to the stocks discussed above  would you like to know about our 10 finest buy and hold tickers for the entirety of 2018 Last year s 2017 Zacks Top 10 Stocks portfolio produced double digit winners  including FMC Corp  NYSE FMC   and VMware which racked up stellar gains of  67 9  and  61   Now a brand new portfolio has been handpicked from over 4 000 companies covered by the Zacks Rank  Don t miss your chance to get in on these long term buys ,2018-02-22,Zacks Investment Research,https://www.investing.com/analysis/cardinal-health-strong-on-medical--pharmaceutical-segments-200293531,200293531
115974,337489,HSIC,Can Diagnostics Business Drive Abbott s  ABT  Q4 Earnings ,opinion,"Abbott s   NYSE ABT   Diagnostics business has been on a growth trajectory of late on solid contributions from all sub segments   Core Laboratories Diagnostics  Molecular Diagnostics and Point of Care  We expect this strength to get reflected in fourth quarter 2017 results  which are scheduled for release on Jan 24 Core Laboratories DiagnosticsIn June 2017  Abbott announced the CE Mark for Alinity hq  which has become the fifth diagnostic system to be launched in Europe along with the ongoing rollout of four instruments in the areas of immunoassay  clinical chemistry  blood screening and point of care  This has strengthened the company s Core Laboratory Diagnostics business considerably Of late  the company has been in the headlines following the receipt of CE Mark and commercial launch of Alinity h series integrated system for hematology testing  Notably  the Alinity portfolio covers clinical chemistry  immunoassay  blood and plasma screening  point of care  hematology and molecular diagnostics along with Abbott s AlinIQ  Interestingly  the company also continued the initial launch of certain new Alinity systems for the core laboratory  including  Alinity c  for clinical chemistry   Alinity i  for immunoassay diagnostics and  Alinity s  for blood and plasma screening globally during the last reported third quarter Continuing with the slew of developments  this Illinois based global medical device company signed a  252 million managed equipment service contract with North West London Pathology  NWLP   hosted by Imperial College Healthcare NHS Trust in August 2017  Per the terms of the collaboration  Abbott will be the authorized supplier of all analytical equipment and consumables  covering its Alinity ci and Alinity h series diagnostics instruments and AlinIQ  Per NWLP  the alliance  which presently covers 6  of the pathology market in the U K   is expected to carry out 26 million tests per year  Thus  investors must be eagerly looking forward to the outcome of this deal on the company s financials  The Zacks Consensus Estimate for Core Laboratory Diagnostics revenues of  1 05 billion indicates a rise of 4 9  from the year ago quarter reported number 
Abbott Laboratories Price and EPS Surprise
     Point of CareAbbott s successful closure of the Alere acquisition after a prolonged legal battle has instilled confidence in investors  The buyout closed in October 2017 under amended financial terms in favor of Abbott  Taking the attractive prospects of Point of Care testing within the in vitro diagnostics market into consideration  Abbott is highly optimistic about the Alere integration  According to the company  the Alere buyout will significantly expand its diagnostics presence and create the broadest Point of Care testing portfolio with strong positions in cardio  metabolic  infectious disease and toxicology testing  Moreover  Abbott expects Alere to contribute around  475 million to its top line in 2017  Thus  the Zacks Consensus Estimate for Point of Care revenues of  661 million indicates a massive rise of 389 6  from the year ago quarter and a surge of 404 6  from the sequential quarter Molecular DiagnosticsThrough 2017  Abbott has effectively focused on core areas and thus  the company has been strongly performing in the infectious disease testing business under Molecular Diagnostics  This has been partially offsetting declines due to planned scale down in other testing areas by the company  The Zacks Consensus Estimate for Molecular Diagnostics revenues of  122 million indicates a rise of 4 3  from the year ago quarter With these positives in place  Abbott anticipates mid single digit increase in Diagnostics sales in fourth quarter 2017 Here is what our quantitative model predicts Abbott does not have the right combination of two main ingredients   a positive   and Zacks Rank  3  Hold  or higher   for increasing the odds of an earnings beat Zacks ESP  The Earnings ESP for Abbott is  0 62   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Abbott carries a Zacks Rank  3  which increases the predictive power of ESP  However  we also need to have a positive ESP to be confident of a positive earnings surprise The Zacks Consensus Estimate for earnings of 73 cents reflects a 12 3  rise on a year over year basis Stocks Worth a LookHere are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter 
Bio Rad Laboratories  Inc    NYSE BIO   has an Earnings ESP of  4 45  and a Zacks Rank  2  Buy   You can see  Myriad Genetics  Inc    NASDAQ MYGN   has an Earnings ESP of  0 42  and a Zacks Rank  3 Henry Schein  Inc    NASDAQ HSIC   has an Earnings ESP of  0 35  and a Zacks Rank  3 Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2018-01-18,Zacks Investment Research,https://www.investing.com/analysis/can-diagnostics-business-drive-abbotts-abt-q4-earnings-200281799,200281799
115975,337490,HSIC,Can Invisalign Drive Align Technology s  ALGN  Q4 Earnings ,opinion,"Align Technology  Inc    NASDAQ ALGN   is set to report fourth quarter 2017 earnings results on Jan 30  after market close Last quarter  the company posted a positive earnings surprise of 23 2   Align Technology has outperformed the Zacks Consensus Estimate in three of the preceding four quarters  the average positive earnings surprise being 16 6   Let s take a look at how things are shaping up prior to this announcement Factors at PlayThis leading manufacturer and marketer of a system of clear aligner therapy  intra oral scanners and CAD CAM  computer aided design and manufacturing  digital services used in dentistry  orthodontics and dental records storage has been witnessing strong revenue growth from the Scanner and Service business over the past few quarters  Moreover  the company has been seeing increased adoption of iTero scanners for Invisalign case submissions instead of PVS impressions  especially in North America  thereby driving Invisalign utilization  Management expects this bullish trend to reflect in the fourth quarter results as well At the same time  Align Technology has been focusing on expanding work flow options of iTero scanners  In this context  we are upbeat about the company s iTero Element intraoral scanning system available as part of Patterson Dental s CAD CAM portfolio in the United States and Canada  Moreover  the company launching a software upgrade to its iTero Element intraoral scanner that is capable of comparing patient scans over time with the latest TimeLapse technology also boosts our confidence on the stock Also  the company collaborated with exocad GmbH last March  whereby the integrated portfolio will result in high tech workflow solution for efficient scanning  designing and manufacturing of in house dental prosthesis  With these positives in place  Align Technology is expected to witness solid top line contributions from the Scanner and Service business in the fourth quarter results Investors may also be looking forward to the company s recent signing of an agreement with Glidewell Dental to distribute the iTero Element intraoral scanning system with the latest glidewell io In Office Solution in North America  Per management  the collaboration will widen iTero s reach to more than 50 000 dentists using Glidewell services  Notably  the company aims a launch in first quarter 2018 
Align Technology  Inc  Price and EPS Surprise
    Align Technology achieved a milestone of five million patients undergoing treatment with its flagship clear aligner system   InvisAlign   in November 2017  The company has been adopting several strategies to drive adoption of its core InvisAlign product line In terms of product development  in 2017  the company received two U S  patents for Align Technology s SmartTrack aligner material that is exclusively used for InvisAlign aligner treatment  Moreover  in a bid to gain traction in the InvisAlign platform  Align Technology collaborated with Digital Smile Design last March Meanwhile  in order to expand its Invisalign brand offerings  Align Technology introduced a patient friendly solution   Invisalign Teen with mandibular advancement   for teens in certain markets of Canada  Europe  Middle East and Africa  EMEA  and Asia Pacific  APAC  in the first half of 2017 Coming to geographic expansion  the company opened its first office in Canada   a major market in terms of opportunity for expansion and growth  Management launched InvisAlign Technology Lite in North America post its introduction in the EMEA  The company witnessed strong adoption  particularly among GP dentists Moreover  Align Technology has been witnessing continued adoption of InvisAlign Technology in core markets in the EMEA and APAC regions  Interestingly  in the recently reported third quarter  the company achieved another milestone in terms of InvisAlign therapy adoption  where China became the second largest InvisAlign market with United States topping the numbers  Align Technology registered almost a threefold year over year increase in its asset customer base  with major contributions from China  Also  in a bid to expand in the region  the company opened a InvisAlign Treatment Planning Facility in China last June The Zacks Consensus Estimate for total revenues of  395 48 million in fourth quarter 2017 indicates a rise of 34 9  from the year ago quarter Earnings Whispers Our proven model does not conclusively show that Align Technology is likely to beat earnings this quarter  That is because a stock needs to have both a positive and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here as you will see below Zacks ESP  Align Technology has an Earnings ESP of  1 39   This is because the Most Accurate estimate is pegged at 95 cents while the Zacks Consensus Estimate stands at 96 cents Zacks Rank  Align Technology carries a Zacks Rank  3 which increases the predictive power of ESP  However  an ESP of  1 39  makes surprise prediction difficult Meanwhile  we caution against stocks with a Zacks Rank  4 and 5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revision momentum Nonetheless  the Zacks Consensus Estimate for fourth quarter 2017 adjusted earnings of 96 cents reflects 43 3  growth from the year ago quarter Stocks Worth a LookHere are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter Bio Rad Laboratories   NYSE BIO   has an Earnings ESP of  4 45  and a Zacks Rank  2  You can see  Myriad Genetics   NASDAQ MYGN   has an Earnings ESP of  0 42  and a Zacks Rank  3 Henry Schein   NASDAQ HSIC   has an Earnings ESP of  0 35  and a Zacks Rank  3 Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2018-01-18,Zacks Investment Research,https://www.investing.com/analysis/can-invisalign-drive-align-technologys-algn-q4-earnings-200281787,200281787
115976,337491,HSIC,Can Thermo Fisher s  TMO  Product Portfolio Up Q4 Earnings ,opinion,Thermo Fisher Scientific Inc    NYSE TMO   is slated to report fourth quarter 2017 results before the market opens on Jan 31  Last quarter  the company delivered a positive earnings surprise of 3 1   Moreover  Thermo Fisher has surpassed estimates in all the trailing four quarters with an average beat of 2 3  Let s see  how things are shaping up for this announcement Key CatalystThermo Fisher has been going strong across its analytical instrument businesses with increasing global demand  Particularly  the company s acquisition of FEI has already started generating synergies and largely contributing to its analytical instruments portfolio from the last three quarters  The buyout has enabled Thermo Fisher to access FEI s industry leading high performance electron microscopy platform used for protein study and facilitating life science research  This is also a vital highlight of the quarter to be reported Thermo Fisher anticipates realizing total synergies of approximately  80 million by the end of three years following the deal s closure with about  55 million of cost synergies and roughly   25 million of adjusted operating income benefits from revenue related synergies  This should get reflected in fourth quarter 2017 performance Thermo Fisher Scientific Inc Price and EPS Surprise    Apart from FEI related development  another notable launch in the company s Analytical Instruments business is its new line of Thermo Scientific air quality monitors called the iQ Series  This platform includes mobile applications for remote monitoring and control as well as wireless connectivity and enhanced services  This in turn is likely to contribute to the company s top line in the yet to be reported quarter Last but not the least  worth mentioning is the company s recent completion of taking over the desktop scanning electron microscopy  SEM  solutions provider  Phenom World  Thermo Fisher plans to integrate the business into its Analytical Instruments segment  Per management  addition of Phenom World s desktop SEM platform is projected to leverage its position in electron microscopy space and expand its entry level plus desktop SEMs offerings for customers working in materials science  industrial manufacturing  life sciences and electronics industries Overall  the Waltham MA based company is gearing up for yet another quarter of strong analytical instruments segmental growth  In the period to be reported  Thermo Fisher expects to see a positive impact from the electron microscopy business as well as robust volume expansion plus productivity The Zacks Consensus Estimate for Analytical Instruments revenues is pegged at  1 303 billion  higher than the sequentially last quarter s reported figure of  1 190 billion  Total revenue estimate for this segment also remains at an impressive level of  1 11 billion Here are other factors that might influence Thermo Fisher s fourth quarter results The company s focus to boost growth through implementation of strategies and consolidating its product offerings is encouraging  These initiatives are likely to help it post impressive results in the fourth quarter The company had spent  750 million on research and development in 2016 and the same trend is continuing through 2017  We expect all innovations and product launches to significantly contribute to the company s top line in the fourth quarter itself The company s aim to expand capabilities in the fast growing Asia Pacific zone as well as the emerging markets should also lead to solid results  Recent standout contributors are China  India and South Korea  With strategic investments to support key customer applications  Thermo Fisher forecasts to maintain this bullish momentum for the rest of 2017 Growth is also estimated in applied markets such as environmental and food safeties apart from life science  In addition  the company is betting on some key areas under focus with enormous opportunities at its disposal including advancing precision medicines from mass spectrometry to the targeted gene sequencing and structural biology  However  we are apprehensive about Thermo Fisher citing a foreign exchange headwind on 2017 revenues and adjusted EPS  Also  a hostile macroeconomic condition continues to weigh heavily on the stock  Plus  stiff competition consistently imposes challenges on the stock s value Here s what our quantitative model predicts Thermo Fisher does not have the right combination of two main ingredients   a positive  and a Zacks Rank  3  Hold  or higher   for increasing the odds of an earnings beat this quarter Zacks ESP  Thermo Fisher has an Earnings ESP of  0 2   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Thermo Fisher s Zacks Rank of 3 increases the predictive power of ESP  However  we need a positive ESP to be confident about an earnings surprise  Hence  this combination leaves surprise prediction inconclusive The Zacks Consensus Estimate for fourth quarter 2017 earnings per share of  2 66 reflects a 10 3  rise on a year over year basis Stocks to ConsiderHere are a few medical stocks worth considering with the right combination of elements to beat estimates this time around Bio Rad Laboratories  Inc    NYSE BIO   has an Earnings ESP of  4 45  and a Zacks Rank  1  Strong Buy   You can see  Myriad Genetics  Inc    NASDAQ MYGN   has an Earnings ESP of  0 42  and is a Zacks  3 Ranked player Henry Schein  Inc    NASDAQ HSIC   has an Earnings ESP of  0 35  and is a  3 Ranked player Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2018-01-18,Zacks Investment Research,https://www.investing.com/analysis/can-thermo-fishers-tmo-product-portfolio-up-q4-earnings-200281786,200281786
115977,337492,HSIC,Illumina s  ILMN  Q4 Earnings To Show Growth In All Lines,opinion,Illumina  Inc    NASDAQ ILMN   is slated to report fourth quarter fiscal 2017 results on Jan 30  after market close  Last quarter  the company delivered a positive earnings surprise of 13 3   Let s see how things are shaping up ahead of this announcement Let s take a look at Illumina s announcement of preliminary fourth quarter results at the J P  Morgan Healthcare Conference held in San Francisco  CA Per the announcement  preliminary revenues for the fourth quarter are estimated at  775 million  up 25  year over year  The figure is also higher than the Zacks Consensus Estimate of  748 million The preliminary figure for 2017 revenues is  2 75 billion  up 15  from 2016 driven by the adoption of NovaSeq and growth in clinical and consumer genomics  The figure is also above the Zacks Consensus Estimate of  2 72 billion Illumina  Inc  Price and EPS Surprise     Similar to last quarter  Illumina is expected to gain from strong Product as well as Service and other revenues  Over the last few quarters  the company s product revenues increased primarily on higher sequencing consumable revenues  Total Service and other revenues demonstrate strong growth led by continued demand for NextSeq from NIPT customers and partners The company expects fourth quarter sequencing consumables to increase more than 30   up  100 million from the year ago quarter on the back of increased utilization in the high throughput systems and strong pull through on NextSeq The Zacks Consensus Estimate for Product revenues of  621 million reflects an increase of 4 2  from the year ago quarter  Also  the Zacks Consensus Estimate for Service and other revenues of  121 million indicates a rise of 2 5  from the year ago quarter Here are the other factors that might influence Illumina s fourth quarter results In November 2017  Illumina introduced its second FDA regulated and CE IVD marked next generation sequencing  NGS  system   NextSeq 550Dx  With this  Illumina now has a solid diagnostic NGS portfolio  courtesy of its NextSeq 550Dx and the MiSeqDx products  This portfolio is capable of meeting any clinical requirement for NGS based in vitro diagnostic  IVD  products  This is likely to boost the top line in the yet to be reported quarter Last October  Illumina announced the availability of the NovaSeq S4 flow cell and reagent kit for its NovaSeq 6000 System  Management expects to witness strong NovaSeq uptake through the fourth quarter of 2017 into 2018 and beyond  Moreover  in the same month  Illumina announced the availability of Nextera DNA Flex   a whole genome sequencing library prep product  We expect these factors to drive revenues as well Also  encouraged by the solid third quarter performance  Illumina raised its adjusted EPS to the band of  3 73  3 78 from the earlier  3 60  3 70 On the flip side  a tough competitive landscape may pose a challenge  We are also apprehensive about issues pertaining to NIH funding  which Illumina has been facing for quite some time now Here is what our quantitative model predicts Illumina has the right combination of two main ingredients   a positive  and a Zacks Rank  3  Hold  or better   for increasing the odds of an earnings beat Zacks ESP  The Earnings ESP for Illumina is  0 84   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Illumina carries a Zacks Rank  3 The Zacks Consensus Estimate for earnings of 98 cents reflects a 1  improvement on a year over year basis Other Stocks Worth ConsideringHere are a few medical other stocks worth considering as they have the right combination of elements to post an earnings beat this quarter Bio Rad Laboratories  Inc    NYSE BIO   has an Earnings ESP of  4 45  and a Zacks Rank  2  Buy   You can see  Myriad Genetics  Inc    NASDAQ MYGN   has an Earnings ESP of  0 42  and a Zacks Rank  3 Henry Schein  Inc    NASDAQ HSIC   has an Earnings ESP of  0 35  and a Zacks Rank  3 Will You Make a Fortune on the Shift to Electric Cars  Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2018-01-18,Zacks Investment Research,https://www.investing.com/analysis/illuminas-ilmn-q4-earnings-to-show-growth-in-all-lines-200281743,200281743
115978,337493,HSIC,Edwards Lifesciences   EW  THVT Likely To Drive Q4 Earnings,opinion,Edwards Lifesciences Corporation   NYSE EW   is scheduled to report fourth quarter 2017 earnings on Feb 1  after market close Edwards Lifesciences has outperformed the Zacks Consensus Estimate in three of the preceding four quarters  with an average positive earnings surprise of 10 2   Let s take a look at how things are shaping up prior to this announcement Key CatalystsSimilar to the prior quarter  Edwards Lifesciences is expected to gain from strength in Transcatheter Heart Valve Therapy segment  THVT   Banking on continued therapy adoption across all geographies  with notable strength in the United States  the company is expected to maintain this bullish trend in the fourth quarter of 2017 as well  In the United States  transcatheter heart valve sales grew 20  year over year in the third quarter  Outside the United States  the underlying growth rate was 21   with strong contribution from Japan Edwards Lifesciences Corporation Price and EPS Surprise    In the last reported quarter  growth in THVT was driven by excellent clinical performance results from SAPIEN 3 as well continued strong therapy implementation across all regions Also  the Zacks Consensus Estimate for THVT net sales of  509 million reflects an increase of 17 8  from the year ago quarter  Overall  fourth quarter revenues are projected at  862 86 million Here are the other factors that might influence Edwards Lifesciences  fourth quarter results Investors are bullish on the Harpoon Medical acquisition  which was completed on Dec 6  2017  with the intention to enhance the Surgical Heart Valve Therapy portfolio  However  the buyout is not expected to contribute significantly to fourth quarter revenues Meanwhile  the INTUITY Elite valve system was approved for Medicare s new tech add on payment effective Oct 1  2017  This recognized INTUITY as the latest technology to provide substantial clinical improvement over conventional valves  The company believes that many hospitals will be helped by this add on payment over the next year and this should simplify adoption of this rapid deployment valve that shortens minimally invasive and complex procedures Edwards Lifesciences expects sales in 2017 to meet the high end of the  3 2  3 4 billion range Moreover  we note that the company projects total sales between  855 million and  895 million and adjusted earnings per share of 84 cents to 94 cents for the fourth quarter However  the company expects some changes in fourth quarter gross margin  Earnings are expected to be impacted by foreign currency fluctuation Also  tough competition in the cardiac devices market and reimbursement issues continue to raise caution Here is what our quantitative model predicts Edwards Lifesciences has the right combination of two main ingredients   a positive  and Zacks Rank  3  Hold  or higher   for increasing the odds of an earnings beat Zacks ESP  The Earnings ESP for Edwards Lifesciences is  1 3   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Edwards Lifesciences carries a Zacks Rank  3  which increases the predictive power of ESP Meanwhile  the Zacks Consensus Estimate for earnings of 90 cents reflects a 20  improvement on a year over year basis Other Stocks Worth a LookHere are a few other medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter Bio Rad Laboratories   NYSE BIO   has an Earnings ESP of  4 45  and a Zacks Rank  2  Buy   You can see  Myriad Genetics   NASDAQ MYGN   has an Earnings ESP of  0 42  and a Zacks Rank  3 Henry Schein   NASDAQ HSIC   has an Earnings ESP of  0 09  and a Zacks Rank  3 The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-01-21,Zacks Investment Research,https://www.investing.com/analysis/edwards-lifesciences-ew-thvt-likely-to-drive-q4-earnings-200282302,200282302
115979,337494,HSIC,Will WATCHMAN Boost Boston Scientific s  BSX  Q4 Earnings ,opinion,"Boston Scientific Corporation   NYSE BSX   is scheduled to report fourth quarter and 2017 results before the opening bell on Feb 1 
Last quarter  the company delivered earnings in line with the Zacks Consensus Estimate  However  the average trailing four quarter beat is pegged at 0 84  
Let s see how things are shaping up prior to this announcement 
Preliminary ResultsOn Jan 9  Boston Scientific announced an upbeat fourth quarter 2017 preliminary sales performance  Year over year  preliminary net sales for the quarter has been forecast at  2 41 billion  up 9 9  on a reported basis  8 1  on an operational basis  at constant exchange rate or CER  and approximately  6 8  on an organic basis  This reported preliminary revenue figure lies above the Zacks Consensus Estimate of  2 35 billion Notably  organic revenue growth excludes the impact of changes in foreign currency exchange rates as well as sales from the recent acquisitions of EndoChoice Holdings and Symetis SA For 2017  the company has announced preliminary net sales of  9 05 billion  reflecting 7 9  growth on a reported basis  7 8  increase on operational basis and a 6 6  rise on an organic basis compared with the prior year number  The company s preliminary tally again compares favorably with the Zacks Consensus Estimate of  8 99 billion Key CatalystsBoston Scientific Corporation Price and EPS Surprise    We are optimistic about the company s gradually improving performance in Interventional Cardiology  IC   led by an innovative portfolio and robust commercial teams  globally  More specifically  the company has of late successfully gained within this business on strong sales of WATCHMAN Left Atrial Appendage Closure device and its portfolio of complex PCI products The WATCHMAN platform is expected to experience another excellent quarter on consistent global momentum as Boston Scientific s multiple market development efforts continue to push for growth  In this regard  Medicare reimbursement rates for DRG 274 increased by an average of 10 6  effective Oct 1  under which  93  of WATCHMAN implants fall All these developments are expected to have significantly boosted the IC business in the fourth quarter itself  The company earlier stated that it expects to end 2017 with more than 375 accounts implanting WATCHMAN and increased reorder rates in previously opened accounts However  ahead of the company s earnings release for the fourth quarter  we believe its IC business to be grossly impacted by the product recall issue within Europe  Notably  in February 2017  the company recalled one of its prime products  the Lotus range of heart devices from Europe  due to device malfunctions  The company also delayed submission of its U S  marketing application for its Lotus Edge device Recently  the company has announced a further delay in its earlier reported timelines for the commercial return of the LOTUS Edge Aortic Valve System in Europe as well as the United States  Notably  while recalling the product last February  Boston Scientific announced the expected time of reintroduction of the LOTUS Edge delivery system in Europe by the first quarter of 2018  The company also expected to file the final Pre Market Approval  PMA  module with the U S  Food and Drug Administration by January 2018 However  per the latest press release  the company is likely to provide a further update on the status of the LOTUS Edge Valve on Feb 1  2018  This delay has been justified by Boston Scientific citing its continuous focus on manufacturing and regulatory milestones to support the long term success of the Lotus platform  The company stated that it is working hard to implement necessary modifications in the device to pass the internal quality standards However  this extra delay might lead to a further setback for the company s fast growing transcatheter aortic valve replacement business within the IC in the soon to be reported quarter The Zacks Consensus Estimate for fourth quarter IC revenues is pegged at  622 million  a 6 3  higher than the year ago reported number of  585 million Other Factors at PlayAmong the segments  MedSurg is estimated to demonstrate a steady performance  led by endoscopy  Urology and Women s Health are also projected to grow beyond market levels  driven by investment strategies in key international geographies The Zacks Consensus Estimate for fourth quarter endoscopy revenues is pegged at  417 million  9 7  above the prior year quarter s reported count of  380 million  For Urology and Women s Health  the consensus mark of  303 million remains 10 5  ahead of the year earlier quarter s reported tally of  274 million On the flip side  severe currency headwinds that Boston Scientific has been facing of late remain a concern  In fact  as the company records 47  of its sales from the international markets  it gets highly exposed to currency fluctuations  For the full year  Boston Scientific predicts an unfavorable foreign exchange challenge to the tune of 700 basis points or 8 cents per share on earnings Here s What Our Quantitative Model Predicts Boston Scientific does not have the right combination of the two main ingredients   a positive  and a favorable Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold    for increasing the odds of an earnings beat Zacks ESP  Boston Scientific has an Earnings ESP of 0 00   which makes surprise prediction difficult  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Boston Scientific carries a Zacks Rank  4  Sell   which lowers the predictive power of ESP Stocks Worth a LookHere are a few medical stocks worth considering with the right combination of elements to beat on earnings this quarter Bio Rad Laboratories   NYSE BIO   has an Earnings ESP of  4 45  and a Zacks Rank  2  You can see  Myriad Genetics   NASDAQ MYGN   has an Earnings ESP of  0 42  and a Zacks Rank  3 Henry Schein   NASDAQ HSIC   has an Earnings ESP of  0 09  and is a Zacks  3 Ranked player The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-01-21,Zacks Investment Research,https://www.investing.com/analysis/will-watchman-boost-boston-scientifics-bsx-q4-earnings-200282262,200282262
115980,337495,HSIC,Will S E T  Arm Drive Zimmer Biomet s  ZBH  Q4 Earnings ,opinion,"Zimmer Biomet Holdings  Inc    NYSE ZBH   is set to report fourth quarter 2017 results on Jan 30  before the markets open Last quarter  the company posted a negative earnings surprise of 1 2   However  Zimmer Biomet has outperformed the Zacks Consensus Estimate in two of the preceding four quarters  the average positive earnings surprise being 0 1   Let s take a look at how things are shaping up prior to this announcement Key CatalystsSimilar to the prior quarter  the company is expected to gain from strength in the S E T   Surgical  Sports Medicine  Foot and Ankle  Extremities and Trauma  arm  In the last reported quarter  revenues at S E T  were driven by surgical business and sports medicine offerings such as Gel One  Subchondroplasty and Quattro Link  Moreover  solid uptake of the A L P S  Plating System within the foot and ankle portfolio boosted the segment s performance  The company witnessed strength in IntelliCart System for fluid waste management Historically  strong performance by key brands and 2016 acquisitions along with increasing focus on sales force specialization have been partially offsetting adverse impacts from supply issues and continued pricing pressure within the segment The Zacks Consensus Estimate for S E T  revenues of  443 million reflects an increase of 3  from the year ago quarter reported number 
Zimmer Biomet Holdings  Inc  Price and EPS Surprise
     We are also upbeat about the Spine  Craniomaxillofacial and Thoracic  Spine   CMF  segment  which is expected to deliver another quarter of promising performance  Under the spine category  Zimmer Biomet should continue to gain from strong uptake of Mobi C Cervical Disc  Also  we are looking forward to top line contributions from the company s launch of products like the Avenue T TLIF Cage and Vitality   and Vital Spinal Fixation Systems in the United States in October 2017 Moreover  although the LDR Holdings acquisition had insignificant contribution to the top line  30 basis points  in the third quarter at the initial phase of integration  it is expected to contribute 120 basis points to full year revenues at CER  Also  management is hopeful of gaining from significant cross selling opportunities that the acquisition provides on the back of a strong spine sales force in the United States Continued uptake of Trauma One Plating System  SternaLock Blu and SternaLock 360 primary closure systems as well as the RibFix Blu Thoracic Fixation System within the craniomaxillofacial and thoracic arm buoys optimism The Zacks Consensus Estimate for Spine revenues of  192 million indicates a rise of 0 5  from the year ago quarter Overall fourth quarter revenues are projected at  2 03 billion  up 0 9  from the prior year quarter Here are the other factors that might influence Zimmer Biomet s fourth quarter results Looking at the focused execution of Zimmer Biomet s sales teams  we expect the global adoption rate of the flagship personalized knee system   Persona   to be impressive  We are also upbeat about the launch of the Persona Partial Knee System last September  The knee system marked the latest addition to the company s portfolio of personalized and anatomically designed knee implant systems  Also  Zimmer Biomet s release of X ray based Patient Specific Instrument  X PSI Knee System  in the first half of 2017 buoys optimism  This is the world s first CE Marked surgical planning system that allows for patient specific implant positioning  solely utilizing the X ray technology  These developments are expected to boost the fourth quarter revenues The Zacks Consensus Estimate for Knee revenues of  723 million indicates an uptick of 0 3  from the year ago quarter Emerging markets have always been a significant revenue generating source for Zimmer Biomet  Despite the recent economic downturn in Latin America  the company managed to drive growth through its operations in other emerging markets  especially the Asia Pacific and EMEA  Europe  the Middle East and Africa   The Zacks Consensus Estimate for third quarter revenues from EMEA of  467 million indicates an improvement of 5 2  from the year ago quarter  Moreover  the Zacks Consensus Estimate for third quarter revenues from APAC of  313 million indicates a rise of 3 9  from the year ago quarter Meanwhile  macroeconomic uncertainties and unfavorable currency fluctuations have been denting sales for the company over the past few quarters  The company has also been dealing with pricing pressure  In this regard  Zimmer Biomet faced a negative pricing pressure of approximately 2 1  in the last reported quarter  In the absence of any favorable changes on these lines  these headwinds might reflect in the company s fourth quarter results For the second half of 2017  management continues to expect impact from reduced sales expectations  continued spending on critical programs and rising manufacturing costs from the Warsaw North Campus facility Earnings Whispers Our proven model does not conclusively show an earnings beat for Zimmer Biomet this quarter  That is because a stock needs to have both a positive and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here as you will see below Zacks ESP  Zimmer Biomet has an Earnings ESP of  0 38   This is because the Most Accurate estimate is pegged at  2 11  while the Zacks Consensus Estimate stands at  2 10 Zacks Rank  Zimmer Biomet carries a Zacks Rank  4  Sell   Please note that we caution against stocks with a Zacks Rank  4 and 5  Strong Sell  going into the earnings announcement  especially when the company is seeing negative estimate revision momentum The Zacks Consensus Estimate for fourth quarter 2017 adjusted earnings of  2 10 reflects a 1 9  decline from the year ago quarter Stocks Worth a LookHere are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter Bio Rad Laboratories   NYSE BIO   has an Earnings ESP of  4 45  and a Zacks Rank  2  You can see  Myriad Genetics   NASDAQ MYGN   has an Earnings ESP of  0 42  and a Zacks Rank  3 Henry Schein   NASDAQ HSIC   has an Earnings ESP of  0 09  and a Zacks Rank  3 The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-01-22,Zacks Investment Research,https://www.investing.com/analysis/will-set-arm-drive-zimmer-biomets-zbh-q4-earnings-200282330,200282330
115981,337496,HSIC,Can IDEXX  IDXX  Post A Beat In Q4 Earnings On CAG Strength ,opinion,"IDEXX Laboratories  Inc    NASDAQ IDXX   is expected to beat earnings when it reports fourth quarter 2017 results on Feb 1  before the opening bell Last quarter  the company delivered a positive earnings surprise of 5 3   It is worth noting that IDEXX has outperformed the Zacks Consensus Estimate in each of the preceding four quarters  the average being 9 4   Let s take a look at how things are shaping up prior to this announcement Key CatalystSimilar to the prior quarter  IDEXX is expected to gain from strong global growth in Companion Animal Group  CAG  Diagnostics recurring revenues  The upside was driven by double digit organic revenue gains across consumable and reference lab  strong acceptance of rapid assays and veterinary software  services and diagnostic imaging systems as well as continued expansion of IDEXX s premium instrument installed base  Management expects the solid performance to reflect in the fourth quarter results as well We are also upbeat about IDEXX enhancing commercial capabilities in the United States to maintain recurring revenue growth at CAG Diagnostics  Management expects fourth quarter results to show a rise in productivity as new sales representatives establish new customer relationships and switch to commission based compensation for instrument placements  Also  we expect the company to report exceptional customer retention rates for reference labs and instrument consumables in the United States and worldwide in the fourth quarter The Zacks Consensus Estimate for CAG Diagnostics revenues of  425 million reflects an increase of 11 9  from the year ago quarter Overall  the Zacks Consensus Estimates for fourth quarter total revenues are projected at  491 million  up 10 9  from the prior year quarter  Notably  IDEXX expects 2017 revenues in the range of  1 950  1 960 million  reflecting organic revenue growth of 9 5  to 10  
IDEXX Laboratories  Inc  Price and EPS Surprise
     Here are the other factors that might influence IDEXX s fourth quarter results We are upbeat about growth in the Water Business  which has been on a growth trajectory of late on encouraging test results in the United States and benefits from global go direct initiatives  Moreover  in the last reported quarter  the business witnessed 10  organic growth  Management is also looking forward to benefits from two favorable regulatory developments pertaining to wastewater in the United States and drinking water in Europe  Accordingly  the Zacks Consensus Estimate for Water revenues of  27 3 million reflects an increase of 12 3  from the year ago quarter IDEXX continues to expand globally  It has been significantly benefitting from the bountiful opportunities in the companion animal diagnostics market of emerging nations  Further  management s consistent share buybacks reflect its strong free cash flow reserve  We believe the outcome of these endeavors will be reflected in the fourth quarter performance Management also estimates 2017 EPS in the band of  3 22  3 26  supported by continued operating margin expansion aligned with its long term goals  The outlook represents year over year EPS growth of 32 34  on a reported basis  The Zacks Consensus Estimate for earnings of 73 cents shows an increase of 25 9  from a year ago On the flip side  foreign currency fluctuation is a major headwind  Another concern is the company s high reliance on third party distributors  The purchasing dynamics of distributors have a significant impact on the company s sales of instrument consumables and rapid assay products  Also  IDEXX has been seeing a rise in operating expenses owing to increased head count along with higher investments in portfolio development and expansion in the United States and internationally Also  the competitive landscape in the domestic and overseas markets weighs on IDEXX s performance  The struggle to gain market traction might prove to be a drag on fourth quarter results Here is what our quantitative model predicts IDEXX has the right combination of two main ingredients   a positive  and a Zacks Rank  3  Hold  or higher   needed for increasing the odds of an earnings beat Zacks ESP  The Earnings ESP for IDEXX is  0 82   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  IDEXX carries a Zacks Rank  2  Buy  Other Stocks Worth a LookHere are a few other medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter Bio Rad Laboratories   NYSE BIO   has an Earnings ESP of  4 45  and a Zacks Rank  1  Stron Buy   You can see  Myriad Genetics   NASDAQ MYGN   has an Earnings ESP of  0 42  and a Zacks Rank  3 Henry Schein   NASDAQ HSIC   has an Earnings ESP of  0 09  and a Zacks Rank  3 Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2018-01-22,Zacks Investment Research,https://www.investing.com/analysis/can-idexx-idxx-post-a-beat-in-q4-earnings-on-cag-strength-200282598,200282598
115982,337497,HSIC,Can Baxter  BAX  Beat Q4 Earnings On Hospital Products ,opinion,Baxter International Inc    NYSE BAX   is scheduled to report fourth quarter 2017 earnings on Feb 1  before market opens Last quarter  the company posted a positive earnings surprise of 8 5   Baxter International has outperformed the Zacks Consensus Estimate in all of the preceding four quarters  the average positive beat being 10 6   Let s take a look at how things are shaping up prior to this announcement Key CatalystsSimilar to last quarter  Baxter International is expected to gain from strength in Hospital Products on solid sales in the U S  Fluid Systems business as well as solid demand for injectable pharmaceuticals Baxter International Inc  Price and EPS Surprise     Within Hospital Products  in the third quarter  sales in Fluid Systems were up significantly on robust IV solution sales in the United States  We expect Fluid Systems to maintain the trend  as is evident from the Zacks Consensus Estimate of  634 million for the fourth quarter  reflecting 3 3  rise from the year ago quarter Global sales of Integrated Pharmacy Solutions  IPS   another sub segment within Hospital Products  increased by a formidable margin in the third quarter  partly on the back of increased sales for premixed injectable drugs  For the fourth quarter  the Zacks Consensus Estimate for IPS is pegged at  576 million  up 2 3  from the year ago reported number Surgical Care  includes anesthesia and BioSurgery  sales also recorded year over year sales growth in the third quarter  on low double digit growth for anesthesia and critical care products  driven by growing demand for inhaled anesthetics internationally as well as increased U S  sales of BREVIBLOC   a fast acting IV beta blocker  The fourth quarter Zacks Consensus Estimate for the segment s sales stands at 576 million  up 1 1  from the year ago quarter Also  BioSurgery sales increased low single digits globally in the last reported quarter  The company expects growth in this business to continue as a result of continuous efforts to enhance commercial effectiveness Overall  the Zacks Consensus Estimate for Hospital Products net sales of  1 67 billion reflects an increase of 2 6  from the year ago quarter Notably  on Sep 27  2017  Baxter announced the launch of comprehensive asset tracking solution DeviceVue  The solution will be used alongside the company s proprietary pump system  Sigma Spectrum Infusion System  It will aid clinicians and biomedical engineers to quickly find unused pumps by viewing location and status data on PCs  iPads or iPhones  We are bullish on the development as it provides an edge to Sigma Spectrum when compared with other smart pumps in the market Here are the other factors that might influence Baxter s fourth quarter results Sales in Renal business grew significantly in the third quarter on the back of solid performance across all lines of the business  Taking the stellar third quarter performance into consideration  we expect the Renal business to perform well in the yet to be reported quarter as well On Sep 26  2017  Baxter announced the commercial launch of a new indication for the company s oXiris set  which can now be used to remove excessive levels of cytokines  endotoxin and other inflammatory mediators from a patient s blood  The launch is likely to drive the top line in the yet to be reported quarter As per the company s earlier provided guidance  sales in the fourth quarter are expected to increase 1  to 2   Net sales in the quarter are expected to rise 2  at constant currency  The company expects Hurricane Maria to have a negative impact on fourth quarter revenues of around  70 million  The company also expects adjusted earnings in the range of 56 cents to 59 cents per diluted share  This includes a 6 cent negative earnings impact from Hurricane Maria  which is mitigated by an increase in the sales projections for U S  cyclophosphamide and a lower than expected tax rate for the fourth quarter  The Zacks Consensus Estimate for fourth quarter revenues is pegged at  2 76 billion  while the same for earnings is at 58 cents  reflecting a 1 6  increase However  pricing pressure continues to raise caution Here is what our quantitative model predicts Baxter has the right combination of two main ingredients   a positive  and Zacks Rank  3  Hold  or higher   for increasing the odds of an earnings beat Zacks ESP  The Earnings ESP for Baxter International is  1 50   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Baxter International carries a Zacks Rank  3 Meanwhile  the Zacks Consensus Estimate for earnings of 90 cents reflects a 20  improvement on a year over year basis Other Stocks to ConsiderHere are a few other medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter Bio Rad Laboratories   NYSE BIO   has an Earnings ESP of  4 45  and a Zacks Rank  1  Strong Buy   You can see  Myriad Genetics   NASDAQ MYGN   has an Earnings ESP of  0 42  and a Zacks Rank  3 Henry Schein   NASDAQ HSIC   has an Earnings ESP of  0 09  and a Zacks Rank  3 Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-01-22,Zacks Investment Research,https://www.investing.com/analysis/can-baxter-bax-beat-q4-earnings-on-hospital-products-200282801,200282801
116018,337533,HSIC,3 Torched Shorts,opinion,"Even though equity markets are making new lifetime highs every single day of the week  there are pockets of weakness that are working out after all  I wanted to offer three Slope ideas that have been getting torched lately  First up is CBL   Associates Properties  NYSE CBL   mentioned in  a couple of weeks ago 

3D Systems Corporation  NYSE DDD   which I ve harped on about for years and summarized just a  

And  finally  Henry Schein  NASDAQ HSIC  mentioned on 

I feel like I m looking for ice cubes in the Sahara  but    they are out there ",2017-11-07,Tim Knight,https://www.investing.com/analysis/torched-trio-200261351,200261351
116019,337534,HSIC,Top Analyst Reports For Pfizer  Occidental Petroleum   Charles Schwab ,opinion,"Monday  November 13  2017
The Zacks Research Daily presents the best research output of our analyst team  Today s Research Daily features new research reports on 16 major stocks  including Pfizer  NYSE PFE   PFE   Occidental Petroleum  OXY  and Charles Schwab  SCHW   These research reports have been hand picked from the roughly 70 reports published by our analyst team today 
You can see 
Pfizer s shares have underperformed the peer group so far this year  the stock is up  8 3  over this period vs  a  14 5  increase for the Zacks Large Cap Pharmaceuticals industry   Pfizer s Q3 results were mixed as it beat earnings estimates but delivered in line sales  However  the company raised its earnings outlook for the year  
Pfizer is facing headwinds in the form of genericization of key drugs  supply challenges in the legacy Hospira portfolio  pricing pressure and rising competition  which are hurting the top line  Neverthetheless  we believe that new products like Ibrance  contribution from acquisitions  cost cutting efforts and share buybacks should help the company achieve its guidance  
Pfizer also boasts a strong pipeline and expects approximately 25 to 30 drug approvals over the next five years  including around 15 products that have blockbuster potential  Its growing immuno oncology portfolio offers a strong potential  Bavencio is being considered a key long term growth driver for Pfizer 
 You can  
Shares of Occidental Petroleum have outperformed the Zacks Domestic Integrated Oil industry over the last six months  gaining  11 2  vs   6 7   The company s third quarter earnings topped expectations but total revenues fell behind  
The Zacks analyst likes the fundamental strength of the company  which will help it overcome the adverse impact from natural disasters  Occidental Petroleum will benefit from more oil production from its Permian Resources and from concentrating on high margin production region  The company generates stable cash flow and its Chemical plant will further improve its cash flow 
Occidental Petroleum  like other oil and natural gas companies  faces the risks of cost overruns and development interruptions due to delays in drilling and other approvals  property or border disputes and equipment failures  As expected  Hurricane Harvey adversely impacted income and production in the third quarter as the company had to shut down operation in Texas to ward off the impact of the storm 
 You can  
Schwab s shares have outperformed the Zacks Investment Brokers industry over the last three months  gaining  7 7  vs  6 9   The performance was supported by impressive earnings surprise history  as the company did not lag expectations in any of the trailing four quarters  
The company s third quarter 2017 results reflect higher revenues and benefits from rising rates  It remains well positioned to gain from the rising rate environment  Also  initiatives to strengthen trading income are likely to support its profitability in the long run despite the near term reduction in the same  
However  a continuous rise in expenses  due to rise in compensation costs  remains a key concern for the company  Further  significant dependence on fee based revenue streams makes us apprehensive 
 You can  
Other noteworthy reports we are featuring today Bank of New York Mellon  NYSE BK   BK   Prudential  LON PRU   PRU  and S P Global  SPGI  
Will You Make a Fortune on the Shift to Electric Cars 
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge 
With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research 
It s not the one you think 

Mark Vickery
Senior Editor
Note  Sheraz Mian heads the Zacks Equity Research department and is a well regarded expert of aggregate earnings  He is frequently quoted in the print and electronic media and publishes the weekly and reports  If you want an email notification each time Sheraz publishes a new article  please 
Today s Must Read









Featured Reports

Per the Zacks analyst  Prudential continues to put in substantial efforts to boost and expand its international operations  thereby resulting in its overall growth 


Per the Zacks analyst  Ventas  life science real estate investments and reduction in exposure to skilled nursing facilities augur well for growth 


Per the Zacks analyst  higher unit volumes and favorable mix across all regions are boosting Johnson Controls  Power Solutions unit  But  volatile prices of steel  aluminum   copper is a concern 


Per the Zacks analyst  higher rates and rise in demand for loans will support BNY Mellon s net interest margin  Yet  concentration risk arising from dependence on fee based income is a concern 


Per the Zacks analyst  S P Global s strategic portfolio restructuring initiatives and core focus are likely to drive growth  while SNL Financial is expected to be accretive to GAAP earnings in 2018 


The Zacks analyst believes that increase in loan balance and higher interest rates will support SunTrust s revenues  However  slowdown in mortgage business remains a major near term concern 


Per the analyst  buyout of nuTonomy will help Delphi to commercialize its autonomous driving solutions 

New Upgrades

Per the Zacks analyst  realization of its new and incremental business backlogs will help American Axle to diversify its business and customer base and continue with its sales growth 


The Zacks analyst believes that U S  Cellular s strategic initiatives of continuous rollout of 4G LTE network and enhancement of LTE handsets have paid off in terms of the huge subscriber gain 


Per the Zacks analyst  ViaSat is set to benefit from accelerating in flight installs  strong momentum in the government business and the upcoming service launch of the ViaSat 2 satellite 

New Downgrades

The Zacks analyst is concerned about CenturyLink s continuous loss in access lines and fall in high speed broadband subscriber count  High debt levels and decreasing cash flows are other headwinds 


Per the Zacks analyst  TJX Companies  high employee payroll costs have been denting its results for a while now  Further the company expects higher wages to weigh on its pre tax margin in fiscal 2018 


Per the Zacks analyst  escalating costs and expenses and unfavorable product mix are weighing on Henry Schein s bottom line  This apart  competitive pricing remains another cause of concern ",2017-11-13,Zacks Investment Research,https://www.investing.com/analysis/top-analyst-reports-for-pfizer-occidental-petroleum--charles-schwab-200264715,200264715
116020,337535,HSIC,Milestone Scientific  A Compelling Opportunity,opinion,"The biotechnology industry is one that is booming with innovation  Cures for some of the world s most devastating illnesses have been and continue to be invented  new technologies are providing physicians with less invasive and more effective options for treating their patients  and breakthroughs in just about every aspect of the industry are taking place at what seems to be a breakneck pace  As a result  finding a corner of the biotechnology space that has little to no competition with a drastic need for innovation can be overwhelmingly difficult to say the least  Nonetheless  one company   Milestone Scientific Inc   NYSE MLSS    has done just that 
An Introduction To MLSS
Founded in 1991  Milestone Scientific is a medical research and development company that s focused on the industry surrounding subcutaneous drug delivery  which is the delivery of drugs under the skin  Interestingly  the hypodermic syringe was invented more than a century ago  In fact  the medical instrument has been around for more than 160 years  Nonetheless  little to no innovation has taken place surrounding this key medical tool since it was invented  This is where MLSS comes in 
When MLSS was founded  the company went on a mission to change what we know about the fear inducing concept known as the hypodermic needle and syringe  A part of the medical industry that has not only led to fear in one third of patients in the United States and around the world  but has also been starved of the innovation the medical industry had been seeing for years  Ultimately  Milestone Scientific wanted to find a way to relieve the pain  discomfort  and anxiety that comes along with this form of drug delivery 
In doing so  the company quickly learned that the hypodermic needle itself wasn t the source of the pain that has caused this fear  discomfort  and anxiety  Instead  the source of this pain was the pressure created when the medication flowed through the needle and into the patient s body  The syringe concept itself was the problem  In fact  as medicine flows through the broad diameter syringe and into the thin diameter hypodermic needle  enormous pressure is created  That pressure can be up to 300 PSI  Considering that most tires are only pumped to around 30 PSI  one could imagine the damage a drug being sent into the body at 300 PSI could do to tissue 
Enter The World Of Dynamic Pressure   Sensing Technology 
Knowing that the hypodermic needle wasn t the source of the pain  discomfort  and anxiety associated with subcutaneous drug delivery  but that pressure was  MLSS set out to solve the problem  This led to the invention of the company s proprietary DPS    dynamic pressure sensing   technology 
Through this technology  Milestone Scientific unlocked the key to largely pain free subcutaneous drug delivery  By monitoring the pressure at which medicine flowed through the needle and into the patient s body  MLSS was able to greatly reduce pain by reducing the flow of medication based on the pain causing pressure associated with the treatment  However  this wasn t the only benefit of the ability to sense pressure dynamically at the injection site 
In fact  through this pressure sensing technology  MLSS realized that they now had the ability to precisely place the needle where it needed to be in order to get the maximum effect of the treatment that was being delivered subcutaneously  Ultimately  the implications of this technology reached further than even the management at the company would have realized early on 
It All Started With The Wand  
With the information amassed through the creation of the DPS  technology  Milestone Scientific moved to the next step  inventing a tool for the dental industry that s like no other  This tool is known as The Wand   Taking advantage of the dynamic pressure sensing technology  The Wand  offers several benefits to clinicians and patients alike  These benefits include 
For Clinicians 
Single Tooth Anesthesia   Due to the unique ability of The Wand  to sense the pressure at the injection site  the tool allows clinicians to anesthetize a single tooth  The proprietary DPS  technology created by MLSS allows clinicians to place the needle in a very small area required to do so  In fact  that area is only about the width of a few of the same hypodermic needles that are used for the procedure  As a result  patients visiting the dentist no longer have to worry about a quarter of their mouth going numb when getting dental work done 
Reduction In Chair Time   At the end of the day  the longer a patient is in a dentist s chair  the more opportunity for earning that dentist is missing out on and perhaps more importantly  the more anxiety takes place in the patient  Through the use of The Wand  by MLSS  patients spend less time in the chair  giving dentists the ability to earn more within their practice while reducing anxiety among patients 
Reduced Quantity Of Anesthetic   With the ability to anesthetize a single tooth  clinicians can now get the desired result with the use of a reduced amount of anesthetic 
Fewer Complications   With less pain for the patient as well as less numbing effects  dentists who take advantage of The Wand  see fewer complications when treating their patients 
Ergonomic Grip   The Wand  was designed by Milestone Scientific with an ergonomic grip  offering comfort to clinicians 
Reduced Patient Cancellations   Because The Wand  eliminates the pain associated with the injection of an anesthetic  fear and anxiety are reduced among patients  leading to less patient cancellations 
Avoidance Of Tachycardia   Through the use of The Wand   clinicians now have the ability to avoid tachycardia  a serious  life threatening condition that is caused when drugs like anesthesia drugs that include the use of epinephrine are injected into the blood vessel  Because The Wand  uses the DPS  technology  dentists can be sure that the needle is not in a blood vessel  but instead  is in the target location for the treatment  avoiding the problem of tachycardia all together 
For Patients 
Painless Injection   The Wand  by MLSS is designed to offer painless injections  bringing a new level of comfort to patients visiting the dentist 
No Collateral Numbness   Through the use of the DPS  technology  dentists now have the ability to anesthetize a single tooth  avoiding collateral numbness throughout the rest of the mouth and tongue 
Faster Onset Of Anesthesia   With the ability to target a single tooth with pinpoint precision  MLSS has created a way to speed up the process of anesthesia 
As a result of all of the benefits listed above  Milestone Scientific has seen great success surrounding The Wand   In fact  the technology has received both FDA and CE marketing clearance  and more than 45 000 units have been sold leading to more than 70 million injections using the technology to date  In 2016  the company generated more than  10 5 million in sales from the product  This technology has also opened several doors for MLSS  as one would imagine 
First and foremost  MLSS has been awarded with 21 patents  many of which are wide ranging  surrounding its proprietary DPS  technology  On top of that  it has seen favorable evaluations in more than 50 peer reviewed independent clinical research reports  Not to mention what is perhaps the largest validation of their work to date  the company has entered into an agreement with Henry Schein  NASDAQ HSIC  
MLSS Enters Agreement With Henry Schein
Recently  Milestone Scientific reached a substantial milestone when they announced that they had entered into an agreement with Henry Schein  NASDAQ HSIC   The recently announced 10 year exclusive distribution agreement signed with the world s largest provider of dental products opens several doors for the company 
First and foremost  Henry Schein has dedicated 25 sales representatives to the product  and they are supported by 900 field representatives  Henry Schein has also agreed to minimum purchase orders in order to maintain exclusivity through the 10 year period  Through this relationship  MLSS plans to ship approximately 2 800 000 disposables in 2017  which represents about 4  market penetration in a market where about 150 000 dentists perform more than 75 million injections annually 
Revenue Growth 
As if the product offering wasn t enough to get excited about  MLSS has seen some impressive revenue growth on a year over year basis throughout the past 3 years  The chart below shows the exceptional revenue growth the company has seen  In the year 2015  the company generated  4 5 million in revenue  followed by  5 8 million in 2016  and  6 2 million in 2017  With the Henry Schein partnership  the potential for future revenue growth is incredible 
Looking Into The Future 
When looking into MLSS at the moment  you re going to see quite a bit about The Wand  and its use in the dental industry  However  the implications of the DPS  technology go far and wide  In fact  Milestone Scientific received CE marketing approval for instruments in both the intra articular and epidural spaces  In the United States market  the company has received FDA clearance for the CompuFlo epidural instrument and is currently working toward FDA clearance for the intra articular instrument  In fact  MLSS is currently in negotiations with regard to forming strategic distribution partnerships around the world surrounding these applications 
This doesn t even go into mentioning the pediatric  cosmetic  veterinary  and many other applications that MLSS is in the process of tackling with their unique technology  In fact  the company is well on their way in some of these applications 
Ophthalmic Injections   At the moment  the Milestone product pipeline includes a proposed plan to develop an Ophthalmic Instrument in the future  MLSS plans on designing this instrument to address several key needs associated with ophthalmic injections  including wet AMD  diabetic macular edema  and retinal vein occlusions  Through the use of their proprietary DPS  technology  the instrument would provide a virtually painless injection while simultaneously controlling the injection pressure to ensure a safe and effective pressure level during an intro ocular administration 
Pediatric Applications   Currently  MLSS products are being used in various pediatric applications  In particular  The Wand  system is being used with great success in pediatric dentistry  as it improves the patients overall experience and decreases fear  Also  due to the ability to pinpoint anesthetic to a single tooth  children don t inadvertently bite themselves after a dental operation  The pediatric community as also benefiting greatly from Milestone s CompuFlo epidural  In fact  two key opinion leaders in the field of pediatric anesthesia have approached MLSS to initiate clinical research using the company s CompuFlo technology for epidurals in children  While this process is relatively young  the company intends to support any such research and will be able to report the results and findings in the future 
Veterinarian Applications   Finally  even the veterinary industry can benefit from Milestone Scientific s proprietary DPS  technology  In fact  Dr  Louis Campoy has completed multiple studies at Cornell College  During the studies  Dr  Louis Campoy used the CompuFlo technology to perform the Maxillary Foramen Block in a horse  To read the studies  click here  This will be a live link upon publication  
DPS  Technology Targets A Potentially Massive Industry 
When looking into the potential of the DPS  among all currently approved applications and applications under development  it becomes clear that MLSS is addressing a massive market  Just take a look at the number of injections that take place in the United States market alone  generating an industry worth more than  1 billion per year 
Epidural   Between labor and delivery  preoperative pain management  and chronic pain  12 8 million epidurals are performed every year in the United States alone 
Peripheral Nerve Block   9 million peripheral nerve block injections are performed in the United States every year 
Intra articular   5 million intra articular injections in the knees  shoulders  hips  and other joints of the body take place in the United States every year 
Cosmetic   8 4 million Botox injections are performed in the United States every year 
DPS  Is The Key Driver Of Value 
In this article  we ve discussed quite a bit surrounding the dental applications as well as the epidural  intra articular  and other applications of this technology  However  these applications  even when combined  aren t the biggest value proposition associated with this technology  The reality is that the technology MLSS has created has the ability to become a disruptive force in both the drug delivery industry and the intellectual property protection industry  Here s how Drug Delivery 
We are already seeing how DPS  can change the shape of drug delivery in dental and other applications  While the dental applications are building revenue right now  the opportunities down the road are endless  and Milestone Scientific knows it  The company has an ultimate goal of creating hundreds of various medical devices designed for different types of injections  and they are well on their way to doing so  With the ability to detect exactly where the needle is in the human body through the use of pressure feedback  there is an abundant need industry wide for a tool like this 
There are hundreds   and potentially thousands   of uses for a tool like this in the medical industry  and the industry needs a solution  On the industry side of things  about 4 5  of epidural injections end in morbidity  This means that the needle has passed the target  touching the membrane surrounding the spinal column  Every time this happens  another anesthesiologist has to perform another epidural and close the hole created with a blood patch  This can leave the patient with severe migraine headaches for up to 6 weeks  transient paralysis for up to 2 years  or even permanent paralysis  The cost of these issues is massive  In fact  the average settlement in an epidural morbidity case costs the facility around  400 000  not to mention the cost of the additional procedure and the cost of the original doctor not being able to work on the patient  With CompuFlo by MLSS  more than 700 epidurals have been performed with a 100  success rate due to the use of the company s DPS  technology  This is just one corner of the vast market 
However  the company isn t stopping with the injections themselves  Another thing to keep in mind here is that  with every device created  MLSS also sells disposables designed to work with that device  Ultimately  these disposables will create a constant stream of revenue beyond the purchase of the medical instruments themselves 
Patent Protection
Patents expire all the time in the medical industry  it s the nature of the beast  When this happens  the company with the brand name drug loses the vast majority of the market to generic competition  However  Milestone Scientific has a solution for this problem as well 
The company intends to partner with the companies that have created drugs with patent expiration  Through these partnerships  MLSS plans to create medical devices designed around the out of patent treatments  Of course  the new devices will only use the brand name drug  giving the pharmaceutical company a leg up in the market once its patent expires  From there  MLSS could license the technology  wholesale the device to the company  or even sell the rights to the device to the company they partnered with 
The Bottom Line
Milestone Scientific is a company that is well worth watching  As the company s Wand Dental subsidiary continues to grow profitability  the company continues to innovate and expand their offering  proving that their product and business model works  With proprietary disposables that provide high margins and continued innovation in new and exciting products surrounding the massive subcutaneous drug delivery market  MLSS is becoming hard to ignore  As revenue continues to grow  the company is expecting continued expansion in operating margins thanks to a highly scalable business model  Moving forward  the CNA Finance team will be watching for continued growth in The Wand  revenue  continued innovation in the subcutaneous drug delivery industry  and expected catalysts including operating results  study publications  and distribution contracts  all of which are expected to come down the wire relatively soon  We ll continue to follow the story closely and bring the news to you as it breaks 
This article was originally featured on   The author has no positions in any stock mentioned herein ",2017-11-15,CNA Finance,https://www.investing.com/analysis/milestone-scientific-mlss-stock-a-compelling-opportunity-in-a-vast-market-200265423,200265423
116021,337536,HSIC,Cardinal Health  Is The Risk Already Priced In  ,opinion,"Introduction
As a value investor  I am totally cognizant of the reality that attractively valued bargains are hard to find in a strong bull market  Moreover  as an experienced value investor I clearly understand that low valuations in a raging bull market are usually associated with issues and challenges sometimes real  sometimes imaginary  The key to success is to identify when current problems are temporary  thereby creating long term opportunity 
With that said  there are a couple of other aspects of value investing that need to be recognized and understood  As a committed value investor  I will never invest in a stock unless I consider it attractively valued  With extremely high quality companies this can simply mean that valuation needs to be sound or reasonable  With less than stellar companies  valuations need to be extremely low to be of interest  Nevertheless  I will never knowingly overpay for even the best of businesses  On the other hand  just because a company is fairly valued doesn t automatically make it investment worthy 
My point being that although attractive valuation is a critically important investment consideration  it is not the only consideration  From this perspective  valuation is primarily a risk assessment metric more than it is a return assessment  Furthermore  I believe that a comprehensive and thorough research and due diligence effort should be conducted before ever investing in any common stock  However  that requires time and effort on the part of the investor 
Consequently  I will not waste my time or take this important step unless I believe that valuation is attractive enough before I start  To me  as a committed value investor  there is little that is more frustrating than getting all excited about a possible stock investment only to determine that its current valuation is excessive  Unfortunately  it is hard to find attractively valued best of breed stock investments when markets are high like they are today  Unless  of course  the company is faced with issues that Mr  Market is concerned about 
On the other hand  there is nothing a value investor likes better than finding a great business that the market is punishing unjustly  Finding a great business that is undervalued is value investing nirvana  In his 1994 annual report Warren Buffett stated this succinctly as follows   Indeed  we have usually made our best purchases when apprehensions about some macro event were at a peak  Fear is the foe of the faddist  but the friend of the fundamentalist  
To summarize this introduction  finding a great business on sale is a fundamental objective of value investing  However  investing in stocks that meet your specific investment objective is also a sound fundamental practice  In other words  a great stock can be discovered at an attractive valuation and still not be appropriate for your portfolio  For example  you might ignore or reject a non dividend paying growth stock at attractive value because your investment objective is income  This represents another situation where just because a stock is available at an attractive valuation doesn t necessarily imply that it s a good fit for your portfolio 
Cardinal Health Inc  NYSE CAH   A Great Business On Sale  
As I have matured  my investment objective has evolved from attempting to achieve maximum total long term returns to achieving a reliable and growing dividend income stream to supplement my income  Consequently  I am actively looking for attractively valued dividend growth stocks offering dividend yields of 3  or better  This 3  dividend yield goal is not arbitrary  For starters  3  is an above market dividend yield  and secondarily  a yield level that exceeds my income needs  Therefore  my dividend income meets my needs without ever having to harvest principle  shares   This solidifies the opportunity to receive more dividend income through future dividend increases 
Moreover  as stock values have become more and more extended  especially on the majority of high quality dividend growth stocks  such as Aristocrats and Champions   finding attractively valued blue chip dividend growth stocks offering yields of 3  or better has become very challenging  In markets like we have today  there is usually a negative catalyst or catalysts associated with attractive valuations  As previously stated  the trick is to find companies that are either being misappraised by the market  or when the market is overreacting to the negative catalysts 
Cardinal Health Inc   NYSE CAH  is a Dividend Aristocrat that has increased its dividend for 32 consecutive years and is currently yielding 3 3   But perhaps most importantly  I believe the company is worth in the neighborhood of  75 share and is currently available in the mid 50s  Consequently  I believe it offers the rare combination of above average and growing current yield with the opportunity to generate above average capital appreciation over the long run and perhaps the short run as well 
To be clear  I believe that Cardinal Health is facing short term issues that have recently generated weak earnings and cash flows  However  I also believe that the market is currently punishing the company s stock price more than it deserves  Consequently  I suggest that Cardinal Health is an extremely undervalued and therefore attractive Dividend Aristocrat on sale  Furthermore  I do believe the company possesses above average long term growth potential  As a result  I would expect above average longer term total returns resulting from growth coupled with P E ratio expansion  But best of all  Cardinal Health meets my current investment objective because it provides an above average current dividend yield coupled with above average dividend growth 
Additionally  it s also important to point out that my investing strategy and objective is long term buy and hold oriented  As a value investor  I understand that purchasing out of favor stocks can often lead to disappointing short term performance  On the other hand  as a value investor I also understand that purchasing out of favor stocks can lead to enhanced long term total returns at reduced levels of risk  In other words  my investment horizon is at a minimum 3 to 5 years  a typical business cycle  and preferably forever  As an experienced value investor  I have learned that it takes time for a business to increase its intrinsic value  Frankly  it s a lot easier to be patient when the business is paying you lavishly while you wait 
Cardinal Health  Investment Thesis
Once I have identified attractive valuation via FAST Graphs  my next step is to conduct some preliminary research  Therefore  I will look to outside sources such as Morningstar and or Zacks to see what they have to say about the company  Morningstar analyst Vishnu Lekraj in an analyst note on November 6  2017 stated that  Cardinal is one of the most critical players along the pharmaceutical supply chain  The following excerpts provide additional insights into Morningstar s view of Cardinal Health 
 While the firm s results for the quarter were not stellar  we don t believe they reflect the wholesaler s long term position  Accordingly  we are reiterating our wide moat rating and  84 fair value estimate for Cardinal  Pressuring the firm s core pharmaceutical segment was a resetting of its generic portfolio pricing  Over the last year  many independent pharmacy clients have demanded lower generic pricing from their respective pharmaceutical wholesalers and Cardinal s two main rivals  Amerisource and McKesson  NYSE MCK   have had to reprice a material portion of their group purchasing contracts as a result  We believe there has been somewhat of a lag of this trend for Cardinal  which is why its results this quarter were below its peers  
After acknowledging some of the issues facing Cardinal Health and its competitors  Morningstar highlighted Cardinal Health s wide moat as follows 
 Out of all the numerous players along the pharmaceutical supply chain  Cardinal stands out as an elite participant  We believe the firm possesses a wide economic moat  as it is able to turn its significant size and market share into key competitive advantages  Cardinal also plays a critical role within the pharmaceutical industry  given that many supply chain participants depend on its services for streamlined product distribution and procurement  We expect the use of pharmaceuticals to increase over the next several years  which should provide a solid platform for Cardinal s continued success 
Cardinal has also made a few strategic moves that we believe will be beneficial over the long term  For one  it signed an agreement with CVS Caremark where the two firms will combine generic sourcing operations  This should allow it an opportunity to enhance profitability  as the combined sourcing entity will be able to garner greater pricing discounts from generic manufacturers 
Cardinal is the third largest pharmaceutical distributor by revenue and is the main supplier to CVS Health s retail pharmacy network  The firm also supplies several large provider GPOs and mass retailers  The razor thin profitability of these contracts and the enormous amount of capital needed to build a top tier global drug wholesaling distribution operation have formed a solid competitive foundation for Cardinal that has largely kept new entrants at bay  
Therefore  at this cursory level of research and due diligence  Morningstar corroborates my thesis that Cardinal Health is undervalued  However  Zacks Research also provided additional insights that further corroborate my thesis 
Zacks summary 
 Over the last year  Cardinal Health has underperformed the broader industry with respect to price  Increasing generic pricing pressure is a major headwind  Intensifying competition and customer concentration are other bottlenecks  A sluggish macroeconomic scenario and tough product pricing environment are likely to impede growth  Meanwhile  the company is banking on strategic buyouts  joint ventures and supply agreements to drive growth  A solid fiscal 2018 guidance instills our confidence in the stock  Also  Cardinal Health ended first quarter on a solid note  courtesy of an encouraging performance at the Medical segment  Although  the Pharmaceutical segment witnessed strong growth in the Specialty business and gained a huge number of Pharmaceutical Distribution customers  profits at the segment were hurt by generic pharmaceutical pricing and the loss of a major Pharmaceutical Distribution customer  
As is Zacks custom in their research reports they also offer reasons to buy and reasons to sell as follows 
 Reasons to Buy  
Acquisition Drives Growth  Cardinal Health follows an acquisition driven strategy and continues to focus on investment in key growth businesses to gain market traction and boost profits  Cardinal Health announced that it has completed the acquisition of Medtronic s Patient Care  Deep Vein Thrombosis and Nutritional Insufficiency business for  6 1 billion  The Patient Care  Deep Vein Thrombosis and Nutritional Insufficiency business operates across 23 product categories in multiple market sites of care  like industry leading brands of Curity  Kendall  Dover  Argyle and Kangaroo   brands used in nearly every U S  hospital  Cardinal Health expects the acquisition to be accretive to adjusted earnings by more than  0 21 per share in fiscal 2018 
The company has recently entered into an agreement to buy the radioactive diagnostic drug Lymphoseek from Navidea Biopharmaceuticals  In fact over the last five years  the company has spent approximately  5 7 billion on acquisitions of the likes of Cordis  2015   The Harvard Group  2015   AccessClosure  2014   AssuraMed  2013   Kinray  2010   Cardinal Health China  2010  and Healthcare Solutions Holding  2010   These have considerably boosted the company s offerings in diversified fields  The Cordis takeover will expand the company s global footprint over the long haul  Cordis along with AccessClosure will boost the company s portfolio of self manufactured products under the Medical segment  The Harvard Group deal not only expands Cardinal Health s product portfolio but also its existing telesales programs and capabilities  We believe the company will continue to pursue acquisitions which are strategic fits and will also diversify its revenue base over the long term  
Cushioned Against Macroeconomic Sluggishness  Large cap  diversified healthcare distributors such as Cardinal Health are relatively insulated from macro economic uncertainty and a weak economy  Cardinal Health is one of the largest distributors of pharmaceuticals and medical supplies  It has a diversified product portfolio  which is a hedge against the risk of sales shortfall in testing times  The company s generics business continues to show healthy growth  supported by a solid customer base  significant scale of operation and the competence to source products from a complex and global supply network  Cardinal Health has rationalized the number of generic suppliers  In addition  the company has expanded relationships with generic manufacturers that include several benefits like higher service levels  greater clarity on generic cost of goods sold  and a more consistent product supply with fewer disruptions 
Long term Supply Agreements Buoys Optimism  Cardinal Health is also pursuing growth via joint ventures and long term supply agreements with several firms  The company entered a long term strategic agreement with Henry Schein  NASDAQ HSIC  in 2014  under which the latter will purchase Cardinal Health s medical supplies for physician practices  The collaboration is expected to drive core sales and prove accretive to Cardinal Health s earnings in the long term  The signing of a 15 year agreement with Bayer  DE BAYGN  Healthcare for the contract manufacturing of Xofigo is significantly positive  In our opinion  this will help the company leverage its expertise in the nuclear pharmacy industry to expand access to a therapeutic agent and increase the use of radiopharmaceuticals in the U S  and Canada  The Red Oak Sourcing joint venture with CVS Health  NYSE CVS   which will negotiate generic pharmaceutical supply contracts on behalf of both companies  also holds significant long term prospects for Cardinal Health 
Good Client Retention  The performance of Cardinal Health s Pharmaceutical segment has been facilitated by good client retention  with the loss of only a few key customers  Walgreens and Express Scripts   Cardinal Health has already renewed many of its chain customer contracts for subsequent years  The concentration of suppliers has also been well managed by the company 
Strong Balance Sheet  Cardinal Health s strong balance sheet and cash flow enable it to pursue growth opportunities and accretive acquisitions  The company uses its cash flow to return value to investors in the form of dividends and share repurchases  In fiscal 2017  the company returned more than  1 2 billion to shareholders through stock repurchases and dividend payouts  Aggressive share buybacks will boost earnings as well as shareholders  value over the long run  In fiscal 2017  operating cash flow at the company was  1 2 billion  of which  387 million was deployed in capital expenditures 
Reasons to Sell 
Share price movement  Cardinal Health stock price has significantly underperformed thus far in 2017 
Probabilities of Loss of a Major Customer Worrisome  Collectively  5 of Cardinal Health s main customers  including CVS  accounted for as much as 40  of its revenues 
Group Purchasing Organizations  Cardinal Health derives a significant quantum of revenues through agreements with group purchasing organizations  GPO s   The company s largest GPO agents are Asembia  HealthTrust  Innovatix Intalere  Premier Purchasing Partners and 6 others  Loss of any of these agents with severely affect the company sells 
Integration Risks  Cardinal Health continues to acquire a large number of companies  This improves revenue but also adds integration risk 
Cutthroat Competition in Niche Space  Cardinal Health faces tough competition in each of its business segments  
By screening the Standard   Poor s Dividend Aristocrats via FAST Graphs looking for attractive value  Cardinal Health was one of only 7 Dividend Aristocrats that appeared reasonably valued  After reviewing research from Morningstar and Zacks I concluded that Cardinal Health was a stock worthy of conducting a more comprehensive research and due diligence process on  Consequently  my next step is to run it through a comprehensive fundamental valuation analysis utilizing the numerous earnings and cash flow metrics available FAST Graphs 
Cardinal Health Inc   FAST Graphs Analyze Out Loud Valuation Analysis
The following analyze out loud video will present a quick overview of Cardinal Health Inc  based primarily on price relative to earnings and cash flow  However  as discussed above  I will also evaluate several other metrics  For any reader concerned with the current valuation of Cardinal Health Inc   this video is a must watch  Furthermore  although I will be only providing a cursory  or a pre more comprehensive due diligence analysis  I believe you will find the video enlightening and hopefully entertaining 

Summary and Conclusions
Cardinal Health is a powerhouse in its respective industry  It is the second largest by market and third largest by revenues and one of three major pharmaceutical distributors in the US  Yes  it s true that the company   and in fact its entire industry   is currently out of favor with Mr  Market  Nevertheless  the following slide from Cardinal Health s recent annual meeting of shareholders on November 8  2017 summarizes the breadth and depth of Cardinal Health s business 

Although there is certainly a significant amount of perceived risks associated with investing in Cardinal Health or the pharmaceutical distribution industry in general  I believe that the risks are already reflected in the price  Cardinal Health is aware of the changing healthcare landscape and is taking steps to maintain their relevance and profitability  The following slide depicts Cardinal Health s commitment to shareholders and to continuing to support future growth 

In conclusion  I believe that Cardinal Health represents an intriguing investment opportunity given the state of today s stock market  The company and its entire industry are currently out of favor with the market  However  I contend that Cardinal Health s low valuation mitigates much of the risk associated with investing in it while simultaneously provides the opportunity for enhanced long term returns  Consequently  whether your investment objective is high current income and dividend growth or above  average total returns Cardinal Health might deserve a closer look 
Disclosure   Long CAH at the time of writing 
Disclaimer  The opinions in this document are for informational and educational purposes only and should not be construed as a recommendation to buy or sell the stocks mentioned or to solicit transactions or clients  Past performance of the companies discussed may not continue and the companies may not achieve the earnings growth as predicted  The information in this document is believed to be accurate  but under no circumstances should a person act upon the information contained within  We do not recommend that anyone act upon any investment information without first consulting an investment advisor as to the suitability of such investments for his specific situation ",2017-11-22,Chuck Carnevale,https://www.investing.com/analysis/cardinal-health-a-dividend-aristocrat-the-risk-is-already-priced-inpart-2-of-7-200267698,200267698
116022,337537,HSIC,Patterson Companies Dental Business Dull  Competition Rife,opinion,"On Nov 24  we issued an updated research report on Patterson Companies  Inc    NASDAQ PDCO    A rapidly changing healthcare environment in the United States  unfavorable price movements and a competitive dental products distribution industry pose significant challenges for Patterson Companies 
Patterson carries a Zacks Rank  5  Strong Sell   The estimate revision trend for Patterson Companies has been unfavorable  For the current year  eight analysts moved south compared to no movement in the opposite direction over the last month  As a result  the Zacks Consensus Estimate for full year earnings fell to  2 09 from  2 29 
The company exited the second quarter on a tepid note recently  Further  a downbeat guidance and lackluster performance by the dental segment indicate looming concerns  In the quarter  dental sales  40  of total sales  declined 8 4  at cc year over year to approximately  553 6 million  The decline at the segment was caused by decreased sales of CEREC and digital technology products 

Management expects headwinds in the technology based equipment business to persist through fiscal 2018  adding to our concerns  Patterson s stock is slightly expensive at the moment  A comparative analysis of the company s forward P E  TTM basis  multiple reflects a relatively gloomy picture that might be a concern for investors 
Cutthroat competition in the U S  dental products distribution industry is a major dampener  Notably  Patterson faces serious competition from at least 15 full service distributors  that include Henry Schein  NASDAQ HSIC  Dental  a unit of Henry Schein  and numerous small and local distributors 
However  we are upbeat about the company s Animal Health segment that witnessed strong sales last quarter  Patterson provides a wide range of consumable supplies  equipment  software and value added services  The company s broad spectrum of products cushions it against economic downturns in the MedTech space  We believe a diversified product portfolio  strong veterinary business prospects  accretive acquisitions and strategic partnerships are key catalysts 
Patterson s price movement in the past three months has been disappointing  The company represented a negative return of almost 6 3   comparing unfavorably with the broader  s addition of around 5 2  
Key Picks
A few better ranked stocks in the broader medical sector are PetMed Express  Inc    NASDAQ PETS    Myriad Genetics  Inc    NASDAQ MYGN   and Luminex Corp    NASDAQ LMNX    While PetMed and Myriad sport a Zacks Rank  1  Strong Buy   Luminex carries a Zacks Rank  2  You can see 
PetMed has a long term expected earnings growth rate of 10   The stock has rallied roughly 76 8  in a year 
Myriad Genetics has a long term expected earnings growth rate of 15   The stock has gained 12 5  over the last three months 
Luminex has a long term expected earnings growth rate of 16 3   The stock has gained 15 5  over the last three months 
Will You Make a Fortune on the Shift to Electric Cars 
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2017-11-27,Zacks Investment Research,https://www.investing.com/analysis/patterson-companies-dental-business-dull-competition-rife-200268562,200268562
116023,337538,HSIC,Henry Schein Buys EVetPractice  Boosts Technology   VAS Arm,opinion,"Henry Schein  Inc    NASDAQ HSIC   recently completed the buyout of eVetPractice   a provider of cloud based practice management solutions to veterinary clinics  Although the financial terms of the deal have been kept under wraps  the company expects the deal to prove accretive to its earnings per share post 2018 Per the company  the eVetPractice will be a part of Henry Schein s Veterinary Solutions portfolio which comprises AVImark and ImproMed in North America  as well as Vision  RxWorks and RoboVet globally  Notably  eVetPractice is a rapidly growing cloud solutions provider in the United States  with a customer base of around 900  We believe the latest takeover will widen Henry Schein s customer base and portfolio Developments in Technology   VASIn September  Henry Schein had announced the receipt of Office of the National Coordinator for Health Information Technology  ONC Health IT  2015 Edition Health IT Module Certification from Drummond Group LLC for its practice management and electronic health record software   MicroMD The company offers a wide range of practice management software systems covering dental  animal health and medical  It has a customer base of more than 95 000 practices  inclusive of MicroMD for physician practices Continuing with the slew of developments  the company had earlier announced a partnership between Medical Systems and Simplifeye  The combined entity aimed at creating a mobile experience by integration of Simplifeye with Henry Schein s MicroMD  Furthermore  this collaboration aims at allowing physicians to provide more customized patient experiences  simplify their practice workflows and keep concerned team members well connected when away from their workplaces Performance of Technology and VASWe believe this latest development will boost sales in the company s global Technology and Value added Services  VAS  business  Interestingly  this segment saw a 4 1  increase in revenues in the last reported quarter  This included 3 7  growth in local currencies and a 0 4  rise related to foreign currency exchange  Acquisitions contributed 0 7  in the quarter under review Market PotentialAccording to a report by MarketsandMarkets  the global veterinary software market is expected to reach a value of  368 7 million by 2019  at a CAGR of 5 6  during 2014 to 2019  Considering the substantial potential of the market  we believe the latest development is a strategic one Per the company  the increasing trend toward cost control has the potential to drive the demand for technology solutions  Going by another report from MarketsandMarkets  the global healthcare IT market is projected to reach a value of  280 25 billion at a CAGR of 15 9  in the 2016 2021 period We believe an ageing population  unhealthy lifestyle along with rising awareness and expenditure in healthcare will continue to drive growth in the healthcare IT market  This market is dominated by a number of well established players  the NextGen division of Quality Systems  Inc    NASDAQ QSII   being a prominent one Share Price Performance

Replace Cancel",2017-12-18,Zacks Investment Research,https://www.investing.com/analysis/henry-schein-buys-evetpractice-boosts-technology--vas-arm-200274341,200274341
116057,337572,HSIC,What s In Store For Cardinal Health  CAH  In Q1 Earnings ,opinion,"Cardinal Health   NYSE CAH    a global player in the healthcare services and products space  is set to report first quarter fiscal 2018 results on Nov 6  before the closing bell The company reported adjusted earnings of  1 31 per share in the last reported quarter  which beat the Zacks Consensus Estimate of  1 24 and increased 7  on a year over year basis  The stock delivered a positive earnings surprise in each of the trailing four quarters  with an average beat of 5 25  Let s take a look at how things are shaping up prior to the fourth quarter earnings announcement Factors at PlayStrong Outlook  Management at Cardinal Health is bullish about significant cash generation in the first quarter  Furthermore  the company s Cordis business is expected to generate accretive returns in the quarter under review We note that despite solid commercial momentum on a global basis  the Cordis segment generated sluggish returns in the last reported quarter  However  in the first quarter  Cardinal Health is expected to leverage on the Patient Recovery business in the Cordis profile Meanwhile  Cardinal Health affirmed the fiscal 2018 guidance for adjusted earnings per share from continuing operations at  4 85  5 10  The outlook represents growth of approximately 2 5  from the prior fiscal Pricing Pressure in Generics Portfolio  Cardinal Health has been grappling with pricing deflation in the generics segment for long  Per management  reimbursement pressure is likely to affect the company s customer base and also impede generic launches in the near term  Incremental expenses  specifically in the Pharma segment  might dent profits in the first quarter Cutthroat Competition in Niche Space  Cardinal Health witnesses tough competition in each of its business segments  For example  its pharmaceutical supply chain business faces competition from several smaller medical surgical distributors  Intensifying competition in the global markets is likely to mar Cardinal Health s top line in the first quarter Estimate Revision Trend  The company s estimate revision trend lacks luster  For the current quarter  one analyst moved south  compared with no upward revision in the last two months  Over the last three months  the current quarter estimates declined almost 6 5  to  1 01 per share  adding to concerns Earnings WhispersOur proven model does not conclusively show that Cardinal Health is likely to beat earnings this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to beat estimates  This is not the case here  as you will see below Zacks ESP  The Earnings ESP for Cardinal Health is 0 00  as both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at  1 01  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Cardinal Health currently carries a Zacks Rank  4  Sell   We caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into the earnings announcement  especially when the company is seeing negative estimate revisions  Cardinal Health  Inc  Price and EPS Surprise   Stocks that Warrant a Look
 Here are a few companies you may want to consider as our proven model shows that they have the right combination of elements to post an earnings beat this quarter INC Research Holdings  Inc   NASDAQ INCR   has an Earnings ESP of  2 02  and carries a Zacks Rank  3  You can see  Medpace Holdings Inc   NASDAQ MEDP   has an Earnings ESP of  0 47  and carries a Zacks Rank  3 Henry Schein  Inc   NASDAQ HSIC   has an Earnings ESP of  1 23  and carries a Zacks Rank  3 Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-10-24,Zacks Investment Research,https://www.investing.com/analysis/whats-in-store-for-cardinal-health-cah-in-q1-earnings-200220691,200220691
116058,337573,HSIC,Can Molecular Diagnostics Drive Myriad s  MYGN  Q1 Earnings ,opinion,Myriad Genetics  Inc    NASDAQ MYGN   is scheduled to report first quarter fiscal 2018 results on Nov 7  after the closing bell Last quarter  the company posted a positive earnings surprise of 15 4   Moreover  Myriad Genetics beat the Zacks Consensus Estimate in three of the trailing four quarters  the average being 6 2  Let s take a look at how things are shaping up prior to this announcement Key CatalystsSimilar to last quarter  Myriad Genetics is expected to gain from strong Molecular Diagnostics performance led by solid contributions from the GeneSight and EndoPredict tests  The Zacks Consensus Estimate for Molecular Diagnostics revenues of  170 million reflects an increase of 3  from the year ago quarter We are also upbeat about management s expectations of double digit volume growth in fiscal 2018 for GeneSight  Vectra DA  Prolaris and EndoPredict revenues  all of which make up most of the Molecular Diagnostics portfolio  Myriad Genetics  Inc  Price and EPS Surprise     Per the company  the GeneSight test represents significant opportunities  As GeneSight is in the initial stages of adoption and is placed in a highly under penetrated preventive care market  the product has huge growth potential  Management expects consistent growth in GeneSight test revenues in the quarters ahead  The Zacks Consensus Estimate for GeneSight test of  26 1 million reflects an increase of 263 9  from the year ago quarter and 2 4  sequentially In March  the company  launched  the EndoPredict test in the United States for patients with early stage breast cancer and since then has received encouraging response for it  In August  Myriad Genetics received positive coverage decision for the test from Palmetto GBA  a Medicare Administrative Contractor  MAC  and Anthem  Inc   one of the largest private insurers in the United States  Notably  full implementation of this decision will lend Myriad Genetics coverage for approximately 90  of breast cancer patients The company recently announced positive results from a clinical study evaluating EndoPredict which highlights its superiority over the first generation Oncotype DX Breast Recurrence Score in predicting breast cancer recurrence in women determined to be at intermediate clinical risk by the Nottingham Prognostic Index  The Zacks Consensus Estimate for GeneSight test of  2 3 million reflects an increase of 35 3  from the year ago quarter Here are the other factors that might influence Myriad Genetics  first quarter results Management seemed upbeat about the prospects of the Prolaris test  In May  the company announced the receipt of a positive final Local Coverage Determination  LCD  to expand Medicare coverage of the Prolaris test by Palmetto GBA  a MAC Again  in May  the company announced plans of showcasing data demonstrating the utility of the Prolaristest in efficiently predicting the 10 year risk of metastases in men treated for prostate cancer at the American Urological Association  AUA  2017 Annual Meeting  These positive flow of news are expected to to boost the top line in the to be reported quarter  The Zacks Consensus Estimate for Prolaris test revenues of  3 3 million reflects an increase of 13 8  from the year ago quarter Management estimates adjusted earnings per share of 19 21 cents on total revenue of  181  183 million for the first quarter of fiscal 2018   The Zacks Consensus Estimate for adjusted earnings of 21 cents and revenues of  182 million is within the company s guided range On the flip side  unfavorable foreign currency translation continues to pose a threat  With a considerable portion of its revenues coming from outside the United States  the company faces the risk of exchange rate fluctuations  Additionally  macroeconomic uncertainty and higher expenses owing to extensive pipeline of some testsmay impact the company s margins Here is what our quantitative model predicts Our proven model shows that Myriad Genetics is likely to beat earnings because it has the perfect combination of two key ingredients Zacks ESP   Myriad Genetics has an  of  1 04   A favorable Zacks ESP serves as a meaningful and leading indicator of a likely positive earnings surprise  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Myriad Genetics currently carries a Zacks Rank  2  Buy   Note that stocks with a Zacks Rank  1  Strong Buy   2 or 3  Hold  have a significantly higher chance of beating earnings estimates Conversely  we caution against stocks with a Zacks Rank  4 or 5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions The combination of Myriad Genetics  Zacks Rank  2 and  1 04  ESP makes us reasonably confident of an earnings beat Other Stocks Worth a LookHere are a few other medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter The Cooper Companies  Inc    NYSE COO   has an Earnings ESP of  0 24  and a Zacks Rank  2  You can see  Henry Schein  Inc    NASDAQ HSIC   has an Earnings ESP of  1 00  and a Zacks Rank  3 Penumbra  Inc    NYSE PEN   has an Earnings ESP of  31 82  and a Zacks Rank  3 Zacks  Best Private Investment IdeasWhile we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ,2017-10-29,Zacks Investment Research,https://www.investing.com/analysis/can-molecular-diagnostics-drive-myriads-mygn-q1-earnings-200257111,200257111
116059,337574,HSIC,Can Pharmacy Services Drive CVS Health s  CVS  Q3 Earnings ,opinion,"CVS Health Corporation   NYSE CVS   is scheduled to report third quarter 2017 results on Nov 8  before the opening bell  Last quarter  the company delivered a positive earnings surprise of 1 5   Its trailing four quarter average positive earnings surprise is 3 7  Let s take a look at how things are shaping up prior to this announcement Key CatalystsCVS Health is optimistic about sustaining a solid year over year earnings trend in 2017 on the back of gains to be realized from the Pharmacy Services segment  The Zacks Consensus Estimate for third quarter Pharmacy Services segment revenues of  33 1 billion reflects an increase of 8 9  from the year ago quarter s reported number However  there are several timing factors that have already affected the cadence of profit delivery last quarter  One such aspect was the timing of profitability in Medicare Part D business  Per the company  the same is expected to continue through the rest of 2017 CVS Health Corporation Price and EPS Surprise
    Per CVS Health  the timing of Medicare Part D profits in the third quarter remains difficult to forecast  since this is the period when the risk sharing corridor is usually least effective at providing risk sharing protection  Hence  any change in any current estimates like utilization  significantly impacts the timing of profits between the third and fourth quarters The timing of Medicare Part D profitability factor apart  the company expects benefits from enterprise streamlining initiatives to be much more in the back half of the year than the year to date figure  Keeping that in mind  at the last earnings call  the company had projected third quarter adjusted earnings per share of  1 47  1 50  reflecting a decline of 2 5  to an increase of 1  year over year Here are some other factors that might also influence CVS Health s third quarter results The company is worried about its Retail Long Term Care business  wherein revenues are expected to be down 3 25 5  in the third quarter from the year ago period due to the restricted network changes  Notably  the decision to restrict CVS Health from participating in the TRICARE network and many fully insured prime networks have continued to negatively impact Pharmacy sales and script comps  Additionally  the company s adjusted script comps are expected to be in the range of down 0 75  to up 0 25  and the total same store sales to be down in the 4 5 75  band in the yet to be reported quarter However  it expects PBM revenues to grow 8 5  9 75   driven by continued strong growth in volumes and specialty pharmacy  Overall  the Zacks Consensus Estimate for third quarter Retail Pharmacy segment net revenues of  19 3 billion reflects a decline of 3 9  from the year ago quarter s reported figure Consolidated net revenues have projected a 2 75 4 25  rise during the third quarter  Overall  the company estimates to deliver healthy PBM growth on a successful PBM selling season  Specialty business is expected to record strong growth and SilverScript s business also hopes to retain its good performance Here is what our quantitative model predicts Our proven model does not conclusively show that CVS Health is likely to beat on earnings this quarter  This is because a stock needs to have both a positive  and a solid Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  But that is not the case here  as you will see below Zacks ESP   CVS Health has an Earnings ESP of  0 28   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  CVS Health currently carries a Zacks Rank  3  which increases the predictive power of ESP Stocks Worth a LookHere are a few medical stocks worth considering with the right combination of elements to come up with an earnings beat this quarter The Cooper Companies  Inc    NYSE COO   has an Earnings ESP of  0 24  and a Zacks Rank  2  You can see  Henry Schein  Inc    NASDAQ HSIC   has an Earnings ESP of  1 00  and a Zacks Rank  3 Penumbra  Inc    NYSE PEN   has an Earnings ESP of  31 82  and a Zacks Rank of 3 Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2017-10-30,Zacks Investment Research,https://www.investing.com/analysis/can-pharmacy-services-drive-cvs-healths-cvs-q3-earnings-200257314,200257314
116060,337575,HSIC,Can DENTSPLY  XRAY  Deliver A Beat This Earnings Season ,opinion,"DENTSPLY SIRONA Inc  s   NASDAQ XRAY   third quarter 2017 results  scheduled for release on Nov 3  are expected to show lackluster performance by dental consumables and laboratories   one of the major revenue generating components  While this could majorly impact third quarter earnings  an expected improvement in revenues at other segments should help the company post solid numbers Last quarter  DENTSPLY s earnings and revenues missed the Zacks Consensus Estimate  The quarter posted lackluster results in dental and healthcare consumables segment that comprises preventive  restorative  instruments  endodontic and laboratory dental products as well as consumable medical device products  Sales increased just 1 9  to  554 1 million in the quarter The Zacks Consensus Estimate for dental consumables and laboratories stands at  520 million for the third quarter  This reflects a decline of almost 6 5  from the last reported quarter  Notably  DENTSPLY has been grappling with issues pertaining to equipment inventory levels at certain distributor bases  Furthermore  unfavorable consumer trend is likely to mar sales at the segment  DENTSPLY SIRONA Inc  Price and Consensus
     Let s see how things are shaping up for the company prior to this release View Upbeat  The Zacks Consensus Estimate for DENTSPLY s third quarter earnings stands at 67 cents per share  signifying year over year growth of 1 1   For revenues  the consensus estimate stands at  978 4 million  up 2 5  year over year  The company has been witnessing a rebound in Asia  particularly Japan  along with strong growth in Russia  However  the company lowered its outlook for the year  In fact  DENTSPLY s results in the first half of the year have lagged expectations Domestic Market Holds Promise  We are upbeat about the gradual recovery in the U S  market  The emerging markets provide significant opportunities for the company as these areas are vastly untapped with low dental product penetration  In fact  the Zacks Consensus Estimate for revenues in the region stands at  335 million  up 1 5  year over year  Apart from the United States  Europe has been a significant revenue contributor  with internal growth of 2 3  in the last quarter Buoyed by the bullish trends  our quantitative model shows an earnings beat for DENTSPLY this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to be able to beat estimates  This is not the case here  as you will see below Zacks ESP  The Earnings ESP for DENTSPLY is  0 41   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  DENTSPLY currently carries a Zacks Rank  3 Here are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter INC Research Holdings  Inc    NASDAQ INCR   has an Earnings ESP of  1 74  and a Zacks Rank  3  You can see  Penumbra  Inc    NYSE PEN   has an Earnings ESP of  31 82  and a Zacks Rank  3 Henry Schein  Inc    NASDAQ HSIC   has an Earnings ESP of  0 45  and a Zacks Rank  3 Zacks  Best Private Investment IdeasWhile we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ",2017-11-01,Zacks Investment Research,https://www.investing.com/analysis/can-dentsply-xray-deliver-a-beat-this-earnings-season-200257955,200257955
116061,337576,HSIC,Henry Schein  HSIC  Misses Q3 Earnings  Revenues Beat Estimate,opinion,Headquartered in Melville  NY  Henry Schein  Inc    NASDAQ HSIC   is a global leading provider of healthcare products and services  The company serves office based dental  medical and animal health practitioners  dental laboratories  government as well as institutional health care clinics and other alternate care sites  Presently  Henry Schein serves more than 1 million customers and has operations in 32 countries  The company entered the prestigious Standard   Poor s  S P  500 Index in Mar  2015 Currently  Henry Schein has a Zacks Rank  3  Hold  but that could change following its third quarter 2017 earnings report which has just released   You can see  We have highlighted some of the key details from the just released announcement below Earnings  The Zacks Consensus Estimate is pegged at 90 cents per share  Henry Schein s adjusted earnings per share of 87 cents missed this estimate by 3 33  Revenues  Henry Schein posted revenues of  3 16 billion  ahead of the Zacks Consensus Estimate for revenues of  3 05 billion Key Stats  Revenues in the third quarter derived from Henry Schein s Dental segment grew 11 1  year over year to  1 48 billion  while Animal Health segment recorded sales of  882 6 million  up 11 7  compared with the prior year quarter  Revenues from Medical segment increased 8  year over year to  690 8 million  while sales from Technology and Value added services segment grew 4 1  to  109 million Henry Schein  Inc  Price and EPS Surprise     Major Factors  Per management  its four global segments gained solid market share during the quarter and delivered solid earnings growth on back of the strategy to grow the business organically and through acquisitions  The company decreased the higher end of the earlier provided range of  3 59  3 65 of  adjusted EPS guidance for 2017 to  3 59  3 61 Stock Price  Following the earnings release  share prices did not show any significant movement in the pre market trading session Check back later for our full write up on this Henry Schein earnings report later Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2017-11-05,Zacks Investment Research,https://www.investing.com/analysis/henry-schein-hsic-misses-q3-earnings-revenues-beat-estimate-200258489,200258489
116085,337600,HSIC,Can CR Bard  BCR  Spring A Surprise This Earnings Season ,opinion,"CR Bard Inc    NYSE BCR   is scheduled to report third quarter 2017 earnings  after market closes on Oct 24  Last quarter  the company reported adjusted earnings of  2 92  exceeding the Zacks Consensus Estimate by 8 cents  Also  the company s earnings surpassed the Zacks Consensus Estimate in all the last four quarters with an average beat of 4 03  Delving into the fundamentals of the stock  let s see how things are shaping up prior to this release Factors at PlayWe believe that the growing adoption of the company s flagship Lutonix drug coated balloon  DCB  will continue to be the key growth catalyst in the to be reported quarter  In this regard  Lutonix DCB is used to treat patients suffering from peripheral arterial disease  PAD   Within the Endovascular business  peripheral PTA line sales are solely driven by accelerating demand for the Lutonix DCB in the United States  We expect this product to significantly contribute to the company s top line in this quarter  The Zacks Consensus Estimate for the third quarter revenues is currently pegged at  989 8 million  up 5 1  However  the management expects revenues growth of 5  to 6  on a reported basis  Excluding the impact of foreign exchange  the company projects revenues to increase between 6  and 7  from the prior year Furthermore  the company s investments in emerging markets have strengthened its position internationally  We are also upbeat on the solid contribution from the company s vascular product line  The urology and oncology segments are likely to drive third quarter sales On a positive note  the company portrays an impressive price performance  In the past three months  shares of CR Bard have returned 1 0  compared with the  s decline of 4 7  On the flip side  a challenging Med tech environment  especially in the hernia fixation and peripheral stent businesses raises concerns  The company continues to witness significant pricing pressure as well  Also  unfavorable foreign currency will continue to hurt top  and bottom line growth Furthermore  uncertainties associated with the possibilities of a repeal of the Affordable Care Act under President Trump add to the company s concerns Earnings WhispersOur quantitative model doesn t point to an earnings beat either this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here as you will see below Zacks ESP  The Earnings ESP for CR Bard is 0 00   This is because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at  2 95  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  CR Bard currently carries a Zacks Rank  3  which increases the predictive power of ESP  However  the company s ESP of 0 00  makes surprise prediction difficult We caution against stocks with a Zacks Ranks  4 or 5  Sell rated  going into the earnings announcement  especially when the company is seeing negative estimate revisions C R  Bard  Inc  Price and EPS Surprise     
Stocks to ConsiderHere are a few companies you may want to consider as our proven model shows that they have the right combination of elements to post an earnings beat this quarter   Abbott   NYSE ABT   has an Earnings ESP of  0 17  and carries a Zacks Rank  2  You can see  Align Technology  Inc   NASDAQ ALGN   has an Earnings ESP of  2 06  and carries a Zacks Rank  3 Henry Schein  Inc   NASDAQ HSIC   has an Earnings ESP of  0 33  and carries a Zacks Rank  3 5 Trades Could Profit  Big League  from Trump PoliciesIf the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course  Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ",2017-10-17,Zacks Investment Research,https://www.investing.com/analysis/can-cr-bard-bcr-spring-a-surprise-this-earnings-season-200219304,200219304
116086,337601,HSIC,Will PBM Slowdown Hamper Express Scripts  ESRX  Q3 Earnings ,opinion,"Express Scripts Holding Company   NASDAQ ESRX   is scheduled to report third quarter 2017 results on Oct 24  after market close  The results are expected to show a decline in revenues at the pharmacy benefit manager  PBM  segment   one of the major revenue components  While this could majorly affect its earnings  let us take a look at how things are shaping up before the release The Zacks Consensus Estimate for PBM revenues stands at  23 226 million  reflecting a decline of 3 8  sequentially and 4 8  from the year ago quarter  This St  Louis  MO based company is the largest PBM in North America  Although PBM is a highly competitive industry  a report by Market Research projects that the U S  PBM market will see a CAGR of 7 2  between 2014 and 2019 Taking this into account  Express Scripts has been consistently trying to expand its core PBM business  The company completed the acquisition of myMatrixx  a pharmacy benefit solution provider for the workers  compensation industry recently  Furthermore  the company anticipates compounded annual EBITDA growth rate between 2  to 4  through 2020 for the core PBM business The Zacks Consensus Estimate for net sales stands at  25 611 billion  up 0 8  on a year over year basis Express Scripts Holding Company Price and Consensus
     Factors at PlayComing to the major components  the Zacks Consensus Estimate for PBM product network stands at  11 069 million  down 8 9  year over year  The Zacks Consensus Estimate for PBM service revenues stands at  365 million  down 3 2  year over year  Lackluster performance in these segments is likely to mar Express Scripts  revenues in the third quarter Coming to the guidance for the third quarter of 2017  Express Scripts expects total adjusted claims in the range of  340 million to  350 million  Notably  the Zacks Consensus Estimate for total claims stands at  243 million  down 2 1  sequentially Adjusted earnings per diluted share for the third quarter are estimated in the range of  1 88 to  1 92  representing growth of 8  to 10  on a year over year basis  This excludes any contribution from Anthem and other transitioning clients In this regard  Express Scripts announced that its biggest customer  leading health insurer Anthem Inc    NYSE ANTM    is not likely to extend its pharmacy benefits management agreement  which is slated for expiration by the end of 2019  Per management  Express Scripts might lose almost 50  of its revenues related to the Anthem contract in the third quarter itself In 2016  Anthem sued Express Scripts for overcharging for its drugs and operational failures  Meanwhile  in the second quarter of 2017  Anthem generated revenues of  52 6 million  compared with  106 6 million in the second quarter of 2016 Here is what our quantitative model predicts Express Scripts has the right combination of two main ingredients   a positive  and Zacks Rank  2  Buy   Notably  the Earnings ESP for Express Scripts is  0 13   You can uncover the best stocks to buy or sell before they re reported with our  In fact  the Zacks Consensus Estimate for earnings reflects an increase of 9 2  on a year over year basis Other Stocks to ConsiderHere are a few other medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter Abbott   NYSE ABT   has an Earnings ESP of  0 17  and a Zacks Rank  2  You can see  Henry Schein  Inc    NASDAQ HSIC   has an Earnings ESP of  0 33  and a Zacks Rank  3 Looking for Stocks with Skyrocketing Upside  Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-10-17,Zacks Investment Research,https://www.investing.com/analysis/will-pbm-slowdown-hamper-express-scripts-esrx-q3-earnings-200219276,200219276
116089,337604,HSIC,Will Recall Issue Hurt Boston Scientific  BSX  Q3 Earnings ,opinion,"Boston Scientific Corporation   NYSE BSX   is scheduled to report third quarter 2017 results before the opening bell on Oct 26 Last quarter  the company delivered a positive earnings surprise of 3 23   The trailing four quarter average beat is pegged at 0 84   Let s see how things are shaping up prior to this announcement Key CatalystsWe are optimistic about the company s gradually improving performance in Interventional Cardiology  IC   led by an innovative portfolio and robust commercial teams globally  The company while gaining share in a number of cardiovascular segments and DES  Drug Eluting Stent   continues to build momentum globally Boston Scientific Corporation Price and EPS Surprise   
 However  ahead of earnings release  we believe the quarter s IC business to be grossly impacted by the company s product recall issue within Europe  Notably  last February  the company recalled one of its prime products  the Lotus range of heart devices from Europe due to device malfunctions  The company also delayed submission of its U S  marketing application for its Lotus Edge device The above product line has little hope to return to the European and other markets before the fourth quarter  This might lead to a major setback for the company s fast growing transcatheter aortic valve replacement  TAVR  business within IC in the soon to be reported quarter While we believe the downbeat IC business to earn some boost from the company s recent  435 million acquisition of Switzerland based Symetis SA  a full recovery may take time Accordingly  the  Zacks Consensus Estimate for third quarter IC revenues is currently pegged at  580 million  lower than the sequentially last quarter s reported number of  603 million Other Factors at PlayAmong the segments  MedSurg is expected to demonstrate a consistent performance  led by endoscopy  Urology and Women s Health are also estimated to grow beyond market levels  driven by investment strategies in key international geographies The Zacks Consensus Estimate for third quarter endoscopy revenues is pegged at  403 million  significantly higher than the year ago quarter s reported figure of  367 million  For Urology and Women s Health  the current Zacks Consensus Estimate of  266 million remains ahead of the year ago reported tally of  248 million On the flip side  severe currency headwinds that Boston Scientific has been facing of late  remain a concern  In fact  as the company records 47  of its sales from international markets  it remains highly exposed to currency fluctuations  In 2017  Boston Scientific expects an unfavorable foreign exchange challenge to the tune of  85 million on revenues and 700 bps or 8 cents per share on earnings Overall  Boston Scientific s third quarter 2017 adjusted earnings are expected in the band of 29 31 cents per share on revenues of  2 18  2 21 billion Here s what our quantitative model predicts Boston Scientific does not have the right combination of two main ingredients   a positive  and a favorable Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold    for increasing the odds of an earnings beat  You can see  Zacks ESP  Boston Scientific has an Earnings ESP of  0 69   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Boston Scientific carries a Zacks Rank  4  Sell   which fails to increase the predictive power of ESP Stocks to ConsiderHere are a few medical stocks worth considering with the right combination of elements to beat estimates this quarter Thermo Fisher Scientific   NYSE TMO   has an Earnings ESP of  0 33  and a Zacks Rank  2 Align Technology  Inc    NASDAQ ALGN   has an Earnings ESP of  2 06  with a Zacks Rank  3 Henry Schein  Inc    NASDAQ HSIC   has an Earnings ESP of  0 33  and also carries a Zacks Rank of 3 The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2017-10-17,Zacks Investment Research,https://www.investing.com/analysis/will-recall-issue-hurt-boston-scientific-bsx-q3-earnings-200219560,200219560
116090,337605,HSIC,Will Edwards Lifesciences  EW  Gain On THVT In Q3 Earnings ,opinion,"Edwards Lifesciences Corporation   NYSE EW   is scheduled to report third quarter 2017 earnings on Oct 24  after market close Last quarter  the company had posted a positive earnings surprise of 22 7   It is worth noting that Edwards Lifesciences has outperformed the Zacks Consensus Estimate in three of the preceding four quarters  with an average positive earnings surprise of 10 8   Let s take a look at how things are shaping up prior to this announcement Key CatalystSimilar to the prior quarter  Edwards Lifesciences is expected to gain from strength in Transcatheter Heart Valve Therapy segment  THVT   Banking on continued therapy adoption across all geographies with notable strength in the United States  the company is expected to maintain this bullish trend in the third quarter of 2017 as well Growth in THVT was driven by excellent clinical performance results from SAPIEN 3 as well continued strong therapy implementation across all regions in the last reported quarter  Moreover  with the receipt of expanded FDA approval for SAPIEN 3 valve in early June 2017 is expected to further boost the top line at the THVT segment in the to be reported quarter Also  the Zacks Consensus Estimate for THVT net sales of  496 million reflects an increase of 20 9  from the year ago quarter  The Zacks Consensus Estimate for transcatheter heart valves  THV  sales in the United States of  322 million shows an increase of 23 8  from the year ago quarter  Overall  third quarter revenues are projected at  833 89 million 
Edwards Lifesciences Corporation Price and EPS Surprise
  
   Here are the other factors that might influence Edwards Lifesciences  third quarter results In the domestic market  Edwards Lifesciences is expected to continue with its strong performance based on strength in THVT and two other segments   Surgical Heart Valve Therapy and Critical Care The company witnessed strength in Surgical Heart Valve Therapy on the back of strong uptake of the EDWARDS INTUITY Elite valve system  Progressing in Surgical Heart Valve Therapy  the company received FDA approval for INSPIRIS RESILIA aortic valves in July 2017  On the other hand  growth in Critical Care group was led by double digit growth in Enhanced Surgical Recovery Program  especially in the United States Also  the Zacks Consensus Estimate for net sales in the United States of  467 million reflects an increase of 11 9  from the year ago quarter Edwards Lifesciences earlier raised its full year 2017 sales expectations to the high end of the previously provided range of  3 2  3 4 billion Moreover  we note that the company projected total sales between  810 million and  850 million and adjusted earnings per share of 80 cents to 90 cents for the third quarter On the flip side  tough competition in the cardiac devices market and reimbursement issues continue to challenge the company We also believe that unfavorable foreign currency will affect the company s gross margin in the to be reported quarter  Also  management expects the third quarter to be the seasonally lowest quarter  which adds to the concerns Here is what our quantitative model predicts Edwards Lifesciencesdoes not have the right combination of two main ingredients   a positive  and Zacks Rank  3  Hold  or higher   for increasing the odds of an earnings beat Zacks ESP  The Earnings ESP forEdwards Lifesciences is  1 83   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Edwards Lifesciences carries a Zacks Rank  3  which increases the predictive power of ESP  However  we also need to have a positive ESP to be confident of a positive earnings surprise Nonetheless  the Zacks Consensus Estimate for earnings of 87 cents reflects a 27 9  improvement on a year over year basis Stocks Worth a LookHere are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter Abbott   NYSE ABT   has an Earnings ESP of  0 17  and a Zacks Rank  2  Buy   You can see  Align Technology  Inc    NASDAQ ALGN   has an Earnings ESP of  2 06  and a Zacks Rank  3 Henry Schein  Inc    NASDAQ HSIC   has an Earnings ESP of  0 33  and a Zacks Rank  3 
The Hottest Tech Mega Trend of All
Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2017-10-17,Zacks Investment Research,https://www.investing.com/analysis/will-edwards-lifesciences-ew-gain-on-thvt-in-q3-earnings-200219554,200219554
116091,337606,HSIC,Can Illumina  ILMN  Maintain Balanced Growth In Q3 Earnings ,opinion,Illumina  Inc    NASDAQ ILMN   is slated to report third quarter fiscal 2017 results  after markets close on Oct 24  Last quarter  the company delivered a positive earnings surprise of 20 6  with average earnings beat of 9 3  in three of the trailing four quarters  Let s see how things are shaping up for this announcement Key CatalystsSimilar to the prior quarter  Illumina is expected to gain from strong performance in Product revenues as well as Service and other revenue segments  Over the last few quarters  the company s product revenues increased primarily onrising sequencing consumable revenues  Total Service and other revenues are demonstrating strong growth led by continued demand for NextSeq from NIPT customers and partners  We expect these factors to drive the yet to be reported quarter s performance as well The Zacks Consensus Estimate for Product revenues of  579 million reflects an increase of 12 6  from the year ago quarter  Also  the Zacks Consensus Estimate for Service and other revenues of  116 million indicates a rise of 24 7  from the year ago quarter Overall  third quarter 2017 total revenues are projected at  694 million  up 14 3  from the prior year quarter  Illumina  Inc  Price and EPS Surprise     Here are the other factors that might influence Illumina s third quarter results Illumina earlier announced that its FDA approved next generation sequencing  NGS     Extended RAS Panel has met the Current Colorectal Cancer Guidelines  This new kit fulfills the most up to date guidance for RAS testing to determine eligibility of epidermal growth factor receptor  EGFR  inhibitors in metastatic colorectal cancer  Management expected the shipment of this kit to start in the third quarter of 2017  Hence  we expect this to drive the top line In the second quarter  Illumina witnessed 12  growth in the Asia Pacific region  propelled by 16  rise in China  Among the emerging markets  China currently offers the most favorable space for Illumina s business growth  In recent times  management has noticed a considerable rise in demand from customers looking to set up NIPT operations in China  With China currently being the fourth largest developing nation  in terms of nominal GDP   we believe the progress in the country will open up channels for Illumina  thereby driving its top line in the yet to be reported quarter Also  encouraged by the solid second quarter performance  Illumina has raised its full year 2017 revenue growth expectations to 12  from the earlier provided range of 10 12   On the flip side  a tough competitive landscape may pose a challenge for the company  We are also apprehensive about issues pertaining to NIH funding which Illumina has been facing for quite some time now Here is what our quantitative model predicts Illumina does not have the right combination of two main ingredients   a positive  and a Zacks Rank  3  Hold  or better   for increasing the odds of an earnings beat Zacks ESP  The Earnings ESP for Illumina is  0 93   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Illumina carries a Zacks Rank  3  which increases the predictive power of ESP  However  we also need to have a positive ESP to be confident of a positive earnings surprise Nonetheless  the Zacks Consensus Estimate for earnings of 98 cents reflects a 1  improvement on a year over year basis Stocks Worth a LookHere are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter Abbott   NYSE ABT   has an Earnings ESP of  0 17  and a Zacks Rank  2  Buy   You can see  Align Technology  Inc    NASDAQ ALGN   has an Earnings ESP of  2 06  and a Zacks Rank  3 Henry Schein  Inc    NASDAQ HSIC   has an Earnings ESP of  0 33  and a Zacks Rank  3 The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2017-10-17,Zacks Investment Research,https://www.investing.com/analysis/can-illumina-ilmn-maintain-balanced-growth-in-q3-earnings-200219542,200219542
116093,337608,HSIC,Walgreens Boots  WBA  To Report Q4 Earnings  What s In Store ,opinion,Walgreens Boots Alliance  Inc    NASDAQ WBA   is slated to release fourth quarter and full year fiscal 2017 results before the market opens on Oct 25 Last quarter  the company had posted a positive earnings surprise of 1 53   It is worth noting that Walgreens has outperformed the Zacks Consensus Estimate in three of the preceding four quarters  with an average positive earnings surprise of 2 63   Let s take a look at how things are shaping up prior to this announcement Factors at PlayWalgreens Boots  Retail Pharmacy USA division continued to witness comparable prescription growth as well as strength in retail prescription market in the last reported quarter  Notably  in the fiscal second quarter  the Retail Pharmacy USA division saw the highest comparable prescription growth in more than seven years Several planned developments  early benefits of new pharmacy contracts and volume increase from previously announced strategic pharmacy partnerships have been driving growth in this space over the past few quarters  We expect this growth momentum to continue in the fiscal fourth quarter as well Walgreens Boots Alliance  Inc  Price and EPS Surprise    Based on a promising performance in the preceding quarter  Walgreens Boots raised the low end of its guidance for fiscal 2017 by 8 cents and currently expects full year adjusted earnings in the range of  4 98 to  5 08  Also  the Zacks Consensus Estimate for fiscal fourth quarter earnings of  1 22 reflects a 14  improvement on a year over year basis  Moreover  the Zacks Consensus Estimate for fiscal fourth quarter revenues of  30 09 billion reflects a 5 1  improvement on a year over year basis However  the sales performance of the Retail Pharmacy international division continued to disappoint  The reduction in government pharmacy funding in the U K  has been affecting performance  In absence of any near term catalyst  we expect the scenario to persist in the upcoming quarter as well We also note that slowdown in generic introduction has been affecting Walgreens Boots  margins  Of late  increased reimbursement pressures as well as generic drug cost inflation have been denting margins  In the third quarter of 2017  Walgreens Boots  gross margin contracted on account of reimbursement pressure and price inflation of branded drugs Management continues to witness lower profitability in Boots UK comparable pharmacy s gross profit due to lower margin products  Although the company is working to boost efficiency and provide high quality  cost effective pharmacy services  the near term outlook remains bleak Meanwhile  market growth is expected to be strong in certain emerging markets backed by the timing of price increase  Also  in order to expand its footprint in Asia  the company launched its first Boots franchise store in South Korea in April 2017  This development is expected to boost the top line in the fiscal fourth quarter In September 2017  Walgreens Boots announced the receipt of U S  Federal Trade Commission  FTC  approval for the purchase of 1 932 stores  three distribution centers and related inventory from Rite Aid for a total value of  4 375 billion  Post the new transaction s initial closing  synergies of  300 million are expected to be entirely realized within four years of its initial completion  Per Walgreens Boots  this modified merger contract will extend its growth strategy and offer additional operational benefits  It will help the company expand and optimize retail pharmacy network in key U S  markets  including the Northeast Here is what our quantitative model predicts Walgreens Bootsdoes not have the right combination of two main ingredients   a positive  and Zacks Rank  3  Hold  or higher   needed for increasing the odds of an earnings beat Zacks ESP  The Earnings ESP forWalgreens Boots is  0 44   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Walgreens Boots carries a Zacks Rank  4  Sell  Meanwhile  we caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks Worth a LookHere are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter The Cooper Companies  Inc    NYSE COO   has an Earnings ESP of  0 62  and a Zacks Rank  2  Buy   You can see  Align Technology  Inc    NASDAQ ALGN   has an Earnings ESP of  2 06  and a Zacks Rank  3 Henry Schein  Inc    NASDAQ HSIC   has an Earnings ESP of  0 33  and a Zacks Rank  3 Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2017-10-19,Zacks Investment Research,https://www.investing.com/analysis/walgreens-boots-wba-to-report-q4-earnings-whats-in-store-200219906,200219906
116097,337612,HSIC,Will GNC Holdings  GNC  Disappoint This Earnings Season ,opinion,GNC Holdings  Inc    NYSE GNC    a specialty retailer of health and nutrition related products  is scheduled to report third quarter 2017 results on Oct 26  before the opening bell Last quarter  the company posted a positive earnings surprise of 2 5   However  GNC Holdings  trailing four quarter earnings average miss stands at 19 9  Let s see how things are shaping up prior to this announcement Factors at PlayGNC Holdings  last reported second quarter 2017 revenues dropped 4 8  year over year  Apart from lower sales at the U S    Canada international and manufacturing wholesale segments  the decline in revenues can be attributed to an overall drop in sales of protein  vitamins  weight management and food and drink categories  In absence of any catalyst to drive growth  we expect a similar trend in the third quarter of 2017 as well Moreover  GNC Holdings has a number of competitors in the market that include large international pharmacy chains  supermarket firms and big U S  based companies with global operations  Thus  we expect the company to slash product prices in the face of stiff competition  which in turn  might hurt margins  GNC Holdings  Inc  Price and EPS Surprise     Also  currency headwinds continue to be a growing concern for GNC Holdings  Management also expects the failure to comply with FTC regulations and changing consumer preferences to hamper business However  on the bright side  the performance of One New GNC is improving gradually  Also  in the last reported quarter  PRO Access members doubled their visits  purchased double the products and spent significantly more in the second quarter  Banking on these factors  we expect the company to continue to gain in the yet to be reported quarter as well  Meanwhile  new consumer enrolment under the myGNC Rewards Program and launch of GNC storefront on Amazon  NASDAQ AMZN  buoy optimism Earnings Whispers   Our proven model does not conclusively show an earnings beat for GNC Holdings this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here  as you will see below Zacks ESP  The Earnings ESP for GNC Holdings is  14 50   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  GNC Holdings carries a Zacks Rank  3  which increases the predictive power of ESP  However  we also need to have a positive ESP to be confident of a positive earnings surprise Stocks to ConsiderHere are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter The Cooper Companies  Inc    NYSE COO   has an Earnings ESP of  0 43  and a Zacks Rank  2  You can see  Henry Schein  Inc    NASDAQ HSIC   has an Earnings ESP of  0 62  and a Zacks Rank  3 Thermo Fisher Scientific Inc    NYSE TMO   has an Earnings ESP of  0 33  and a Zacks Rank  2 Wall Street s Next AmazonZacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2017-10-19,Zacks Investment Research,https://www.investing.com/analysis/will-gnc-holdings-gnc-disappoint-this-earnings-season-200220015,200220015
116102,337617,HSIC,Henry Schein  HSIC  Q3 Earnings To Show Growth In All Lines,opinion,"Henry Schein  Inc    NASDAQ HSIC   is expected to report third quarter 2017 results on Nov 1 
Last quarter  the company delivered a positive earnings surprise of 1 2   Encouragingly  Henry Schein s earnings surpassed the Zacks Consensus Estimate in all of the past four quarters  at an average of 2 8  
Let s see how things are shaping up prior to this announcement 
Why a Likely Positive Surprise 
Our proven model shows that Henry Schein is likely to beat earnings because it has the perfect combination of two key ingredients 
Zacks ESP   Henry Schein has an  of  1 23  as the Most Accurate estimate is 91 cents  while the Zacks Consensus Estimate is lower at 90 cents  A favorable Zacks ESP serves as a meaningful and leading indicator of a likely positive earnings surprise  You can uncover the best stocks to buy or sell before they re reported with our  
Zacks Rank  Henry Schein currently carries a Zacks Rank  3  Hold   Note that stocks with a Zacks Rank  1  Strong Buy   2  Buy  or 3 have a significantly higher chance of beating earnings estimates 
Conversely  we caution against stocks with a Zacks Rank  4 or 5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions 
The combination of Henry Schein s Zacks Rank  3 and  1 23  ESP makes us reasonably confident of an earnings beat 
Henry Schein  Inc  Price and EPS Surprise
 
   Factors at Play
Henry Schein s second quarter 2017 results were quite impressive  recording growth across all four segments   Dental  Animal Health  Medical and Technology and Value Added Services  Geographically  the company gained traction in both North America and overseas  We expect a similar trend in the third quarter as well 
The company s strategy to expand digital dentistry globally is also encouraging  We are also upbeat about management s expectations to witness at least low single digit growth in North America s dental consumable merchandise market in the second half of 2017  The Zacks Consensus Estimate for third quarter total revenues of  3 049 billion reflects an increase of 6 4  from the year ago quarter 
The company is currently banking on digital dentistry  which is part of its strategic plan  Henry Schein is busy promoting digital workflows for general dentistry as well as dental specialties  Beginning Sep 1  2017  the company started selling the full range of Dentsply Sirona dental equipment across North America  including the leading CEREC CAD CAM restoration system  This is expected to boost the top line to some extent 
Notably  during the second quarter  Henry Schein Animal Health opened a new National Distribution Service Center  NDSC  in Columbus s Brookhollow neighborhood  This has helped the company operate as a complete solution provider for veterinary practices across the country  We expect this to boost the top line in the yet to be reported quarter 
On the flip side  Henry Schein s disappointing gross and operating margins over the past few quarters due to higher cost of sales and expenses is a matter of concern 
This apart  currency fluctuations and a tough competitive landscape add to the woes  Also  the entry of group purchasing organizations  GPOs  in the United States has intensified competition 
Overall  Henry Schein expects 2017 EPS in the range of  7 17  7 30  reflecting 8 10  growth from the 2016 EPS figure of  6 61 
Stocks Worth a Look
Here are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter 
The Cooper Companies  Inc    NYSE COO   has an Earnings ESP of  0 43  and a Zacks Rank  2  You can see  
Thermo Fisher Scientific Inc    NYSE TMO   has an Earnings ESP of  0 19  and a Zacks Rank  2 
Align Technology  Inc    NASDAQ ALGN   has an Earnings ESP of  0 74  and a Zacks Rank  3 
Will You Make a Fortune on the Shift to Electric Cars 
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2017-10-23,Zacks Investment Research,https://www.investing.com/analysis/henry-schein-hsic-q3-earnings-to-show-growth-in-all-lines-200220502,200220502
116120,337635,HSIC,DENTSPLY SIRONA Strong On Deal Renewals  Forex Woes Stay,opinion,On Oct 11  we issued an updated research report on New York based DENTSPLY SIRONA Inc    NASDAQ XRAY     a global leader in the design  development  manufacture and marketing of dental consumables and dental laboratory products DENTSPLY recently announced the renewal of an existing distribution agreement with Henry Schein  NASDAQ HSIC  Canada  Inc  which will continue till Dec 31  2020  Henry Schein s agreement with DENTSPLY was initiated in August 2005 We feel that the deal extension is a smart move by DENTSPLY as the preexisting agreement did not include the CEREC CAD CAM restoration system and the Schick line of imaging sensors  By including the aforementioned lines of products  the company will benefit from Henry Schein s distribution network in Canada Among the recent developments  DENTSPLY announced the renewal of its partnership with Pacific Dental Services  The duo s latest agreement extends for a period of five years which was signed in 2012 This move is also a strategic one as Pacific Dental s network consists of over 580 centers across 17 states  During the tenure of the present agreement  management expects the number of such offices utilizing DENTSPLY technologies to exceed 800 DENTSPLY s dual branding strategy  product innovation  growth opportunities in emerging markets  especially Asia Pacific and Middle East Africa   diversified product portfolio and recurring revenue base are key catalysts  The company expects a solid guidance for full year 2017 projecting adjusted EPS in the range of  2 65  2 75 On the flip side  apart from a series of macroeconomic headwinds  currency fluctuation continues to be a major dampener  In fact  strengthening of the U S  dollar against Euro and other emerging market currencies has dented the company s growth trajectory  Furthermore  higher capital expenditure on product development is expected to keep margins under pressure Share Price   Estimate Revisions Lack LusterDENTSPLY s estimate revision trend looks unfavorable at the moment  For the third quarter  two analysts moved south  compared to no upward revision in the last two months  Notably  the current quarter estimates dropped 1 5  to 67 cents per share over the last 60 days DENTSPLY s share price movement has been unfavorable over the last three months  The company shed 11 7   much higher than the  s decline of 4 4    Zacks Rank   Key PicksDENTSPLY currently carries a Zacks Rank  3  Hold   A few better ranked stocks in the broader medical sector are Abbott   NYSE ABT    IDEXX Laboratories  Inc   NASDAQ IDXX   and Thermo Fisher Scientific Inc   NYSE TMO    Abbott  IDEXX Laboratories and Thermo Fisher carry a Zacks Rank  2  Buy   You can see  Abbott has a long term expected earnings growth rate of 10 7   The stock has rallied roughly 35 2  over a year IDEXX Laboratories has a long term expected earnings growth rate of 19 8   The stock has gained 40 8  over a year Thermo Fisher has a long term expected earnings growth rate of 11 7   The stock has gained 25 3  last year Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2017-10-11,Zacks Investment Research,https://www.investing.com/analysis/dentsply-sirona-strong-on-deal-renewals-forex-woes-stay-200218410,200218410
116123,337638,HSIC,Henry Schein Closes Merritt Buyout  Expands In Animal Health,opinion,Henry Schein  Inc    NASDAQ HSIC   recently completed the earlier announced buyout of Merritt Veterinary Supplies under certain undisclosed financial terms  With this  Merritt will be part of the veterinary business of Henry Schein  namely  Henry Schein Animal Health Merritt is an independent  family owned supplier of animal health products  Merritt has 4 500 veterinary clinics across the eastern United States  with a strong presence in the southeastern part of the nation  The company offers a comprehensive line of products  including pharmaceuticals  diagnostics and equipment  Merritt generated revenues of approximately  115 million in 2016 According to Henry Schein  this acquisition will drive earnings per share after 2017 Henry Schein has been consistently trying to expand its Animal Health business  The company s global Animal Health segment witnessed 4 4  improvement in revenues in the last reported second quarter  Recently  Henry Schein Animal Health announced the opening of a new National Distribution Service Center in Columbus  Brookhollow neighborhood  expanding its presence in central Ohio   At the beginning of 2017  Henry Schein had entered the Brazilian animal health market with a 51  investment in Tecnew  a privately held distributor of animal health products  Prior to that  the company had acquired RxWorks  a leading provider of veterinary practice management software  primarily to customers in Australia  New Zealand  the U K   the Netherlands and other countries According to a report by Grand View Research  the global animal health market is expected to reach a value of  58 4 billion by 2025  Considering the huge potential of the market  we believe the latest development is strategic Over the past year  Henry Schein has underperformed the broader   The stock has gained 3 4   compared with the broader industry s 10 2  rise Estimate Revision Trend The estimate revision trend has been favorable for the company  For the current quarter  two estimates moved north compared with two movements in the opposite direction over the last month  As a result  the Zacks Consensus Estimate for the current quarter has increased to 90 cents per share from 89 cents Zacks Rank   Key PicksHenry Schein currently carries a Zacks Rank  3  Hold   A few better ranked stocks in the medical sector are QIAGEN   NASDAQ QGEN    IDEXX Laboratories  Inc    NASDAQ IDXX   and Thermo Fisher Scientific Inc    NYSE TMO    QIAGEN  IDEXX Laboratories and Thermo Fisher carry a Zacks Rank  2  Buy   You can see QIAGEN has a long term expected earnings growth rate of 13 1   The stock has rallied roughly 31 9  last year IDEXX Laboratories has a long term expected earnings growth rate of 19 8   The stock has gained 42 8  last year Thermo Fisher has a long term expected earnings growth rate of 11 7   The stock has gained 27 2  last year Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2017-10-12,Zacks Investment Research,https://www.investing.com/analysis/henry-schein-closes-merritt-buyout-expands-in-animal-health-200218422,200218422
116128,337643,HSIC,Can ResMed  RMD  Maintain Balanced Growth In Q1 Earnings ,opinion,"ResMed   NYSE RMD   is slated to report first quarter fiscal 2018 results  after markets close on Oct 26  Last quarter  the company delivered a positive earnings surprise of 2 7   with average earnings beat of 1 7  for three of the trailing four quarters  Let s see how things are shaping up for this announcement Key CatalystsSimilar to the prior quarter  ResMed is expected to gain from strong performance in the domestic and international front  The company s revenues in the domestic front were driven by solid growth in devices as well as low double digit software sales growth in the previous quarter Internationally  the company s receipt of French reimbursement approval for telemonitoring buoys optimism  The company believes this reimbursement grant will drive the uptake of Air Solutions ecosystem  including the AirSense 10 and the AirCurve 10 device platforms as well as AirView and myAir software platforms in the to be reported quarter The Zacks Consensus Estimate for domestic revenues  including the contributions from Brightree  of  334 million reflects an increase of 10 9  from the year ago quarter  Also  the Zacks Consensus Estimate for international revenues of  177 million indicates a rise of 7 5  from the year ago quarter Overall  fiscal first quarter total revenues are projected at  501 million  up 7 7  from the prior year quarter 
ResMed Inc  Price and EPS Surprise   Here are the other factors that might influence ResMed s first quarter results Management is particularly upbeat about top line contributions from launches made in the last fiscal and the last reported quarter  The introduced products include the AirFit  N20  the AirFit  F20  AirTouch full face masks  and the world s smallest continuous positive airway pressure  CPAP    ResMed AirMini ResMed continues to progress steadily on the back of its three pronged growth strategy  In this regard  the company recently announced two tuck in acquisitions under the Brightree product portfolio   Conduit Technology  LLC and AllCall Connect  Moreover  during the last reported quarter  the company progressed with Brightree s new offering Outcome and Assessment Information Set  OASIS  for the home health and hospice market  We expect this to get reflected in ResMed s top line in the first quarter  The current Zacks Consensus Estimate for Brightree revenues of  36 9 million reflects an increase of 11 5  from the year ago quarter On the flip side  management expects SG A expenses margin in the band of 26 27  in the to be reported quarter  while it was 26 6  in fourth quarter fiscal 2017  Also  R D expenses margin is projected at 7 8  for first quarter fiscal 2018 as compared to 6 6  in the preceding quarter  This guidance reflects another quarter of gloomy operating margin scenario Meanwhile  the company generates a significant portion of its revenues from international markets  This exposes the company to foreign currency fluctuations  Notably  in the last reported quarter  foreign exchange movements hurt earnings by 3 cents per share  reflecting the unfavorable impact of the weaker Euro and stronger Australian dollar relative to the U S  dollar  This is likely to dent results in the first quarter Moreover  overall macroeconomic uncertainties are a major obstacle for the company s international operations Also  the market for sleep disordered breathing  SDB  products is highly competitive with respect to product price  features and reliability  Other challenges like competitive bidding and reimbursement pressure continue to hurt the stock Here is what our quantitative model predicts ResMed does not have the right combination of two main ingredients   a positive  and Zacks Rank  3  Hold  or higher   for increasing the odds of an earnings beat Zacks ESP  The Earnings ESP for ResMed is 0 00  as the Most Accurate estimate and the Zacks Consensus Estimates are pegged at 65 cents  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  ResMed carries a Zacks Rank  2  Buy   which increases the predictive power of ESP  However  we also need to have a positive ESP to be confident of a positive earnings surprise Nonetheless  the Zacks Consensus Estimate for earnings of 65 cents reflects a 4 8  improvement on a year over year basis Stocks Worth a LookHere are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter Abbott   NYSE ABT   has an Earnings ESP of  0 17  and a Zacks Rank  2  You can see  Align Technology  Inc    NASDAQ ALGN   has an Earnings ESP of  2 06  and a Zacks Rank  3 Henry Schein  Inc    NASDAQ HSIC   has an Earnings ESP of  0 33  and a Zacks Rank  3 5 Trades Could Profit  Big League  from Trump PoliciesIf the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ",2017-10-15,Zacks Investment Research,https://www.investing.com/analysis/can-resmed-rmd-maintain-balanced-growth-in-q1-earnings-200219073,200219073
116130,337645,HSIC,Here s Why Investors Should Sell Patterson Companies Now,opinion,"Patterson Companies Inc    NASDAQ PDCO   has had a dismal run on the bourses of late  Year to date  the company has lost 8 8   underperforming the broader industry s gain of 15 3  
A rapidly changing healthcare environment in the United States  unfavorable price movement  a competitive dental products distribution industry and integration risks pose significant challenges for the company 
Political Qualms  The ongoing political conundrum pertaining to the repealing of Obamacare by the Republicans has given rise to uncertainties in the dental space  Last week  the MedTech space received a heavy blow with Trump s latest  Executive Order   where he pulled the plug on Obamacare subsidies that reduce net health care costs for Americans with low income again 
These legislations and regulations are expected to affect expenditures or reimbursements for dental services through private dental insurance plans  We believe this will mar Patterson s overall results in the quarters to come 
Dental Segment Lacks Luster  Patterson s dental segment contributes significantly to total revenue every year  42 7  of net revenues in fiscal 2017   However  decrease in sales of CEREC and other digital technology equipment is likely to mar revenues for dental consumables and dental equipment 
Furthermore  management at Patterson anticipates headwinds in technology equipment business to persist through fiscal 2018 as the company transitions to its new go to market strategy with an expanded technology product portfolio 
Declining Estimates  The estimate revision trend for Patterson has been unfavorable  For the full and next year  two analysts moved south compared to no movement in the opposite direction over the last two months 
As a result  the Zacks Consensus Estimate for the full year inched down 0 9  to  2 29 per share  The next year earnings estimates dropped 1 2  to  2 48 per share  The stock has a Zacks Rank  4  Sell  Patterson Companies  Inc  Price and Consensus
 

   Cutthroat Competition  The U S  dental products distribution industry is highly competitive and consists principally of national  regional and local full service and mail order distributors  Patterson faces competition from another national full service firm  Henry Schein Dental  a unit of Henry Schein   NASDAQ HSIC   
In addition  there are at least 15 full service distributors that operate on a regional level and hundreds of small local distributors  Patterson needs to continue to introduce products in the market to counter competition  Failure to do so will dent the company s market share 
Key Picks
A few better ranked stocks in the broader medical sector are SONOVA HOLDING   OTC SONVY   and Luminex Corp    NASDAQ LMNX    SONOVA and Luminex sport a Zacks Rank  1  Strong Buy   You can see  
SONOVA represented a solid return of 14 5  over the last year  The company has a long term expected earnings growth rate of 7  
Luminex came up with a positive earnings surprise of 188 9  last quarter  The stock has a long term expected earnings growth rate of 16 3  
5 Trades Could Profit  Big League  from Trump Policies
If the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course 
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates and spending surges in defense and infrastructure ",2017-10-16,Zacks Investment Research,https://www.investing.com/analysis/heres-why-investors-should-sell-patterson-companies-now-200219109,200219109
116132,337647,HSIC,Henry Schein  HSIC  Inks Distribution Agreement With Terason,opinion,Henry Schein Medical  a subsidiary of Henry Schein  Inc    NASDAQ HSIC    announced an exclusive distribution agreement with Terason to distribute the latter s uSmart 3200T NexGen  This development remains a part of Henry Schein Medical s Emergency Medical Services   EMS   business Terason a division of Teratech Corporation is a manufacturer of portable ultrasound machine  uSmart 3200T is a portable ultrasound device that allows emergency responders to carry out exams in emergency medical transport vehicles and aircrafts  This reduces the need to speculate for EMS professionals  uSmart 3200T NexGen is a portable light weight ultrasound tablet  easy to transport and operate  The Terason uSmart 3200T features many advanced features including customized presets  fast boot up  grab and go portability and Wi Fi capabilities  Responders can recognize issues at the point of care  during transportation and also alert emergency room staff of important vitals with uSmart 3200T  According to the company  accessing patient s vitals will help emergency responders make more informed decisions on treatment  Also  it helps emergency room staff to prepare ahead of the patient s arrival   Henry Schein is consistently working toward boosting its Medical segment  Notably  worldwide Medical revenues rose 6 1  year over year in the last reported second quarter  Henry Schein Medical recently inked an agreement with Cerebral Assessment Systems   CAS   to distribute Cognivue  This is the first computerized cognitive assessment screening device cleared by the FDA for the detection of early signs of dementia  Moreover  Henry Schein announced a partnership with Simplifeye to create a mobile platform for health care providers who use its practice management and electronic health record software   MicroMD According to a report by Markets and Markets  the ultrasound market is expected to reach a value of  6 86 billion by 2021  at a CAGR of 5 2  during 2016 to 2021  Considering the substantial potential of the market  we believe the latest development is a strategic one Over the past year  Henry Schein has underperformed the broader   The stock has gained 6 8   compared with the 10 3  gain of the broader industry Estimate Revision TrendThe estimate revision trend has been favorable for the company  For the current quarter  two estimates moved north compared with five movements in the opposite direction over the last two months  As a result  the Zacks Consensus Estimate for current quarter earnings per share has increased to 90 cents from 89 cents Zacks Rank   Key PicksHenry Schein has a Zacks Rank  3  Hold   A few better ranked stocks in the medical sector are Abbott   NYSE ABT    IDEXX Laboratories  Inc    NASDAQ IDXX   and Thermo Fisher Scientific Inc    NYSE TMO    Abbott  IDEXX Laboratories and Thermo Fisher carry a Zacks Rank  2  Buy   You can see Abbott has a long term expected earnings growth rate of 10 7   The stock rallied roughly 32 7  over the last year IDEXX Laboratories has a long term expected earnings growth rate of 19 8   The stock gained 40 9  last year Thermo Fisher has a long term expected earnings growth rate of 11 7   The stock gained 26 1  last year Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2017-10-16,Zacks Investment Research,https://www.investing.com/analysis/henry-schein-hsic-inks-distribution-agreement-with-terason-200219266,200219266
116136,337651,HSIC,What To Expect From Thermo Fisher  TMO  In Q3 Earnings,opinion,Medical instruments manufacturer  Thermo Fisher Scientific  Inc    NYSE TMO   is slated to release third quarter 2017 results on Oct 25  before the market opens Last quarter  the company posted earnings of  2 30 per share  surpassing the Zacks Consensus Estimate by 1 3   In fact  Thermo Fisher s earnings outpaced the Zacks Consensus Estimate in all the past four quarters with an average beat of 2 3   Let s see how things are shaping up prior to this announcement Key CatalystThe acquisition of FEI has already started generating synergies and largely contributing to this Waltham MA based company s analytical instruments portfolio from the last two quarters  The acquisition has enabled Thermo Fisher to access FEI s industry leading high performance electron microscopy platform used for protein study and facilitating life science research  This is also a vital highlight of the quarter to be reported Thermo Fisher Scientific Inc Price and EPS Surprise   Thermo Fisher anticipates realizing total synergies of approximately  80 million by the end of three years following the deal s closure with about  55 million of cost synergies and roughly  25 million of adjusted operating income benefits from revenue related synergies  This should get reflected in third quarter 2017 performance Overall  the company is gearing up for yet another quarter of strong analytical instruments segmental growth  In the third quarter  Thermo Fisher expects to see a positive impact from the electron microscopy business as well as strong volume leverage and productivity The Zacks Consensus Estimate for Analytical Instruments operating income is pegged at  233 million  in line with the sequentially last quarter s reported number  Total revenue estimate for this segment also remains at an impressive level of  1 11 billion Here are other factors that might influence Thermo Fisher s third quarter results The company s focus to boost growth through implementation of strategies and strengthening of its product offerings is encouraging  These initiatives are likely to help it post solid results in the third quarter The company had spent  750 million on research and development in 2016 and the same trend is continuing through the last couple of quarters in 2017  A major development in this field is that Novartis  chimeric antigen receptor T cell  CAR T  therapy Kymriah  the first FDA approved cell therapy for Leukemia  utilizes Thermo Fisher s CTS Dynabeads Technology We expect all innovations and product launches to significantly contribute to the company s top line in the third quarter itself The company s aim to expand capabilities in the fast growing Asia Pacific zone as well as the emerging markets should also lead to impressive results  Standout contributors in recent times are China  India and South Korea  With strategic investments to support key customer applications  Thermo Fisher hopes to maintain this bullish momentum for the rest of 2017 Growth is also likely to be seen in applied markets such as  environmental and food safeties apart from life science  In addition  the company is currently betting on some key areas under focus with enormous opportunities  These are advancing precision medicines from mass spectrometry to the targeted gene sequencing and structural biology  However  we are apprehensive about Thermo Fisher citing a foreign exchange headwind on 2017 revenues and adjusted EPS  Also  an unfavorable macroeconomic condition continues to weigh heavily on the stock  Plus  stiff competition continues to impose challenges on the stock s value Here s what our quantitative model predicts Thermo Fisher has the right combination of the two main ingredients   a positive  and a favorable Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold    for an earnings beat  You can see  Zacks ESP  Thermo Fisher has an Earnings ESP of  0 37   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Thermo Fisher carries a Zacks Rank  2  Buy   which increases the predictive power of ESP Other Stocks to ConsiderHere are a few medical stocks worth considering as our model indicates them to consist of the right combination of elements to to post an earnings beat this quarter Abbott   NYSE ABT   has an Earnings ESP of  0 17  and a Zacks Rank of 2 Align Technology  Inc    NASDAQ ALGN   has an Earnings ESP of  2 06  with a Zacks Rank  3 Henry Schein  Inc    NASDAQ HSIC   has an Earnings ESP of  0 33  and aslo carries a Zacks Rank of 3 Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2017-10-16,Zacks Investment Research,https://www.investing.com/analysis/what-to-expect-from-thermo-fisher-tmo-in-q3-earnings-200219339,200219339
116160,337675,HSIC,Patterson Companies Grapples With Multiple Issues  Dump Now ,opinion,On Jul 4  we issued an updated research report on St  Paul  MN based The Patterson Companies   NASDAQ PDCO    a leading distributor in the dental  companion pet veterinarian and rehabilitation supply markets  The company currently carries a Zacks Rank  4  Sell  Patterson Companies  unimpressive performance at the dental segment is a key concern  In fact  the 8 3  deterioration on a year over year basis in the last reported quarter dented overall results Coming to dental equipment  sales declined 17  in the last quarter  primarily due to lower sales of Sirona products and a tough comparison with regard to the year ago quarter Patterson Companies  stock looks a little expensive at the moment  A comparative analysis of the company s forward P E  TTM basis  multiple reflects a relatively gloomy picture that might be a concern for investors  The multiple currently stands at 20 14  a bit stretched when compared with its own range over the last one year  median of 18 32  Cutthroat competition in the U S  dental products distribution industry is a major dampener  Notably  Patterson Companies faces serious competition from at least 15 full service distributors  that include Henry Schein  NASDAQ HSIC  Dental  a unit of Henry Schein  and hundreds of small and local distributors The company is also expected to face challenges from the disruption caused by its sales force realignment initiative  High operating expenses have been a major drag on margins Unfavorable Estimate RevisionOwing to the above mentioned factors  the Zacks Consensus Estimate for full year 2017 earnings dropped almost 3  to  2 33 per share  as seven out of eight analysts revised their estimates downward over the last 60 days For the current quarter  four analysts moved south compared to no movement in the opposite direction over the last two months  As a result  the Zacks Consensus Estimate for the current quarter fell 6 7  to 45 cents Dismal Share Price TrendPatterson Companies has had a disappointing run on the bourse over the past three months  The company returned almost 6 3   lower than the Zacks categorized  sub industry s gain of almost 10 5   However  the current level is slightly higher than the S P 500 s return of 4 0  over the same time period Stocks to ConsiderBetter ranked stocks in the broader medical sector include Inogen Inc    NASDAQ INGN    Mesa Laboratories  Inc    NASDAQ MLAB   and Edap Tms S a    NASDAQ EDAP    Notably  all these stocks sport a Zacks Rank  1  Strong Buy   You can see  Inogen has a long term expected earnings growth rate of 17 50   Notably  the stock represents an impressive one year return of 100  Mesa Laboratories delivered a positive earnings surprise of 2 84  over the last four trailing quarters  Notably  the stock represents an impressive one year return of 16 7  Edap Tms represents an impressive one year return of 2 2  for the last three months  The company pulled off a solid earnings surprise of 533 3  in the last reported quarter Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2017-07-04,Zacks Investment Research,https://www.investing.com/analysis/patterson-companies-grapples-with-multiple-issues:-dump-now-200199223,200199223
116161,337676,HSIC,Med Product Stocks Aug 8 Earnings Roster  HSIC  AGIO   More,opinion,"We are at the last lap of Q2 earnings season and per the   till Aug 4  around 420 S P 500 members  86 7  of the Index s total market cap  have reported their quarterly numbers Putting together these results  we can see that the pace of earnings and revenue growth is steadily accelerating from relative to pre season expectations  The latest scorecard shows an 11 6  year over year increase in total earnings for these members on 5 6  higher revenues  The earnings beat ratio was 74 5  and the revenue beat ratio was 69 2  What s in Store for the Medical Space Medical  one of the 16 broader Zacks sectors  is absolutely no exception to this improvement trend  So far  83 6  of the members from this sector have released the quarterly earnings results with earnings and revenue beats registered at impressive levels of 87  and 69 6   respectively  With more and more companies lining up for their earnings announcement  the aggregate growth pace of this sector is expected to pick up further Notably  the medical device industry boasts some powerful long term tailwinds  including mergers   acquisitions  M A   emerging market expansion  positive demographic trends and new product innovation  These have been a major driving force behind the sector s laudable performance over the past few quarters even amid severe socio economic and political instabilities Let s find out how five major Medical   Products companies within the broader  space are placed ahead of their earnings releases on Aug 8 Henry Schein  Inc    NASDAQ HSIC    This renowned healthcare products and service distributor s strategy to expand digital dentistry globally is encouraging  Notably  management expects at least mid single digit growth in North America s dental equipment market in the second quarter  The company is currently banking on digital dentistry as part of its strategic plan  It is thus busy promoting digital workflows for general dentistry as well as dental specialties Henry Schein is scheduled to report second quarter 2017 results before the market opens However  our proven model does not conclusively show that the company is likely to beat on earnings this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  But that is not the case here as the stock currently carries a Zacks Rank  2 with an Earnings ESP of 0 00   which makes surprise prediction difficult Based on the Zacks methodology  a positive Zacks ESP serves as a leading indicator of a likely earnings surprise  while a bullish Zacks Rank increases the predictive power of the ESP  You can uncover the best stocks to buy or sell before they re reported with our   Read More   Henry Schein  Inc  Price and Consensus    Agios Pharmaceuticals  Inc    NASDAQ AGIO    As a development stage company  Agios has not approved of products in its portfolio yet  Investors are thus expected to keep an eye on pipeline updates at the earnings call  It is worth mentioning that the company has several interesting pipeline candidates  Its cancer pipeline comprises Idhifa  enasidenib   AG 120  IDH1 mutant inhibitor  and AG 881  pan IDH mutant inhibitor   Importantly  Agios is developing enasidenib and AG 881 in collaboration with Celgene Corporation  NASDAQ CELG   Research Report   which should bring in collaboration revenues  Agios Pharmaceuticals is scheduled to report second quarter 2017 results on Aug 8  In our previous article      we were not certain of an earnings beat this season  However  estimates changed thereafter  The company currently carries a Zacks Rank  3 with an Earnings ESP of  1 99   which makes us confident about a positive earnings surprise  Hence  we expect it to beat estimates this quarter We caution against all Sell rated stocks   4 or 5  going into an earnings announcement   Agios Pharmaceuticals  Inc  Price and Consensus

    Penumbra Inc    NYSE PEN    We are content with the company s focus on product development and innovation which should get reflected in the second quarter itself  Significantly  research and development expenses surged 40 1  in the first quarter  In line with this  the company introduced a product under the Indigo family  CAT D  Also  the company recently received an FDA clearance for 3D revascularization device within its neuro franchise segment The company is scheduled to report second quarter 2017 earnings after the market closes  It currently carries a Zacks Rank  3  which increases the predictive power of ESP  However  the company s Earnings ESP of 0 00  makes surprise prediction difficult  Hence  we are unable to conclude if Penumbra is likely to beat on earnings this quarter  Read More   You can see  Penumbra  Inc  Price and Consensus    OPKO Health  Inc    NASDAQ OPK    This is a multinational biopharmaceutical and diagnostics company  Its diagnostics business includes Bio Reference Laboratories  the nation s third largest clinical laboratory with a core genetic testing business  Its pharmaceutical business features RAYALDEE  an FDA approved treatment for SHPT in stage 3 4 CKD patients with vitamin D deficiency and VARUBI for chemotherapy induced nausea and vomiting among others The company is also scheduled to report second quarter 2017 earnings after the closing bell  It currently carries a Zacks Rank  2 and an Earnings ESP of 0 00  Opko Health  Inc  Price and Consensus    STERIS Plc   NYSE STE    Headquartered in Ohio  STERIS develops  manufactures and markets infection prevention  decontamination  microbial reduction  plus surgical and gastrointestinal support products and services The company is scheduled to report first quarter fiscal 2018 earnings before the opening bell  It currently carries a Zacks Rank  2  which though increases the predictive power of ESP  its Earnings ESP of  1 25  however leaves our earnings surprise prediction inconclusive STERIS PLC Price and Consensus   5 Trades Could Profit  Big League  from Trump PoliciesIf the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ",2017-08-06,Zacks Investment Research,https://www.investing.com/analysis/medproduct-stocks-aug-8-earnings-roster-hsic-agio--more-200205681,200205681
116162,337677,HSIC,Henry Schein  HSIC  Q2 Earnings   Revenues Beat  View Intact,opinion,"Henry Schein  Inc    NASDAQ HSIC   reported adjusted earnings per share  EPS  of  1 75 in the second quarter of 2017  up 6 7  year over year  Adjusted EPS also surpassed the Zacks Consensus Estimate of  1 73  The year over year upside in earnings was driven by strong revenue growth Henry Schein s reported net income in the second quarter came in at  139 3 million or  1 75 per share  reflecting year over year growth of 2 9  and 6 7   respectively Revenues in DetailHenry Schein reported revenues of  3 06 billion in the second quarter  up 6 5  year over year and also above the Zacks Consensus Estimate of  3 05 billion  The year over year improvement came on the back of 7 7  growth in local currencies partially offset by a 1 2  decline owing to foreign currency exchange  At local currencies  internally generated sales increased 4 4  and acquisition growth was 3 3  
Henry Schein  Inc  Price  Consensus and EPS Surprise   The company recorded sales of  2 03 billion in the North American market  up 5 6  year over year  Sales were  1 03 billion in the international market  up 8 3  year over year Segment Analysis    Henry Schein derives revenues from four operating segments  Dental  Medical  Animal Health  and Technology and Value added services In the second quarter  the company derived  1 49 billion in revenues from global Dental sales  up 8 4  year over year  This includes 9 4  growth in local currencies and 1  decline owing to foreign currency exchange  At local currencies  internally generated sales increased 3 1  and acquisition growth was 6 3   Internal growth at local currencies included 3 8  growth in North America and 2  rise internationally The company s global Animal Health segment witnessed 4 4  improvement in revenues to  891 3 million  This includes 6 7  growth in local currencies and 2 3  decline related to foreign currency exchange  At local currencies  internally generated sales increased 5 8  and acquisition growth was 0 9   The 5 8  internal growth in local currencies included 5 9  growth in North America and 5 7  growth internationally Worldwide Medical revenues scaled 6 1  year over year to  571 4 million  Growth in local currencies was 6 2   with a 0 1  decrease owing to adverse foreign exchange Revenues from global Technology and Value added Services grew 1 4  to  108 5 million  This included 2 8  growth in local currencies and a 1 4  decline related to foreign currency exchange  There was 0 6  contribution from acquisitions during the quarter under review Margin Trends         Gross profit increased 4 7  to  839 2 million in the reported quarter  However  gross margin declined 50 basis points  bps  from the year ago quarter to 27 4  due to a 7 2  rise in cost of sales  higher than the revenue growth rate   Despite a 4 7  rise in selling  general   administrative expenses of  628 5 million  adjusted operating income improved 4 8  year over year to  210 7 million  Moreover  adjusted operating margin remained flat year over year at 6 9  in the reported quarter Financial PositionHenry Schein exited second quarter 2017 with cash and cash equivalents of  74 7 million  compared with  62 8 million at the end the first quarter  Year to date net cash provided by operating activities was  228 7 million  compared with  277 2 million in the year ago period During the quarter under review  the company bought back approximately 289 000 shares for almost  50 million  At the close of the second quarter  the company had  150 million authorized for future repurchases of its common stock 2017 EPS Guidance IntactHenry Schein reaffirmed its 2017 reported EPS guidance  except for the  0 04 litigation settlement expense   The company still expects EPS in the range of  7 17  7 30  reflecting 8 10  growth from the 2016 EPS figure of  6 61   The Zacks Consensus Estimate for 2017 adjusted EPS is  7 28  within the guided range Our TakeHenry Schein exited second quarter 2017 on a solid note with earnings and sales beating the Zacks Consensus Estimate  All four of its operating segments delivered strong year over year growth  The company s strong share gains in both the North American and overseas markets along with strong revenues raise optimism However  despite the better than expected earnings performance  we are disappointed with the company s unchanged EPS guidance for 2017  Meanwhile  the year over year deterioration in Henry Schein s gross and operating margin was due to higher cost of sales and expenses  Also  foreign currency fluctuations continued to mar the company s financials Zacks Rank   Key PicksHenry Schein has a Zacks Rank  2  Buy   A few other top ranked medical stocks are Edwards Lifesciences Corporation   NYSE EW    INSYS Therapeutics  Inc    NASDAQ INSY   and Align Technology  Inc    NASDAQ ALGN    Notably  Edwards Lifesciences  INSYS Therapeutics and Align Technology sport a Zacks Rank  1  Strong Buy   You can see INSYS Therapeutics has a long term expected earnings growth rate of 20   The stock posted a stellar four quarter average earnings surprise of 60 7  Align Technology has an expected long term adjusted earnings growth of almost 26 6   The stock has added roughly 25 9  over the last three months Edwards Lifesciences has a long term expected earnings growth rate of 15 2   The stock has gained around 5 9  over the last three months Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-08-07,Zacks Investment Research,https://www.investing.com/analysis/henry-schein-hsic-q2-earnings--revenues-beat-view-intact-200206077,200206077
116163,337678,HSIC,Henry Schein  HSIC  Tops Q2 Earnings And Revenues Estimate,opinion,Headquartered in Melville  NY  Henry Schein Inc    NASDAQ HSIC   is a global leading provider of healthcare products and services  The company serves office based dental  medical and animal health practitioners  dental laboratories  government as well as institutional health care clinics and other alternate care sites  Presently  Henry Schein serves more than 1 million customers and has operations in 28 countries  The company entered the prestigious Standard   Poor s  S P  500 Index in Mar  2015 Currently  Henry Schein has a Zacks Rank  2  Buy  but that could change following its second quarter 2017 earnings report which has just released   You can see  We have highlighted some of the key details from the just released announcement below Earnings  The Zacks Consensus Estimate remained steady at  1 73 per share over the last 60 days  Henry Schein s adjusted earnings per share of  1 75 beat this estimate by a couple of cents Revenues  Henry Schein posted revenues of  3 05 billion  ahead of the Zacks Consensus Estimate for revenues of  3 04 billion Key Stats  Revenues in the second quarter derived from Henry Schein s Dental segment grew 8 4  year over year to  1 48 billion  while Animal Health segment recorded sales of  891 3 million  up 4 4  compared with the prior year quarter  Revenues from Medical segment increased 6 1  year over year to  571 4 million  while sales from Technology and Value added services segment grew 1 4  to  108 5 million Henry Schein  Inc  Price and EPS Surprise   Major Factors  Per management  its four global segments gained solid market share during the quarter and delivered solid earnings growth on back of the strategy to grow the business organically and through acquisitions  The company reaffirmed adjusted EPS guidance for 2017 Stock Price  Following the earnings release  share prices did not show any significant movement in the pre market trading session Check back later for our full write up on this Henry Schein earnings report later Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2017-08-08,Zacks Investment Research,https://www.investing.com/analysis/henry-schein-hsic-tops-q2-earnings-and-revenues-estimate-200206006,200206006
116164,337679,HSIC,Top Stock Reports For CVS Health  Marriott   Enbridge,opinion,"Wednesday  August 9  2017
The Zacks Research Daily presents the best research output of our analyst team  Today s Research Daily features new research reports on 16 major stocks  including CVS Health  NYSE CVS   CVS   Marriott  MAR  and Enbridge  ENB   These research reports have been hand picked from the roughly 70 reports published by our analyst team today 
You can see 
CVS Health shares have outperformed the Zacks categorized Drug Stores industry year to date losing  0 4  vs   4 4   CVS Health posted better than expected second quarter 2017 with both adjusted EPS and revenues beating expectations  Year over year top line growth was driven by a strong Pharmacy Services segment  benefiting from the upside in the Specialty Pharmacy 
The company s strong PBM selling season is a major positive  However  poor year over year Retail LTC numbers along with margin debacle resulted in a dull earnings performance by the company in the quarter  Despite an unimpressive bottom line scenario the company has raised the lower end of its earnings outlook for 2017 raising investors optimism  The Zacks analyst thinks the Omnicare and Target Pharmacy buyouts should drive enterprise value significantly in the days ahead 
 You can 
Shares of Marriott have outperformed the Zacks Hotels industry in the year to date period  the stock is up  25 7  vs   3 3  gain for the industry   Marriott s second quarter 2017 earnings beat expectations and increased year over year  Notably  with the purchase of Starwood  Marriott became the world s largest hotel company  In fact  the acquisition is likely to result in a bigger brand with increased scale and a robust development pipeline in the long run 
The Zacks analyst likes Marriott s rising North American business  sizeable international exposure and attractive brand position  Further  its investments in technology for hotel bookings will improve guest experience  which in turn should boost occupancy  Yet lingering political uncertainties in key international markets  oversupply in some regions and currency headwinds might continue to limit revenue growth  Integration risks linked to Starwood purchase is an added concern 
 You can  
Enbridge s shares have declined  1 9  over the last one year  significantly underperforming the Zacks Oil   Gas Production industry s gain of  5 7  during the aforesaid period  The company has the longest and most sophisticated crude and liquids pipeline system in the world that spreads over 17 511 miles 
The Zacks analyst likes the merger with Spectra Energy  F SEP  as it has made Enbridge the largest energy infrastructure company in North America in terms of enterprise value  Also  the transaction has given Enbridge the industry s largest backlog of growth projects  worth around C 75 billion  The company believes that this huge backlog will help it to grow its dividend by 10 12  annually from 2018 to 2024 
However  the company s substantial debt load is a matter of concern  Also  during second quarter 2017  Enbridge reported lower than expected results owing to higher operating expenses and accelerated maintenance work at the upstream operations of customers 
 You can  
Other noteworthy reports we are featuring today include MetLife  NYSE MET   MET   Deutsche Bank  DB  and Aon  AON  
3 Stocks to Ride a 588  Revenue ExplosionAt Zacks  we re mostly focused on short term profit cycles  but the hottest of all technology mega trends is starting to take hold   
By last year  it was already generating  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for those who make the right trades early 
Mark Vickery
Senior Editor
Note  Sheraz Mian heads the Zacks Equity Research department and is a well regarded expert of aggregate earnings  He is frequently quoted in the print and electronic media and publishes the weekly and reports  If you want an email notification each time Sheraz publishes a new article  please 
Today s Must Read









Featured Reports

Per the Zacks analyst  Take Two s growth will be driven by increasing digital revenues  Social Point buyout and strength in its franchises like Grand Theft Auto 


Per the Zacks analyst  Ralph Lauren s first quarter was backed by cost savings  and lower markdowns and promotions  This reflects the company s focus on Way Forward Plan that remains a growth driver 


Per the Zacks analyst  Emergent s deals with BARDA for its key product BioThrax bodes well for growth  Moreover  the company s follow on contract with CDC may further boost the performance of the drug 


Per the Zacks analyst  although sufficient generation of cash flow paves the way for Aon s organic and inorganic growth oriented investments  its rising level of debt is worrying 


The Zacks analyst is concerned about the rising operating expenses of Henry Schein which are further getting intensified with the recent distribution deals with DENTSPLY SIRONA  XRAY  


The Zacks analyst remains optimistic about Deutsche Bank s cost control efforts  several strategic initiatives and strong capital position  


Per the Zacks analyst  Arista is benefiting from the robust product portfolio  which is helping it to win customers  

New Upgrades

Per the Zacks analyst  Alexandria Real Estate Equities is set to ride high  backed by solid growth in rental rate and sound leasing activities  Occupancy will also be high amid robust demand 


The Zacks analyst is bullish on solid market adoption of Haemonetics  FDA approved NexSys PCS plasmapheresis system  The company s reaffirmed guidance for fiscal 2018 instills investor confidence 


The Zacks analyst notes that the acquisition of Cascade Microtech is strengthening FormFactor s end market foothold  contributing significantly to the company s top line 

New Downgrades

Per the Zacks analyst  Avon s second quarter results were marred by decline in Active Representatives across all segments  Active Representatives is likely to be flat or up 1  in the second half 


The Zacks analyst is concerned with declining revenues from the past more than two years   Spin off charges related to BrightHouse Financial will dent MetLife s margins in the coming quarters  


Per the Zacks analyst  Taubman Centers  performance in the near term will be marred by the shrinking footfall amid shift toward online channels  store closures and bankruptcy of retailers ",2017-08-09,Zacks Investment Research,https://www.investing.com/analysis/top-stock-reports-for-cvs-health-marriott--enbridge-200206381,200206381
116166,337681,HSIC,Henry Schein To Offer CAEK s HIPAA Software LayerCompliance,opinion,Leading distributor of health care products and services  Henry Schein  Inc   NASDAQ HSIC   is constantly focusing on expanding its dental business which accounts for nearly half of the its total revenues  Keeping in line with this  Henry Schein Dental entered into an agreement to distribute CAEK  Inc  s flagship product and a Health Insurance Portability and Accountability Act  HIPAA  software  LayerCompliance  Notably  CAEK is a Software as a Service  SaaS  company focusing on compliance related software for the healthcare industry LayerCompliance is a cloud based tool to help doctors navigate the requirements of the HIPAA  Notably  HIPAA is a federal law that provides privacy and security standards to protect patients  health information  LayerCompliance helps users manage their data security program through an online dashboard and tools that help streamline the process Oral health care expenditures in the dental industry are likely to rise with the increase in population  We believe this will boost demand for Henry Schein s products and services as well Meanwhile  management has entered into a three year agreement with DENTSPLY SIRONA to broaden Henry Schein s digital dentistry product line  Moreover  during the second quarter  Henry Schein announced the extension of its agreement with DENTSPLY SIRONA  Per the extended agreement  that is valid till Dec 31  2020  Henry Schein will include the CEREC CAD CAM restoration system and the Schick line of imaging sensors  Henry Schein will also be entitled to represent the entire DENTSPLY SIRONA product line starting Sep 1  2017 In addition  Henry Schein will continue to offer Planmeca  3Shape and 3M as well as the dental equipment and consumer products from its longstanding partner Danaher  NYSE DHR  under the KaVo Kerr brands Over the past one year  Henry Schein has outperformed the broader   The stock has gained 5 5   compared with the 2 9  gain of the broader industry  Zacks Rank   Key PicksHenry Schein currently carries a Zacks Rank  3  Hold   A few better ranked medical stocks are Edwards Lifesciences Corp    NYSE EW    Lantheus Holdings  Inc    NASDAQ LNTH   and Align Technology  Inc    NASDAQ ALGN    Edwards Lifesciences and Align Technology sport a Zacks Rank  1  Strong Buy   while Lantheus Holdings carries a Zacks Rank  2  Buy   You can see Edwards Lifesciences has a long term expected earnings growth rate of 15 2   The stock has gained around 3 2  over the last three months Align Technology has a long term expected earnings growth rate of 26 6   The stock has rallied roughly 29 6  over the last three months Lantheus Holdings has a long term expected earnings growth rate of 12 5   The stock has gained 66 1  over the last six months One Simple Trading IdeaSince 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing  and exclusive of fees  it can turn thousands into millions of dollars This proven stock picking system is grounded on a single big idea that can be fortune shaping and life changing  You can apply it to your portfolio starting today ,2017-08-16,Zacks Investment Research,https://www.investing.com/analysis/henry-schein-to-offer-caeks-hipaa-software-layercompliance-200207941,200207941
116168,337683,HSIC,Henry Schein s Merritt Buyout To Boost U S  Veterinary Arm,opinion,"Leading veterinary product distributor Henry Schein  Inc    NASDAQ HSIC   continues to expand its global footprint successfully through several partnerships and acquisitions  Latest on the list is the company s agreement to buy Merritt Veterinary Supplies  Inc   an independent  family owned supplier of animal health products  Although  financial terms of the deal have been kept under wraps  the company declared that it expects the transaction to get completed in the third quarter of 2017 Headquartered in Columbia  South Carolina  Merritt has 4 500 veterinary clinics across the eastern United States with a strong presence in the southeastern part of the nation  The company offers a comprehensive line of products  including pharmaceuticals  diagnostics and equipment  This leading independent regional veterinary supplier had total sales of approximately  115 million in 2016 Post the closing of the transaction  Merritt will become  part of Henry Schein Animal Health  Per the company  the acquisition will meaningfully strengthen its existing U S  animal health business  It will also benefit animal health diagnostic  equipment and surgical instruments businesses  including scil  KRUUSE and Veterinary Instrumentation of Henry Schein Henry Schein  Inc  Price
    Notably  Henry Schein s revenue growth in its animal health business has been consistently supported by niche acquisitions  Its robust buyout strategy helps it pursue targets  providing access to additional product lines In the beginning of 2017  Henry Schein entered into the Brazilian animal health market with a 51  investment in Tecnew  a privately held distributor of animal health products  Prior to that  the company acquired RxWorks  a leading provider of veterinary practice management software  primarily to customers in Australia  New Zealand  the UK  the Netherlands and other world wide countries  Like all these businesses  the impending Merritt buyout is set to fortify its global Animal Health operations going forward Henry Schein has outperformed the broader  in a year  The stock has gained 3 5  compared with the broader industry s 3 3  rise  Zacks Rank   Key PicksHenry Schein currently carries a Zacks Rank  3  Hold   A few better ranked medical stocks are IDEXX Laboratories  Inc    NASDAQ IDXX    Lantheus Holdings  Inc    NASDAQ LNTH   and Edwards Lifesciences Corporation   NYSE EW    Edwards Lifesciences sports a Zacks Rank  1  Strong Buy   while Lantheus Holdings and IDEXX Laboratories carry a Zacks Rank  2  Buy   You can see IDEXX Laboratories has a long term expected earnings growth rate of 19 8   The stock has gained around 2 3  over the last six months Lantheus Holdings has a long term expected earnings growth rate of 12 5   The stock has surged 26 9  over the last six months Edwards Lifesciences has a long term expected earnings growth rate of 15 2   The stock has rallied roughly 20 4  over the last six months Zacks  10 Minute Stock Picking SecretSince 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing  and exclusive of fees  it can turn thousands into millions of dollars But here s something even more remarkable  You can master this proven system without going to a single class or seminar  And then you can apply it to your portfolio in as little as 10 minutes a month ",2017-08-28,Zacks Investment Research,https://www.investing.com/analysis/henry-scheins-merritt-buyout-to-boost-us-veterinary-arm-200210221,200210221
116172,337687,HSIC,Henry Schein Joins IMF   LUGFA  On Prostate Cancer Awareness,opinion,Henry Schein  Inc    NASDAQ HSIC   has recently teamed up with Integrated Medical Foundation  IMF  and LUGPA  an association of independent urology group practices  to raise awareness on prostate cancer  More specifically  Henry Schein s global corporate social responsibility program   Henry Schein Cares   will work on this matter Per Henry Schein  it will support IMF and LUGPA with a series of communication efforts to increase awareness among practitioners and public about the importance of early detection of prostate cancer  According to them  it has been widely accepted how early detection of prostate cancer can greatly enhance a patient s chances of recovering from the disease We believe  the company s move is well timed taking into consideration the frequency rate at which prostate cancer is growing  The National Cancer Institute estimates that approximately one in nine men will be diagnosed with the disease in their lifetime  Per the American Cancer Society  more than 160 000 men are expected to be diagnosed with prostate cancer and more than 26 000 men may succumb to the disease in 2017 Though Henry Schein is yet to make a foray into the world of cancer research  it has already come up with several awareness drives of late  Only last month  the company announced to offer its dental  animal health and medical customers an opportunity to join in the fight against cancer The proposal will be open from from September through December  By purchasing a range of pink products  customers can support the company s Practice Pink program  an initiative designed to increase awareness and back the cure for breast cancer as well as other cancer therapies Over the past three months  Henry Schein has underperformed the broader   The stock has lost 5 7  compared with the the broader industry s 1 7  decline Zacks Rank   Key PicksHenry Schein carries a Zacks Rank  3  Hold   A few better ranked medical stocks are Edwards Lifesciences Corporation   NYSE EW    Lantheus Holdings  Inc    NASDAQ LNTH   and IDEXX Laboratories  Inc    NASDAQ IDXX    Edwards Lifesciences sports a Zacks Rank  1  Strong Buy   while Lantheus Holdings and IDEXX Laboratories carry a Zacks Rank  2  Buy   You can see Edwards Lifesciences has a long term expected earnings growth rate of 15 2   The stock has rallied roughly 19 8  over the last six months Lantheus Holdings has a long term expected earnings growth rate of 12 5   The stock has surged 21 6  over the last six months IDEXX Laboratories has a long term expected earnings growth rate of 19 8   The stock has gained around 2 9  over the last six months Zacks  10 Minute Stock Picking SecretSince 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing  and exclusive of fees  it can turn thousands into millions of dollars But here s something even more remarkable  You can master this proven system without going to a single class or seminar  And then you can apply it to your portfolio in as little as 10 minutes a month ,2017-09-04,Zacks Investment Research,https://www.investing.com/analysis/henry-schein-joins-imf--lugfa--on-prostate-cancer-awareness-200211540,200211540
116183,337698,HSIC,Henry Schein  HSIC  Tops Q1 Earnings And Revenues Estimate,opinion,Headquartered in Melville  NY  Henry Schein Inc    NASDAQ HSIC   is a global leading provider of healthcare products and services  The company serves office based dental  medical and animal health practitioners  dental laboratories  government as well as institutional health care clinics and other alternate care sites  Presently  Henry Schein serves more than 1 million customers and has operations in 28 countries  The company entered the prestigious Standard   Poor s  S P  500 Index in Mar  2015 Currently  Henry Schein has a Zacks Rank  2  Buy  but that could change following its impressive first quarter 2017 earnings report which has just released   You can see   We have highlighted some of the key details from the just released announcement below Earnings  The Zacks Consensus Estimate remained steady at  1 66 per share over the last 60 days  Henry Schein s adjusted earnings per share of  1 76 beat this estimate by 2 4  Henry Schein  Inc  Price and EPS Surprise   Revenues  Henry Schein posted revenues of  2 92 billion  ahead of the Zacks Consensus Estimate for revenues of  2 83 billion Key Stats  Revenues in the first quarter derived from Henry Schein s Dental segment grew 7 9  year over year to  1 40 billion  while Animal Health segment recorded sales of  812 9 million  up 5 4  compared with the prior year quarter  Revenues from Medical segment increased 11 3  year over year to  598 9 million  while sales from Technology and Value added services segment grew 4 2  to  105 9 million Major Factors  Per management  the markets that Henry Schein serves are growing in a healthy manner and all its four global segments gained solid market share during the quarter  The company affirmed adjusted EPS guidance for 2017 Stock Price  Following the earnings release  share prices did not show any significant movement in the pre market trading session Check back later for our full write up on this Henry Schein earnings report later Zacks  2017 IPO Watch ListBefore looking into the stocks mentioned above  you may want to get a head start on potential tech IPOs that are popping up on Zacks  radar  Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential  This Special Report gives you the current scoop on 5 that may go public at any time One has driven from 0 to a  68 billion valuation in 8 years  Four others are a little less obvious but already show jaw dropping growth ,2017-05-09,Zacks Investment Research,https://www.investing.com/analysis/henry-schein-(hsic)-tops-q1-earnings-and-revenues-estimate-200188053,200188053
116186,337701,HSIC,Stocks Today   Retail Sector Earnings Scorecard,opinion,"Thursday May 11  2017
Stocks started today s session in the red  on downbeat earnings results from Macy s  M  and Kohl s  KSS  and a hotter than expected wholesale inflation reading that adds to the likelihood of a Fed rate move at the June FOMC meeting  Tomorrow s CPI reading has assumed relatively more significance following this morning s PPI report 
Macy s and the broader department store space has been struggling for a while given their inability to adjust to the changing consumer spending landscape of growing online sales weighing on foot traffic in the brick and mortar facilities  Macy s results were a bit more disappointing this morning as it not only came out with a bigger than expected decline in same store sales but also missed consensus EPS and revenue estimates  Kohl s did better with respect to EPS and revenue results  on the back of disciplined inventory management  but same store sales missed the mark 
We provide the Q1 earnings season scorecard for the Retail sector below  but please note that this daily publication features the best research output of the Zacks analyst team  In today s write up  we are featuring analyst reports on 16 major stocks  including reports on NVIDIA Corp   NVDA   PNC Financial  PNC  and Anthem  ANTM   These reports have been hand picked from amongst the 70 or so stock research reports published by our analyst team today  You can see all of today s research reports 
Retail Sector Scorecard  as of Thursday  May 11th 
Including this morning s releases from Macy s and Kohl s  we now have Q1 results from 23 of the 42 retailers in the S P 500 index  for the index as whole  we now have results from 452 members   Total earnings for these 23 retailers are up  1 9  from the same period last year on  4 7  higher revenues  with 56 5  beating EPS estimates and an equal proportion beating revenue estimates 
Please note that we have a stand alone Retail sector  unlike the official Standard   Poor s placement of this space in the Consumer Discretionary sector  The Zacks Retail sector includes  besides the traditional department stores and other brick and mortar retailers  the online vendors like Amazon  NASDAQ AMZN  and Priceline and restaurant operators  Most of the 23 Zacks Retail sector companies that have reported Q1 results already at this stage are online vendors and restaurant players  with the traditional retail operators starting the reporting process with this morning s Macy s disappointment 
The aggregate results from the 23 retailers that have reported Q1 results already are tracking below what we had seen from the same companies in other recent periods  This is despite the  41 1  growth in Amazon s earnings on  22 6  higher revenues  On an ex Amazon basis  the sector s Q1 earnings growth would be modestly in the negative 
You can read more about our views about this earnings season in the weekly Earnings Trends report      
Today s Featured Research Reports
NVIDIA shares have surged following the strong quarterly report on Tuesday that eased some of the earlier worries about the company s exposure to a slowing gaming market  The stock was a standout performer last year  but was modestly in the red through the May 9th earnings release  But it is now up  18 3  since the start of the year following the market s enthusiastic reception to its earnings report  The Zacks analyst likes NVIDIA s innovative product pipeline and strength in gaming and high end notebook GPUs  The stock has had impressive run over the past year and the market s post earnings response indicates that the momentum likely has staying power   You can  
Shares of Buy rated PNC Financial outperformed the Zacks Regional Banks industry over the last six months gaining  13 3  vs   8 8   The Zacks analyst likes the company s efforts to generate positive operating leverage through its cost saving initiatives  Also  management projects revenues to rise at a mid single digit rate in 2017  aided by loan growth  Further  its deal to acquire the commercial and vendor finance business of ECN Capital is expected to be marginally accretive to earnings in 2017  On the flip side  the bank remains vulnerable to developments on the interest rate  which have stabilized lately  but still remain below the March level   You can  
Buy rated Anthem shares gained  25 3  year to date compared with the Zacks HMO industry s increase of  12 9   The company reported better than expected first quarter results with earnings surpassing expectations and increasing year over year  The Zacks analyst likes the company s diverse product portfolio  divestitures  prudent capital management  modest cash position  strategic acquisitions and ACO arrangements  Although its proposed merger with Cigna  NYSE CI  has been blocked  this month the company made another move to salvage the deal  However  high debt levels and a weak public exchange business pose risks for Anthem s future earnings   You can  
Other noteworthy reports we are featuring today include Restaurant Brands  QSR   Marathon Petroleum  MPC  and TE Connectivity  TEL  
Free Access  All Zacks Research ReportsStarting today  you are invited to download in depth analysis reports covering more than 1 000 of the most widely followed stocks  Valued at  25 each  they are yours to consult over the next 30 days absolutely free  They feature sensitive Zacks Rank information on each stock that you won t find anywhere else  Sheraz Mian
Director of Research
Note  Sheraz Mian heads the Zacks Equity Research department and is a well regarded expert of aggregate earnings  He is frequently quoted in the print and electronic media and publishes the weekly  and  reports  If you want an email notification each time Sheraz publishes a new article  please 
Today s Must Read









Featured Reports

The Zacks analyst thinks solid expansion led to Q1 sales and earnings growth at Restaurant Brands  despite minor comps decline 


While appreciating MPC s scale advantage  impressive asset quality and extensive midstream retail network  the covering analyst remains concerned over the tepid outlook for refining margins 


TE Connectivity beat Q2 earnings on impressive top line growth  However  sluggishness in industrial  data   devices  and communications businesses are likely to decelerate the company s growth 


Despite growth from the enhanced international presence  the Zacks analyst is concerned about the impact of global economic crisis on Liberty Interactive s business 


The covering analyst thinks Henry Schein s solid Q1 was on segmental growth and gains in U S  and overseas markets which boosted its share price  


The Zacks analyst thinks Archer Daniels  first quarter 2017 results grew year over year  driven by improved results at most segments and focus on cost savings  


According to the Zacks analyst  Microchip s expanding product portfolio and growing analog business will enable it to continuously outperform going ahead 

New Upgrades

The Zacks analyst is impressed by Agnico Eagle s forecast topping Q1 results and thinks that it will gain from good progress at its major projects and efforts to improve mine life and output 


The covering analyst thinks ON Semi s first quarter results reflected improving end markets   particularly automotive   which will drive top line growth in the rest of 2017 


Though Ocwen witnessed a fall in revenues in Q1  the Zacks analyst believes that the company s initiatives to restructure servicing portfolio should help in improving top line going forward 

New Downgrades

News Corporation reported second straight quarter of earnings beat  when it posted third quarter fiscal 2017 results  Per the Zacks analyst  soft print advertising demand remains a cause for worry 


Juno s Q1 sales beat estimates while loss was wider than expected  The covering analyst believes that the immunotherapy market is fast becoming crowded which may pose threat to the company 


Despite huge investments in Fioptics products  the Zacks analyst is concerned about Cincinnati Bell s persistent losses in local access lines  heavy capital expenditures and legal woes ",2017-05-11,Zacks Investment Research,https://www.investing.com/analysis/stocks-today---retail-sector-earnings-scorecard-200188643,200188643
116187,337702,HSIC,Henry Schein  HSIC  Rides On Global Growth  Strategic Deals ,opinion,"On May 25 2017  we issued an updated research report on Melville  NY based Henry Schein  Inc    NASDAQ HSIC    It is a leading distributor of health care products and services across the globe  The company currently carries a Zacks Rank  2  Buy  
Having delivered better than expected first quarter 2017 performance a month back  Henry Schein has consistently outperformed the S P 500 market at large with respect to share price movement  The stock is up 4 88   significantly above the 0 96  gain of the market 

 
We expect this bullish trend to continue in the ongoing quarter as well  Per last reported quarter  the company has delivered strong year over year growth in all of its four operating segments  Also Henry Schein s strong share gains in both North American and overseas markets along with solid revenues  further raise investors  optimism on the stock 
We are also encouraged by Henry Schein s growing distribution business  boasting a wide global footprint with 61 distribution centers  Apart from North America and Europe  it has presence in Australia and New Zealand as well as in the emerging nations like China  Brazil  Israel  Czech Republic and Poland being the latest 
In 2016  the company completed its majority buyout of the Poland based Dental Cremer  Its decision to acquire an 80  ownership of a Poland based dental distributor of Marrodent will also help it fortify its position in the emerging dental markets 
Also  Henry Schein might gain from several trends in its end markets  one of them being customer demographics  According to a recent estimation  between 2015 2025  the population aged 45 and above will likely grow approximately 12   This demographic trend is expected to boost the utilization of dental and medical products distributed by the company 
However a comparative study of Henry Schein s forward P E  F12M basis  multiple reflects that the stock is quite overvalued  The multiple currently stands at 23 9  stretched when compared to its own range  median of 23 4   Even when compared to the Zacks categorized Medical Dental Supplies industry  the comparison is unfavorable as the current P E  F12M basis  for the industry is 18 3 for the last one month 
It is also overvalued when compared with the S P 500 market of P E  F12M basis  multiple of 18 2  We believe the company s recent developments including several acquisitions and tie ups will keep the valuation stretched for sometime 
This apart  escalating costs and expenses continue to be a drag on the company s margins and put pressure on the bottom line  A tough competitive landscape and pricing pressure also weigh on Henry Schein s stock 
Key Picks
Some other well ranked stocks in the broader medical sector are Luminex Corp    NASDAQ LMNX    Inogen  Inc    NASDAQ INGN   and Edwards Lifesciences Corp    NYSE EW    Notably  Luminex and Inogen sport a Zacks Rank  1  Strong Buy   while Edwards Lifesciences carries a Zacks Rank  2  Buy   You can see 
Luminex has an expected long term adjusted earnings growth of almost 16 3   The stock added roughly 6 8  over the last three months 
Inogen has long term expected earnings growth rate of 17 5   The stock has a solid one year return of around 81 7  
Edwards Lifesciences has an expected long term adjusted earnings growth of almost 15 6   The stock roughly added 14 8  over last year 
Looking for Ideas with Even Greater Upside 
Today s investment ideas are short term  directly based on our proven 1 to 3 month indicator  In addition  I invite you to consider our long term opportunities  These rare trades look to start fast with strong Zacks Ranks  but carry through with double and triple digit profit potential  Starting now  you can look inside our home run  value  and stocks under  10 portfolios  plus more ",2017-05-26,Zacks Investment Research,"https://www.investing.com/analysis/henry-schein-(hsic)-rides-on-global-growth,-strategic-deals-200191740",200191740
116189,337704,HSIC,Henry Schein Grows On Strategic Buyouts  Competition Rife,opinion,On Jun 15  we issued an updated research report on Melville  NY based Henry Schein  Inc    NASDAQ HSIC    It is a leading distributor of health care products and services across the globe  The company currently carries a Zacks Rank  3  Hold  Post the impressive first quarter 2017 earnings results  Henry Schein has been consistently trading above the S P 500 market with respect to share price  Over the last three months  the stock has gained 7 6   significantly above the 2 7  gain of the market We expect this bullish trend to continue on balanced growth across all four operating segments of Henry Schein  We are also encouraged by the company sefforts to grow internationally  Apart from North America and Europe  it has presence in Australia and New Zealand as well as emerging nations like China  Brazil  Israel  Czech Republic and Poland Henry Schein s revenue growth has been consistently supported by niche acquisitions  At the beginning of 2017  Henry Schein forayed into the Brazilian animal health market with a 51  investment in Tecnew  Around the same time  the company announced its decision to acquire Southern SAS  Henry Schein s dental business is expected to gain from Southern SAS  controlled and non controlled pharmaceuticals as well as surgical supplies  In 2016  the company completed its majority buyout of the Poland based Dental Cremer  Its decision to acquire 80  of Poland based dental distributor Marrodent will also help fortify its position in emerging dental markets Also  Henry Schein might gain from several trends in its end markets  one of them being customer demographics  The increasing number of lives covered  following the healthcare reforms in the U S   is likely to benefit Henry Schein  Additionally  the company s animal health business is gaining traction on the back of tailwinds in North America as well as overseas markets  The burgeoning demand for animal health products in the U S  should drive growth  On the flip side  a comparative study of Henry Schein s forward P E  F12M basis  multiple reflects that the stock is quite overvalued  The multiple currently stands at 24 1  stretched when compared to its own range  median of 23 2   Even when compared to the Zacks categorized  industry  the comparison is unfavorable as the current P E  F12M basis  for the industry is 18 6 for the last three months It is also overvalued when compared to the S P 500 market of P E  F12M basis  multiple of 18 4  We believe the company s recent developments  including several acquisitions and tie ups  will keep the valuation stretched for some time This apart  escalating costs and expenses continue to be a drag on the company s margins and bottom line  A tough competitive landscape and pricing pressure also weigh on Henry Schein s stock Key PicksA few better ranked medical stocks are Align Technology  Inc    NASDAQ ALGN    Inogen  Inc    NASDAQ INGN   and Accelerate Diagnostics  Inc    NASDAQ AXDX    Notably  Align Technology and Inogen sport a Zacks Rank  1  Strong Buy   while Accelerate Diagnostics carries a Zacks Rank  2  Buy   You can see Align Technology has an expected long term adjusted earnings growth of almost 24 1   The stock added roughly 30 6  over the last three months Inogen has a long term expected earnings growth rate of 17 5   The stock has a solid one year return of around 90 2  Accelerate Diagnostics has an expected long term adjusted earnings growth of 30   The stock added roughly 14 2  over the last three months 3 Stocks to Ride a 588  Revenue Explosion At Zacks  we re mostly focused on short term profit cycles  but the hottest of all technology mega trends is starting to take hold   By last year  it was already generating  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for those who make the right trades early ,2017-06-14,Zacks Investment Research,"https://www.investing.com/analysis/henry-schein-grows-on-strategic-buyouts,-competition-rife-200195416",200195416
116192,337707,HSIC,Here s Why Henry Schein Is Worth Adding To Your Portfolio ,opinion,"Henry Schein Inc    NASDAQ HSIC    the worldwide distributor of health care products and services is on a healthy growth trajectory of late  Over the last six months  the stock has been consistently trading ahead of the S P 500 Index  It has rallied 19 9  in this period compared with the market s mere 8  gain  The stock has a market cap of  14 5 billion Over major part of this period  the company s share price outperformed the Zacks categorized sub industry  Recently the broader industry has advanced to reach a higher level  However we believe  Henry Schein with its strong growth parameters is expected to match that level soon With solid growth prospects  this Zacks Rank  2  Buy  stock is an attractive pick at present  Let s find out whether the recent positive trend is a sustainable one or is it just a short term gain Henry Schein  Inc  Price
    Key PositivesA stellar first quarter 2017 result was a major market sentiment booster  thanks to the strong year over year growth in all its four operating segments Henry Schein is well positioned to gain from an extensive global foothold and diverse channel mix  The company s consistent strong share gains in both the North American and overseas markets along with solid revenues further raise investors  optimism on the stock Notably  the company s animal health business is gaining traction on the back of tailwinds in the North American as well as overseas markets  The burgeoning demand for animal health products in the U S  should accelerate growth  The company s medical segment also continues to improve as it gains traction in large group practices including those within health systems Market is visibly positive about Henry Schein s recent announcement to enter into a three year agreement with Dentsply Sirona to broaden its digital dentistry product offering with the highly respected global brands associated with the latter Henry Schein will distribute Dentsply Sirona s full line dental equipment in the U S  Besides  the company will continue to represent products from Planmeca  3Shape  3M as well as the dental equipment and consumer product lines of its longstanding partner  Danaher  NYSE DHR  under the KaVo Kerr brands During the first quarter of 2017  the company inked a deal with medical device developer Rijuven Corp for distributing the latter s cardiovascular device in the U S  The company has significantly gained from the certifying CE Mark approval for da Vinci X in Europe  The stock has further received a boost with the recent U S  FDA approval of the same  The company has been riding high on its niche acquisitions  Its robust acquisition strategy helps it to pursue targets that provide access to additional product lines In the beginning of 2017  Henry Schein had penetrated the Brazilian animal health market with a 51  investment in Tecnew  a privately held distributor of animal health products  Around the same time  the company also declared to acquire Southern SAS Henry Schein s dental business is expected to gain from SAS  controlled and non controlled pharmaceuticals as well as the surgical supplies Key PicksOther top ranked medical stocks include Align Technology  Inc    NASDAQ ALGN    Inogen  Inc    NASDAQ INGN   and Accelerate Diagnostics  Inc    NASDAQ AXDX    While Align Technology and Inogen sport a Zacks Rank  1 Strong Buy   Accelerate Diagnostics carries a Zacks Rank  2  Buy   You can see Align Technology has an expected long term adjusted earnings growth of almost 24 1   The stock has roughly added 32 3  over the last three months Inogen has a long term expected earnings growth rate of 17 5   The stock has approximately added 26 2  over the last three months Accelerate Diagnostics has an expected long term adjusted earnings growth of 30   The stock has roughly gained 24 5  over the last three months Looking for Ideas with Even Greater Upside Today s investment ideas are short term  directly based on our proven 1 to 3 month indicator  In addition  I invite you to consider our long term opportunities  These rare trades look to start fast with strong Zacks Ranks  but carry through with double and triple digit profit potential  Starting now  you can look inside our home run  value  and stocks under  10 portfolios  plus more ",2017-06-21,Zacks Investment Research,https://www.investing.com/analysis/here's-why-henry-schein-is-worth-adding-to-your-portfolio-200196969,200196969
116197,337712,HSIC,DENTSPLY SIRONA Renews Canadian Distribution Agreement ,opinion,York  PA based DENTSPLY SIRONA Inc    NASDAQ XRAY    a dental solutions company  recently announced the renewal of an existing distribution agreement with Henry Schein  NASDAQ HSIC  Canada  Inc   Stock PerformanceThe price performance of the stock has been unfavorable in the last three months  DENTSPLY SIRONA rose only 3 67   underperforming the Zacks classified  sub industry s gain of almost 9 16   The current level compares unfavorably with the S P 500 s return of 3 82  over the same time frame The estimate revision trend for the stock has been dismal  with 10 estimates moving south in the last two months and no estimate moving north  Notably  the current year estimate for the stock fell 2 cents to  2 83 per share over the same time frame  The company currently holds a Zacks Rank  3  Hold  Coming back to the news  the renewal agreement would be effective from Sep 1  2017 through Dec 31  2020  We feel the agreement is a smart move by DENTSPLY SIRONA as the preexisting distribution agreement did not include the CEREC CAD CAM restoration system and the Schick line of imaging sensors  By including the aforementioned lines of products  the company would be able to take full advantage of Henry Schein s distribution network in Canada  Henry Schein Canada s existing agreement with DENTSPLY SIRONA was originally initiated in Aug 2005 Headquartered in York  PA  DENTSPLY SIRONA is a global leader in the design  development  manufacture and marketing of dental consumables  dental laboratory products  dental specialty products and consumable medical device products Looking ahead  robust performance by the company s flagship dental implants  CAD CAM systems  imaging systems  treatment centers and orthodontic product platforms hold considerable promise over the long haul  However  higher capital expenditure on product development and tough competition are expected to put margins under pressure  Unfavorable foreign exchange rate and integration are also major risks in the near term Key PicksA few other top ranked stocks in the broader medical sector are Inogen Inc    NASDAQ INGN    IDEXX Laboratories  Inc    NASDAQ IDXX   and Luminex Corporation   NASDAQ LMNX    Notably  Inogen and Luminex sport a Zacks Rank  1  Strong Buy   while IDEXX Laboratories holds a Zacks Rank  2  Buy   You can see  Inogen has a long term expected earnings growth rate of 17 50   Notably  the stock represents an impressive one year return of 99 5  IDEXX Laboratories has a long term expected earnings growth rate of 19 4   Notably  the stock represents an impressive one year return of 99 5  Luminex has a long term expected earnings growth rate of 16 25   Additionally  the stock represents an impressive one year return of 20 3  Today s Stocks from Zacks  Hottest Strategies It s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively                                                                                          And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2017-06-28,Zacks Investment Research,https://www.investing.com/analysis/dentsply-sirona-renews-canadian-distribution-agreement-200198259,200198259
116198,337713,HSIC,Abaxis  ABAX  Product Portfolio Strong  Competition Rife,opinion,On Jun 28  we issued an updated research report on California based Abaxis  Inc    NASDAQ ABAX    The company manufactures portable Medical  human  and Veterinary  animal  blood analysis systems that provide clinicians with rapid blood constituent measurements in medical and veterinarian markets worldwide  Abaxis currently carries a Zacks Rank  3  Hold  Over the past one month  Abaxishas been trading above the Zacks categorized industry  Per the last trading price  the company has gained 8 8   compared to the 4 6  gain of the broader industry We are encouraged to note that Abaxis has been working on expanding its portfolio of rapid test menu over the recent past  Earlier  the company signed a partnership with the American Animal Hospital Association  AAHA  to develop a wellness testing initiative to improve veterinary blood work compliance and implementing preventive care  We believe successful expansion of the product portfolio will boost the top line and help foray into new regions  We also expect the distribution relationship with Henry Schein  NASDAQ HSIC  Animal Health  Patterson Veterinary Supply and Abbott Point of Care to expand its market presence in North America as well as Europe Also  the company is successfully selling Piccolo instruments globally  To date  Abaxis  Piccolo is the only point of care technology that can deliver comprehensive diagnostic grade chemistry results within the 15 minute visit window that retailers target  During the third quarter of fiscal 2017  the company sold 200 Piccolo Xpress instruments to Fuzhou Kelian Medical Devices  Ltd   a point of care diagnostics distributor based in China  Under the distribution agreement with Abbott   the company continues to sell and distribute Piccolo instruments to Catapult Health LLC and specified customer segments in the U S  The company s consistent efforts to capture a lion s share of the diagnostic test global market are encouraging On the flip side  over the last three months  a comparative analysis of Abaxis  forward P E  F12M basis  multiple reflects a gloomy picture that might be a cause for investor concern  Abbott currently trades at a P E ratio of 41 40  overvalued when compared with 21 35 of the Zacks categorized Medical Product industry  In fact  comparing the company s current P E level with its own range  median of 38 1  depicts that the stock is a little overvalued  Also  currency headwinds and a competitive landscape are major dampeners Key PicksA few top ranked medical stocks are Align Technology  Inc    NASDAQ ALGN    Inogen  Inc    NASDAQ INGN   and Accelerate Diagnostics  Inc    NASDAQ AXDX    Notably  Inogen sports a Zacks Rank  1  Strong Buy   while Align Technology and Accelerate Diagnostics carry a Zacks Rank  2  Buy   You can see Align Technology has an expected long term adjusted earnings growth of almost 24 1   The stock added roughly 30 4  over the last three months Inogen has a long term expected earnings growth rate of 17 5   The stock gained around 21 9  over the last three months Accelerate Diagnostics has an expected long term adjusted earnings growth of 30   The stock added roughly 12 9  over the last three months 5 Trades Could Profit  Big League  from Trump Policies If the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ,2017-06-29,Zacks Investment Research,"https://www.investing.com/analysis/abaxis-(abax)-product-portfolio-strong,-competition-rife-200198548",200198548
116213,337728,HSIC,Henry Schein  HSIC  Grows Through Acquisitions  Runs Risks,opinion,On Sep 22  we issued an updated research report on Melville  NY based Henry Schein  Inc    NASDAQ HSIC    a leading distributor of health care products and services across the globe We are disappointed by Henry Schein s guidance cut for 2016 EPS  Also  foreign currency fluctuations and competitive headwinds continue to hurt the company We note that  Henry Schein s business continues to suffer from the emergence of group purchasing organizations  GPOs  and the consequent pricing pressure they are exerting on single healthcare providers like Henry Schein Moreover  Henry Schein operates in the highly competitive U S  healthcare products and service distribution industry  wherein the presence of other large players puts the company in a tight spot  Fluctuating currency rates and macroeconomic weaknesses are other threats to the company On the positive side  Henry Schein has been focused on making strategic acquisitions as part of its expansion plans  The company has been on an acquisition spree over the last couple of years  In this regard  the latest development is the company s decision to buy an 80  ownership position in Marrodent  one of Poland s largest full service dental distributors This deal will fortify Henry Schein s position in Poland by foraying into the region s emerging dental market  Additionally  with this deal  Henry Schein will be able to strengthen its operations in various sectors across 27 countries Earlier this year  the company acquired an 80 1  interest in Vetstreet  a leading provider of marketing solutions and health information analytics  Another important acquisition has been a 90  ownership stake in Dental Trey  an Italy based distributor of dental consumable merchandise and equipment Henry Schein also stands to gain from several trends in its end markets  such as customer demographics  According to a recent estimation  between 2015 and 2025  the population aged 45 and older will likely grow approximately 12   This demographic trend is expected to boost the utilization of dental and medical products distributed by the company Currently  Henry Schein has a Zacks Rank  4  Sell   Better ranked stocks in the broader medical sector are Align Technology Inc    NASDAQ ALGN    Merit Medical Systems  Inc    NASDAQ MMSI   and Derma Sciences Inc    NASDAQ DSCI    all carrying a Zacks Rank  2  Buy   You can see  Align Technology has gained 42 9  year to date  much better than the S P 500 s 5 9  over the same period  Over the past two months  the company has seen 9 estimates move higher  compared to no downward movement Merit Medical Systems has an impressive long term earnings growth rate of 12 5   Year to date  the stock has performed better than the S P 500  with a gain of 28 9  Derma Sciences  current year earnings growth rate is 94 5   way higher than the industry s 7 4   The stock recorded a gain of 7 9  year to date Confidential from Zacks Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-09-25,Zacks Investment Research,"https://www.investing.com/analysis/henry-schein-(hsic)-grows-through-acquisitions,-runs-risks-200155562",200155562
116216,337731,HSIC,Henry Schein  HSIC  Q3 Earnings  Disappointment In Store ,opinion,Henry Schein  Inc    NASDAQ HSIC   is scheduled to report third quarter 2016 financial numbers on Nov 2  before the opening bell Last quarter  this renowned healthcare products and service distributor posted a positive earnings surprise of 1 23   Encouragingly  Henry Schein s earnings surpassed the Zacks Consensus Estimate in the past four quarters  at an average of 2 51  Let s see how things are shaping up prior to this announcement HENRY SCHEIN IN Price and EPS Surprise    Factors at PlayOn a disappointing note  Henry Schein reported lower than expected dental sales in North America in the last reported quarter  Dental sales in North America were impacted by the decision to halt the sale of certain precious metal products that offered a low gross margin  Additionally  the company has also been registering high restructuring costs  Management expects Henry Schein to record similarly high restructuring costs in the third quarter of 2016 as well  Moreover  headwinds in the form of increased competition in the medical product distribution market as well as market uncertainties continue to raise concerns However  the Medical  Animal Health and Technology and Value Added Services businesses demonstrated a strong performance  We expect these businesses to continue to contribute to the top line in the yet to be reported quarter Further  management is highly optimistic about the company s ability to win new customers in the medical space  The company has effectively capitalized on the growing medical market whose benefits would be reflected in the coming quarters The company s core software products and upgrades at Technology and Value Added Services businesses aim to provide customers with efficient and easy to use solutions  This has helped the company generate more business  manage content among multiple sites and improve the overall management Meanwhile  Henry Schein s commitment to offer enhanced services in the U K  and European Union remains unchanged despite Brexit  Both the regions are believed to represent long term opportunities in the Dental  Animal Health and Medical space  The strategy to enter Poland s dental market through the 80  acquisition of Poland s dental distributor Marrodent is a major positive as the country has approximately 26 000 practicing dentists and roughly 20 000 dental offices Earnings WhispersOur proven model does not conclusively show that Henry Schein is likely to beat earnings this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here as you will see below Zacks ESP   Henry Schein has an Earnings ESP of  0 61   That is because the Most Accurate estimate is  1 64 while the Zacks Consensus Estimate is pegged at  1 65 Zacks Rank  Henry Schein has a Zacks Rank  4  Please note that we caution against stocks with a Zacks Rank  4 or 5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderHere are a few companies you may want to consider as our model shows that they have the right combination of elements to post an earnings beat this quarter Glaukos Corporation   NYSE GKOS   has an earnings ESP of  200  and a Zacks Rank  1 Penumbra  Inc    NYSE PEN   has an earnings ESP of  45 46  and a Zacks Rank  2  You can seeInvuity  Inc    NASDAQ IVTY   has an earnings ESP of  1 61  and a Zacks Rank  2 Confidential from Zacks Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-10-25,Zacks Investment Research,https://www.investing.com/analysis/henry-schein-(hsic)-q3-earnings:-disappointment-in-store-200160935,200160935
116221,337736,HSIC,Henry Schein  HSIC  Tops Q3 Earnings  Sales Meet  Guides  17,opinion,Henry Schein  Inc    NASDAQ HSIC   reported adjusted earnings per share  EPS  of  1 68 in the third quarter of 2016  up 8 4  year over year  Adjusted EPS also surpassed the Zacks Consensus Estimate of  1 65  The year over year earnings improvement was driven by strong revenue growth in the quarter Including one time adjustments  Henry Schein s reported net income in the third quarter was  133 7 million or  1 63 per share  reflecting year over year growth of 4 7  and 7 2   respectively Revenues in DetailHenry Schein reported revenues of  2 865 billion in the third quarter  up 6 7  year over year but almost in line with the Zacks Consensus Estimate  The year over year improvement came on the back of 7 7  growth in local currencies  with a 6  and 1 7  rise in internal sales and acquisitions  respectively  However  unfavorable foreign currency exchange accounted for a decline of 1  in overall revenue growth HENRY SCHEIN IN Price  Consensus and EPS Surprise   Region wise  Henry Schein experienced 7 3  year over year sales growth in the North American market  while sales in the international market improved 5 2  Segment Analysis     Henry Schein derives revenues from four operating segments  Dental  Medical  Animal Health  and Technology and Value added services In the third quarter  the company derived  1 3 billion in revenues from global Dental sales  up 5 1  year over year  including local currency growth of 5 6  and a 0 5  decline owing to unfavorable foreign exchange   Local currency growth comprised acquisition growth of 1 7  and internal sales growth of 3 9   The company s decision to stop selling low margin precious metals earlier this year negatively impacted growth by approximately 50 basis points  bps   According to the company  while the domestic dental consumable merchandise market continued to reflect slower than historical growth  it appears to be stable The company s global Animal Health segment witnessed a 7 9  improvement in revenues to  790 3 million  including local currency growth of 10 6  and a 2 7  decline related to foreign exchange headwind   The local currency growth included 8 6  growth in internal sales and 2  acquisition growth Worldwide Medical sales scaled up 7 1  year over year to  639 6 million based on local currency growth of 7 1   Foreign currency exchange had no impact on this segment s revenue growth in the third quarter  Revenues from global Technology and Value added Services grew 16 7  to  104 7 million  This included an 18 3  rise in local currencies  with acquisition growth of 10 7  and internal sales improvement of 7 6   However  revenues at this segment declined 1 6  due to unfavorable foreign currency Margin Trends          Gross profit increased 5 4  to  789 5 million in the reported quarter  However  gross margin declined 33 bps from the year ago quarter to 27 6   due to a 7 1  rise in cost of sales  higher than the revenue growth rate   Backed by a 5 8  rise in selling  general   administrative expenses to  583 4 million  adjusted operating income improved 4 4  year over year to  206 1 million  However  adjusted operating margin declined 15 bps to 7 2  in the reported quarter Financial PositionHenry Schein exited the quarter with cash and cash equivalents of  76 1 million  compared with  63 6 million at the end of second quarter 2016  Year to date net cash flow from operating activities was  350 9 million  compared to the year ago equivalent of  288 5 million  During the quarter under review  the company bought back approximately 1 2 million shares for  193 million  On Oct 19  2016  Henry Schein announced that its board of directors authorized the repurchase of up to  400 million of shares  This program is in addition to the  400 million repurchase program announced in Dec 2015 GuidanceHenry Schein reiterated its adjusted EPS guidance for 2016  The company still expects to deliver adjusted EPS in the range of  6 55  6 60  reflecting 10 11  year over year growth  The Zacks Consensus Estimate for 2016 is  6 57  within the company s guided range  The company also expects current restructuring activities to be completed in 2016 Management also provided its full year 2017 EPS guidance  The company expects EPS in the band of  7 17  7 30  reflecting annualized growth of 9  11  Our TakeHenry Schein ended the third quarter of 2016 on a mixed note with earnings handily beating the Zacks Consensus Estimate and revenues in line with the mark  The company s strong share gains in both the North American and overseas markets along with the strong revenues raise optimism However  despite each segment posting strong sales growth  we are disappointed with respect to the company s EPS guidance for 2016 which remained unchanged  The year over year deterioration in Henry Schein s gross and operating margin stemming from higher cost of sales and expenses also concerns us  Meanwhile  foreign currency fluctuations continued to hamper the company s business Zacks Rank   Key PicksHenry Schein currently holds a Zacks Rank  2  Buy   Other well ranked medical stocks are GW Pharmaceuticals plc   NASDAQ GWPH    Baxter International Inc    NYSE BAX   and Bovie Medical Corporation   NYSE BVX    All these stocks sport a Zacks Rank  1  Strong Buy   You can see GW Pharmaceuticals surged 67 5  year to date compared to the S P 500 s 3 3  over the same period  The company s four quarter average earnings surprise is 41 6  Baxter international rallied 22 91  year to date  above the S P 500 s 3 3   It has a trailing four quarter average positive earnings surprise of 27  Bovie Medical recorded a 20 1  gain in the past one year  above the S P 500 s 2 4   The company has a trailing four quarter average earnings surprise of 6 3  Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-11-01,Zacks Investment Research,"https://www.investing.com/analysis/henry-schein-(hsic)-tops-q3-earnings,-sales-meet,-guides-'17-200162249",200162249
116222,337737,HSIC,Top Research Reports For Facebook  JNJ  Wells Fargo   Others,opinion,"Friday  November 4  2016
Today s Research Daily features new research reports on 17 major stocks  including Johnson   Johnson  NYSE JNJ   Wells Fargo  NYSE WFC   Facebook  NASDAQ FB  and Qualcomm  NASDAQ QCOM  
Johnson   Johnson shares have bucked the broader healthcare slump this year and are up almost 12  year to date  While the company is faced with a number of headwinds like unfavorable currency movements  increased competition from generics  pricing pressures and an uncertain global macroeconomic backdrop  the analyst believes that JNJ s diversified business model  deep product pipeline  lack of cyclicality and financial strength position it for continued momentum going forward  We saw this in the company s Q3 earnings report when it beat on the top  and bottom lines and provided favorable outlook  The analyst expects these trends to continue in the coming periods as well   You can  
Wells Fargo has long maintained a reputation for disciplined and reliable operations and an attractive retail banking franchise  Recent quarterly results showing strong growth in loans and deposits reconfirm the bank s inherent strengths  but they have been totally offset lately by the sales practices controversy that has already cost the well regarded CEO his position  The new management team is making all the right moves and further downside risks in the stock may be low at this stage  the stock is already down  more than  16  year to date vs  a roughly 2  decline for the peer banks   but it will likely take a while for clouds to fully lifted   You can  
Facebook shares have lagged following the company s quarterly report when it came out with blowout numbers for the September period  but appeared cautious on future growth prospects  These near term challenges notwithstanding  Facebook s status as a Technology powerhouse with an enviable future earnings potential remains unchanged  Driving this is the company s huge user and advertiser base  higher engagement levels along with monetization opportunities presented by the  Instagram  Oculus  Messenger and WhatsApp properties   You can  
Qualcomm shares have surged nearly 34  year to date  Qualcomm  which reported strong fourth quarter fiscal 2016 results  has entered into an agreement to buy Netherlands based chipset giant NXP Semiconductors  The analyst likes this deal since the combined entity is likely to generate annual revenues of over  30 billion position itself as a strong player in the next generation mobile chipset segment  However  regulatory proceedings against Qualcomm are a major headwind   You can  
Other noteworthy reports we are featuring today include Charter Communications  NASDAQ CHTR   State Street Corp  NYSE STT  and Molson Coors  TAP  
Free Access  All Zacks Research ReportsStarting today  you are invited to download in depth analysis reports covering more than 1 000 of the most widely followed stocks  Valued at  25 each  they are yours to consult over the next 30 days absolutely free  They feature sensitive Zacks Rank information on each stock that you won t find anywhere else  
Sheraz Mian
Director of Research
Note  If you want an email notification each time Sheraz publishes a new article  please    
Today s Must Read












Featured Reports

The Zacks analyst believes that Charter Communications will continue to enjoy significant merger benefits going forward 


The covering analyst remains optimistic as the synergies from the GE Asset Management deal and the cost control initiatives will continue supporting State Street s bottom line growth 


Despite volume declines  the Zacks analyst remains positive on the recent acquisition of 58  stake in MillerCoors 


The Zacks analyst believes that Newmont should gain from its cost   efficiency actions  efforts to de lever its balance sheet and progress with its key projects amid a volatile pricing environment  


The covering analyst thinks the Q3 beat came on the back of strong share gains in both the North American and overseas markets 


The Zacks analyst thinks repair and remodeling activity will drive further demand for Masco s leading products 


The covering analyst believes that the strength in its cloud business and new cloud booking levels will drive revenues 

New Upgrades

The Zacks analyst believes OGE Energy s steady investments in infrastructural and aggressive energy efficiency programs are driving growth  Its strong sales improvement also buoys optimism 


Both segments of j2 Global  Cloud Services and Digital Media saw good growth in revenues on a year over year basis  The y o y increase in earnings and revenues and dividend hike are also encouraging 


The covering analyst believes CONSOL Energy  NYSE CNX  s focus on E P assets is reaping benefits  even though the quarterly loss was wider than expected 

New Downgrades

The Zacks analyst is bearish on Cerner s missing the Zacks Consensus Estimates for both earnings and revenue in Q3  Also expected lower hardware revenue in 2016 is a concern 


The covering analyst is disappointed with the company s Q3 earnings miss  Also  revenues and earnings fell year over year due to the weak pricing environment 


The Zacks analyst believes that Maxwell s quarterly results were affected by the latest subsidy changes in the China bus market  which have been causing certain revenue challenges in the short term",2016-11-03,Zacks Investment Research,"https://www.investing.com/analysis/top-research-reports-for-facebook,-jnj,-wells-fargo---others-200162897",200162897
116224,337739,HSIC,Henry Schein s Q3 Results Impress  Pricing Pressure A Drag,opinion,On Dec 6  we issued an updated research report on Melville  NY based Henry Schein Inc    NASDAQ HSIC    The company is a leading global distributor of health care products and services  It serves office based dental  medical and animal health practitioners  dental laboratories  government as well as institutional health care clinics and other alternate care sites Over the past three months  the share price trend of Henry Schein was almost at par with the Zacks categorized Medical Product Market  However  the company s trend picked up stream post third quarter earnings  The stock is down 6   which compares favorably with the negative return of 7 9  for the broader Medical product industry Adding to it is Henry Schein s favorable estimate revision trend for the current year with one upward and no downward movement in the last 30 days  Henry Schein also recorded a five year CAGR of 5 7  for revenues  reflecting strong fundamentals Also  the company is reported to have gained a strong share in both North American and overseas markets in the recently concluded quarter  Currently  Henry Schein s distribution business boasts a wide global footprint with 61 distribution centers We are also optimistic about the company s plan to acquire 80  ownership of Poland based dental distributor   Marrodent  The deal is expected to help Henry Schein fortify its market position in the emerging dental markets in the region  Thus  we note that the company well positioned to gain from its extensive global foothold Henry Schein is also poised to benefit from several favorable market trends  One of the major positives is the domestic demographic trends  which are expected to drive utilization of dental and medical products distributed by the company  Factors like aging population and increasing healthcare expenditure across the globe will provide additional top line opportunities Moreover  in the dental industry  a rise in oral health care expenditures is predicted  We believe that this will boost demand for Henry Schein s products and services as well  Additionally  the company s animal health business is gaining traction on the back of demand for animal health products in the U S  Further  the company s wide range of products hedges it from any substantial sales decline during an economic downturn  All these factors are expected to pave the way for Henry Schein to carve out its niche in the market Despite each segment s strong sales growth  the company s unchanged earnings guidance for 2016 in the third quarter report was disappointing  The year over year decline in Henry Schein s gross and operating margin due to higher cost of sales and expenses also raise concerns Also  some large integrated health care providers and group purchasing organizations  GPO  have gained considerable purchasing power of late  GPOs have also increased pricing pressure in the industry  This might be a drag on Henry Schein s business in the future  Moreover  foreign currency fluctuations and stiff market competition continue to hinder the company s business Zacks Rank   Key PicksHenry Schein currently carries a Zacks Rank  3  Hold   Some better ranked medical stocks are NxStage Medical Inc    NASDAQ NXTM    Baxter International Inc    NYSE BAX   and Bovie Medical Corporation   NYSE BVX    NxStage Medical and Baxter International sport a Zacks Rank  1  Strong Buy   while Bovie Medical carries a Zacks Rank  2  Buy   You can see NxStage Medical surged 29 9  over the last one year compared with the S P 500 s 9 5  over the same period  The company has a four quarter average positive earnings surprise of 46 3  Baxter International rallied 23 9  over one year  much higher than the S P 500  It has a trailing four quarter average positive earnings surprise of 27  Bovie Medical recorded a 119 4  gain in the past one year  way better than the S P 500 s 5 9   The company has a trailing four quarter positive average earnings surprise of 28 7  Zacks  Best Private Investment Ideas In addition to the recommendations that are available to the public on our website  how would you like to follow all Zacks  private buys and sells in real time Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors  Starting today  for the next month  you can have unrestricted access ,2016-12-07,Zacks Investment Research,"https://www.investing.com/analysis/henry-schein's-q3-results-impress,-pricing-pressure-a-drag-200168935",200168935
116226,337741,HSIC,Medical Product Q1 Earnings Due On May 9  XRAY  HSIC   More,opinion,"It is so far so good for the first quarter reporting cycle  which is in its tail end with financial results from 412 members in the S P 500 cohort  For Medical  one of the 16 broader Zacks sectors  we have results from 88 6  of the total market cap  Per the latest   this sector has demonstrated a bullish trend with earnings and revenue beats standing at impressive levels of 86 0  and 69 8   respectively Road Ahead for Medical Product SpaceMedical product  an important part of the medical device subcategory within the broader Medical sector  looks promising at the moment  Investors are bullish as the Zacks categorized  industry registered growth of 8 27  in the last three months  comfortably outperforming the S P 500 Index s gain of 4 95  Notably  the growth story in the space exclusively pertains to market dynamics and the shift in consumer demand  courtesy of the growing prevalence of minimally invasive surgeries  liquid biopsy tests  and use of IT for ensuring quick and improved patient care among other things  Furthermore  cost effective products and techniques targeting emerging markets raise optimism On the flipside  the recent political conundrum in the healthcare space pertaining to  Trumpcare  is a headwind  Amid such unpredictability  let us take a look at how the players of this industry are positioned this earnings season Let s take a look at the major Medical products  stocks expected to release first quarter 2017 reports on May 9 DENTSPLY Sirona Inc    NASDAQ XRAY    This global manufacturer of professional dental products and technologies is scheduled to report results before the opening bell However  our proven model does not conclusively show that DENTSPLY Sirona is likely to beat on earnings this quarter  A stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for an earnings beat  You can see  Currently  DENTSPLY Sirona has a Zacks Rank  2  Buy  and an Earnings ESP of 0 00   That is because both the Most Accurate estimate and the Zacks Consensus Estimate currently stand at 70 cents  On average  the company delivered a positive earnings surprise of 5 41  for the trailing four quarters  You can uncover the best stocks to buy or sell before they re reported with our  Though a favorable Zacks Rank increases the predictive power of ESP  we need a positive ESP to be confident about an earnings beat    Read More    DENTSPLY SIRONA Inc  Price and EPS Surprise
    Henry Schein  Inc    NASDAQ HSIC    This leading worldwide distributor of health care products and services is expected to come up with sluggish dental sales that will impact top line in the quarter to be reported  Year over year deterioration in gross and operating margin due to higher cost of sales and expenses is another matter of concern While a Zacks Rank  2 increases the predictive power of the ESP  a 0 00  ESP makes surprise prediction uncertain  This is because both the Most Accurate estimate and the Zacks Consensus Estimate stand at  1 66   Read more   
  Henry Schein  Inc  Price and EPS Surprise
    Penumbra  Inc    NYSE PEN    Penumbra is an active player in the fast growing interventional therapies space  The company s products primarily cater to the unmet clinical needs in neuro and peripheral vascular markets  Meanwhile  consistent growth in neuro franchise is driven by expansion in the ischemic stroke market as well as sales of Penumbra System  Accordingly  Penumbra s strategy to focus on impactful product development across a varied portfolio may boost investors  confidence in the stock This time  Penumbra is unlikely to come up with a beat as it currently has a Zacks Rank  3 and an Earnings ESP of 0 00   Both the Most Accurate estimate and the Zacks Consensus Estimate stand at a loss of 6 cents   Read More   Penumbra  Inc  Price and EPS Surprise
    Steris Plc   NYSE STE    Headquartered in Ohio  Steris develops  manufactures and markets infection prevention  decontamination  microbial reduction  and surgical and gastrointestinal support products and services  The company was originally known as STERIS Corporation Our proven model does not conclusively show an earnings beat for the company   Steris currently has a Zacks Rank  4  Sell  and an Earnings ESP of 0 94   We caution against stocks with a Zacks Rank  4 or 5  Strong Sell  going into the earnings announcement  STERIS PLC Price and EPS Surprise
    Inogen Inc    NASDAQ INGN   is a provider of innovative respiratory products for use in the homecare setting  Inogen s unique direct to customer business model  innovative product portfolio and growing patient base are currently drawing investor attention Our proven model does not conclusively show an earnings beat for Inogen which currently has a Zacks Rank  3 and an Earnings ESP of 0 00   This is because both the Most Accurate estimate and the Zacks Consensus Estimate stand at 12 cents Inogen  Inc Price and EPS Surprise
    Zacks  2017 IPO Watch ListBefore looking into the stocks mentioned above  you may want to get a head start on potential tech IPOs that are popping up on Zacks  radar  Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential  This Special Report gives you the current scoop on 5 that may go public at any time One has driven from 0 to a  68 billion valuation in 8 years  Four others are a little less obvious but already show jaw dropping growth ",2017-05-07,Zacks Investment Research,"https://www.investing.com/analysis/medical-product-q1-earnings-due-on-may-9:-xray,-hsic---more-200187752",200187752
116229,337744,HSIC,Henry Schein  HSIC  Tops Q1 Earnings  Reaffirms  17 View,opinion,"Henry Schein  Inc    NASDAQ HSIC   reported adjusted earnings per share  EPS  of  1 76 in the first quarter of 2017  up 24 8  year over year  Adjusted EPS also surpassed the Zacks Consensus Estimate of  1 66  The year over year upside in earnings was driven by strong revenue growth Henry Schein s reported net income in the first quarter came in at  140 7 million or  1 76 per share  reflecting year over year growth of 23 7  and 28 5   respectively Revenues in DetailHenry Schein reported revenues of  2 92 billion in the first quarter  up 7 7  year over year and also above the Zacks Consensus Estimate of  2 83 billion  The year over year improvement came on the back of 8 7  growth in local currencies and a 1 0  decline owing to foreign currency exchange  At local currencies  internally generated sales increased 5 9  and acquisition growth was 2 8  Henry Schein  Inc  Price  Consensus and EPS Surprise
    The company recorded year over year sales growth of 5 6  or  1 94 billion in the North American market and 12 3  or  980 7 million in the international market Segment Analysis     Henry Schein derives revenues from four operating segments  Dental  Medical  Animal Health  and Technology and Value added services In the first quarter  the company derived  1 40 billion in revenues from global Dental sales  up 7 9  year over year  This includes 8 2  growth in local currencies and 0 3  decline related to foreign currency exchange  At local currencies  internally generated sales increased 2 9  and acquisition growth was 5 3   Internal growth at local currencies included 0 8  growth in North America and 6 8  rise internationally The company s global Animal Health segment witnessed 5 4  improvement in revenues to  812 9 million  This includes 8 1  growth in local currencies and 2 7  decline related to foreign currency exchange  At local currencies  internally generated sales increased 7 1  and acquisition growth was 1 0   The 7 1  internal growth in local currencies included 5 5  growth in North America and 8 9  growth internationally Worldwide Medical sales scaled 11 3  year over year to  598 9 million  Internal sales growth in local currencies was 11 5   with a 0 2  decrease owing to adverse foreign exchange Revenues from global Technology and Value added Services grew 4 2  to  106 0 million  This included 5 5  growth in local currencies and a 1 3  decline related to foreign currency exchange  There was no contribution from acquisitions during the quarter under review Margin Trends          Gross profit increased 5 8  to  822 9 million in the reported quarter  However  gross margin declined 52 basis points  bps  from the year ago quarter to 28 2   due to an 8 5  rise in cost of sales  higher than the revenue growth rate   On the back of a 5 2  rise in selling  general   administrative expenses of  628 9 million  adjusted operating income improved 7 6  year over year to  193 9 million  However  adjusted operating margin declined 1 bps to 6 6  in the reported quarter Financial PositionHenry Schein exited first quarter 2017 with cash and cash equivalents of  62 8 million  compared with  62 3 million at the end of fiscal 2016  As of Apr 1  2017  the company used cash of  52 5 million in operating activities  compared with  77 7 million at the end of Mar 26  2016 During the quarter under review  the company bought back approximately 308 000 shares for almost  50 million  At the close of the fourth quarter  the company had  200 million authorized for future repurchases of its common stock 2017 EPS Guidance IntactHenry Schein reaffirmed its 2017 reported EPS guidance  The company still expects to deliver EPS in the range of  7 17  7 30  reflecting 16 18  growth from the 2016 EPS figure of  6 19   The Zacks Consensus Estimate for 2017 adjusted EPS is  7 25 Our TakeHenry Schein exited first quarter 2017 on a solid note with earnings and sales beating the Zacks Consensus Estimate  All four of its operating segments delivered strong year over year growth  The company s strong share gains in both the North American and overseas markets along with strong revenues raise optimism  Management was particularly upbeat about the strategic acquisitions made under the company s technology and Value Added Services segments However  despite the better than expected earnings performance  we are disappointed with the company s unchanged EPS guidance for 2017  Meanwhile  the year over year deterioration in Henry Schein s gross and operating margin was due to higher cost of sales and expenses  Also  foreign currency fluctuations continued to mar the company s financials Zacks Rank   Other Key PicksHenry Schein currently has a Zacks Rank  2  Buy   Other top ranked medical stocks include Hologic  Inc    NASDAQ HOLX    Baxter International Inc    NYSE BAX   and Progenics Pharmaceuticals  Inc    NASDAQ PGNX    Hologic sports a Zacks Rank 1  Strong Buy   while Baxter International and Progenics Pharmaceuticals carry a Zacks Rank  2  You can see Hologic gained 31 6  in the last one year  in comparison to the S P 500 s 15 0   The company has a stellar four quarter average earnings surprise of over 4 16  Baxter International rose around 22 4  in the last one year  in comparison to the S P 500  It has a four quarter average earnings surprise of 17 14  Progenics Pharmaceuticals gained 38 8  in the past one year  better than the S P 500 mark  It has a four quarter average earnings surprise of 10 01  Zacks  Best Private Investment Ideas While we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public                                                                                              Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ",2017-05-08,Zacks Investment Research,"https://www.investing.com/analysis/henry-schein-(hsic)-tops-q1-earnings,-reaffirms-'17-view-200188080",200188080
116256,337771,HSIC,Henry Schein Rides High On Strategic Buyouts  Price Hurts,opinion,On Jul 5  we issued an updated research report on Melville  NY based Henry Schein  Inc     NASDAQ HSIC     a leading distributor of health care products and services across the globe  The company currently carries a Zacks Rank  3  Hold  Henry Schein stands to gain from several trends in its end markets  one of them being demographics According to a recent estimation  between 2015 and 2025  the population of people aged 45 and older is expected to grow approximately 12   This demographic trend is expected to boost the utilization of dental and medical products distributed by the company Of late  Henry Schein has been focused on making prudent acquisitions as part of its expansion strategies  The company was virtually on an acquisition spree throughout 2015  which is expected to continue in 2016 as well  In this regard  the latest development includes the completion of its takeover of 50  interest in J Morita s subsidiary  One Piece Corp  Henry Schein believes that the deal will expand its share in the Japanese dental market but will be neutral to its financial results Another buyout was that of RxWorks to boost the growing practice management software business  Henry Schein also boasts a strong cash balance position  which allows it to indulge in high value acquisitions as well as share repurchase activities On the flip side  the recent emergence of group purchasing organizations  GPOs  and the consequent pricing pressure they are exerting on single healthcare providers like Henry Schein might hamper the latter s business effectively Moreover  Henry Schein operates in the highly competitive U S  healthcare products and service distribution industry  wherein the presence of other large players puts the company in a tight spot  Fluctuating currency rates and macroeconomic weaknesses are other threats to the stock Stocks to ConsiderSome better ranked medical stocks areNuVasive  Inc    NASDAQ NUVA    Boston Scientific Corporation   NYSE BSX   and ICU Medical  Inc    NASDAQ ICUI    While NuVasive sports a Zacks Rank  1  Strong Buy   both Boston Scientific and ICU Medical carry a Zacks Rank  2  Buy  ,2016-07-06,Zacks Investment Research,"https://www.investing.com/analysis/henry-schein-rides-high-on-strategic-buyouts,-price-hurts-200140536",200140536
116257,337772,HSIC,Henry Schein To Buy Marrodent Stake  Expand In Poland,opinion,"Keeping in line with its strategy of growth through rapid expansion internationally  Henry Schein Inc   NASDAQ HSIC   has agreed to acquire 80  ownership of Marrodent  a Poland based distributor of dental consumables  equipment and dental laboratory supplies  However  all the financial terms of the agreement have been kept under wraps This deal in fact paves the way for Henry Schein to fortify its market position in Poland by foraying into the emerging dental markets in the region  In this regard we note that Henry Schein has been serving the animal health customers in Poland since 2014 Additionally  with this deal  Henry Schein will be able to strengthen its operations in various sectors across 27 countries  The deal is anticipated to close by the fourth quarter of fiscal 2016  after a thorough scrutiny by Poland s competition authorities HENRY SCHEIN IN Price
    Coming to share price movement  Henry Schein witnessed a nominal decline of 0 01  to close at  163 79  following the news  However  a further analysis reveals a strong one year return of 20 9  in share price  much better than the S P 500 s 11 4  over the same time frame As per management  the deal should help Henry Schein tap into the bountiful dental market opportunities in Poland  which currently has as many as 26 000 practicing dentists and around 20 000 dental offices Our TakeA glimpse at the global market trends reveal projections that hint at  dental consumables market  growth at a CAGR of 6 8  to  35 3 billion by 2021  Markets And Markets   Further  we are also impressed with the company s promising performance in the last reported second quarter 2016 registering a 4  rise in global Dental sales on a year over year basis Buoyed by the strength in these trends  we presume Henry Schein  with its latest collaboration with Marrodent  will significantly gain traction in the dental care and related ancillary markets Zacks Rank   Key PicksHenry Schein currently has a Zacks Rank  3  Hold   Better ranked medical stocks are IDEXX Laboratories Inc    NASDAQ IDXX    Masimo Corp    NASDAQ MASI   and Quidel Corp    NASDAQ QDEL    All these stocks sport a Zacks Rank  1  Strong Buy  Confidential from Zacks Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-08-31,Zacks Investment Research,"https://www.investing.com/analysis/henry-schein-to-buy-marrodent-stake,-expand-in-poland-200151327",200151327
116258,337773,HSIC,Henry Schein Poised On Strategic Buyouts  Pricing Hurts,opinion,On Sep 1  we issued an updated research report on Melville  NY based Henry Schein  Inc    NASDAQ HSIC    a leading distributor of health care products and services across the globe  The company currently carries a Zacks Rank  3  Hold  Henry Schein stands to gain from several trends in its end markets  one of them being customer demographics  According to a recent estimation  between 2015 and 2025  the population aged 45 and older will likely grow approximately 12   This demographic trend is expected to boost the utilization of dental and medical products distributed by the company Of late  Henry Schein has been focused on making prudent acquisitions as part of its expansion strategies  The company is virtually on an acquisition spree in the last couple of years  In this regard  the latest development is the company s decision to buy an 80  ownership position in Marrodent  one of Poland s largest full service dental distributors Earlier this year  the company acquired an 80 1  interest in Vetstreet  a leading provider of marketing solutions and health information analytics  Another important acquisition has been a 90  ownership stake in Dental Trey  an Italy based distributor of dental consumable merchandise and equipment Henry Schein also boasts a strong cash balance position  which allows it to indulge in high value acquisitions as well as share repurchase activities On the flip side  the recent emergence of group purchasing organizations  GPOs  and the consequent pricing pressure they are exerting on single healthcare providers  like Henry Schein  might hamper the latter s business efficacy Moreover  Henry Schein operates in the highly competitive U S  healthcare products and service distribution industry  wherein the presence of other large players puts the company in a tight spot  Fluctuating currency rates and macroeconomic weaknesses are other threats to the stock Stocks to ConsiderSome better ranked medical stocks are Align Technology Inc    NASDAQ ALGN    Derma Sciences Inc    NASDAQ DSCI   and Merit Medical Systems  Inc    NASDAQ MMSI    All the three stocks carry a Zacks Rank  2  Buy  Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand    ,2016-09-01,Zacks Investment Research,"https://www.investing.com/analysis/henry-schein-poised-on-strategic-buyouts,-pricing-hurts-200151265",200151265
116289,337804,HSIC,The Only Way You Should Be Investing In Stocks Right Now,opinion,What the heck is going on with this market  On two occasions this week  the major indexes opened sharply lower and then clawed back higher as the trading session wore on  From hour to hour  the bears    who fear a spreading European contagion  and the market bulls    who ve been digesting solid recent quarterly profits  are wrestling for control of the market My take  the risks that could trigger a market pullback remain formidable  and I don t want to touch stocks that don t have some form of downside protection  This protection can come in many forms  from a bulletproof balance sheet to a history of solid  recurring cash flow I also like companies that are prepared to defend their stock  The companies I discuss below have recently announced major stock buyback plans  and in a market slump  they d be active buyers at a time when few friends can be found  Just as important  any market swoon that does impact these stocks will mean more bang for the buyback buck  In some instances  they may have a chance to sharply lower the number of shares outstanding  which would set the stage for solidly higher earnings per share  EPS  in the future I ve compiled a list of 19 companies that have made buyback announcements since the second quarter began  And their reasons to pursue a buyback now are numerous  Getting to the heart of why they are buying back shares is the key behind seeing if they represent real value Not for me    As a personal rule of thumb  I never like companies that look to buyback shares unless the forward P E  price to earnings  ratio is well below the market average  The only exception  if the near term P E ratios fail to represent what kind of earnings power a company can eventually have    Biotech firm Biogen Idec  Nasdaq  BIIB  and dental supplies distributor Henry Schein  Nasdaq  HSIC  aren t trying to bring attention to a lagging stock    each trades near its 52 week high  Instead  they simply don t know what to do with their excess cash  I think these companies would be far better off holding tight    let cash build higher and buy back shares some time down the road when they ve fallen sharply from their highs    A previous favoriteHecla Mining  NYSE  HL  is a different story   I ve recently written quite a bit about this silver miner  As   if the company can keep its promise that a major shuttered mine will come back online in about eight months  then 2013 results will be far better  The company is using roughly one third of its  280 million cash balance to buy back stock now  in anticipation of a better outlook  and a higher stock price  in the future      The long slog back to relevance  In a similar vein  health care information provider Allscripts  Nasdaq  MDRX  is currently suffering from a botched merger    Allscripts  troubles means earnings per share  EPS  are constrained  likely staying below  1 this year and next  Yet if management can make the right moves to fix the business and return margins to historical levels  then EPS could move sharply higher  In the interim  the  200 million stock buyback can be used to aggressively re absorb shares while they remain deeply out of favor  And this isn t a one time move  In fact  there is already another  200 million buyback plan in place    and even after that  400 million total is earmarked  Allscripts still has  350 million available for future buybacks    So why should investors expect profits to eventually move higher  It s because the current numbers are being impacted by a series of controllable factors that can be fixed  Allscripts  expenses have spiraled too high as management never made a big cost cutting push after the company s mishandled merger with hospital information systems provider Eclipsys    Indeed  the recent moves to bring in fresh management and a new chairman will likely lead to those cost cutting measures investors had already expected to see  As analysts at Auriga Securities note   the problems at Allscripts stem from the top  and we wouldn t be surprised to see further leadership turnover   That creates uncertainty right now  and shares may languish until the new team is fully in place and investors hear more about their turnaround strategies    Yet Auriga s analysts  even as they rate shares a  hold   have a  14 target price  nearly 30  above current levels  And that target is based on very low expectations  by their math  shares are worth more than 15 times the downwardly revised 2012 EPS of  0 90  15 x  0 90    13 50   That multiple currently stands at 12  To put that in perspective  rival Cerner  Nasdaq  CERN  trades for around 35 times projected 2012 profits  Both of these companies operate in the same high growth industry  And Cerner surely deserves a premium for better execution  but should Cerner s P E multiple be higher by a factor of three  If anything  Cerner is operating at peak levels and has little fat to cut  Allscripts s profit potential is more robust  simply because it is currently too bloated and also has room for improvement in terms of salesforce execution    This isn t an endorsement for Allscripts right now  though  Instead  it s a chance for you to really come to understand this business model while it s deeply out of favor    and then buy when you think the time is right  Just a few months ago  investors were looking at Allscripts as a decent company in a really attractive business  After a deep fix  that will likely again be the investor sentiment several quarters from now    Risks to Consider  Buybacks don t prevent stocks from falling    they just cushion the blow against even deeper falls  Share count bloat is one of the key factors behind disappointing EPS growth  Conversely  falling share counts can make a tepid growth story look like much better  That s why these stocks are often a fertile area for investment ideas  Aside from Allscripts  any of the stocks in the list above should give you a good head start on your research  BY David Sterman,2012-05-13,StreetAuthority,https://www.investing.com/analysis/the-only-way-you-should-be-investing-in-stocks-right-now-123011,123011
116290,337805,HSIC,Henry Schein  HSIC  Tops Q1 Earnings  Keeps  16 View ,opinion,"Henry Schein  Inc    NASDAQ HSIC   reported adjusted earnings per share  EPS  of  1 41 in the first quarter of 2016  up 10 2  year over year  Adjusted EPS also exceeded the Zacks Consensus Estimate by a couple of cents  The year over year earnings improvement was driven by record revenue growth in the quarter 
Including one time adjustments  Henry Schein s reported net income in the first quarter was  113 8 million or  1 37 per share  reflecting a year over year improvement of 10  and 12 3   respectively 
Revenues in Detail
Henry Schein reported revenues of  2 713 billion in the first quarter  up 10 1  year over year  The top line also comfortably beat the Zacks Consensus Estimate of  2 658 billion  The year over year improvement was led by 12  growth in local currencies with a 9 3  and a 2 7  rise in internal sales and acquisitions  respectively  However  unfavorable foreign currency exchange accounted for a decline of 1 9  in overall revenue growth 
Region wise  Henry Schein experienced 13 4  year over year sales growth in the North American market  while sales in the international market improved 3 9  
Segment Analysis     
Henry Schein derives revenues from four operating segments  Dental  Medical  Animal Health  and Technology and Value added services 
In the first quarter  the company derived  1 3 billion in revenues from global Dental sales  up 4 1  year over year  including local currency growth of 6 1  and a 2  decline owing to unfavorable foreign exchange   Local currency growth comprised acquisition growth of 1 2  and internal sales rise of 4 9   The Dental franchise witnessed an improvement of 5 8  in North America while international sales grew 1 3  
The company s global Animal Health segment witnessed a 12 7  improvement in revenues of  771 4 million  including local currency growth of 15 6  and a 2 9  decline related to foreign exchange headwind   The local currency growth included 9 8  growth in internal sales and 5 8  acquisition growth  Franchise revenues grew 18  in North America while overseas revenues improved 7 5  
Worldwide Medical sales scaled up 21 3  year over year to  538 1 million based on local currency growth of 21 5   However  revenues slipped 0 2  owing to unfavorable foreign currency exchange  The local currency growth was solely driven by 21 5  growth in internal sales 
Revenues from global Technology and Value added Services grew 18 6  to  101 7 million  This included a 19 9  rise in local currencies  with acquisition growth of 12 4  and internal sales improvement of 7 5   However  revenues at this segment declined 1 3  due to unfavorable foreign currency 
Margin Trends
Gross profit increased 9 2  to  779 3 million in the reported quarter  However  gross margin dropped 30 basis points  bps  from the year ago quarter to 28 7   due to a higher rate of rise in cost of sales compared to revenue growth 
Despite a 9 9  rise in selling  general   administrative expenses to  599 1 million  adjusted operating income improved 7 1  year over year to  180 3 million on account of higher gross profit  However  adjusted operating margin declined 20 bps to 6 6  in the reported quarter as the rise in operating expense was more than that in gross profit 
Financial Position
Henry Schein exited the quarter with cash and cash equivalents of  71 6 million  compared with  72 1 million at the end of 2015  In the first quarter  net cash outflow from operating activities was  101 5 million  compared to the year ago equivalent of  26 7 million  
During the quarter under review  the company bought back approximately 0 7 million shares for  100 million and was left with  300 million worth of repurchase authorization 
Guidance
Henry Schein reaffirmed its adjusted EPS guidance for 2016  The company continues to project adjusted EPS at  6 55  6 65  reflecting 10  12  year over year growth  The Zacks Consensus Estimate for 2016 is  6 62  within the company s guided range 
Our Take
Henry Schein kick started 2016 on an impressive note  with its first quarter top and bottom line beating the Zacks Consensus Estimate  The company s strong share gains in both North American and overseas markets along with the record revenues raise optimism  This in turn drove the robust double digit growth in the company s adjusted EPS figure 
However  we remain on the sidelines with respect to the company s unchanged adjusted EPS guidance for 2016 despite each segments posting strong sales growth  The year over year deterioration in Henry Schein s gross margin figure also disappoints us  Meanwhile  foreign currency fluctuations continued to hamper the company s business 
Nevertheless  the recent acquisitions of VetStreet and RxWorks add to the company s strength  These efforts reflect the company s strong cash balance and its ability to finance buyout deals  We expect these investments to not only enhance the company s geographic presence but also boost its business 
Zacks Rank   Key Picks
Currently  Henry Schein carries a Zacks Rank  3  Hold   Better ranked medical stocks are Baxter International Inc    NYSE BAX    Align Technology Inc    NASDAQ ALGN   and Boston Scientific Corp    NYSE BSX    While Baxter sports a Zacks Rank  1  Strong Buy   Boston Scientific and Align carry a Zacks Rank  2  Buy  ",2016-05-03,Zacks Investment Research,"https://www.investing.com/analysis/henry-schein-(hsic)-tops-q1-earnings,-keeps-'16-view-200127608",200127608
116291,337806,HSIC,Henry Schein  Q1 Results Strong  Expansion Plans On Track,opinion,On Jun 3  we issued an updated research report on Melville  NY based Henry Schein  Inc    NASDAQ HSIC     a leading distributor of health care products and services across the globe  The company currently carries a Zacks Rank  2  Buy  Henry Schein made an impressive start to 2016  with its top and bottom line beating the Zacks Consensus Estimate in the first quarter  The recent acquisitions of VetStreet and RxWorks add to the company s strength as these are expected to enhance Henry Schein s geographic presence Henry Schein s distribution business has a wide global footprint with 61 distribution centers  Earlier  the company had forayed into Japan  the world s second largest dental market and Poland  the sixth largest economy in the European Union  To expand its dental business in Japan  the company recently collaborated with J Morita which will allow Henry Schein serve approximately 20  of the nation s dental market Henry Schein s revenue growth has been long supported by niche acquisitions  In the first quarter  Henry Schein took over an 80 1  interest in Vetstreet  a leading provider of marketing solutions and health information analytics  The company expects this deal to meaningfully complement its U S  Animal Health business and prove accretive to earnings by  0 01  0 02 in 2017 and beyond We are looking forward to the company s recent takeover of a 90  stake in Italy based Dental Trey which has has already brought in  8 5 million of initial goodwill  According to Henry Schein  this deal will be accretive by less than  1 cent to the company s earnings in 2017 and beyond  Henry Schein has also agreed to acquire a majority ownership interest in Dental Cremer   a distributor of dental supplies and equipment in Brazil  The deal is expected to close by the end of 2016  Henry Schein also bought RxWorks in the first quarter of 2016 to strengthen its practice management software business On the flip side  unfavorable currency translation continues to be a major dampener for the stock  accounting for a 1 9  decline in overall revenues in the first quarter Foreign currency exchange also had a 2 cent per share impact on EPS in the reported quarter  Intensifying competition and increasing pricing pressure owing to rising group purchasing organizations pose threat to the stock  Key Picks in the Sector                 Other favorably ranked medical stocks are Baxter International Inc    NYSE BAX    Boston Scientific Corporation   NYSE BSX   and LeMaitre Vascular  Inc    NASDAQ LMAT    While Baxter sports a Zacks Rank  1  Strong Buy   Boston Scientific and LeMaitre Vascular carry a Zacks Rank  2 ,2016-06-02,Zacks Investment Research,"https://www.investing.com/analysis/henry-schein:-q1-results-strong,-expansion-plans-on-track-200133895",200133895
116292,337807,HSIC,Trading Opportunity  Henry Schein Rally Shows No Signs Of Stopping,opinion,"Along with many other stocks  it took Henry Schein  NASDAQ HSIC  three months to lose half of its value in the last financial crisis at the end of 2008  But unlike many other stocks  Henry Schein used this situation to kick off a huge rally   that is still going on 
In the beginning of 2013  the stock managed to break out of the sideways range that had lasted longer than a decade  With this breakout  the stock once more gained momentum and started to move from new high to new high 
In the actual situation it is very likely that the price will sky rocket above the more than six year old uptrend channel  On a long term view  these breakouts normally fall back into the old channel  but as a short term trading opportunity traders could benefit from the increasing momentum with long positions 
On the daily chart it is easy to see that on Thursday the price broke out from the last sideways range above the upper border line  and the price kept on moving strongly in the trend direction  The retest of the upper border of the sideways range already took place on Friday  Another indication for a continuation of the uptrend is that the correction in the beginning of the week was not able to make new lows  even though it took place with unusual big volume 
A new high above Thursday s daily high could be used for a long entry with a tight stop  A stop at 172 00 lies under the last strong momentum candle  under the last relative low on the daily chart as well as under the upwards trend line from this year 
If the market opens lower on Monday an entry at a price around 174 00 is also possible  but then you should use a larger stop at 168 80  which is below the last relative low on the weekly chart  Through the projection of the last sideways range  the expected target is 184 50 
Disclaimer  Trading financial instruments  including foreign exchange on margin  carries a high level of risk and is not suitable for all investors  The high degree of leverage can work against you as well as for you  Before deciding to invest in financial instruments or foreign exchange you should carefully consider your investment objectives  level of experience  and risk appetite  The possibility exists that you could sustain a loss in excess of your initial investment and therefore you should not invest money that you cannot afford to lose  You should be aware of all the risks associated with trading and seek advice from an independent financial advisor if you have any doubts ",2016-06-06,Martin Goersch,"https://www.investing.com/analysis/henry-schein--trading-opportunity-for-monday,-06.06.2016-200134091",200134091
